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ABSTRACT 
 
Crimean Congo haemorrhagic fever virus (CCHFV) is a tick borne nairovirus 
responsible for a highly fatal human disease with increased recent incidence within 
the human population of southern Europe. Hazara virus (HAZV), another tick borne 
nairovirus of the same serogroup as CCHFV, is not pathogenic in humans, but 
infection with HAZV results in a similar disease progression in interferon receptor 
knockout mice to CCHFV. In order to investigate further similarities between HAZV 
and CCHFV, and to support the use of HAZV as a model for CCHFV infection, various 
structural and cell biological aspects of the CCHFV and HAZV replication cycle were 
investigated. We present the X-ray crystal structure of the nucleocapsid protein (N) of 
HAZV at a resolution of 2.7 Å, and the crystal structure of RNA-bound HAZV N at a 
resolution of 3 Å. HAZV N had a highly similar overall structure to CCHFV N, 
consisting of a globular domain containing amino acid residues from both the N and 
the C-termini, and an extended arm domain. A crevice within the globular domain of 
HAZV N had 3 nucleotides of RNA bound, in the RNA-bound HAZV N structure. RNA 
binding is a crucial function of HAZV N and CCHFV N, and the identification of an 
RNA binding site in HAZV N provides a model for the structure guided design of anti-
virals to disrupt this interaction.  
Cellular heat shock protein 70 (HSP70) was found to be an interacting partner 
of the N protein of CCHFV and HAZV, both in cells and in secreted HAZV particles. 
The functional role of this interacting partner within the HAZV replication cycle was 
investigated using siRNA knock down and small molecule inhibitors of endogenous 
HSP70. HAZV induced apoptosis in SW13 cells, and HAZV N was cleaved during a 
72 hr time course of infection. The data presented here also reveals new insights into 
the replication cycles of HAZV and CCHFV.   
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CHAPTER 1: INTRODUCTION 
1.1 GENERAL INTRODUCTION 
 
1.1.1 Discovery of Crimean Congo haemorrhagic fever virus and Hazara virus 
 
Crimean Congo haemorrhagic fever (CCHF) was first described as a new tick borne 
disease during a large outbreak of severe haemorrhagic fever in Crimea in 1945  
when approximately 200 patients were infected (M. P. Chumakov 1945). The disease 
was named Crimean haemorrhagic fever (CHF), and a viral aetiology was suggested 
after infecting psychiatric patients with a filterable agent isolated from the blood of 
CCHF patients (Whitehouse 2004; Bente, Forrester et al. 2013). The virus was first 
isolated through inoculation of new born white mice with samples from a CCHF 
patient  in Astrakhan  in 1967 and the resulting virus strain (Drozdov) enabled 
researchers to develop the necessary reagents (e.g antigens and antibodies) for 
subsequent serological surveys and investigations of virus isolates from several 
different geographic regions (Chumakov, Butenko et al. 1968; Whitehouse 2004). In 
1969 it was shown that the virus isolated in Crimea in 1945 was antigenically 
indistinguishable from a virus isolated from human patients from the Congo and 
Uganda in 1956, and the virus was renamed Crimean Congo haemorrhagic fever 
virus (CCHFV) (Hoogstraal 1979; Simpson, Knight et al. 1967; Woodall, Williams et al. 
1967; Casals 1969).  
The outbreak of CCHF in Crimea in 1945 was the first full medical description 
of this disease that brought it to the attention of modern medical science. However 
references have been found in several scholarly texts which date from as far back as 
the 12th century to a human disease circulating in the region that is present day 
Tajikistan. This disease presented with haemorrhagic symptoms (the presence of 
blood in the urine, vomit, gums, rectum, and sputum) and was associated with ticks 
(Semiatkovskaia and Sidtdykova 1950; Shapiro and Barkagan 1960; Hoogstraal 1979, 
Whitehouse 2004). In southern Uzbekistan a disease that is likely to be CCHFV has 
been known for centuries under several different names including khungribta (blood 
taking) and khunymuny (nose bleeding) (Chumakov 1974; Whitehouse 2004). It is 
therefore probable that CCHFV has been circulating in human populations in Asia for 
centuries. However, the recent expansion of the geographic range of this virus, and 
the increase in the number of countries in which CCHFV is now considered to be 
endemic, is a cause for concern. As a result CCHFV is now described as an emerging 
virus. 
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Hazara virus (HAZV) was first isolated from Ixodes redikorzevi ticks collected from a 
mountain vole (Alticola roylei) in the Kaghan Valley, Hazara District, Western Pakistan 
in 1964 (Begum, Wisseman et al. 1970; Begum, Wisseman et al. 1970). This strain of 
HAZV (JC280) was isolated in suckling mice, and antigen and immune serum from 
these mice were shown to cross react strongly in neutralisation assays with CCHFV, 
but not in the haemagglutination inhibition or complement fixation assays (Begum, 
Wisseman et al. 1970), indicating that HAZV was serologically related to, but a distinct 
virus from CCHFV. Similar to CCHFV, HAZV was lethal when suckling mice were 
inoculated intracerebrally, with the highest viral loads detected in the brain and liver 
(Smirnova, Shestopalova et al. 1977). In contrast to CCHFV, HAZV has not been 
documented to infect or cause disease in humans and current knowledge regarding 
the global distribution of HAZV is limited.  
 
1.1.2 Classification 
 
CCHFV and HAZV are both members of the Bunyaviridae family (ICTV), which 
together with members of the Arenaviridae and Orthomyxoviridae family are 
collectively known as the segmented negative-strand RNA viruses (sNSVs) by virtue 
of their multiple genome segments. The Bunyaviridae family is one of the largest virus 
families, containing over 350 named species, which are classified into five genera, the 
Orthobunyaviruses, Tospoviruses, Phleboviruses, Hantaviruses and Nairoviruses. 
CCHFV and HAZV both belong in the Nairovirus genus. Defining features of members 
of the Bunyaviridae family include the possession of a segmented genome containing 
three RNA segments of negative sense or ambi-sense polarity, a cytoplasmic 
replication strategy and a spherical virion morphology of 90-120 nm in diameter 
(Walter and Barr 2011). The three genomic segments are termed small (S), medium 
(M) and large (L), based on their relative sizes, and bunyaviruses share fundamental 
mechanisms of RNA synthesis (Walter and Barr 2011).  
Viruses within the Bunyaviridae family are arthropod and rodent-borne, 
infecting animals, plants, humans, and insects. Viruses within the Tosposvirus genus 
infect plants and are predominantly transmitted by thrips, and viruses within the 
Hantavirus genus are transmitted by rodents; humans become infected primarily 
through inhalation of aerosolised virus particles present in rodent excrement and 
saliva (Song, Baek et al. 2007). Viruses in the Orthobunyavirus, Phlebovirus and 
Nairovirus genus are arthropod-borne and are transmitted by ticks, mosquitos, midges 
and sandflies (Walter and Barr 2011).  
Noteworthy human pathogens of the Orthobunyavirus genus include 
Oropouche virus, which causes Oropouche fever, a febrile disease often associated 
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with headache, dizziness, weakness, myalgias (muscle pain) and arthralgias (joint 
pain) (Pinheiro, Travassos da Rosa et al. 1981; Aguilar, Barrett et al. 2011). 
Oropouche virus (OROV) is transmitted by mosquitos and midges and is widespread 
in South America, with >30 epidemics reported between 1960-2009, causing 
significant morbidity with over half a million people estimated to have been infected 
(Vasconcelos, Nunes et al. 2011). Bunyamwera virus (BUNV), the prototypic member 
of the Orthobunyaviruses also causes febrile illness, the symptoms of which include 
headache, arthalgias, rash, and infrequent nervous system involvement (Aguilar, 
Barrett et al. 2011). La Crosse virus is the leading cause of paediatric encephalitis in 
North America, and Tahyna virus causes an influenza-like syndrome in central Europe 
(McJunkin, de los Reyes et al. 2001; Gould, Higgs et al. 2006).  
In the Phlebovirus genus, Rift Valley fever virus (RVFV) is a human pathogen 
endemic to sub-Saharan Africa, generally causing an influenza-like illness; however in 
~1% of cases patients develop haemorrhagic manifestations, which have a 50% case 
fatality rate (Boshra, Lorenzo et al. 2011; Raymond, Piper et al. 2012). Various 
member of the Hantavirus genus are known to be pathogenic to humans (Hantaan 
virus, Seoul virus, Puumala virus, Sin nombre virus) causing two distinct disease 
syndromes: haemorrhagic fever with renal syndrome (HFRS) and hantavirus cardio-
pulmonary syndrome (HCPS) (Manigold and Vial 2014, Walter and Barr 2011). 
Members of the Tospovirus genus (e.g Tomato spotted wilt virus, the most important 
plant virus in economic terms) cause significant losses in yield and quality of produce 
of legume, vegetable and ornamental crops from many different countries in Africa, 
Asia, North America, Europe and Australasia (Pappu, Jones et al. 2009). 
 Within the Nairovirus genus, the most significant human pathogen is CCHFV. 
The Nairovirus genus is separated from other bunyavirus genera by their large L 
segments and includes seven different serogroups of tick transmitted viruses, which 
contain 43 virus strains; the CCHF serogroup contains only CCHFV and HAZV (Bente, 
Forrester et al. 2013, Whitehouse 2004, ICTV). The other Nairovirus serogroup 
containing human pathogens is the Nairobi sheep disease group, which includes 
Nairobi sheep disease virus; this is primarily a pathogen of sheep and goats, causing 
severe haemorrhagic gastroenteritis (but has been known to infect humans), and 
Dugbe virus, which causes a mild febrile illness and thrombocytopenia in humans 
(Burt, Spencer et al. 1996, Marczinke and Nichol 2002).  
Individual viruses are classified into the 5 genera within the Bunyaviridae 
family based on similar segment lengths and protein sizes, the presence of conserved 
nucleotide sequences within each segment termini and the segment coding strategy 
used to express viral proteins. For example members of the Phlebovirus genus 
encode a non-structural protein (NSs) generated by an ambisense coding strategy of 
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the S segment, whereas members of the Nairovirus genus do not encode an NSs 
protein (Walter and Barr 2011). 
 
1.1.3 The CCHFV Tick vector and mammalian host life cycle 
 
CCHFV is a zoonotic virus, in nature CCHFV cycles between tick and vertebrate hosts; 
humans become infected when they are bitten by an infected tick, or come into 
contact with the blood of an infected animal or human (Figure 1.2). CCHFV is 
maintained within several species of Ixodes (hard) ticks (Hyalomma, Rhipicephalus 
and Dermacentor ticks), although ticks of the Hyalomma genus (Figure 1.1) are 
thought to be the principle source of human infection; indeed the global distribution of 
Hyalomma ticks closely mirrors that of CCHF incidence (Bente, Forrester et al. 2013; 
Yesilbag, Aydin et al. 2013).  
 
 
                             
 
Figure 1.1 Female Hyalomma dromedarii tick 
Ticks of the Hyalomma species are thought to be the principle source of human 
CCHFV infection. Photograph courtesy of Alan Walker. 
 
 
Ticks become infected with CCHFV when they take a blood meal to acquire the 
nutrients they need for metamorphosis from larvae to nymph to adult; ticks need to 
acquire these nutrients once during every developmental stage. In addition, adult 
female ticks also need a blood meal to acquire the nutrients required to produce eggs 
(Bente, Forrester et al. 2013). Once a tick has become infected with CCHFV it 
remains infected throughout its lifetime; CCHFV is maintained throughout 
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metamorphosis from larvae to nymph to adult and is transmitted to other ticks through 
trans-ovarial (passed from adult females into their eggs), and venereal routes 
(transmitted through copulation) (Dohm, Logan et al. 1996). In addition, CCHFV can 
also spread directly to other ticks through the mechanism of co-feeding, which 
involves the transference of CCHFV from an infected tick feeding on a vertebrate host 
directly through their saliva to another tick feeding nearby on the same infected host 
(Jones, Davies et al. 1987; Nuttall and Labuda 2003; Nuttall and Labuda 2004). This 
is also known as ‘non-viraemic’ transmission, and enhances the efficiency of virus 
spread since it does not require CCHFV to reach the certain titre in infected 
vertebrates required to initiate infection in ticks (a factor that varies among different 
ticks hosts), and overcomes the transmission barrier due to the fact that not all the 
mammalian hosts that ticks feed on are susceptible to CCHFV infection (Bente, 
Forrester et al. 2013). 
Several members of the Hyalomma genus are two-host ticks; they feed on 
small animal hosts (generally hares, ground-feeding birds, and rodents) as larvae and 
nymphs; adult ticks feed on large animal hosts (both domestic animals such as cattle 
and sheep, and wild animals such as deer) and mate while attached to the host 
(Figure 1.2). When mammalian hosts become infected with CCHFV they display a 
transient, asymptomatic viraemia which is resolved in 1-2 weeks (Bente, Forrester et 
al. 2013). CCHFV can replicate in a wide variety of wild and domestic animals (horses, 
donkeys, sheep, cattle, scrub hares, mice, rats and ostriches) in the absence of any 
clear signs of illness (Smirnova 1979, Bente, Forrester et al. 2013). CCHFV is capable 
of being transmitted from ticks to mammals; naïve ticks can then become infected 
when they feed on the blood of a viraemic animal (Figure 1.2). Humans however, are 
not a source of infection for ticks and are therefore thought to be only accidental or 
‘dead-end’ hosts for the virus (Bente, Forrester et al. 2013). Ticks are considered to 
be the true natural reservoirs for CCHFV as ticks remain infected with CCHFV 
throughout their several-year long life spans. 
 
 
 
Chapter 1: Introduction 
6 
 
 
 
Figure 1.2 The natural life cycle of Hyalomma ticks 
The life cycle of Hyalomma spp. requires both a small animal host (3) and a large 
animal host (5). A CCHFV infected tick maintains CCHFV replication for the duration 
of its life cycle, and females transmit CCHFV to their offspring transovarially. Humans 
become infected with CCHFV when they are bitten by an infected tick at any stage of 
the tick lifecycle, however questing adult Hyalomma ticks are considered to be the 
main source of human infection.    
 
 
CCHFV has also been detected in other arthropod vectors such as biting midges, 
however this probably reflects the recent feeding of the biting midge on a CCHFV 
infected mammalian host, as there is no evidence that CCHFV is maintained 
throughout the lifecycle of any other arthropod host, or that any other arthropod apart 
from an Ixodid tick is a competent vector (Causey, Kemp et al. 1970). 
 
1.1.4 HAZV mammalian hosts 
 
Although the natural mammalian hosts of HAZV are largely unknown, antibodies 
against HAZV have been detected in wild rodent sera (Darwish, Hoogstraal et al. 
1983). In a similar manner to CCHFV, experimentally HAZV has been shown to 
replicate in a variety of mammals including various species of mice and rats, guinea 
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pigs, rabbits, and donkeys, amongst others (Smirnova 1979). In the case of both 
CCHFV and HAZV, the only animals that display clinical symptoms and die are 
suckling mice (Smirnova, Shestopalova et al. 1977; Bente, Forrester et al. 2013). 
Excluding the Ixodes redikorzevi ticks from which HAZV was first isolated, there have 
been no further reports of other tick species maintaining HAZV replication.  
 
1.1.5 Epidemiology and Geographic range of CCHFV 
 
CCHF is the most geographically widespread tick borne human viral disease and 
CCHFV is the second most widespread of all medically important arboviruses (insect-
borne viruses) after Dengue virus (Appannanavar and Mishra 2011). The known 
geographic distribution of CCHFV now ranges from western China, throughout Asia 
and the Middle East, across South Eastern Europe and throughout most of Africa 
(Mild, Simon et al. 2010). After CCHFV was first described in Crimea in 1945, the 
majority of reported cases initially originated from the former Soviet Union and 
Bulgaria (Appannanavar and Mishra 2011). Outbreaks of CCHF were then reported 
from several African countries such as the Democratic Republic of the Congo, 
Uganda and Mauritania. Middle Eastern countries such as Iraq, the United Arab 
Emirates and Saudi Arabia also reported a significant number of cases, and more 
recently, a large number of CCHF cases have been reported from Pakistan, Iran, 
Bulgaria and Turkey (Appannanavar and Mishra 2011).    
Currently 52 countries are recognised as endemic or potentially endemic 
regions; most endemic countries report a number of human CCHF cases every year; 
some only report evidence of CCHFV circulation through the recovery of CCHFV RNA, 
or live virus, from wild or domestic animals, or from ticks (Appannanavar and Mishra 
2011; Bente, Forrester et al. 2013). In some countries evidence of CCHFV circulation 
is based on detection of CCHFV specific antibodies in serosurveys of humans and 
animals. Figure 1.3 is taken from the World Health Organisation (WHO) website and 
shows the known global distribution of CCHFV in 2008 as well as the underlying 
evidence for the circulation of CCHFV in these regions. 
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Figure 1.3 Geographic distribution of CCHFV   
More than 50 human cases of CCHF are reported annually to the WHO by countries 
coloured red, whereas fewer than 50 annual cases are reported by countries coloured 
orange. Human cases of CCHFV have not been reported by countries coloured yellow, 
but CCHFV has been isolated from ticks or animals in these countries, or the 
presence of CCHFV has been inferred from serological studies, and a competent 
CCHFV tick vector has also been detected. The northernmost limit of Hyalomma 
marginatum and Hyalomma asiaticum tick species is indicated. The figure is taken 
from the World Health Organisation (WHO) website 
(http://www.who.int/csr/disease/crimean_ congoHF).    
 
 
CCHF is considered to be an emerging disease due to a recent increase in both the 
number of cases of CCHF in countries where CCHF is endemic, and an increase in 
the number of countries where CCHFV is now considered to be endemic. The first 
reported case of CCHF in Turkey was documented in 2002 and since then there have 
been over 6000 reported cases, representing a special case of CCHF epidemiology 
(Karti, Odabasi et al. 2004, Bente, Forrester et al. 2013). The first CCHF case was 
reported in Greece in 2008; a person who was living close to the Bulgarian border 
was bitten by a tick and subsequently developed a haemorrhagic fever (Papa, Dalla et 
al. 2010) and more recently CCHFV RNA was isolated from ticks in Spain in 2010 
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(Estrada-Pena, Palomar et al. 2012). The CCHFV tick vector (adult Hyalomma 
marginatum) has been identified on livestock in Hungary and Romania, demonstrating 
these ticks can survive and replicate in more northern regions than had previously 
been documented, and in 2013 ticks of the Hyalomma species were identified in 
Cornwall in the UK (Jameson and Medlock 2011; Ceianu, Panculescu-Gatej et al. 
2012; Hornok and Horvath 2012; Bente, Forrester et al. 2013).  
The expanding geographic distribution of the CCHFV tick vector increases the 
possibility that the geographic range of the disease might also expand as the global 
distribution of CCHFV closely mirrors that of its primary vector. People most at risk of 
developing CCHFV include those with an increased risk of exposure to tick bites, such 
as agricultural workers and foresters, as well as abattoir workers, veterinarians and 
hospital staff, who come into contact with the blood of potentially infected animals or 
humans.  
The majority of reported cases of CCHFV occur as sporadic, isolated incidents, 
however occasionally larger outbreaks occur, such as the infection of 200 Soviet 
soldiers in 1944 (M. P. Chumakov 1945). Nosocomial outbreaks of infection in 
hospital workers who do not employ appropriate barrier nursing methods are also 
common in countries where CCHFV is endemic. This can be illustrated by the central 
government hospital in Pakistan, where a nosocomial outbreak of CCHF occurred in 
1976 (Hoogstraal 1979; Burney, Ghafoor et al. 1980). A shepherd was admitted 
displaying typical CCHF symptoms and was operated on the day of his admission, but 
died later that night. His father, who was caring for him at home, died of CCHF two 
days later despite intensive care and repeated blood transfusions. Of the 12 hospital 
staff who came into contact with, or treated the shepherd, 10 became ill with CCHF 
and were hospitalised, two of these died (a nurse who assisted during the operation 
died three days later, and the surgeon, who cut his finger during the operation, died 
two weeks later) and 8 eventually recovered after becoming severely ill (including the 
doctor who admitted the shepherd after he vomited blood on her hands and face, and 
an assistant surgeon who pricked his finger whilst operating) (Whitehouse 2004). 
Incidences such as this highlight the threat posed to medical personnel by CCHFV 
and illustrate why CCHF is considered to be such a public health problem in countries 
where the virus is endemic.  
Excluding the Ixodes redikorzevi ticks found in the Kaghan valley in Western 
Pakistan from which HAZV was originally isolated, and the anti-HAZV antibodies 
detected in the sera of a wild jird (a gerbil-like mammal) found in the lowland, semi-
arid environment of Pakistan, there have been no further reports of HAZV being 
isolated from any other country. Knowledge regarding the known geographic 
distribution of HAZV therefore remains limited. 
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 1.1.6 Genetic diversity and evolution 
 
Isolates of CCHFV show great genetic diversity, ranging from 20 % nucleotide 
sequence differences between viral S segments, to 31 % nucleotide sequence 
differences between viral M segments (Bente, Forrester et al. 2013). Several 
processes are thought to contribute to the present genetic diversity of CCHFV 
including genetic drift, reassortment, recombination, and long distance virus transport. 
Genetic drift is proposed to be caused by an error prone viral RNA dependent RNA 
polymerase (RdRp) which has helped the adaptation of CCHFV to many different 
vertebrate and tick hosts by introducing random sequence changes to the genome, 
thereby providing the fundamental diversity needed for the evolution of CCHFV (Bente, 
Forrester et al. 2013). This has contributed to the emergence of 6-7 discrete CCHFV 
lineages or clades, which have several labels assigned to them by various 
investigators, including the designation by Atkinson et al who refer to them as Africa 1, 
Africa 2, Africa 3, Asia 1, Asia 2, Europe 1 and Europe 2 (Atkinson, Chamberlain et al. 
2012; Atkinson, Latham et al. 2012). These clades are thought to have arisen due to 
the fact that CCHFV and its tick vectors are endemic in several different geographic 
regions. Tick species have evolved separately in these regions as they have different 
climates and vegetation. It is thought the co-evolution of CCHFV with region specific 
ticks has resulted in the generation of many different local virus isolates, which gave 
rise to the different clades (Bente, Forrester et al. 2013).  
There is evidence that genetic reassortment occurs between different CCHFV 
strains; the genome of CCHFV is tripartite and simultaneous infection of the same 
host with multiple strains of CCHFV can result in the generation of viruses with novel 
combinations of S, M and L segments (Hewson, Gmyl et al. 2004; Burt, Paweska et al. 
2009). Reassortment is thought to occur within the tick host as ticks remain infected 
with CCHFV throughout their life spans, whereas replication of CCHFV within 
mammals is transient and mammals are only viraemic for 1-2 weeks. It is therefore 
more likely for a tick to become simultaneously infected with two different strains of 
CCHFV to allow reassortment to occur (Davies, Jones et al. 1987; Jones, Davies et al. 
1987). M segment reassortment is detected most frequently and it is thought that 
viruses which contain an RdRp and N protein that have co-evolved together replicate 
more efficiently than those viruses whose RdRp and N protein have not co-evolved 
with each other (Chamberlain, Cook et al. 2005; Goedhals, Bester et al. 2014).  
Genetic reassortment has the potential to create CCHFV strains with novel 
phenotypes, such as an altered ability to be transmitted between vertebrate and tick 
hosts, or an increased pathogenicity in humans; a phenomenon that has been 
detected in other bunyaviruses. A recently detected member of the Orthobunyavirus 
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genus has been associated with outbreaks of haemorrhagic fever in Somalia and 
Kenya and was named Ngari virus (Bowen, Trappier et al. 2001; Gerrard, Li et al. 
2004; Briese, Bird et al. 2006). Genetic analysis revealed Ngari virus was composed 
of the M segment of Batai virus, and the S and L segments of Bunyamwera virus. 
Iquitos virus (specifically the IQT9924 strain) was associated with cases of febrile 
illness in Peru and was shown to be a novel reassortment of the S and L segments of 
Oropouche virus, genotype II, and the M segment of a still unidentified Simbu-
serogroup virus (Aguilar, Barrett et al. 2011). 
Long distance virus transport is thought to contribute to the genetic diversity of 
CCHFV through the introduction of CCHFV strains to regions that were previously 
naïve to them. This increases the possibility that a vertebrate or tick host may become 
simultaneously infected with two different strains of CCHFV and enables the possible 
emergence of new virus strains through reassortment and recombination (Mild, Simon 
et al. 2010). Evidence of long distance virus transport can be seen through the 
analysis of CCHFV phylogenetic trees; these reveal that several clades contain virus 
isolates with similar sequences that originate from very distant geographic regions. 
Long distance movement of CCHFV strains is thought to occur when migratory birds 
transport CCHFV infected ticks to different geographic regions, and through 
international livestock trading between countries (Carroll, Bird et al. 2010; Mild, Simon 
et al. 2010).  
There is also evidence that recombination has taken place between CCHFV 
strains; sequence alignment of genome segments reveals the interruption of the 
nucleotide sequence of a particular CCHFV strain, and its replacement with the 
sequence of a different strain, which suggests that strand exchange took place 
through recombination between different CCHFV isolates (Hewson, Chamberlain et al. 
2004; Lukashev 2005; Bente, Forrester et al. 2013).  
 
1.1.7 CCHF symptoms and pathogenesis in humans  
 
Humans become infected with CCHFV through several different routes, including 
through the bite of an infected tick, by crushing an engorged infected tick or through 
contact with the infected body fluids of a viraemic animal or human (Whitehouse 2004; 
Bente, Forrester et al. 2013). Following an incubation period typically lasting 1-6 days 
(however there have been reports of incubation periods lasting > 13 days (Kaya, 
Engin et al. 2011)), the onset of symptoms of CCHF is rapid, and are typified by a 
sudden onset of high fever (39-41 °C), headache, myalgia and arthralgia, fatigue, and 
dizziness. The onset of symptoms may also include nausea, vomiting and diarrhoea. 
This is known as the prehaemorrhagic phase and typically lasts 3-7 days. These initial 
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symptoms are sometimes described as ‘general influenza-like symptoms’ (Ergonul 
2008) and are not specific to CCHF, therefore early misdiagnosis is common; it has 
been estimated that ~2/3 patients with CCHF are initially misdiagnosed (Tasdelen 
Fisgin, Doganci et al. 2010).  
The haemorrhagic phase of infection follows in severe cases of CCHF, 
frequently beginning with a petechial rash which develops into ecchymosis. 
Uncontrolled bleeding from the gums and nose is common (gingival haemorrhage and 
epistaxis) and is sometimes followed by haemorrhagic involvement of the airways, 
gastrointestinal tract, brain and urinary tract. This haemorrhagic phase lasts 2-3 days, 
and it is during this stage that patients die, often due to shock, haemorrhage, severe 
liver necrosis and multi-organ failure (Burt, Swanepoel et al. 1997). For those who 
survive, the final stage of CCHF disease is convalescence, which typically begins 10-
20 days after symptom onset and is lengthy, often involving clinical symptoms such as 
breathing impairment, poor vision, loss of hearing, loss of memory, polyneuritis and 
tachycardia. Fortunately these sequelae are scarcely ever permanent (Ergonul 2008; 
Bente, Forrester et al. 2013; Zivcec, Safronetz et al. 2013).  
Hallmarks of CCHFV infection include leukopenia, thrombocytopenia, 
increased serum levels of proinflammatory cytokines and chemokines, and elevated 
serum levels of liver enzymes (transaminase alanine aminotransferase or ALT) (Cevik, 
Erbay et al. 2007). These, as well as high viral loads, increased clotting times and low 
antibody titres correlate with disease severity, and can be used to predict a fatal 
outcome in up to 90% cases (Ergonul, Tuncbilek et al. 2006; Papa, Bino et al. 2006; 
Duh, Saksida et al. 2007; Cevik, Erbay et al. 2008; Weber and Mirazimi 2008; Onguru, 
Dagdas et al. 2010; Saksida, Duh et al. 2010). A viral load of > 109 copies/mL is a 
strong factor (p < 0.001) for differentiating CCHF patients who die from those who 
survive (Cevik, Erbay et al. 2007). It has been suggested that the ability of CCHFV to 
replicate to such high copy numbers in the blood may be a contributing factor to the 
propensity of CCHFV to be transmitted nosocomially; other arboviruses such as 
Dengue virus, which are not commonly transmitted nosocomially do not replicate to 
such high levels (Chen and Wilson 2004).  CCHF has been reported to be fatal in 5-
70% cases. This large range of case fatality rates has been attributed to several 
different factors, including the mode of transmission, as well as improved diagnostics 
and raised awareness of CCHF; this increases detection of mild cases of CCHF, 
which may not present with haemorrhagic manifestations (Atkinson, Chamberlain et al. 
2013).  
Patients who die from CCHF generally have an absent or weak antibody 
response and high levels of pro-inflammatory cytokines (Bente, Forrester et al. 2013). 
Cytokines are important factors influencing the pathogenesis of viral haemorrhagic 
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fevers and cytokine levels often correlate with disease severity. During the course of 
CCHFV infection patient serum levels of TNFα (tumor necrosis factor alpha), IL-6 
(interleukin 6) and IL-10 are elevated, however significantly higher levels of TNFα and 
IL-6 are seen in patients with fatal outcome, than in non-fatal cases (Ergonul, 
Tuncbilek et al. 2006; Papa, Bino et al. 2006). Other cytokines thought to play a role in 
CCHF pathogenesis include IFN-γ, IL-1β and CCL-2; IL-1β is a major mediator of 
innate immune reactions and CCL-2 is a marker of severe disease in murine and 
primate models of Ebola virus (Dinarello 1996; Geisbert, Hensley et al. 2003). It was 
hypothesised that as CCHFV infects primarily macrophages and dendritic cells the 
high levels of IFN-1β and CCL-2 expression enhances virus infection by recruiting 
these cells to sites of inflammation at the beginning of the infection, enabling 
increased CCHFV replication and dissemination (Bente, Alimonti et al. 2010; 
Peyrefitte, Perret et al. 2010). 
The pathogenesis resulting from CCHFV infection is still not completely 
understood and a lot of what is known is derived from human case studies and some 
in vitro experiments, as well as being extrapolated from what is known about other 
haemorrhagic fever viruses. Hepatocytes, Kupffer cells, endothelial cells, 
macrophages and dendritic cells are all targets for CCHFV infection (Burt, Swanepoel 
et al. 1997; Peyrefitte, Perret et al. 2010). During severe CCHFV infection 
erythrocytes and plasma leak from the vascular system into surrounding tissues 
(Ergonul 2006; Karlberg, Tan et al. 2011). In the case of CCHF this vasculature 
dysfunction is linked to endothelial cell destruction, which can lead to capillary fragility, 
and can cause deregulated stimulation of platelet aggregation and degranulation, 
which can impair the bloods ability to clot, and lead to haemorrhages through 
activation of the intrinsic coagulation cascade (Schnittler and Feldmann 2003; 
Karlberg, Tan et al. 2011). It is not known whether the destruction of endothelial cells 
seen during CCHF is a direct result of CCHFV infection of these cells, or an indirect 
consequence of virus induced host factors, such as high levels of pro-inflammatory 
cytokines. A correlation has been observed between disease severity, vascular 
leakage and the strength of the proinflammatory response during infection with other 
haemorrhagic fever viruses (Bray and Mahanty 2003; Schnittler and Feldmann 2003; 
Karlberg, Tan et al. 2011). In addition, varying degrees of hepatic damage have been 
observed histopathologically in human CCHF patients, ranging from mild to more 
severe necrosis (Joubert, King et al. 1985; Burt, Swanepoel et al. 1997).  
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1.1.8 The CCHFV mouse model 
 
In 2010 two different transgenic mouse models, an interferon α/β (type 1) receptor 
knockout mouse (IFN-α/βR-/-), and a STAT1 (signal transducer and activator of 
transcription 1 protein) knockout mouse, were evaluated for their ability to recapitulate 
human CCHF disease (Bente, Alimonti et al. 2010; Bereczky, Lindegren et al. 2010). 
The pathogenesis reported from the STAT-1 and IFN-α/βR-/- mouse models shows a 
similar disease progression to human CCHFV infection, beginning with elevated body 
temperature, and the detection of leukopenia and thrombocytopenia on day 1 post 
infection. Increased serum levels of liver enzymes, such as liver transaminase alanine 
aminotransferase (ALT) are also detected in CCHFV infected STAT-1 and IFN-α/βR-/- 
mice, as well as a significant increase in serum levels of various proinflammatory 
cytokines and chemokines.   
Similar to fatal human cases of CCHF, high levels of viraemia were detected in 
both mouse models by quantitative RT-PCR, reaching 7.32 x 109 GEQ/mL (genome 
equivalents per mL) at day 3 post infection in the STAT 1 knock out mouse model 
(Bente, Alimonti et al. 2010). In both mouse models immunohistochemical analysis 
revealed the presence of viral antigen in the liver and spleen with hepatocytes, 
Kupffer cells, occasionally the endothelial lining of sinusoids, and macrophages 
staining positive (Zivcec, Safronetz et al. 2013). The intensity and the frequency of the 
CCHFV antigen-positive cells in the liver increased until death, when severe liver 
damage could be detected.   
Evidence of haemorrhages were not detected in either mouse model, in 
contrast to human disease, where haemorrhaging, especially intestinal 
haemorrhaging is common. This may be linked to the rapid disease progression in 
mice or differences in the murine and human coagulation cascades (Bente, Alimonti et 
al. 2010). However, both mouse models faithfully reproduce major hallmarks of 
human disease and currently represent the most appropriate animal models of CCHF, 
despite the limitations of the model due to the impaired IFN and immune response 
phenotypes (Bente, Alimonti et al. 2010; Bereczky, Lindegren et al. 2010). 
 
1.1.9 The HAZV mouse model 
 
The IFN-α/βR-/- mouse was also susceptible to HAZV infection, where a dose-
dependent, lethal disease similar to CCHF was observed (Dowall, Findlay-Wilson et al. 
2012). Similar to CCHFV infection, all mice inoculated with the highest virus dose 
(4x104 pfu) died, whereas wild type mice inoculated with this virus dose survived with 
no clinical signs of disease. Consistent with CCHFV infected mice, the target organs 
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of HAZV were also the liver and spleen; the highest viral titre was detected in these 
organs day 3 post infection, and histopathological changes were observed in the liver 
and spleen that were similar to those resulting from CCHFV infection (Dowall, Findlay-
Wilson et al. 2012). As HAZV infection of IFN-α/βR-/-  mice follows a similar disease 
course to CCHFV, HAZV could be used as a model for CCHFV infection with the aim 
of rapidly assessing potential therapeutics and vaccines against CCHFV, without 
having to work under containment level 4 conditions (Dowall, Findlay-Wilson et al. 
2012).   
 
1.1.10 CCHF diagnosis, treatment and vaccine 
 
CCHF is diagnosed through the detection of viral RNA in patient serum samples with 
specific RT-PCR and quantitative RT-PCR assays. Enzyme linked immunosorbant 
assays (ELISA) are also used to detect virus specific IgM or IgG antibodies (Bente, 
Forrester et al. 2013). The most reliable method of diagnosis is considered to be 
detection of viral RNA by RT-PCR however, as severely ill patients often fail to 
develop an antibody response and therefore will not test positive in an ELISA 
(Shepherd, Swanepoel et al. 1989; Burt, Leman et al. 1994). In addition, quantitative 
RT-PCR provides a measurement of viral load and therefore also enables a prediction 
of disease severity and likelihood of death (Saksida, Duh et al. 2010). A recently 
developed RT-PCR assay targets a highly conserved portion of the 5’ non-translated 
region of the viral S segment, that is required for the ‘panhandle’ formation and 
genome replication (Atkinson, Chamberlain et al. 2012). This RT-PCR assay is able to 
detect virus strains in all 7 clades and allays concerns that a sequence specific 
diagnostic assay may fail to detect all strains of CCHFV, based on the high genetic 
diversity of the virus (Duh, Saksida et al. 2006). 
The majority of people infected with CCHFV are either asymptomatic or 
develop a nonspecific febrile illness that does not require hospitalisation; for those few 
who fall severely ill treatment is largely supportive. Ribavirin has been used in the 
treatment of CCHFV patients for decades and has been reported to be beneficial in 
most cases, as long as it is administered early on during the course of infection 
(Ergonul, Celikbas et al. 2004). However a recent review of human cases where 
ribavirin was used to treat CCHF patients concluded that the quality of the evidence 
was low, and a randomised clinical trial was unable to show that ribavirin treatment 
had any significant effect on CCHF disease progression (Koksal, Yilmaz et al. 2010; 
Soares-Weiser, Thomas et al. 2010). When administered to CCHFV infected IFNα/βR-
/- mice, ribavirin prolonged the time until death, but did not prevent it (Oestereich, 
Rieger et al. 2014). The efficacy of ribavirin treatment therefore remains unclear. 
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CCHFV is considered to be interferon sensitive, and human IFN was administered to 
6 patients during the Tygerberg outbreak in South Arica however no benefit was 
observed (Joubert, King et al. 1985). There is therefore an urgent need to develop 
novel therapeutics for CCHF. The IFNα/βR-/- mouse was recently used to test the 
efficacy of the drug T705 (favipiravir; currently in late stage clinical trials as an antiviral 
against influenza virus infection) during CCHFV infection; T705 protected 100 % mice 
against lethal challenge with CCHFV when administered 1 hr, or up to 2 days post 
exposure (Oestereich, Rieger et al. 2014).   
There is no vaccine available for CCHFV that has been licensed by the 
European Medicines Agency, or the US Food and Drug Administration. A formalin 
inactivated mouse-brain derived vaccine has however, been in use in Bulgaria since 
the 1970’s/1980’s. The Bulgarian V42/81 vaccine strain is administered to soldiers, 
medical personnel and other high risk groups in endemic regions (Papa, Christova et 
al. 2004; Papa, Papadimitriou et al. 2011). This vaccine effectively protected 
inoculated individuals (CCHFV has never been reported in any vaccinated individuals) 
however, controlled studies on the protective efficacy of this vaccine have not been 
performed, and it is unlikely to gain widespread international approval due to its crude 
preparation.  
Recent efforts to develop a more effective vaccine have focused on using a 
recombinant vaccine based on Modified Vaccinia virus Ankara (MVA), which is a 
poxviral vector and can tolerate the insertion of the cDNA corresponding to the 
CCHFV M segment (Buttigieg, Dowall et al. 2014). The CCHFV M segment encodes a 
large polyprotein precursor, which is proteolytically cleaved to generate multiple 
different protein products, including the mature glycoproteins GN and GC. The 
recombinant MVA vaccine (MVA-GP) was tested in the recently described IFNα/βR-/- 
mouse model, and was shown to elicit both a cellular and humoral response against 
CCHFV challenge. The MVA-GP vaccine candidate protected all of the IFNα/βR-/- 
mice against lethal challenge with CCHFV, and it is hoped that the MVA-GP vaccine 
could provide the basis for a novel CCHFV vaccine that can meet modern 
international regulatory standards (Buttigieg, Dowall et al. 2014).  
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1.2 THE VIRUS  
 
1.2.1 Virion structure 
 
The virions of CCHFV and HAZV are enveloped, spherical and approximately 80-100 
nm in diameter (Martin, Lindsey-Regnery et al. 1985). The glycoproteins GN and GC 
protrude though the envelope creating ‘surface projections’ 5-10 nm in length, are 
responsible for virions binding to cellular receptors, and are the targets for neutralising 
antibodies (Bergeron, Vincent et al. 2007). The interior of the virions contain the viral 
ribonucleoprotein particles (RNPs); as previously stated, the genome of CCHFV and 
HAZV is encoded on 3 separate segments of negative sense RNA, termed the Large 
(L), Medium (M), and Small (S) segments, named according to their relative lengths. 
The RNA segments are encapsidated along their entire length by the nucleocapsid 
protein (N) to form functional RNPs. Viral RNPs are thought to have at least one copy 
of the viral RNA dependent RNA polymerase (RdRp, or L protein) associated with 
them, to initiate transcription and genome replication in the host cell. The cytoplasmic 
tails of the glycoproteins extend into the interior of the virion, and are thought to 
interact directly with the RNPs; this interaction is thought to be essential for virus 
assembly.  
It is assumed that each infectious particle must contain at least one copy of 
each of the RNPs. The RNPs within the virion are thought to be relatively unorganised 
(in contrast to influenza for example, where the 8 RNPs generally maintain the same 
array) which suggests that virion morphology is more likely to be dependent on lateral 
interactions between GN and GC heterodimers (Walter and Barr 2011). A schematic 
representation of CCHFV and HAZV virions is depicted in Figure 1.4 (A). An electron 
micrograph of HAZV (Figure 1.4 (B)) reveals the spherical morphology of these virions, 
and their relative sizes (Clerx, Casals et al. 1981; Ellis, Southee et al. 1981; Martin, 
Lindsey-Regnery et al. 1985).  
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Figure 1.4 Schematic representation of CCHFV and HAZV virions and electron 
micrograph of HAZV.  
 (A) Schematic representation of CCHFV and HAZV virions depicting the glycoprotein 
spikes of GN and GC in the virus envelope, surrounding the 3 viral RNPs, with attached 
L proteins. (B) Electron micrograph of HAZV virions, taken by (Clerx, Casals et al. 
1981).  
 
   
1.2.2 CCHFV and HAZV genome structure 
 
One of the interesting features of segmented negative sense RNA viruses (sNSVs) is 
the fact that their genomes are never found as naked RNA, but instead are always 
encapsidated by the viral nucleocapsid protein (N) (Green, Cox et al. 2014). The three 
genomic RNA segments possessed by CCHFV and HAZV are organised in a similar 
fashion across all 5 genera of the Bunyaviridae family; each segment termini contains 
3’ and 5’ non-translated regions (NTRs) that surround an open reading frame (ORF) 
(Figure 1.5) (Walter and Barr 2011). In members of the same genus the length of 
each RNA segment is similar, and the nucleotide sequence of the extreme 3’ and 5’ 
termini of each segment is highly conserved and invariant (Table 1). All members of 
the Nairovirus genus have the following nucleotides at the extreme 3’ and 5’ termini of 
A 
B 
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each of the 3 genome segments: 3’ –AGAGUUUCU and 5’-UCUCAAAGA (Walter and 
Barr 2011).  
There is extensive nucleotide complementarity between the 3’ and 5’ NTRs of 
each segment, which interact with each other through canonical Watson-Crick base 
pairing, to form an open circular panhandle structure. Bunyavirus RNA segments exist 
as open circular molecules both within virus particles and infected cells (Pettersson 
and von Bonsdorff 1975; Obijeski, Bishop et al. 1976; Raju and Kolakofsky 1989). 
Adjacent to the complimentary, conserved 11 nucleotides at the extreme 3’ and 5’ 
termini, there are additional complementary nucleotide motifs, which are shorter, and 
conserved only on a segment-specific basis. The interaction of the segment NTRs is 
essential in order to initialise RNA synthesis, as the promoters for RNA synthesis are 
thought to contain elements from both the 5’ and 3’ NTRs (Kohl, Dunn et al. 2004).  
 
 
 
 
Figure 1.5 Schematic representation of Nairovirus genomic segments. 
The genomic segments of CCHFV and HAZV (S, M and L) encode the N protein, viral 
glycoproteins GN  and GC and the RdRp, respectively. Each segment contains a single 
ORF, represented by horizontal black arrows, flanked by 3’ and 5’ NTRs. The NTRs 
possess both highly conserved 3’ and 5’ extreme termini nucleotide sequences (*), as 
well as non-conserved nucleotide sequences within the NTR regions (vertical arrows). 
 
 
In contrast to the extreme termini of the 3’ and 5’ NTRs, which show high sequence 
conservation, the internal nucleotides of the NTRs do not. There is much variation in 
the nucleotides sequences of these regions both among viruses in the same genera, 
and between genomic segments of the same virus (Walter and Barr 2011). Reverse 
genetic analysis has shown that the NTRs contain cis acting elements that are 
involved in regulating RNA synthesis and segment packaging for both BUNV and 
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RVFV (Barr, Elliott et al. 2003; Gauliard, Billecocq et al. 2006). In BUNV it was shown 
that 22 nucleotides at the genomic 3’ end and 113 nucleotides at the 5’ terminus 
within the unconserved regions of the segment NTRs were essential for infectious 
virus replication (Lowen and Elliott 2005). This implies that although many of these 
nucleotides are dispensable for virus replication, some sequences within segment 
specific NTRs are important for virus replication and affect virus fitness. During BUNV 
replication, the segment specific 3’ sequences were shown to mainly affect the 
balance of replication and transcription, whereas segment specific sequences at the 5’ 
regions predominantly affected overall virus growth (Lowen and Elliott 2005; Walter 
and Barr 2011).  
 
Table 1. Features of Bunyavirus genome segments used for virus classification 
 
Genus 
(prototype) 
Consensus terminal 
sequences 
Segment length (nts) 
S M L 
Nairovirus  
(Dugbe virus) 
3’-AGAGUUUCU… 
5’-UCUCAAAGA… 
1712 4888 12255 
Orthobunyavirus  
(Bunyamwera virus) 
3’-UCAUACCAUG… 
5’-AGUAGUGUGC… 
961 4458 6875 
Phlebovirus 
(Rift Valley fever virus) 
3’-UGUGUUUC… 
5’-ACACAAAG… 
1690 3885 6404 
Hantavirus 
(Hantaan virus) 
3’-AUCAUCAUCUG… 
5’-UAGUAGUAUGC… 
1696 3616 6533 
Tospovirus 
(Tomato spotted wilt virus) 
3’-UCUCGUUA… 
5’-AGAGCAAU… 
2916 4821 8897 
 
 
Rearrangement of the NTRs and ORFs of different BUNV genomic segments results 
in virus that cannot be rescued into infectious virus particles using the mini-genome 
replicon system; the only tolerated combination is when the L segment ORF is flanked 
by the M segment NTRs (MLM) (Lowen, Boyd et al. 2005). This suggests there is 
some kind of interplay between the NTRs and the ORF; in the MLM recombination, 
rescued virus had 100-fold decreased titres, and a greatly increased particle to plaque 
forming unit ratio, indicating there may be a reduced incorporation of MLM segments 
into infectious virus particles (Lowen, Boyd et al. 2005). The sequences at the 
NTR/ORF boundaries may therefore play a role in segment packaging, similar to 
Influenza packaging (Fujii, Goto et al. 2003; Fujii, Fujii et al. 2005; Walter and Barr 
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2011). Although not much is known about the specific NTR sequence requirements of 
CCHFV and HAZV, they are likely to play a similar role to those of BUNV during the 
virus replication cycle as organisation of the genomic segments is similar across the 
Bunyaviridae family. 
 
1.3 THE REPLICATION CYCLE OF CCHFV 
 
The replication cycle of CCHFV and HAZV takes place in the cytoplasm of infected 
cells. An overview of the CCHFV replication cycle is presented diagrammatically in 
Figure 1.6, and is adapted from (Bente, Forrester et al. 2013). The following sections 
describe the replication cycle of CCHFV; the replication cycle of HAZV has not been 
well characterised but is thought to be fairly analogous. 
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Figure 1.6. Overview of the replication cycle of CCHFV 
Following binding to cellular receptors (1), CCHFV entry is via clathrin mediated 
endocytosis (2). CCHFV envelope fuses with early endosomal membranes to release 
viral RNPs (3), which traffic to perinuclear regions where viral factories are thought to 
form. Here, the genomic segments (vRNA) are transcribed to generate mRNA (4), 
which is translated to synthesise viral proteins (5). Genomic segments are also 
replicated to form complementary copies of the genomic segments (cRNA), which act 
as a template for subsequent vRNA production (4). vRNAs are encapsidated by newly 
synthesised N proteins to form RNPs (6). Once translated, viral glycoproteins GN and 
GC traffic through the ER to the Golgi membrane (7), where they undergo extensive 
post-translational processing (8). Assembly occurs when newly synthesised viral 
RNPs interact with GN and GC, causing virions to bud into the Golgi cisternae (9). 
Virions are released from the cell after trafficking through the secretory pathway (10).  
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1.3.1 Virus entry and uncoating 
 
CCHFV entry is mediated predominantly by GC, which binds to cell surface nucleolin, 
which has been shown to be essential for virus entry (Xiao, Feng et al. 2011). 
Internalisation of CCHFV occurs through clathrin-dependent endocytosis; siRNA 
knock down of clathrin, or one of its essential adaptor proteins, AP2, results in 
decreased CCHFV replication (Simon, Johansson et al. 2009). CCHFV entry is also 
dependent on low pH and cholesterol; the use of bafilomycin A1 or NH4Cl to inhibit 
endosomal acidification, or methyl-β-cyclodextrin to reduce levels of cholesterol in 
cells, results in a loss of CCHFV replication (Simon, Johansson et al. 2009; Garrison, 
Radoshitzky et al. 2013).  
Following cell entry, CCHFV virions fuse with early endosomal vesicle 
membranes to release viral RNPs into the cytoplasm. It is thought that acidification of 
early endocytic vesicles, which occurs as they bud from the plasma membrane and 
mature into late endocytic vesicles, changes the conformation of CCHFV GN and GC, 
allowing them to fuse with the endosomal membrane (Garrison, Radoshitzky et al. 
2013). Efficient CCHFV replication relies on a functional Rab5 protein, rather than 
Rab7, indicating that CCHFV fusion occurs in the early endosomes, not the late 
endosomes, and the early endosomes rather than the late endosomes are important 
for CCHFV trafficking (Garrison, Radoshitzky et al. 2013).  
CCHFV internalisation is also dependent on intact, dynamic microtubules. It 
was shown that in the first hour of CCHFV infection intact microtubules were required 
for efficient early RNA synthesis; it is thought they are required not only for virus 
internalisation, but also for subsequent transport of CCHFV virions or virion 
components to sites of virus replication (Simon, Johansson et al. 2009). Upon 
infection the N protein is trafficked to perinuclear regions in infected cells in an actin 
dependent manner; these perinuclear regions are thought to be the sites of CCHFV 
replication and virus factory formation (Andersson, Simon et al. 2004). 
The mechanism of HAZV binding and internalisation is not known, however it 
is likely to be fairly similar to CCHFV, given the similarities in both the virion 
morphology and cell types targeted by these viruses. 
 
1.3.2 RNA transcription and replication  
 
Each encapsidated RNA segment within the virion must act as a template for two 
different RNA synthesis activities; transcription to generate mRNA, and replication to 
synthesise complementary copies of the full length genomic segments (cRNA), that 
subsequently act as templates for synthesis of viral genomic segments (vRNA) 
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(Figure 1.7). These RNA products have a fundamentally different structure; the mRNA 
is extended at the 5’ end relative to the genome by the addition of a capped 
oligoribonucleotide stolen from host cell mRNAs, and the 3’ end is truncated relative 
to the genome template (Walter and Barr 2011).  
Although there is little specific information concerning the mechanism of RNA 
transcription and replication of CCHFV and HAZV, work with Dugbe virus, another 
Nairovirus, reveals that the mechanism of mRNA transcription initiation is similar in 
Nairoviruses to other members of the Bunyaviridae family (Jin and Elliott 1993). 
Therefore although the following section summarises what we know about 
transcription and replication of other members of the Bunyaviridae family, we can infer 
that the mechanisms employed by CCHFV and HAZV are similar. 
Upon entry to an infected cell and transport to perinuclear regions, virus RNA 
transcription and replication takes place in the cytoplasm. In the currently accepted 
model, the first RNA synthesis event is transcription (‘primary transcription’), carried 
out by the template associated RdRp on the input RNA strand to generate 5’ capped 
mRNA (Walter and Barr 2011). The viral polymerase (L-protein) can only initiate RNA 
synthesis once per segment, at the segment termini; it is thought this might be due to 
the fact that sequences from both the 3’ and 5’ segment termini contribute to the 
formation of a functional promoter (Kohl, Dunn et al. 2004). The L protein therefore 
cannot re-initiate synthesis if RNA synthesis is prematurely terminated, and each 
bunyavirus genomic RNA strand must encode a maximum of one transcription unit 
(Walter and Barr 2011). This is in contrast to non-segmented negative sense RNA 
viruses (nsNSVs, e.g respiratory syncytial virus, RSV), where following transcription of 
each gene within the genomic RNA strand, the RNA polymerase terminates 
transcription at the gene end, then re-initiates transcription again at the next gene 
start site.  
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Figure 1.7. Negative sense gene expression.  
CCHFV and HAZV vRNA must act as a template for two distinct RNA synthesis 
activities; transcription and replication.  
 
 
Transcription initiation relies on primers that are generated from capped host cell 
mRNAs, and is distinct from replication in this regard. The evidence of cap-snatching 
for Dugbe virus (in addition to other members of the Bunyaviridae family) lies in the 
discovery of heterogeneous non-viral RNA sequences at the 5’ ends of the Dugbe 
virus S segment mRNA (Jin and Elliott 1993). These are an average of 10 nucleotides 
in length, and are derived from host cell mRNA when the L protein cleaves cellular 
mRNA to steal the cap required for translation of viral mRNAs (Reguera, Weber et al. 
2010). The mechanism by which capped mRNAs are selected is unknown, however it 
has been noted for Dugbe virus, as well as other bunyaviruses, that the 3’ end of the 
primer resembles the 5’ end of the viral RNA (Jin and Elliott 1993; van Knippenberg, 
Lamine et al. 2005). It could be that the L protein selects a specific subset of cellular 
mRNAs to generate primers, specifically those that allow at least partial base pairing 
with the 3’ end of the vRNA template. It is thought the ‘prime and realign’ mechanism 
of transcription initiation then follows, which involves annealing the capped primer to 
internal regions of the 3’ NTR within a tri-nucleotide repeat sequence (3’-
AUCAUCAUC-5’). Following extension by the L protein by a few nucleotides the short 
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primer slips backwards and re-aligns with the 3’ proximal triplet repeat on the template 
RNA (Garcin, Lezzi et al. 1995; Walter and Barr 2011). After a few cycles of prime and 
realign, a longer complementary primer is generated. This could form a more stable 
transcription complex that is more suitable for elongation, however the reason behind 
employing the prime and realign mechanism is still unclear.  
The 3’ termini of bunyavirus mRNAs are consistently truncated with respect to 
the genomic RNA template, indicating there is some sort of transcription termination 
signal in the template RNA. In the case of BUNV S segment this transcription 
termination signal was shown to be around 33 nucleotides in length, and was located 
in the 5’ NTR (Barr, Rodgers et al. 2006). A related sequence was identified in the L 
segments 5’ NTR that also mapped closely to the 3’ end of the L mRNA; interestingly 
the M segment 5’ NTR did not possess a similar signal, raising the possibility that 
mRNA synthesis is terminated via a different mechanism. Bunyaviral mRNA is not 
polyadenylated at the 3’ termini; this could potentially affect protein synthesis, as the 
poly(A) tail is important for stability of mRNA transcripts, as well as recruitment of the 
ribosomes for efficient translation. There is some evidence that in the case of BUNV 
at least, nucleotide sequences at the 3’ terminus of the mRNA transcripts functionally 
replace the poly(A) tail through the formation of secondary structural elements, such 
as a strong stem loop structure (Blakqori, van Knippenberg et al. 2009; Walter and 
Barr 2011). The sequence and the structure of the BUNV 3’ mRNA terminus is 
strikingly similar to that of the 3’ end of cellular histone mRNA, which is also poly(A) 
deficient, possibly indicating that BUNV may have hijacked a pre-existing cellular 
mechanism for poly(A) independent mRNA translation (Marzluff 1992). Little is known 
about the RNA synthesis activities of RNPs of CCHFV and HAZV; however the overall 
mechanism could be analogous.    
Viral mRNA is not recognised and bound by the N protein. This is in contrast to 
the cRNA, which is a full length copy of the viral genome, bound to multiple copies of 
N along its length, and in some members of the bunyavirus genera (Phleboviruses 
and Tospoviruses) can also act as a template to generate mRNA that encode non-
structural (NS) proteins. In some genera (for example the Phlebovirus RVFV) cRNA 
segments are also packaged into virions to enable expression of NSs proteins 
immediately upon entry to the host cell (Ikegami, Won et al. 2005). Viral mRNA on the 
other hand, is not packaged into virions.  
The promoters for transcription and replication of BUNV segments have been 
mapped to distinct sets of nucleotide sequences at both the 3’ and 5’ termini of the 
segments. These nucleotide sequences are arranged so that the genomic strand NTR 
contains signals for both transcription and replication of the segment, whereas the 
cRNA strand only contains signals for replication of the segment (Barr, Elliott et al. 
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2003; Flick, Katz et al. 2004; Kohl, Dunn et al. 2004; Gauliard, Billecocq et al. 2006). 
After primary transcription has occurred, the viral polymerase switches to segment 
RNA replication. The signal that initiates the switch to segment replication from mRNA 
synthesis is poorly defined, and may be as a result of a change in the RdRp function 
either through modification of the polymerase or its interaction with host-cell factors 
(Walter and Barr 2011). It is assumed, however, that cytoplasmic N protein 
concentration is also important for the switch from transcription to replication, as 
sufficient N protein must be translated to encapsidate the newly synthesised cRNA 
and vRNA segments (Reguera, Cusack et al. 2014). In contrast to mRNA synthesis, 
synthesis of cRNA is initiated using 5’ nucleoside triphosphates. The relative 
abundance of each genomic segment varies within infected cells; nucleotide 
sequences within the segment specific NTRs contain elements that influence the 
relative abundance of each segment that is replicated. During BUNV infection, the 
relative abundance of genome replication of the 3 segments is M>L>S (Barr, Elliott et 
al. 2003).  
The subcellular localisation of CCHFV cRNA and vRNA during infection has 
been determined (Andersson, Henriksson et al. 2012). Simultaneous staining of the N 
protein revealed that vRNA subcellular distribution is fairly diffuse in the cytoplasm, 
only occasionally co-localising in areas where N assembled or aggregated. cRNA on 
the other hand was greatly enriched in the CCHFV-N containing areas of the 
cytoplasm, and co-localised extensively with the perinuclear N aggregates, rather than 
having a more diffuse cytoplasmic distribution. The reason for the varying cytoplasmic 
distribution of cRNA and vRNA is unknown, but may be related to their different roles 
within the CCHFV replication cycle (Andersson, Henriksson et al. 2012).   
 
1.3.3 CCHFV and HAZV assembly and egress 
 
CCHFV and HAZV are thought to assemble and bud from perinuclear viral factories 
that are built around the Golgi complex, in a similar manner to other members of the 
Bunyaviridae family (Kuismanen, Hedman et al. 1982; Matsuoka, Chen et al. 1991; 
Novoa, Calderita et al. 2005). This may be a result of the accumulation of the 
structural glycoprotein heterodimer GN and GC in the membrane of the Golgi complex, 
where they are trafficked for post-translational processing following synthesis in the 
ER. Virion formation is thought to occur when viral RNPs traffic to the Golgi 
membrane and interact with the cytoplasmic tails of GN and GC, which protrude into 
the cytoplasm.  
It is not known how CCHFV RNPs are transported to the GN and GC 
heterodimers in the Golgi complex, however several components of the cytoskeletal 
Chapter 1: Introduction 
28 
 
system, including actin filaments and microtubules, are thought to be involved, 
especially in N protein transportation (Andersson, Simon et al. 2004; Ramanathan, 
Chung et al. 2007; Simon, Johansson et al. 2009). Depolymerisation of microtubules 
affects CCHFV assembly, and results in a redistribution of both N and GN, as well as 
significantly reducing progeny virus release. Stabilisation of microtubules also results 
in the accumulation of progeny virions in the cytoplasm, indicating a role for both 
intact and dynamic microtubules in CCHFV egress (Simon, Johansson et al. 2009). 
Once viral RNPs have trafficked to the GN and GC heterodimer in the Golgi 
membrane they are thought to directly interact with the cytoplasmic tails of GN and GC, 
as CCHFV does not encode any non-structural or matrix proteins that can mediate 
this interaction. Recent structural studies of the cytoplasmic tail of CCHFV GN 
revealed it contained a dual CCHC-type zinc finger domain (Estrada and De Guzman 
2011). The cytoplasmic tail of GN was able to bind RNA, specifically RNA resembling 
the hairpin-like M segment panhandle, raising the intriguing possibility that the 
cytoplasmic tail of GN may interact with the RNA component of the RNPs, rather than 
the N protein (Estrada and De Guzman 2011). The concentration of structural 
components of CCHFV in the vicinity of the Golgi membrane within a ‘budding 
compartment’ is thought to drive the formation and budding of new CCHFV virions into 
the cisternae of the Golgi complex. Virions are subsequently released along the 
secretory pathway.  
 
1.3.4 Proteins encoded by the CCHFV M segment 
 
The CCHFV M segment possesses a single ORF that encodes a polyprotein 
precursor of 1,689 amino acids. This polyprotein is co-translationally inserted into the 
membrane of the rough endoplasmic reticulum (RER), where it undergoes a complex 
series of cleavage events and post-translational modifications, both in the RER, and 
as it migrates through the Golgi network. This results in the synthesis of multiple 
protein products, which are summarised in Figure 1.8.  
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Figure 1.8 Diagrammatic representation of CCHFV glycoprotein polypeptide 
The CCHFV M ORF is initially translated as a large polyprotein that undergoes 
complex processing by cellular proteases (listed above the polyprotein) to generate 
the structural glycoproteins GN and GC amongst other protein products (labelled on 
the polyprotein). 
 
 
The polyprotein precursor contains two distinct regions; the C terminal 1,441 residues, 
which are highly conserved among CCHFV strains (91.6 % sequence identity) and the 
N terminal 243-248 amino acids residues, which are highly variable (up to 56.4 % 
sequence variation, labelled ‘mucin’ in Figure 1.8). This N terminal domain has mucin-
like features, including a high serine, threonine and proline content (up to 47.3 %) and 
is predicted to be heavily O-glycosylated (Sanchez, Vincent et al. 2002). The 
possession of a mucin-like domain is a unique feature among the Bunyaviridae family, 
and notably, this mucin like domain resembles that present within the Ebola virus 
glycoprotein, which is predicted to play an important role in immune evasion 
(Simmons, Wool-Lewis et al. 2002). Interestingly, analysis of the efficacy of a novel 
CCHFV vaccine which uses the M segment ORF revealed that a large part of the 
cellular immune response detected in protected mice mapped to epitope regions in 
the non-structural regions of the M segment polyprotein, including the mucin-like 
domain (Buttigieg, Dowall et al. 2014).  
The main structural proteins derived from the M segment are the membrane 
bound glycoproteins GN and GC, which are found inserted in the viral envelope. GN is 
37 kDa, and GC is 75 kDa, and both are initially produced by cleavage of the 
polyprotein to generate a 140 kDa pre-GN precursor, and an 85 kDa pre-GC precursor. 
Cleavage of pre-GN at a conserved tetrapeptide RRLL519 motif by the protease SKI-
1/S1P releases GN from pre-GN; this cleavage is essential for infectious virus release; 
cells deficient in SKI-1/S1P are susceptible to infection with CCHFV, but infectious 
particles are not released by these cells (Bergeron, Vincent et al. 2007, Vincent, 
Sanchez et al. 2003). GC is cleaved from pre-GC at the conserved RKPL1040 motif, 
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which closely resembles the motif recognised by SKI-1/S1P, however the protease 
involved in this cleavage remains unknown (Bergeron, Vincent et al. 2007, Vincent, 
Sanchez et al. 2003). During infection both GN and GC localise to the Golgi complex, 
however only GN contains the Golgi localisation signal; heterodimerisation of GN and 
GC is required for the Golgi localisation of GC (Bertolotti-Ciarlet, Smith et al. 2005). 
Both GN and GC undergo N-linked glycosylation, GN is N-linked glycosylated at one site 
on its ectodomain (557N) and GC is glycosylated at two sites on its ectodomain 
(1054N and 1563N) (Erickson, Deyde et al. 2007). Antibodies targeting GC were able 
to neutralise CCHFV prior to infection, but antibodies directed against GN could not, 
indicating that GC is involved in recognising and binding to cellular receptors 
(Bertolotti-Ciarlet, Smith et al. 2005).  
Other viral proteins generated by M ORF polyprotein cleavage include GP38 
and a non-structural protein designated NSm (Sanchez, Vincent et al. 2006, Altamura, 
Bertolotti-Ciarlet et al. 2007). The function of GP38, NSm and the mucin-like domain 
during the virus replication cycle are not known; these proteins could not be detected 
in partially purified virions, indicating they are not structural proteins required for virion 
formation.   
 
1.3.5 Proteins encoded by the HAZV M segment  
 
Fewer studies have investigated the proteins encoded by the HAZV M segment ORF. 
Similar to CCHFV, HAZV also encodes at least two glycoproteins of ~75 kDa and ~30 
kDa, which are embedded in the virus envelope (Clerx, Casals et al. 1981; Foulke, 
Rosato et al. 1981). There is some evidence to suggest that HAZV may also encode a 
third envelope glycoprotein, of ~45 kDa (Foulke, Rosato et al. 1981); however Clerx et 
al do not report the detection of this third envelope glycoprotein, therefore further work 
needs to be carried out to resolve this point.  
 
1.3.6 Proteins encoded by the L segment 
 
The L segment of CCHFV and HAZV encodes the viral RNA dependent RNA 
polymerase (RdRp), or L protein, whose function is to both transcribe and replicate 
genomic RNA segments. The nairovirus L protein is considerably larger than the L 
protein of other bunyaviruses; the full length protein has an approximate molecular 
weight of 448 kDa. The full length L protein possesses the core catalytic domains 
common to all viral RdRps; pre-A, A, B, C and D, in addition to a motif specific for all 
sNSVs, termed region E, that together make up the polymerase module (Muller, Poch 
et al. 1994; Walter and Barr 2011). The L proteins of nairoviruses also encode 
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additional sequences, predominantly at their N termini, that perform as yet 
uncharacterised functions. In the case of CCHFV, some of these additional regions 
show some homology with known transcription factor, gyrase, helicase, and 
topoisomerase domains (Honig, Osborne et al. 2004; Kinsella, Martin et al. 2004). 
Additionally, some of these N-terminal nairovirus specific sequences show 
strong similarity to cysteine proteases within the ovarian tumor (OTU) super-family 
and the L protein of CCHFV and Dugbe virus possesses OTU-like protease activity 
(Frias-Staheli, Giannakopoulos et al. 2007). The viral OTU (vOTU) protease domain 
of CCHFV L directly deconjugates ubiquitin and ISG15 from their target proteins in 
vitro and in cell culture, resulting in an overall decrease in the amount of ubiquitinated 
or ISG15 conjugated proteins in cells (Frias-Staheli, Giannakopoulos et al. 2007). 
Furthermore, this deconjugation of ubiquitin and ISG15 results in antagonism of the 
innate antiviral response, both through directly abrogating the antiviral effects of 
ISG15, which are mediated through its ability to conjugate to target proteins, and 
though interference with any immune pathways that are regulated by ubiquitination. 
The NF-KB dependent antiviral signalling pathway is regulated by ubiquitination for 
example, and upon L protein expression, nuclear translocation of endogenous p65 is 
inhibited, thus expression of antiviral genes under the control of the NF-KB promoter 
does not occur (Frias-Staheli, Giannakopoulos et al. 2007).   
Interestingly cellular OTU-domain containing proteases only deconjugate 
ubiquitin, not ISG15. The molecular basis for the ability of vOTU proteases to cleave 
both substrates was recently revealed though structural analysis of CCHFV OTU-
domain with either ubiquitin or ISG15 covalently bound in the active site (Akutsu, Ye 
et al. 2011; James, Frias-Staheli et al. 2011) (Figure 1.9). 
It has been proposed that the OTU-like protease domain may cleave the 
CCHFV L protein autoproteolytically to release both the polymerase as well as various 
other proteins that are required to carry out transcription and replication of the viral 
genome. Such a mechanism has been described for the equine arteritis virus (EAV) 
nsp2 protein, which is an OTU-like protease with dual purpose; nsp2 cleaves the viral 
polyprotein to release individual proteins, and also deconjugates ubiquitin and ISG15 
from cellular proteins to interfere with innate antiviral signalling pathways, and 
suppress the innate immune response (Frias-Staheli, Giannakopoulos et al. 2007; van 
Kasteren, Bailey-Elkin et al. 2013). However, the CCHFV vOTU domain is not 
necessary for efficient transcription and replication of the CCHFV genome, as deletion 
of this domain did not affect the activity of the L-protein in a CCHFV minireplicon 
assay (Bergeron, Albarino et al. 2010). This implies that the CCHFV vOTU is not 
required for polyprotein processing of the L protein to generate an efficient RNA 
polymerase. 
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Figure 1.9 Crystal structure of vOTU domain of CCHFV L protein in complex 
with ubiquitin or ISG15 
Taken from (James, Frias-Staheli et al. 2011). Crystal structure of CCHFV vOTU 
(cyan) bound to ubiquitin (orange) or ISG15 (green). In both cases ribbon diagrams of 
the complex highlight the 3 main regions of interaction between ubiquitin or ISG15, 
and the vOTU domain of CCHFV L protein. The C-terminal ubiquitin like domain of 
ISG15 binds the substrate binding groove of the protease in an analogous manner to 
ubiquitin. 
 
 
It was recently shown that the N terminal domain of the LACV L protein encodes a 
cap snatching endonuclease with very close structural and biochemical features to 
that of the N terminal domain of the influenza virus polymerase PA subunit (Reguera, 
Weber et al. 2010). Mutational analysis revealed that this endonuclease activity was 
essential for efficient transcription of LACV mRNA, and the endonuclease activity was 
inhibited by DPBA, a drug that targets the influenza endonuclease. Sequence 
alignment with other members of the Bunyaviridae family indicated the endonuclease 
active site motif (typically composed of 5 potentially catalytic amino acid residues; H34, 
D52, D79, D92, and K94) is conserved among members of the Orthobunyavirus, 
Phlebovirus, Hantavirus and Tospovirus genus (Reguera, Weber et al. 2010). 
Although the nairoviruses were not included in this original alignment, they were found 
to possess a putative endonuclease motif of the Phlebo/Hanta/Orthomyxo type in the 
residue range 630–710, in the case of CCHFV. However, endonuclease activity of the 
CCHFV L protein needs to be confirmed with structural and functional data, and it 
Chapter 1: Introduction 
33 
 
should be noted that although the cap snatching endonuclease activity of CCHFV 
could possibly be attributed to this domain in the L protein, there is no evidence as yet 
that the L protein also contains the cap binding site.  
 
1.4 PROTEINS ENCODED BY THE S SEGMENT: CCHFV N AND HAZV N 
 
The S segment of CCHFV and HAZV encodes the nucleocapsid protein (N), often the 
most highly abundant structural protein present in infectious virions. CCHFV N and 
HAZV N are significantly larger than the N proteins of most other Bunyaviridae family 
members, apart from members of the Hantavirus genus (Table 1). The best 
characterised role of N is to bind to viral RNA to form functional RNPs, which are 
essential for both transcription and replication of the viral genome, by analogy with 
other bunyaviruses. One of the unique features of NSVs is the fact that RNPs, not 
naked genomic RNA segments, are used as a template for viral RNA synthesis 
(Green, Cox et al. 2014). Multiple copies of CCHFV N are proposed to interact with 
viral RNA along the length of the genome or anti-genome segments, possibly via 
homotypic interactions between adjacent monomers in a ‘head-tail’ manner (Wang, 
Dutta et al. 2012).  
By encapsidating the viral genome or anti genome, but not the viral mRNA or 
cellular RNA, it is thought N protects the viral genome from degradation, helps avoid 
the formation of dsRNA structures between viral RNA strands of opposite polarity, and 
compacts the viral RNA into RNPs (Reguera, Cusack et al. 2014). It is thought 
genome encapsidation and RNP assembly occurs concurrently with genome 
synthesis; this property is thought to be one way of ensuring that only genomic or anti-
genomic RNA is packaged into virions during assembly, rather than viral or cellular 
mRNA (Reguera, Cusack et al. 2014). RNP assembly of N with nascent genome or 
anti-genome strands is thought to be initiated at the RNA 5’ termini, as there are no 
conserved sequences, other than those in the NTRs, that could serve as initiation 
sites for N-assembly (Osborne and Elliott 2000; Reguera, Cusack et al. 2014).  
Extensive analysis of N proteins and RNPs from multiple members of both the 
segmented NSVs (sNSVs) and non-segmented NSVs (nsNSVs), reveals the N 
proteins and RNPs of these two groups of viruses have fundamentally different 
properties (Reguera, Cusack et al. 2014). The RNPs of sNSVs are highly flexible and 
are able to adopt a number of different conformations (Young and Howard 1983). The 
flexibility of the sNSV RNPs has been proposed to be required for multiple stages of 
the virus replication cycle; the inherent flexibility of the N:RNA chains may be 
essential in enabling the complementary terminal sequences of each genomic RNA 
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strand to find each other and anneal during genome replication, for example (Reguera, 
Cusack et al. 2014).  
In general, the nucleocapsid proteins of sNSVs are structurally diverse; they 
do not share similar folds in their domains. However, they do all possess at least 2 
separate domains; an RNA binding domain, and another domain that mediates 
oligomerisation between neighbouring monomers. These domains are linked by highly 
flexible hinge regions that allows N proteins to adopt a number of different 
conformations, enabling the formation of RNP assemblies with variable geometries 
(Reguera, Cusack et al. 2014).  
The bunyavirus N protein is multifunctional, and in addition to encapsidating 
viral RNA, N has other critical functions within the virus replication cycle; N interacts 
with both the viral L protein during RNA synthesis (Eifan and Elliott 2009), and the 
virus glycoproteins (GN and GC) during virus assembly and budding (Overby, 
Pettersson et al. 2007; Overby, Popov et al. 2007; Ribeiro, Borst et al. 2009). It is 
thought that interaction of the L protein with N induces local conformational changes 
in N that allow it to release the RNA genome temporarily, so it can be used as a 
template for RNA synthesis by the L protein. As the L protein then continues 
downstream RNA synthesis, it is thought N re-encapsidates the viral RNA to avoid the 
formation of dsRNA intermediates (Green, Cox et al. 2014).  
The S segment of members of other bunyavirus genera encode additional 
non-structural proteins, either using a negative sense coding strategy and a second 
ORF (orthobunyaviruses) or the NSs protein ORFs are transcribed as mRNAs from 
positive sense templates (phleboviruses and tospoviruses) (Elliott 2014). Bunyavirus 
NSs proteins are generally thought to be interferon antagonists that enhance virus 
pathogenicity (Weber, Bridgen et al. 2002; Hollidge, Weiss et al. 2011; Eifan, 
Schnettler et al. 2013). There is no evidence of the CCHFV or HAZV S segment 
expressing any non-structural protein product, although the CCHFV S segment does 
encode an additional open reading frame in the positive sense orientation that is 
conserved in almost all CCHFV strains (Hewson, Chamberlain et al. 2004).  
 
1.4.1 The crystal structure of CCHFV N 
 
The crystal structure of several different strains of the CCHFV N protein have been 
determined. The YL04057 strain was solved to a resolution of 2.3 Å by (Guo, Wang et 
al. 2012), the Baghdad-12 strain to a resolution of 2.1 Å by (Carter, Surtees et al. 
2012), and the IbAr10200 strain to 3.1 Å by (Wang, Dutta et al. 2012). In all cases the 
structure of the full length protein was determined (residues 1-482) and consistent 
with other sNSVs, CCHFV N possesses two domains; a globular domain and an arm 
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domain; the arm domain is flexible and free to adopt a number of different positions. In 
the Baghdad-12 strain the globular domain comprises 23 alpha helices from both the 
N and the C terminus of N (α1 to α11 of the N-terminus, and α18 to α29 of the C 
terminus), where the C terminal alpha helices are located in the core of the globular 
domain, and are surrounded by alpha helices from the N-terminus (helices are 
numbered according to Figure 1.10 (B)) (Carter, Surtees et al. 2012). The arm domain 
comprises two long alpha helices (α15 and α17) that extend away from the globular 
domain and have a loop at the apex that is supported by a small 3-helix bundle (α12 
to α14) (Figure 1.10) (Carter, Surtees et al. 2012). Figure 1.10 (B) also shows the 
primary sequence alignment between strains YL04057 and Baghdad-12, and the 
conserved caspases-3 cleavage motif on the apex of the arm domain is highlighted in 
(B).  
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Figure 1.10 Crystal structure of CCHFV N Baghdad-12 strain, and primary 
sequence alignment of YL04057 and Baghdad-12 strains  
Taken from (Carter, Surtees et al. 2012). (A) Crystal structure of CCHFV N Baghdad-
12 strain with the N terminus shown in grey, the C-terminus blue, and the extended 
arm domain in purple. The N and C-termini are highlighted by red and yellow balls, 
respectively. (B) primary sequence alignment of YL04057 and Baghdad-12 strains 
with alpha helices numbered accordingly.   
 
 
In both the YL04057 and Baghdad-12 strain only 474 of the 482 residues were able to 
be built into the model; residues 183-191 form a disordered loop that is missing in 
electron density. In the IbAr10200 structure this flexible loop is visible in only one of 
the three monomers in the asymmetric unit, in the other two it remains disordered, 
with no detectable electron density (Wang, Dutta et al. 2012). This disordered loop 
links the arm domain to the globular domain, and it has been hypothesised that the 
loop could become ordered upon RNA binding, and therefore the arm domain may 
‘gate’ RNA binding, in a similar manner to the RVFV and LASV gate (Ferron, Li et al. 
2011; Hastie, Liu et al. 2011; Carter, Surtees et al. 2012). Analysis of the electrostatic 
A 
B 
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surface potential of all three structures revealed two positively charged surfaces that 
were proposed to be involved in RNA binding (Figure 1.11). One positively charged 
patch is on the surface of N, adjacent to the arm domain and is termed the platform. 
The other is a crevice that channels between the base of the globular domain and the 
beginning of the arm domain, in a region similar to where RNA binds in the LASV N 
terminal domain (Figure 1.13) (Wang, Dutta et al. 2012). However, these structures 
were all devoid of RNA and attempts to co-crystallise purified CCHFV N with short 
sequences of RNA were unsuccessful, thus the RNA binding domain of CCHFV N 
remains unidentified.  
 
 
 
 
 
 
Figure 1.11 Surface electrostatic potential of CCHFV N 
Taken from (Carter, Surtees et al. 2012). Surface electrostatic potential of CCHFV N 
reveals areas of positive charge (blue) and negative charge (red), and two possible 
RNA binding regions termed the ‘platform’ and the ‘crevice’. 
 
 
The globular domains of all three CCHFV N structures are very similar, for example 
comparison of the YL04057 and Baghdad-12 strains reveals the globular domains 
superpose very closely on one another; the Cα root mean square deviation (RMSD) is 
0.975 Å for 357 residues with 92.16 % sequence identity (Carter, Surtees et al. 2012). 
The arm domains of these strains also contain the same fold and superpose closely 
on one another (Cα RMSD of 0.642 Å, 99 residues, 77.78 % identity), however the 
position of the arm domain is different in the two structures. The arm is rotated by 
about 180 °, and the apex of the loop is shifted by a distance of 39.59 Å in the 
YL04057 strain compared to the Baghdad-12 strain (Carter, Surtees et al. 2012). This 
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change in the arm domain position could be a result of amino acid differences 
between the strains. Alternatively, given that the arm domain and globular domain are 
linked by a single α helix, which is unlikely to be rigid, and a disordered loop not 
visible in electron density, the arm domain could be fairly flexible, and might be free to 
adopt several different conformations (Carter, Surtees et al. 2012). It is not known 
whether the change in the position of the arm domain is involved in N multimerisation, 
or whether the RNA binding ability of the respective proteins is affected by the position 
of the arm domain, as this might alter the distribution of electrostatic surface potential 
(Carter, Surtees et al. 2012).    
Structural alignment (superposition) of CCHFV N with RVFV N (a member of 
the Phlebovirus genus), revealed very little structural similarity between their globular 
domains, and no similarity at all was detected between their arm domains. Instead, 
the greatest structural similarity was observed between CCHFV N and the N terminal 
domain of Lassa virus (LASV) N, a member of the Arenaviridae family. The N terminal 
domain of LASV N, comprising residues 1-340 (the RNA binding domain of LASV N), 
when structurally aligned with the globular domain of CCHFV N, had a Cα RMSD of 
3.38 Å for 237 residues with 8.01% sequence identity (Carter, Surtees et al. 2012). 
Interestingly this suggests that despite CCHFV and RVFV both being classified as 
members of the Bunyaviridae family, CCHFV is more closely related to the arenavirus 
LASV than RVFV. This suggestion is supported both by a phylogenetic analysis of the 
L and N sequences from sNSVs, which suggests that nairoviruses are more closely 
related to arenaviruses then other members of the Bunyaviridae family (Carter, 
Surtees et al. 2012), and also the fact that nairoviruses and arenaviruses share 
elements of their replication cycles that are unique to nairoviruses within the 
Bunyaviridae family, such as their reliance on cellular SKI-1/S1P protease to process 
their glycoprotein precursors (Lenz, ter Meulen et al. 2001; Vincent, Sanchez et al. 
2003).  
 
1.4.2 Potential multimerisation mechanism of CCHFV N 
 
In all three studies, purified CCHFV N was mainly monomeric, although (Wang, Dutta 
et al. 2012) also reported the existence of higher order structures. These higher 
ordered oligomers (apparent MW over 300 kDa) had OD260/OD280 ratios of 1.49, which 
is consistent with them containing nucleic acid (presumably RNA) (Wang, Dutta et al. 
2012). In contrast the reported monomeric N (apparent MW approximately 53 kDa) 
was apparently devoid of bound nucleic acid, having an OD260/OD280 ratio of 0.69. 
Wang et al did not crystallise the higher ordered structures with bound nucleic acid, 
however they did observe antiparallel double superhelical polymers of CCHFV N 
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within crystals of monomeric N. Crystallisation of monomeric N in solution and the 
subsequent formation of higher ordered structures and oligomers in crystals is not 
uncommon – for example the monomeric form of RVFV N once crystallised forms 
hexameric rings, as well as other oligomeric structures (Ferron, Li et al. 2011). It is 
thought that while free in solution the presence of RNA may be required to stabilise 
the interactions between monomers, however the much greater concentration of N 
during crystallisation trials and within crystals may drive N proteins to form larger, 
more stable oligomers (Wang, Dutta et al. 2012).  
CCHFV N formed long helical structures in crystals where N monomers were 
organised in a ‘head-to–tail’ manner, with the loop on the end of the arm domain 
directly interacting with the base of the globular domain of an adjacent monomer 
(Wang, Dutta et al. 2012). Although these polymeric structures could just be the result 
of crystallographic packing artefacts, they could also represent the physiological 
organisation of CCHFV RNPs. Wang et al also propose a model for the mechanism of 
RNA transcription from the RNP templates. They were able to show that incubation of 
CCHFV N with short, primer length (16-21 nucleotides) ssRNA induced a 
conformational change in N, causing the arm domain to rotate away from the globular 
domain such that N could no longer take part in multimerisation. They propose that 
this disruption causes the release of monomeric CCHFV N from higher ordered 
structures. Wang et al further propose that during transcription the presentation of 
capped, primer length ssRNA stolen from host cell mRNAs, to CCHFV RNPs would 
induce a similar conformational change in N, causing the release monomeric N and 
exposing vRNA to the RdRp for transcription (Wang, Dutta et al. 2012).   
 
1.4.3 Cap-binding and endonuclease potential of CCHFV N  
      
CCHFV N does not bind mRNA cap analogues (m7G, m7Gp or m7Gppp), and is 
therefore unlikely to be responsible for cellular mRNA cap snatching during the virus 
replication cycle (Guo, Wang et al. 2012). Guo et al did however show that CCHFV N 
bound single stranded RNA (ssRNA) with a very weak affinity, and that N possessed 
divalent-cation dependent, DNA specific, endonuclease activity (Guo, Wang et al. 
2012). This is somewhat surprising; CCHFV N is so far the only sNSV N protein that 
has been attributed with DNA specific endonuclease activity, although the C-terminal 
domain of LASV N (not the domain that CCHFV N shares a strong structural similarity 
with) has been shown to possess a dsRNA specific 3’-5’ exonuclease activity (Qi, Lan 
et al. 2010; Hastie, Kimberlin et al. 2011). The possible function of the endonuclease 
activity of CCHFV N within the replication cycle of CCHFV remains to be determined. 
The weak binding affinity of NSV nucleocapsid proteins for ssRNA in vitro has 
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previously been reported despite the function of N being RNA binding during the virus 
replication cycle (Ferron, Li et al. 2011).  
 
1.4.4 Cleavage of CCHFV N by active caspase-3 
 
The crystal structure of CCHFV N also reveals the position of the DEVD motif which is 
cleaved by activated caspase-3 during apoptosis in CCHFV infected cells (Karlberg, 
Tan et al. 2011). The DEVD motif is located on the loop at the apex of the arm domain, 
in a position that is theoretically easily accessible by proteases. Recombinant CCHFV 
N is cleaved in vitro, resulting in the generation of 2 fragments of N of approximately 
30 kDa and 24 kDa. In vitro cleavage of N is not very efficient; incomplete cleavage of 
N is observed after overnight incubation of N with recombinant caspase-3 in 
equimolar ratios, and this reflects cleavage in infected cells, where only a small 
proportion of N is cleaved (Karlberg, Tan et al. 2011; Carter, Surtees et al. 2012). It is 
possible that oligomerisation of CCHFV N completely obscures the DEVD motif, as it 
is thought the loop of the arm domain directly interacts with the base of the adjacent 
globular domain, suggesting that only monomeric N would be an available substrate 
for activated caspase-3. This might explain the slow rate of caspase-3 cleavage; 
indeed incubation of CCHFV N with primer length ssRNA, which disrupts the 
multimeric structure and releases monomeric N, increases the efficiency of CCHFV N 
cleavage by caspase-3 (Wang, Dutta et al. 2012).   
Following cleavage by activated caspase-3, size exclusion chromatography 
analysis indicates that the two fragments of CCHFV N remain bound to each other, 
and the monomer remains intact as a single unit (Carter, Surtees et al. 2012). This 
suggests that caspase cleavage of CCHFV N may not affect protein function; 
alternatively cleaved CCHFV N may have an altered tertiary or quaternary structure 
which may affect its function (Carter, Surtees et al. 2012). Analysis of N function in a 
CCHFV mini-genome replicon system, using mutated CCHFV N possessing a 
DEV(E/G) motif that cannot be cleaved by caspase-3, has conflicting results. (Wang, 
Dutta et al. 2012) report an increase in RdRp function, indicating cleavage by 
caspase-3 is detrimental to CCHFV replication, (Carter, Surtees et al. 2012) report no 
difference in the level of reporter gene expression. The exact function of caspase-3 
cleavage of N during the replication cycle of CCHFV remains to be determined.    
 
1.4.5 Cellular binding partners of CCHFV N 
 
CCHFV N has been shown to interact with the interferon (IFN) inducible protein Mx1 
and the cytoskeletal protein actin (Andersson, Bladh et al. 2004; Andersson, Simon et 
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al. 2004). During infection N localises to perinuclear regions in infected cells; initially N 
is expressed in a small granular pattern in the cytoplasm, and is then targeted to 
perinuclear regions in the first 8 hrs after infection (Andersson, Simon et al. 2004). 
This perinuclear staining was not associated with the Golgi membrane, and was 
shown to be dependent on the presence of intact actin filaments; disruption of actin 
filaments with cytochalasin D resulted in a much more granular cytoplasmic 
distribution of N (Andersson, Simon et al. 2004). Actin also co-immunoprecipitated 
with N from CCHFV infected cells. An 80-97 % reduction in viral titre was observed 
when cells were treated with cytochalasin D (1 or 10 µg/mL) implying that actin 
filaments may be involved in or enhance virus assembly or release (Andersson, 
Simon et al. 2004).  
Mx1 binds to CCHFV N during infection; Mx1 co-immunoprecipitates with N 
from infected cells, and co-localises with N in large perinuclear inclusions (Andersson, 
Bladh et al. 2004). Mx1 inhibits the replication of CCHFV; expression of Mx1 in Vero 
cells results in a significant reduction in CCHFV titre, and during IFN-mediated 
inhibition of CCHFV replication, Mx1 was shown to be an important effecter protein 
(Andersson, Lundkvist et al. 2006). Mx1 belongs to the dynamin family of large 
GTPases and its expression is induced exclusively by IFN α and IFN β. Mx1 
expression also has an inhibitory effect on the replication of viruses from multiple 
different families; within the Bunyaviridae family Mx1 was shown to inhibit the 
replication of Dugbe virus, a member of the Nairobi sheep disease serogroup, as well 
as members of the Hantavirus and Phlebovirus genera (Frese, Kochs et al. 1996; 
Kanerva, Melen et al. 1996). 
In the case of CCHFV it is thought the interaction of Mx1 with N might 
sequester N away from sites of active virus replication, preventing N from fully 
participating in the virus replication cycle (Andersson, Bladh et al. 2004). Alternatively 
Mx1 might interact with N in the context of the RNPs or capsid-like structures and 
prevent their functions. Mx1 did not interfere with the early stages of CCHFV entry, S 
segment transcription and N protein translation (up to 12 hrs post infection), but rather 
seemed to inhibit virus genome replication. RT-PCR analysis revealed a reduction in 
vRNA, and a similar loss in virus titre as new infectious particles could not form 
(Andersson, Bladh et al. 2004).  
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1.4.6 Comparison between CCHFV N and HAZV N 
 
Alignment of the nucleotide sequences of CCHFV and HAZV S segments reveals 
slight differences in their overall length and the length of their 3’ and 5’ NTRs (Table 2). 
The nucleotide sequence homology between CCHFV N and HAZV N ORFs is 49.7 %. 
 
 
Table 2. Comparison between CCHFV and HAZV S segments 
Comparison between CCHFV and HAZV S segments reveals slight differences in 
segment and NTR length. Data was acquired from (Marriott and Nuttall 1992). 
 
 
Overall segment 
length (nts) 
5’ NTR length 
(nts) 
3’ NTR length 
(nts) 
Size of N 
protein 
CCHFV 1672 55 171 
482 aa 
(53.966 kDa) 
HAZV 1677 82 140 
485 aa 
(54.186 kDa) 
 
 
 
The amino acid sequences of CCHFV N and HAZV N proteins are more highly 
conserved, sharing an overall 60% amino acid sequence identity (Figure 1.12); HAZV 
N encodes 3 extra amino acids in comparison to CCHFV N. It is thought HAZV N and 
CCHFV N perform the same function in their virus replication cycles; although very 
few studies have investigated HAZV N, HAZV N has been found associated with RNA 
in purified viral RNPs, presumably encapsidating viral RNA in a similar manner to 
CCHFV N (Clerx, Casals et al. 1981; Foulke, Rosato et al. 1981). Interestingly in the 
study performed by Foulke et al, HAZV RNPs co-sedimented with small amounts of 
GC, possibly implying the interaction between the RNPs and GC is stronger than the 
interaction between the RNPs and GN. 
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Figure 1.12 Amino acid sequence alignment of CCHFV N and HAZV N. 
Conserved amino acid residues between CCHFV N and HAZV N are highlighted in 
green. These proteins share an overall 60% amino acid sequence identity; HAZV N 
encodes 3 extra amino acids. Alignment was generated with ClustalW. 
 
1.5 THE  N PROTEIN STRUCTURE OF RELATED VIRUSES 
 
The crystal structures of the N proteins of many sNSVs have been determined, both 
with and without RNA bound. These include N proteins from the orthomyxoviruses; 
Influenza A and B (Ye, Krug et al. 2006) (Ng, Lam et al. 2012), and Infectious Salmon 
Anaemia virus (Zheng, Olson et al. 2013). Within the Bunyaviridae family, the 
structure of N proteins from members of the Phlebovirus genus RVFV (Raymond, 
Piper et al. 2010; Ferron, Li et al. 2011; Raymond, Piper et al. 2012) and Severe fever 
with thrombocytopenia syndrome virus, SFTSV (Jiao, Ouyang et al. 2013; Zhou, Sun 
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et al. 2013)) have been solved. Within the Orthobunyavirus genus the structure of the 
N protein of BUNV (Ariza, Tanner et al. 2013), LACV (Reguera, Malet et al. 2013), 
Schmallenburg virus (SHMV) (Ariza, Tanner et al. 2013; Dong, Li et al. 2013), and 
Leanyer virus (Niu, Shaw et al. 2013)) have been solved. The structure of CCHFV N 
from the Nairovirus genus has also been determined. The crystal structure of the N 
protein of several arenaviruses, including Lassa fever virus (LASV) (Qi, Lan et al. 
2010; Hastie, Liu et al. 2011) and Junin virus (Zhang, Li et al. 2013), have also been 
determined. The following section briefly summarises what is known about the LASV 
N protein structure, as the crystal structure of CCHFV N showed greatest homology to 
the N terminal domain of LASV N.  
LASV N consists of 2 domains, an N and C terminal domain joined by a 
flexible linker region. The N terminal domain is compact and mostly α-helical, 
consisting of head and body regions that contain 4 and 8 helices respectively, 
whereas the C terminal domain possesses a single β-sheet surrounded by α helices 
(Hastie, Kimberlin et al. 2011; Hastie, Liu et al. 2011). The crystal structures of LASV 
N with RNA bound and without RNA bound have been solved, and reveal that LASV 
N possesses a novel gating mechanism for RNA binding. Six to seven ssRNA 
nucleotides bind per monomer of LASV N, in a crevice located in the N terminal 
domain. Although most of the RNA sequence bound to LASV N seemed to be non-
specific, LASV N did show some preference for a purine base at position 3 in the RNA 
strand (Hastie, Liu et al. 2011). 
RNA binding to LASV N is mostly mediated though interactions of the 
phosphate residues and backbone of the RNA with arginine and lysine residues 
present on α helices α12 and α14, and a hydrogen bond network between the 
phosphate backbone and several serine and threonine residues of N (Hastie, Liu et al. 
2011). Mutational analysis of several of these residues revealed their absolute 
necessity to the function of a LASV mini-genome replicon system, presumably 
because they are key RNA binding residues. The gating mechanism of LASV RNA 
binding is mediated by two α helices, helix α5 and helix α6, as well as the flexible loop 
that links these two helices (Figure 1.13). In the RNA free structure helix α5 is 10 
residues longer, and both the longer helix α5 and helix α6 lie across the RNA binding 
crevice, blocking RNA from binding. In contrast, in the RNA bound monomer, these 10 
residues are flexible and disordered, and as a result helix α5 does not extend across 
the crevice and helix α6 is rotated away from the crevice. In addition the loop 
connecting helix α5 and helix α6 is moved away from the crevice in the presence of 
RNA and seems to form a ‘gate’; in the RNA free monomer (the closed conformation) 
this loop sterically clashes with the RNA, whereas in the RNA bound ‘open 
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conformation’ several residues in this loop interact with the RNA backbone and sugar 
residues (Hastie, Liu et al. 2011). 
 
 
 
 
 
 
Figure 1.13 The LASV N ‘gating’ mechanism of RNA binding 
Taken from (Hastie, Liu et al. 2011). Ribbon diagram depicting the novel LASV N 
gating mechanism of RNA binding. The N terminal domain is shown in both the open 
conformation (blue) with RNA bound, and the closed conformation (silver), which does 
not bind RNA.  
  
 
It has been hypothesised that in the ‘closed conformation’ (in which N is trimeric) 
LASV N cannot bind RNA, and this closed conformation therefore performs one of the 
functions of the P protein (the polymerase co-factor present in other NSVs but not 
bunyaviruses) and prevents N polymerisation and non-specific encapsidation of 
cellular RNA. The factor that catalyses the shift from the closed conformation to the 
open conformation is currently unknown, however the L protein is thought to be 
involved. The fact that the RNA is bound in such a deep crevice and is inaccessible 
for base pairing during replication supports the hypothesis that during RNA synthesis 
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the L protein induces a conformational change in N that causes N to transiently 
release the RNA for replication and transcription. N then re-encapsidates the RNA 
after the L protein has continued downstream RNA synthesis (Hastie, Liu et al. 2011). 
In contrast to previous hypotheses, LASV N did not bind mRNA cap analogues 
(m7GTP), similar to the lack of cap binding ability displayed by CCHFV N. The C 
terminal domain of LASV N is a dsRNA specific 3’-5’ exonuclease, which is thought to 
be an important part of the LASV strategy to evade detection by the innate immune 
system. The exonuclease activity of the C terminal domain of LASV N is thought to 
eliminate any dsRNA products resulting from RNA replication that could be 
recognised the cellular RNA helicases MDA5 or RIG-I (Hastie, Kimberlin et al. 2011). 
CCHFV N does not have an equivalent domain, despite that fact Guo et al reported 
DNA specific endonuclease activity of CCHFV N. 
 
1.6 INTERACTION OF CCHFV WITH THE INNATE IMMUNE RESPONSE 
 
CCHFV is classified as an IFN sensitive virus. IFNs are key signalling molecules 
expressed upon detection of viral (or other microbial) pathogen associated molecular 
patterns (PAMPs). Induction of IFNs results in the expression of a range of viral 
restriction factors such as Mx1, 2’5’OAS and IFITM (IFN inducible transmembrane 
proteins) which not only induces an antiviral state that reduces viral replication, but 
also initiates the adaptive immune response (Medzhitov and Janeway 1999, Habjan, 
Andersson et al. 2008). Pre-treatment of cells with IFNα prevents replication of 
CCHFV (Andersson, Lundkvist et al. 2006), and siRNA experiments indicate this 
antiviral effect is mediated for the large part by Mx1. Inhibition of CCHFV replication is 
not complete when expression of Mx1 is experimentally reduced, therefore other 
components of the innate antiviral response are also thought to play a role in the 
inhibition of CCHFV replication. To counter this inhibition, CCHFV infection has been 
shown to delay activation of the innate antiviral response, partially through inhibition of 
IRF-3 translocation to the nucleus (Andersson, Karlberg et al. 2008). Minor amounts 
of IFNβ mRNA are detected 24 hrs post-infection and secreted IFN is only detected 
48 hrs post infection. Interestingly if cells are treated with IFNα after infection with 
CCHFV, even as little as 6 hrs post infection, there is no effect on progeny virus titre 
compared to mock treated cells (Andersson, Karlberg et al. 2008). This suggests that 
CCHFV delays activation of the innate antiviral response until sufficient viral protein 
synthesis and replication has occurred, and at this point the induction of the IFN 
response has no effect on virus replication.  
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These observations are reflected in the IFN-α/βR-/- and STAT-1 knock out mouse 
models for CCHFV infection. All IFN-α/βR-/- mice exhibited 100% mortality when 
infected intraperitoneally with 10 ffu (focus forming units) CCHFV, whereas wild type 
mice survived doses as high as 106 ffu (Bereczky, Lindegren et al. 2010). Similarly 
STAT-1 knockout mice challenged with CCHFV doses as low as 10 ffu exhibited 100% 
mortality in 3-5 days whereas wild type mice exhibited neither morbidity nor mortality 
(Bente, Alimonti et al. 2010). Wild type (WT) mice with functioning IFN pathways do 
not develop CCHF; CCHFV can replicate within these animals, but they do not 
succumb to disease, and are asymptomatic (Bente, Alimonti et al. 2010; Bereczky, 
Lindegren et al. 2010; Bowick, Airo et al. 2012) whereas STAT-1 and IFN-α/βR-/- 
knockout mice exhibit key features of the disease seen in human cases, and die 
within 3-5 days.  
CCHFV infection delays activation of the innate antiviral response in STAT-1 
and IFN-α/βR-/- knockout mice compared to WT mice. At 24 hrs post infection WT 
mice showed a greater transcriptional expression of genes involved in the 
inflammatory response compared to knockout mice (Bowick, Airo et al. 2012). By 48 
hrs post infection, there was no obvious difference in the expression profiles of these 
genes in WT compared to STAT1 knockout mice, and actually the transcriptional 
levels of many of the IFN target genes were increased in knockout mice compared to 
WT. However expression of these genes 48 hrs post infection is not sufficient to 
enable these mice to survive CCHFV infection, and indeed may have a detrimental 
effect: CCHF pathogenesis is thought to be partly contributed to by high expression 
levels of pro-inflammatory cytokines. It could be that the delay in induction of antiviral 
genes is critical to CCHFV replication, and while the IFN response is crucial in the 
control of CCHFV, the kinetics of the IFN response is in fact one of the most important 
factors in determining the outcome of infection (Bowick, Airo et al. 2012).  
CCHFV has several ways of avoiding detection by the innate antiviral 
response, thereby preventing induction of IFN expression. The main pattern 
recognition receptors (PRRs) thought to be responsible for CCHFV detection in the 
cytosol and subsequent expression of IFNα/β are retinoic acid inducible gene 1 (RIG-I) 
and melanoma differentiation factor 5 (MDA5). Rig-I and MDA5 are both constitutively 
expressed RNA helicases found in most cell types, whose expression is strongly 
induced by IFNs in a positive feedback loop of virus detection (Takeuchi and Akira 
2010). The agonist for RIG-I has been defined as an RNA with both a triphosphate 
moiety (PPP) and a blunt-ended base-paired region of ~20 nt at the 5’ end, and as 
such should recognise the panhandle structures possessed by the genomic RNA 
segments of CCHFV (Goubau, Deddouche et al. 2013). To counteract this and avoid 
RIG-I detection, the 5’ termini of CCHFV genomic segments are processed such that 
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the terminal nucleotide possesses a 5’-monophosphate group rather than a 
triphosphate group (Habjan, Andersson et al. 2008). Therefore CCHFV genomic 
segments do not bind to and are not recognised by RIG-I, and RIG-I dependent 
signalling is not induced by the presence of viral genomic segments (Habjan, 
Andersson et al. 2008).  
Although the genomic segments of CCHFV do not induce innate antiviral 
signalling, other components of the virus particle may be capable of activating other 
PRRs and inducing IFN expression. Other mechanisms possessed by CCHFV to 
combat the innate antiviral response reside in the OTU-like cysteine protease 
encoded by the L segment (the vOTU), as previously described in section 1.3.6. The 
vOTU of CCHFV deconjugates ubiquitin and ISG15 from their protein targets, thereby 
potentially interfering with any innate signalling pathways regulated by ubiquitin or 
ISG15, as well as directly antagonising the antiviral effects of ISG15, which are 
mediated though the ability of ISG15 to be conjugated to cellular proteins.  
 
1.7 THE INDUCTION OF APOPTOSIS BY CCHFV 
 
Apoptosis is a tightly regulated mechanism of programmed cell death that leads to 
destruction of cells in a manner that is distinct from necrosis, and that does not result 
in the activation of an inflammatory response. Hallmarks of apoptosis are DNA 
fragmentation, membrane ‘flipping’ (the expression of the normally inward facing 
phosphatidylserine on the plasma membrane outer leaflet), expression of Annexin V 
on the outer leaflet of the plasma membrane, cell shrinkage, membrane ‘blebbing’ and 
extensive protein cross linking (Elmore 2007). Caspases are also activated during 
apoptosis by cleavage of their inactive procaspase form, which is constitutively 
expressed in the cytoplasm. Active caspases are aspartic acid residue specific 
cysteine proteases that cleave proteins at specific aspartic acid motifs during 
apoptosis. 
Two distinct apoptotic pathways exist, the extrinsic pathway, which is activated 
in response to extracellular stimuli, and the intrinsic pathway, which is activated by 
intracellular stimuli and mediated by mitochondria. Many different stimuli result in the 
induction of apoptosis, including the detection of viral PAMPs; apoptosis is induced as 
a result of IFN signalling, cell entry of viruses, activation of protein kinase R (PKR), 
activation of the transcription factor p53, and ER stress (Everett and McFadden 1999). 
These stimuli ultimately lead to an increase in the permeability of the mitochondrial 
outer membrane, and the release of normally sequestered pro-apoptotic proteins. A 
diagrammatic summary of the intrinsic apoptotic pathway is shown in Figure 1.14. 
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Figure 1.14 Diagrammatic summary of the intrinsic apoptotic pathway 
Adapted from (Postigo and Ferrer 2009). The intrinsic apoptotic pathway is regulated 
by pro-apoptotic and pro-survival members of the Bcl-2 family of proteins. An increase 
in mitochondrial outer membrane permeability results in the release of cytochrome C 
from the intermembrane space, and activation of caspase-9 and caspase-3, which 
ultimately leads to cell death. 
 
 
The Bcl-2 family of proteins govern mitochondrial membrane permeability and they 
can either be pro-apoptotic or anti-apoptotic. Some of the pro-apoptotic members 
include Bcl-10, BAX, BAK, Bid, Bad, Noxa and PUMA, and some of the anti-apoptotic 
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members include Bcl-2, Bcl-x, Bcl-xL, Bcl-XS, Bcl-w, BAG (Figure 1.14). These 
proteins have special significance as they can determine whether a cell commits to or 
aborts the apoptotic process, and the ratio of BAX:Bcl-2 or Bcl-xL is thought to be able 
to determine whether a cell lives or dies (Elmore 2007; Rodrigues, Paranhos-Baccala 
et al. 2012). The transcription factor p53 also has a critical role to play in the 
regulation of expression of the Bcl-2 family of proteins (Schuler and Green 2001; 
Elmore 2007).   
Apoptotic stimuli can result in dimerisation of two proteins embedded in the 
outer mitochondrial membrane, BAX and BAK, and an increase in outer mitochondrial 
membrane permeability. This results in the release of two main groups of pro-
apoptotic proteins into the cytosol from the mitochondrial intermembrane space 
(Saelens, Festjens et al. 2004). This first group of protein includes cytochrome C and 
SMAC/DIABLO, amongst others, and the second group is released later on during 
apoptosis, after the cell has committed to die and includes apoptosis inducing factor 
(AIF) and endonuclease G (EndoG) (Elmore 2007). Cytochrome C and 
SMAC/DIABLO activate the caspase dependent apoptotic pathway; cytochrome c 
binds to and activates Apaf 1 as well as procaspase-9, forming the apoptosome (Hill, 
Adrain et al. 2004). The local concentration of procaspase-9 in the apoptosome 
results in self cleavage and activation of procaspase-9, and SMAC/DIABLO promotes 
apoptosis by inhibiting inhibitors of apoptosis (IAPs).  
Caspase-8, -9, and -10 are initiator caspases whose role once activated is to 
cleave and activate the executioner procaspases, procaspase-3, -6, and -7. Activation 
of the executioner caspases begins the execution phase, the final pathway leading to 
cell death. Active caspase-3 cleaves a variety of substrates including poly(ADP)ribose 
polymerase (PARP), inhibitor of caspase activated Dnase (ICAD) to release caspase 
activated Dnase (CAD), and gelosolin, which once cleaved is involved in actin 
cleavage and cytoskeletal disruption (Elmore 2007).   
AIF and endonuclease G are both members of the second group of proteins to 
be released from the mitochondrial intermembrane space, and they translocate to the 
nucleus and act independently of caspases. AIF cleaves DNA into ~50-300 bp 
fragments, and begins condensation of peripheral nuclear chromatin, and 
endonuclease G cleaves nuclear chromatin into oligonucleosomal DNA fragments. 
CAD then leads to oligonucleosomal DNA fragmentation and a more pronounced and 
advanced chromatin condensation (Elmore 2007). DNA fragmentation is the final 
stage of apoptosis and indicates cell death. 
CCHFV induces apoptosis in infected cells at a relatively late time point after 
infection (Karlberg, Tan et al. 2011; Rodrigues, Paranhos-Baccala et al. 2012). 
Expression of active caspase-3 and DNA fragmentation can be detected 48 hrs post 
Chapter 1: Introduction 
51 
 
infection, and increases 72 hrs post infection when major cytopathic effect (CPE) is 
observed. The ability of CCHFV to induce apoptosis was shown to be dependent on 
the ability of the virus to replicate as UV-inactivated CCHFV failed to induce apoptosis. 
CCHFV infection of hepatocytes induced ER stress, as shown by detection of the 
unfolded protein response (UPR); ER stress can activate the intrinsic apoptotic 
pathway and CCHFV was shown to modulate both the intrinsic and extrinsic apoptotic 
pathways and activate inflammatory mediators such as IL-8 (Rodrigues, Paranhos-
Baccala et al. 2012).  
Mitochondrial dependent apoptosis was thought to occur in CCHFV infected 
hepatocytes as elevated levels of BAX mRNA was detected, and although there was 
a minor increase in Bcl-xL expression, overall the BAX:Bcl-xL ratio was positive. 
Increased mRNA levels of PUMA and Noxa, both pro-apoptotic Bcl-2 family members  
was also observed; it is thought that CCHFV induces apoptosis through multiple 
pathways that involve cross talk between the ER stress response and the 
mitochondrial mediated apoptotic pathway (Rodrigues, Paranhos-Baccala et al. 2012).  
CCHFV N is cleaved at a conserved DEVD motif on the apex of the arm 
domain by active caspase-3 during infection, resulting in the production of a 30 kDa 
fragment of CCHFV N (Karlberg, Tan et al. 2011). Interestingly, if the DEVD site is 
mutated and no longer cleaved by caspase-3 the other N cleavage products become 
more pronounced. This indicates that while the conserved DEVD motif is the major 
site for caspase-3 cleavage, there are other sites or motifs that are available for 
cleavage during apoptosis, especially if the DEVD motif is disrupted. Inhibition of 
caspase-3 was shown to increase virus titres, implying that caspase-3 cleavage of N 
is not beneficial for the virus replication cycle, and apoptosis may be induced by the 
host cell immune response as a way of limiting virus replication (Karlberg, Tan et al. 
2011). However the reason why CCHFV infection results in apoptosis so late after 
infection is unclear; it could be that CCHFV has evolved mechanisms of delaying 
activation of caspase-3 and apoptosis, similar to the way in which CCHFV delays 
activation of the IFN response, until sufficient virus replication has occurred to ensure 
the spread of progeny virions.   
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1.8 PROJECT AIMS 
 
The N protein of CCHFV is indispensable to virus replication, and therefore represents 
a potential therapeutic target. The crystal structure of CCHFV N has recently been 
solved; the aim of this project was to determine the crystal structure of the N protein of 
the closely related HAZV virus. HAZV is not pathogenic to humans, and it was hoped 
that structural similarities between CCHFV N and HAZV N would be revealed that 
would support the use of HAZV as a model for CCHFV infection. The identification of 
areas of structural similarity could also potentially be exploited in the structure guided 
design of small molecule inhibitors, whose efficacy against HAZV could be tested 
under containment level 2 conditions, prior to testing against CCHFV.        
Given the limited protein coding capacity of CCHFV and HAZV, it is thought 
their N proteins would have non-structural roles within the cellular environment during 
virus replication, roles which are mediated through interaction of CCHFV N and HAZV 
N with cellular proteins. The aim of this project was also to identify cellular proteins 
that interact with CCHFV N using a mass spectrometry based approach. We also 
aimed to determine whether a specific cellular protein, heat shock protein 70 (HSP70) 
interacted with HAZV N during HAZV replication. We aimed to investigate the role of 
HSP70 during the replication cycle of HAZV through the use of siRNA and small 
molecule inhibitors of HSP70. Little is known about the HAZV replication cycle and the 
final aim of this project was to determine whether HAZV infection resulted in apoptosis, 
and whether HAZV N is a target for proteolytic cleavage by cellular caspases, as is 
the case during CCHFV infection.  
In summary, the aims of this project were to determine the crystal structure of 
HAZV N, and to identify cellular proteins and pathways that might be important during 
the replication cycle of CCHFV and HAZV, such that they might become the targets of 
host-directed antiviral therapeutic strategies.  
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CHAPTER 2 : MATERIALS AND METHODS 
 
2.1 MATERIALS 
 
2.1.1 Vectors 
 
The HAZV N open reading frame (ORF) optimized for bacterial expression was 
synthesized by Dundee Cell Products, and was provided cloned into a pET28-SUMO 
expression vector. The HAZV N ORF was subcloned into a pGEX6P2 expression 
vector (GE Healthcare); this fusion vector encodes glutathione S-transferase (GST) 
that is used to N-terminally tag the ORF of interest with GST, and a human rhinovirus 
3C (HRV) protease (GE Healthcare) cleavage site. The HAZV N nucleotide sequence 
was confirmed by DNA sequencing; expression of this HAZV N ORF resulted in the 
production of a protein whose amino acid sequence matched that of HAZV isolate 
JC280, GenBank accession number; M86624.1. 
 The CCHFV N ORF was synthesized by Dundee Cell Products, and was 
provided cloned into a pCAGGs vector. pCAGGs vectors enable high level gene 
expression in mammalian cells, driven by the synthetic CAG promoter, that contains a 
hybrid CMV enhancer/chicken β-actin promoter. The CCHFV N ORF was subcloned 
into a pEGFP-C2 expression vector (Clontech); this fusion vector contains an 
enhanced green fluorescent protein (EGFP) tag, and enables the expression of ORFs 
of interest with an N-terminal EGFP tag. Gene expression from pEGFP-C2 is driven 
by a CMV promoter and results in strong, constitutive expression of N terminally 
tagged EGFP-fusion proteins in many mammalian cell types. pEGFP-C2 also contains 
an SV40 poly(A) signal, which increases RNA stability, and enables high level protein 
expression. The CCHFV N nucleotide sequence was confirmed as correct by DNA 
sequencing and matched that of CCHFV strain 10200, accession number; U88410. 
See appendix I for HAZV N and CCHFV N ORF sequences.  
     
2.1.2 Bacterial strains 
 
Plasmid DNA constructs were amplified, and recombinant GST-HAZV N was 
expressed, through transformation of competent Escherichia coli (E. coli) cells. 
Bacterial strains used were: Subcloning efficiency JM109 Competent cells (Promega) 
for initial transformation of ligation reactions; TOP10 cells prepared in the laboratory 
using the standard Inoue method for routine retransformation; and the BL21 derivative 
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Rosetta-2 for isopropyl β-D-1-thiogalactopyranoside (IPTG) inducible protein 
expression. 
 
2.1.3 Continuous human cell lines  
 
HEK293T (human embryonic kidney cell origin) (Graham, Smiley et al. 1977), HUH-7 
(human hepatocellular carcinoma origin) (Nakabayashi, Taketa et al. 1982) and SW13 
(human adrenal cortex carcinoma origin) (Leibovitz, McCombs et al. 1973) cells were 
utilised to express recombinant proteins or for virus replication. HEK293T cells are a 
human kidney epithelial cell line that constitutively expresses the SV40 large T 
antigen, HUH-7 cells are a hepatocyte derived carcinoma cell line, originally isolated 
from a liver tumor and SW13 cells are a human adrenal cortex carcinoma cell line, 
originally derived from a small cell carcinoma tissue biopsy. 293T cells and HUH-7 
cells were obtained from the Health Protection Agency Culture Collections (HPACC), 
and SW13 cells were a kind gift from Dr Stuart Dowall and Dr Roger Hewson, of 
Public Health England (PHE).  
 
2.1.4 HAZV strain 
 
HAZV strain JC280 was kindly provided by Dr Stuart Dowall and Dr Roger Hewson 
(PHE, UK) as an infectious cell culture supernatant from SW13 cells. The cRNA 
sequence of HAZV S, M, and L segments from strain JC280 has been published on 
GeneBank with the respective accession numbers: M86624.1, DQ813514.1 and 
DQ076419.1. 
 
2.2 METHODS 
 
2.2.1 Manipulation of recombinant DNA 
 
2.2.1.1 The polymerase chain reaction (PCR) 
During subcloning the cDNA representing HAZV N and CCHFV N ORFs were 
amplified by PCR, incorporating terminal restriction endonuclease recognition sites, to 
facilitate insertion into expression plasmids. PCR reactions were performed in 50 µL 
reaction volumes and contained; 100 ng of template DNA, 0.4 µM of each forward and 
reverse primer, 0.3 mM of each deoxyribonucleotide triphosphate (dNTPs; Roche), 10 
Chapter 2: Materials and Methods 
55 
 
x Thermopol buffer (New England Biolabs) and 1 unit of Vent polymerase (New 
England Biolabs). Reaction cycles were carried out in a thermocycler (Microfuge) as 
follows; initial denaturation at 95 °C for 5 minutes; 30 cycles of denaturation at 95 °C 
for 30 seconds, annealing at 50 °C - 65 °C for 30 seconds (dependent on primer 
sequence), and elongation at 72 °C for 90 seconds, then final extension at 72 °C for 5 
minutes. PCR products were kept at 4 °C until removal from thermocycler; PCR 
products were then isolated and purified by agarose gel electrophoresis followed by 
gel extraction.  
2.2.1.2 Restriction digest 
Plasmid DNA was subjected to restriction enzyme digestion for cloning and diagnostic 
purposes. Restriction digests were carried out in a 50 µL volume and contained: 1 µg 
DNA, +/- 1 x bovine serum albumin (BSA; restriction enzyme dependent), 1 x 
compatible NEBuffer (New England Biolabs), and 2 units of each restriction enzyme 
(New England Biolabs). Reactions were incubated at 37 °C for 2-3 hrs, or were left at 
37 °C overnight. The products of digestion were purified by agarose gel 
electrophoresis followed by gel extraction using the Zymoclean Gel DNA recovery kit 
(Zymo Research) as per the manufacturer’s protocol. 
2.2.1.3 Agarose gel electrophoresis  
Size, integrity and purity of PCR products, plasmid DNA, products of restriction 
enzyme digestion, and ligations were determined using 1 % agarose gels composed 
of 0.5 g analytical grade agarose, 50 mL of 1 x TAE buffer (40 mM Tris-acetate, 1 mM 
ethylene-diamine-tetraacetic acid (EDTA)) and SYBR Safe DNA stain (Life 
Technologies) diluted 1:10,000. DNA samples were mixed with 1 x GelPilot DNA 
loading dye (Qiagen) and loaded alongside the molecular marker Hyperladder I 
(Bioline); gels were then run at 90 V for 30-60 minutes, in 1 x TAE buffer. Blue light 
transillumination was used to visualise DNA.  
2.2.1.4 Ligations   
Ligations were carried out in 20 µL reaction volumes containing: 3:1, 6:1 or 10:1 molar 
ratio of insert:vector DNA, 1 x Ligase Reaction Buffer (30 mM Tris-HCl (pH 7.8), 10 
mM MgCl2, 10 mM DTT and 1 mM ATP; Promega) and 1 unit T4 DNA Ligase 
(Promega). Ligase reactions were incubated at 4 °C overnight, then transformed into 
DH5α cells. 
2.2.1.5 Bacterial transformations 
When using subcloning efficiency DH5α competent cells (Life technologies), 
transformations were carried out according to the manufacturer’s instructions, or 
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transformations were carried out as follows for laboratory-made cells: 1 µL of plasmid 
DNA at a concentration of 25 - 50 ng/µL, or 1 µL ligation mix were added to 50 µL 
competent cells that had been thawed on ice. Transformation mixes were incubated 
on ice for 30 minutes, heat shocked at 42 °C for 45 seconds, and rapidly cooled on 
ice for 2 minutes. 450 µL of pre-warmed LB (Luria-Bertani) media (10 g tryptone, 5 g 
yeast extract, 10 g NaCl in 1 L water) was added to transformation mixes, which were 
then incubated at 37 °C for 1 hr with shaking. Transformed bacteria were pelleted by 
centrifugation at 300 x g for 2 minutes at room temperature, the supernatant was 
removed, and bacteria were resuspended in 50 µL LB media prior to being spread 
onto antibiotic-selective LB agar plates and incubated at 37 °C overnight.     
2.2.1.6 Starter cultures   
Starter cultures of 5 mL LB medium (small-scale) or 50 mL (large scale) were grown 
from single colonies picked from transformation plates. Single colonies were allowed 
to grow overnight in LB medium containing the appropriate antibiotic (final 
concentration 50 µg/mL kanamycin or 100 µg/mL ampicillin); these starter cultures 
were then used to inoculate overnight cultures either for protein expression or plasmid 
DNA amplification. Aliquots of starter cultures were mixed in a 70:30 ratio with glycerol 
and stored frozen at -80 °C as glycerol stocks. 
2.2.1.7 Plasmid DNA amplification 
Overnight cultures of 200 mL LB medium containing the appropriate concentration of 
antibiotic were inoculated with 200 µL starter cultures, and the following morning, 
bacteria were pelleted by centrifugation at 4000 x g at 4 °C for 20 minutes. Plasmid 
DNA was isolated from pelleted bacteria using Plasmid Maxiprep kits (Qiagen) 
according to the manufacturer’s instruction, where isolation of plasmid DNA is based 
on the alkaline lysis method followed by isopropanol precipitation. Plasmid DNA was 
also isolated from starter cultures using Spin Miniprep kits (Qiagen) according to the 
manufacturer’s instruction, where isolation of plasmid DNA is based on adsorption to 
a silica membrane under high-salt conditions. A NanoDrop 1000 (Thermo Scientific) 
was used to quantify DNA by spectrophotometry.  
 
2.2.2 Protein expression and purification in E. coli. 
 
2.2.2.1 Culture growth, IPTG induction and lysis 
Large-scale 50 mL starter cultures were grown from stabs of glycerol stocks of pGEX-
GST-HAZV N transformed E. coli Rosetta-2 cells, 50 mL starter cultures were then 
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used to inoculate 1 L overnight cultures of LB medium containing 100 µg/mL 
ampicillin. Cultures were grown to OD600 0.6 - 0.8 at 37 °C, then were induced with 
100 µM IPTG for 16 hrs at 18 °C. Bacterial cells were recovered by centrifugation at 
4000 x g at 4 °C for 30 minutes, the supernatant was removed, and cells were either 
frozen at -20 °C, or resuspended immediately in lysis buffer containing: 100 mM NaCl, 
20 mM Tris pH 8, 1 % (v/v) Triton X-100, 1 mg/mL chicken egg white lysozyme 
(Sigma Aldrich), 1 mM MgCl2, 1x complete protease inhibitor cocktail EDTA-free 
(Roche), 1 unit (U) DNase and 1 U RNase. 25 mL lysis buffer was used per 1 L 
bacterial culture. Cells were incubated in lysis buffer on ice for 30 minutes, then lysis 
was completed by sonication on ice with 15 cycles of 10 seconds on, 5 seconds off, at 
8 micron amplitude. Lysates were clarified by centrifugation at 18,000 x g for 30 
minutes at 4 °C and the supernatant was retained for GST-HAZV N purification by 
glutathione affinity chromatography.  
2.2.2.2 Purification by glutathione affinity chromatography 
Clarified bacterial supernatant containing soluble GST-HAZV N protein was applied to 
glutathione sepharose 4B resin (GE Healthcare) in batch at room temperature for 1 hr 
with rotation. Resin with bound GST-HAZV N was transferred to a gravity flow column 
attached to a peristaltic pump, and unbound bacterial lysate was removed from the 
resin. Resin was then washed once in 4 volumes of binding buffer (100 mM NaCl, 20 
mM Tris pH 8), once in 4 volumes binding buffer containing 1.5 M NaCl to remove 
RNA derived from the bacterial expression host to generate Apo-HAZV N, (or this step 
was excluded when RNA-bound HAZV N was purified), then resin was washed once 
more in 4 volumes of binding buffer. Elution buffer (40 mM reduced glutathione, 5 % 
glycerol, 50 mM NaCl, 15 mM HEPES pH 7, 1 mM DTT) was used to dissociate GST-
HAZV N from the resin in 3 successive elutions. Solutions containing eluted GST-
HAZV N were pooled and protein concentration was determined by adding 1 µL 
protein to a 1:5 dilution of Protein Assay reagent (Bio-Rad) in ddH2O, and reading the 
absorbance at 595 nm. Eluted GST-HAZV N was then incubated overnight at 4 °C 
with HRV 3C protease to cleave the GST tag from HAZV N; HRV 3C protease was 
expressed and purified in house from glycerol stocks.  
2.2.2.3 Size exclusion chromatography 
Size exclusion chromatography was used analytically to examine the oligomeric 
status of HAZV N. A 320 mL HiLoad 26/600 Superdex 75 pg column (GE Healthcare) 
was used with an Akta Prime pump system at 4 °C, and absorbance at 280 nM was 
used to monitor protein elution. All buffers used were filtered through 0.2 µM filters 
and degassed. The column was equilibrated with running buffer (500 mM NaCl, 20 
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mM Tris pH 7.5, 1 mM EDTA, 1 mM DTT) and the protein was concentrated to a just 
over 5 mL volume with 10 kDa molecular weight cut off (MWCO) Vivaspin centrifugal 
concentraters (Sartorius Stedim). The protein sample was then passed through a 0.2 
µm syringe filter prior to injection onto the column with a 5 mL loop. The cloumn was 
run at approximately 2 mL/minute until the void volume (~90 mL) had eluted, then 3 
mL fractions were collected until a full column volume of buffer had eluted (320 mL). 
The column was calibrated using a gel filtration standard kit (Bio-Rad) containing 
thyroglobulin (670,000 Da), γ-globulin (158,000 Da), ovalbumin (44,000 Da), 
myoglobin (17,000 Da), vitamin B12  (1,350 Da).  
2.2.2.4 Ion exchange chromatography  
A 1 mL Resource S cation exchange column (GE Healthcare) was used at pH 7 
(below the isoelectric point (pI) of HAZV N (8.73)) with an Akta purifier pump system 
at 4 °C, and absorbance at 280 nM was used to moniter protein elution. All buffers 
used were 0.2 µM filtered and degassed. The Resource S coumn was equilibrated in 
buffer A (50 mM NaCl, 15 mM HEPES pH 7, 1 mM DTT); cleaved HAZV N was 
dialysed into 5 L buffer A overnight at 4 °C using snakeskin dialysis tubing (10,000 Da 
MWCO, Thermo Scientific), prior to concentration to just over 5 mL volume. The 
column was run at a flow rate of approximately 1 mL/minute and the protein sample 
was injected onto the column using a 5 mL loop. 1 mL fractions were collected from 
this point until the 280 nm trace returned to baseline. To elute bound HAZV N, the 
NaCl concentration was linearly increased by applying a gradient of 0-100 % buffer B 
(1 M NaCl, 15 mM HEPES pH 7, 1 mM DTT). Appropriate fractions were pooled and 
concentrated to 10-12 mg/mL using 10,000 Da MWCO centrifugal concentrators 
(Sartorius Stedim) and stored either at 4 °C or at -80 °C.  
 
2.2.3  Crystallographic techniques 
 
2.2.3.1 Sparse matrix screening  
Initial crystallisation trials were carried out using commercially available sparse matrix 
screens. The following kits were used: Wizard I and II, Wizard III and IV (Emerald 
Biosystems), Salt RX, Matrix, Index, and Crystal Screen I and II (Hampton Research). 
Sitting drops were set up in 96-well MRC-2 drop plates (Molecular Dimensions) using 
an Oryx 6 robot (Douglas Instruments) with 60 µL reservoire solution. Protein 
concentrated to 10-12 mg/mL was dispensed into 1 µL droplets containing 
protein:reservoire ratios of 50:50 or 70:30. Plates were sealed with Viewseal pressure 
adhesive clear seals (Greiner Bio-One) and incubated at 11 °C, 18 °C or 25 °C.  
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2.2.3.2 Crystal optimisation 
Sparse matrix screen sitting drops were monitered for crystal growth 24 hrs after they 
were set up, and then periodically for 2 weeks afterwards. Conditions that resulted in 
crystal growth were further optimised in 24-well plates in hanging drop orientations, 
using 1-2 µL drops at 50:50 and 70:30 protein:reservoire ratios. Matrices were set up 
to vary concentration of precipitants, type of precipitants, pH of buffer, protein 
concentration, and temperature of crystal growth. An additive screen (Hampton 
Research) was also used in an attempt to improve crystal growth.   
2.2.3.3 Crystal harvesting and data collection 
Appropriately sized loops (Hampton Research) were used to pick crystals, which were 
then soaked in a cryprotectant solution containing 1:1 reservoir solution and one of 
the following cryoprotectants (60 % glycerol, 60 % PEG-400, 60 % PEG-200, 60 % 
ethylene glycol, or 60 % 2-Methyl-2, 4-pentanediol (MPD)) prior to cyro-cooling in 
liquid nitrogen. All data were collected at -173 °C at the Diamond Light Source on 
beamlines I02 and I03. Crystals were screened for diffraction by taking test images at 
Φ=0° and 90°, using 12,658 eV X-rays (0.9795 Å). Full datasets were collected from 
crystals that diffracted to better than 4 Å.  
2.2.3.4 Data processing and structure solution 
X-ray data were integrated using XDS (Kabsch 2010) or iMOSFLM (Leslie 2006; 
Battye, Kontogiannis et al. 2011) from the Collaborative Computer Project 4 (CCP4) 
suite (Potterton, Briggs et al. 2003; Winn, Ballard et al. 2011). POINTLESS was used 
to confirm the space group identity, and to test for twinning, then AIMLESS (Evans 
2006; Evans 2011) was used to scale the reduced data from all crystals. Datasets 
from both Apo-HAZV-N and RNA-bound HAZV N were solved via molecular 
replacement (MR) with the globular domain of CCHFV N (Protein Data Bank (PDB) 
accession number 4AKL) residues 1-182, and 296-482 using PHASER (McCoy, 
Grosse-Kunstleve et al. 2007). BUCANNEER (Cowtan 2006) was used to build an 
initial model into the calculated electron density maps; this was followed by 
consecutive cycles of manual building in COOT (Emsley and Cowtan 2004) and 
structure refinement in REFMAC5 (Murshudov, Skubak et al. 2011). Refined models 
were analysed with the MolProbity server, models were examined in COOT and 
figures were made using PyMOL.  
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2.2.4 Cell culture methods 
 
2.2.4.1 Continuous cell culture 
All cells were maintained at 37 °C with 5 % CO2 in humidified incubators. HEK293T 
and SW13 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM; Sigma) 
supplemented with 10 % (v/v) foetal bovine serum (FBS; Invitrogen), 100 IU 
penicillin/mL, and 100 µg streptomycin/mL. This is referred to as complete media. 
HUH-7 cells were grown in complete media supplemented with 1 % non-essential 
amino acids (NEAA). Cell lines were passaged using trypsin-EDTA (Sigma) 3 times 
per week as they approached confluency. Cells were seeded at the following densities 
24 hrs prior to manipulation to achieve 60-70 % confluency: 96 well plate (104 
cells/well), 12 well dish (105 cells/well), 6 well dish (2 x 105 cells/well) and 10 cm2 dish 
(106 cells/well). Autoclaved glass coverslips (VWR) were placed in wells prior to 
seeding for immunofluorescence (IF) experiments.  
2.2.4.2 Freezing and thawing cells 
Cells were frozen for long term storage in liquid nitrogen. Cells were trypsinised and 
washed 3 times in ice-cold PBS, with centrifugation at 1000 x g at 4 °C for 5 minutes 
between each wash step. Cells were counted, then resuspended in ice-cold FBS 
supplement with 10 % DMSO, to a final concentration of 106 cells/mL. 1 mL cell 
suspension was aliquoted in each cryovial, which were cooled at a controlled rate in 
an isopropanol chamber to -80 °C overnight prior to being transferred to liquid 
nitrogen. Frozen cells were rapidly thawed at 37 °C, centrifuged once at 600 x g at 4 
°C for 5 minutes, the supernatant was removed and the cell pellet resuspended in 
complete media and transfered to a 25 cm2 flask. Cell cultures were expanded when 
cells reached 80 % confluency. 
2.2.4.3 Stable isotope labelling of amino acids in cells culture (SILAC)     
Frozen HEK293T cells were thawed, then cultured in isotopically distinct labelled 
SILAC-DMEM (Dundee Cell Products Ltd) for a minimum of seven population 
doublings (approximately 2 weeks) to ensure >95 % labelling. SILAC-DMEM recipes 
used were R0K0 (Light), which contained 12C L-arginine and 12C L-lysine, and R6K4 
(Medium) which contained 13C L-arginine and 2D L-lysine. SILAC-DMEM was 
supplemented with 10 % dialysed foetal calf serum (FCS; Dundee Cell Products Ltd), 
and passaged using a PBS-based cell dissociation buffer (Invitrogen) instead of 
trypsin, to avoid the introduction of unlabelled amino acids.  
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2.2.5 Transfections 
 
2.2.5.1 Calcium phosphate mediated transfection of HEK293T cells 
In order to identify cellular interacting partners of EGFP-CCHFV N, SILAC labelled 
HEK293T cells were transfected via calcium phosphate (CaPO4) with 10 µg plasmid 
DNA encoding EGFP-CCHFV N or EGFP per 10 cm2 dish, for immunoprecipitation 
(IP) experiments (4 x 10 cm2 dishes were transfected with each construct to ensure 
the IP of sufficient amounts of EGFP-CCHFV N to identify cellular proteins that co-IP 
by mass spectrometry). Unlabelled 293T cells were also transfected with EGFP-
CCHFV N and EGFP, as well as pCAGGs-CCHFV N via CaPO4. The appropriate 
amount of plasmid DNA was added to a solution containing 244 mM CaCl2, this was 
added dropwise to 2 x HBS (274 mM NaCl, 302 µM (Na2HPO4).12H2O, 55 mM 
HEPES pH 7). CaCl2 and 2 x HBS were 0.2 µm filtered. Solutions of calcium chloride, 
DNA and 2 x HBS were incubated at room temperature for 30 minutes to allow 
calcium phosphate-DNA precipitates to form, prior to being adding dropwise to 
HEK293T cells; CaPO4 facilitates binding of the DNA to the cell surface, where it then 
enters the cell by endocytosis. Fresh complete media was added to cells immediately 
prior to transfection. Complete media containing transfection mixes were incubated 
with HEK293T cells overnight; this was replaced with fresh complete media the 
following morning, or cells were harvested. 
2.2.5.2 Lipofectamine mediated transfection of HUH-7 and SW13 cells with pCAGGs-
CCHFV N, and siRNA  
HUH-7 cells were transfected with pCAGGs-CCHFV N for IF experiments and SW13 
cells were transfected with siRNA (small interfering RNA) for protein depletion 
experiments. siRNA targeting HSP70 (gene HSPA1A; Life Technologies) was a 
duplex of 21 nucleotides, the sequence of the siRNA from 5’->3’ is as follows: 5’-
AAUUUAUACUGCCAUCUUATT-3’. Scrambled siRNA (MISSION universal negative 
control 1; Sigma Aldrich) was used as a negative control; HSPA1A siRNA and 
scrambled siRNA were obtained as lyophilised RNA, and stock solutions were made 
up to the same concentration (10 µM) in nuclease free ddH2O. SW13 cells (12-well 
plate) were transfected with 80 pmole HSP70 siRNA per well to deplete HSP70, or 80 
pmole scrambled siRNA was transfected as a negative control for off-target effects 
due to siRNA transfection. RNAiMAX (Life Technologies) was used to transfect SW13 
cells with siRNA, and Lipofectamine 2000 (Life Technologies) was used to transfect 
HUH-7 cells with pCAGGs-CCHFV N.  
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RNAiMAX and Lipofectamine 2000 are both cationic lipid-based transfection reagents 
that facility entry of DNA and siRNA into cells, and their transfection protocols are the 
same; cells are seeded in 12-well plates 24 hrs before transfection such that their 
confluency is 60-70 % when transfected. 80 pmole siRNA, or 0.71 µg pCAGGs-
CCHFV N was added to 100 µL Opti-MEM. In a separate microfuge, 3 µL RNAiMAX 
or Lipofectamine 2000 was added to 100 µL Opti-MEM; both solutions were mixed 
gently and allowed to equilibrate for 5 minutes. The Opti-MEM-DNA solution was 
dropwise added to the Opti-MEM-RNAiMAX/Lipofectamine 2000 solution, mixed 
gently, and incubated at room temperature for 20 minutes to allow complexes to form 
between the positively charged cationic lipids and the negatively charged DNA/RNA 
backbone. The cationic lipids bind to and fuse with the plasma membrane, and entry 
of DNA into cells is thought to occur through endocytosis. Complete media was 
removed from cells, and was replaced with serum- and antibiotic-free media (SFM), 
after cells were washed once in SFM. OptiMEM containing DNA/RNA-cationic lipid 
complexes was dropwise added to cells in SFM, complexes were removed the 
following morning and replaced with complete media, or cells were harvested.  
 Depletion of HSP70 was optimised by varying incubation times and ratios of 
siRNA:RNAiMAX. Efficacy of HSP70 depletion was analysed by western blot 24 hrs, 
48 hrs, and 72 hrs after transfection; western blot membranes were probed with an 
anti-HSP70/HSP72 mAb (monoclonal antibody) (C92F3A-5; Enzo Life Sciences) that 
specifically detected the HSPA1A gene product. When assessing the effect of HSP70 
depletion on HAZV replication, media containing transfection complexes was removed 
from cells 20 hrs after transfection, cells were washed once with PBS, then cells were 
infected with HAZV MOI 1, in 250 µL SFM. Cells were incubated at 37 °C with rocking 
to allow HAZV to adsorb to plasma membranes, then virus containing SFM was 
removed and replaced with DMEM containing 2 % FBS. HAZV was allowed to 
replicate for 6 hrs or 24 hrs prior to harvesting cells.     
 
2.2.6 Analysis of protein expression 
 
2.2.6.1 Preparation of whole cell lysate 
Cells were harvested from cell culture dishes and flasks by scraping whilst in media. 
Cell pellets were recovered by centrifugation at 4 °C at 2000 x g for 5 minutes, 
washed 3 x in PBS, with the same centrifugation step between each wash, then 
resuspended in lysis buffer (10 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 
0.5% NP40, 1x EDTA-free complete protease inhibitor (Roche)) for IP, or 
radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 
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1 % (v/v) NP40 alternative, 0.5 % (w/v) sodium deoxycholate, 0.1 % and 1 x EDTA-
free complete protease inhibitor cocktail) for western blot analysis. Cell pellets were 
incubated in lysis or RIPA buffer for 30 minutes on ice, then cell lysates were clarified 
by centrifugation at 13,000 x g at 4 °C for 10 minutes, and the supernatant containing 
total protein was either directly utilised or stored at -80 °C for future use.  
2.2.6.2 Determining protein concentration by BCA assay  
Total protein concentration was determined from whole cell lysates using the micro 
bicinchoninic acid (BCA; Pierce) protein assay system according to the 
manufacturer’s 96-well plate protocol. Bovine serum albumin (BSA) standards were 
prepared to create a standard curve ranging from 25 µg/mL - 2000 µg/mL BSA. Whole 
cell lysates were diluted 1:25 and 50 µL of both standards and diluted sample were 
mixed with 200 µL assay working reagent (created by diluting reagent B 1:50 with 
reagent A) then transferred to 96-well plates and incubated at 37 °C for 30 minutes. 
Protein concentration of samples was determined by measuring their absorbance at 
570 nm in a TECAN infinite F50 plate reader and comparing them to the standard 
curve. Protein samples of the appropriate concentration (2-10 µg) were mixed with 4 x 
lithium dodecyle sulphate (LDS) buffer (Invitrogen) supplemented with 50 mM DTT 
reducing agent, prior to denaturation and resolution by SDS PAGE.  
2.2.6.3 SDS polyacrylamide gel electrophoresis (SDS PAGE) 
5 mL SDS PAGE gels were made with a 12 % (or 15 %) resolving gel (4 mL (5 mL) 30 
% bis-acrylamide, 2.5 mL 1.5 M Tris-HCl pH 8.8, 3.3 mL (2.3 mL) ddH2O, 100 µL 10 
% SDS, 100 µL 10 % ammonium persulphate (APS), 10 µL TEMED) and a 5 % 
stacking gel (0.83 mL 30 % bis-acrylamide, 0.63 mL 1 M Tris-HCl pH 6.8, 3.4 mL 
ddH2O, 50 µL 10 % SDS, 50 µL 10 % APS, 5 µL TEMED). Protein samples were 
either mixed 1:1 with 2 x denaturing sample buffer (60 mM Tris pH 6.8, 25 % (v/v) 
glycerol, 2 % (w/v) SDS, 5 % β-mercaptoethanol, 0.01 % (w/v) bromophenol blue) or 
2-10 µg protein sample was mixed with 4 x LDS sample buffer (Invitrogen), 
supplemented with 50 mM DTT reducing agent. Protein samples were denatured by 
heating at 95 °C for 5 minutes, or at 70 °C for 10 minutes, immediately prior to loading 
onto gels. Samples were loaded alongside 7.5 µL ColorPlus prestained protein 
marker (New England Biolabs) or SeeBlue Plus 2 prestained protein marker 
(Invitrogen), and electrophoresis was performed in SDS running buffer (25 mM Tris, 
192 mM glycine, 0.1 % (w/v) SDS) at 200 V for 40-60 minutes. 
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 2.2.6.4 Protein visualisation by Coomassie and silver stain 
Proteins resolved by SDS PAGE were directly visualised by incubating gels in 
Coomassie stain (0.25 % (w/v) Coomassie R-250, 50 % (v/v) methanol, 10 % (v/v) 
glacial acetic acid) at room temperature for 1 hr, followed by destaining for 1 hr at 
room temperature in destain solution (40 % (v/v) methanol, 10 % (v/v) glacial acetic 
acid), and rehydration of gels in ddH2O prior to imaging. Gels were silver stained 
using a SilverQuest staining kit (Invitrogen) according to the manufacturer’s 
instructions.  
2.2.6.5 Western blot analysis   
Proteins were transferred from SDS PAGE gels (section 2.2.6.3) to polyvinylidene 
fluoride (PVDF) membranes (Immobilon-P Transfer membrane; Millipore), or 
fluorescence compatible PVDF membranes (FL-PVDF) (Immobilon-FL Transfer 
membranes; Millipore) using a Trans-Blot semi-dry cell (Bio-Rad) in Towbin buffer (25 
mM Tris, 192 mM glycine, 20 % (v/v) methanol) for 1 hr at 15 V. PVDF membranes 
were blocked for 1 hr at room temperature in 10 % (w/v) non-fat powdered milk 
(Sigma) in Tris buffered saline supplemented with Tween-20 (TBS-T) (50 mM Tris-HCl 
pH 7.5, 150 mM NaCl, 0.1 % Tween-20). FL-PVDF membranes were blocked for 1 hr 
at room temperature in 50 % (v/v) Odyssey blocking buffer (LiCor) in TBS (50 mM 
Tris-HCl pH 7.5, 150 mM NaCl). Blocking buffer was then replaced with primary 
antibody diluted to the appropriate concentration in 5 % (w/v) non-fat powdered milk in 
1 x TSB-T, or in 50 % Odyssey blocking buffer in TBS, either for 1 hr at room 
temperature or at 4 °C overnight. A full list of primary antibodies used to detect 
immobilised proteins is provided in Table 3.   
 PVDF membranes were then extensively washed in TBS-T, before 
incubating with the appropriate secondary antibody conjugated to horseradish 
peroxidase (HRP), under the same conditions and dilutions as for the primary 
antibody incubation. FL-PVDF membranes were extensively washed in TBS, then 
incubated with the appropriate fluorescently labelled secondary antibody under the 
same conditions and dilutions as for the primary antibody incubations. A full list of 
secondary antibodies used is provided in Table 4. PVDF membranes were washed in 
TST-T, once in water, and proteins were visualised using enhanced 
chemiluminescence on photographic film. Enhanced chemiluminescence solution 
(ECL) was made with a 1:1 mix of each of the following solutions, and applied to the 
membrane: solution 1, 25 mM Luminol (3-aminophthalydazide), 0.3 mM p-coumaric 
acid, 100 mM Tris-HCl pH 8.5; solution 2, 0.01 % (v/v) hydrogen peroxide, 100 mM 
Tris-HCl pH 8.5. After incubation of membranes for 1 minute in ECL, they were 
exposed to film (CL-Xposure film; Thermo Scientific) and proteins were visualised 
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after fixation and development of film with a Konica SRX-101A processor. FL-PVDF 
membranes were washed in TBS, once in water, then fluorescently labelled 
secondary antibodies were directly visualised using a LiCor Odyssey Sa Infrared 
imaging system (LiCor). 
2.2.6.6 Immunofluorescence (IF)  
IF experiments were carried out to visualise the subcellular localisation of various 
proteins. Cells were grown on 19 mm glass coverslips housed in 12 well plates prior 
to manipulation and subsequent fixation. Media was removed from cells, which were 
washed twice in PBS, prior to fixation of cells either in formalin (37 % formaldehyde 
(BHD Chemicals) diluted to 4 % in PBS)) for 10 minutes at room temperature, or 4 % 
(w/v) paraformaldehyde (4 % PFA) for 20 minutes at room temperature. The fixative 
was removed from cells following the appropriate incubation, cells were washed 3 
times with PBS, then either stored in PBS at 4 °C, or cells were permeabilised in 0.5 
% (v/v) Triton-X 100 in PBS for 12 minutes at room temperature. Permeabilised cells 
were washed 3 times in PBS, then blocked in 2 % (v/v) FBS in PBS for 30 minutes.  
 Primary and secondary antibody incubations were both performed with 
antibodies diluted to the appropriate concentration in 2 % (v/v) FBS in PBS; after 
blocking, cells were incubated with 50 µL of the appropriate primary antibody for 1 hr 
at room temperature. Cells were then washed in PBS and incubated with 50 µL of the 
appropriate fluorescently labelled secondary antibody for 1 hr at room temperature. A 
list of the primary and secondary antibodies used for IF, and their concentrations, is 
provided in table 3 and 4. Cells were washed in PBS prior to mounting onto glass 
slides using ProLong Gold anti-fade reagent (Invitrogen) containing DAPI (4',6-
diamidino-2-phenylindole) to allow visualisation of cell nuclei. Mounted coverslips 
were allowed to cure at room temperature for 24 hrs prior to visualisation, and kept at 
4 °C in the dark for long term storage. Slides harbouring fixed and stained cells were 
analysed by confocal microscopy; confocal images were captured on either an 
inverted LSM (laser scanning microscope) 510 META Axiovert 200M, or an upright 
LSM 510 META Axioplan microscope (Carl Zeiss Ltd). The excitation and emission 
spectra of the lasers used are as follows; for the detection of DAPI, excitation 
wavelength 405 nm, emission wavelength 450 nm, for the detection of Alexa Fluor  
488 conjugated secondary antibodies, excitation wavelength 488 nm, emission 
wavelength 518 nm, and for the detection of Alexa Fluor 568 conjugated secondary 
antibodies, excitation wavelength 543 nm, emission wavelength 590 nm. All pinholes 
were set to allow optical sections of 1-2 µm to be captured. 
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2.2.6.7 Live cell imaging 
Cells were seeded into glass bottom plates prior to transfection with EGFP-CCHFV N 
or EGFP (as described in section 2.2.5.1). 24 hrs after transfection, complete media 
was replaced with CO2 independent, phenol red-free media (Life Technologies) and 
images of cells expressing EGFP or EGFP-CCHFV N were captured on the inverted 
LSM 510 META confocal microscope (Carl Zeiss). Cells were maintained at 37 °C 
with a heated stage throughout imaging. EGFP allowed direct visualisation of EGFP-
CCHFV N in transfected cells when illuminated with light of wavelength 488 nm, the 
excitation wavelength of EGFP.  
 
2.2.7 Immunoprecipitations  
 
2.2.7.1 GFP-Trap IPs 
Immunoprecipitation (IP) was used to enrich EGFP-CCHFV N and EGFP from SILAC 
labelled 293T cells using a GFP-Trap (chromotek). GFP-Traps are composed of 
agarose beads covalently conjugated to camelid antibodies (only contain the antibody 
‘heavy’ chain) that specifically recognise and bind to EGFP. Lysates from 4 x 10 cm2 
dishes containing SILAC labelled cells transfected with EGFP or EGFP-CCHFV N 
were prepared as described in section 2.2.6.1. EGFP was transfected into Medium 
(R6K4) labelled cells and EGFP-CCHFV N was transfected into Light (R0K0) labelled 
cells. Two IPs were performed separately, each using 30 µL GFP-Trap bead slurry. 
GFP-Trap beads were pre-equilibrated in ice-cold dilution buffer (10 mM Tris-HCl pH 
7.5, 150 mM NaCl, 0.5 mM EDTA, and 1 x protease inhibitor cocktail (Roche)) as 
follows; GFP Trap beads were sedimented by centrifugation at 2700 x g at 4 °C for 2 
minutes, the storage buffer (20 % ethanol) was removed, and GFP-Trap beads were 
washed twice in dilution buffer with the above centrifugation step repeated between 
each wash, then resuspended in 500 µL dilution buffer. Cell lysates from EGFP and 
EGFP-CCHFV N transfected cells were adjusted to a total volume of 1 mL with 
dilution buffer, equilibrated GFP-Trap beads were centrifuged at 2700 x g for 2 
minutes at 4 °C, dilution buffer was removed, and GFP-Trap beads were resuspended 
in 1 mL cell lysates.  
 Cell lysates were incubated with GFP-Trap beads for 2 hrs with rotation at 4 
°C to allow anti-GFP antibodies to bind EGFP and EGFP-CCHFV N. EGFP or EGFP-
CCHFV N bound GFP-Trap beads were centrifuged at 2700 x g to sediment GFP-
Trap beads, then supernatant containing unbound cellular proteins was removed. 
GFP-Trap beads were then washed once in dilution buffer, once in dilution buffer 
containing 275 mM NaCl and proteins were eluted from GFP-Trap beads by heating 
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at 95 °C for 10 minutes in the presence of 50 µL 2 x LDS-sample buffer (10 mM Tris-
HCl pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 1 x protease inhibitor cocktail, 1 x LDS and 
50 mM DTT). Equal volumes (15 µL) of material from EGFP and EGFP-CCHFV N IPs 
were combined and sent to Dundee Cell Products Ltd for MS analysis. GFP-Trap IPs 
were also performed on unlabelled cells transfected with EGFP or EGFP-CCHFV N.    
 
2.2.7.2 Dynabead IPs 
Recombinant protein G-coupled Dynabeads (Novex) were used to IP untagged 
CCHFV N and HAZV N from cell lysates using anti-CCHFV N or anti-HAZV N 
antibodies (section 3.2.4 describes the generation of these antibodies). Recombinant 
Protein G is a bacterial protein that binds antibodies via their Fc region. Dynabeads 
are uniform, 2.8 μm superparamagnetic beads with recombinant protein G covalently 
conjugated to their surface. Dynabead IPs were carried out using a Dynabead Protein 
G immunoprecipitation kit (Life Technologies) according to the manufacturer’s 
instructions. 50 µL Dynabeads were transferred into 1.5 mL microfuge tubes, and 
placed against a magnet; beads migrated to the side of the tube facing the magnet, 
the supernatant was removed, and replaced with 10 µL anti-CCHFV N or anti-HAZV N 
diluted in 200 μL Ab Binding and washing buffer (Life Technologies). Dynabeads were 
incubated with anti-CCHFV N or anti-HAZV N for 30 minutes with rotation at room 
temperature to allow antibodies to bind Protein G, then tubes were placed next to a 
magnet and supernatants containing unbound antibodies were removed. Dynabeads 
were washed once in Ab binding and washing buffer, then anti-CCHFV N or anti-
HAZV N bound Dynabeads were incubated with cell lysates prepared as described in 
section 2.2.6.1, for 15 minutes at room temperature with rotation.  
 Dynabeads with antigen-antibody complexes bound were washed three 
times in wash buffer (Life Technologies). Dynabeads with bound antigen-antibody 
complexes were transferred to a new microfuge tube, and proteins were eluted by 
heating at 95 °C for 10 minutes in 2 x LDS buffer (10 mM Tris-HCl pH 7.5, 150 mM 
NaCl, 0.5 mM EDTA, 1 x protease inhibitor cocktail, 1 x LDS and 50 mM DTT). 
 
2.2.8 Mass spectrometry (MS) analysis of SILAC labelled GFP-Trap IPs  
 
2.2.8.1 SDS PAGE, tryptic digest, and NanoLC MS ESI MS/MS analysis  
MS analysis was performed by Dundee Cell Products Ltd. Protein samples generated 
by EGFP immunoprecipitations were separated by one- dimensional SDS-PAGE (4-
12% bis-Tris Novex mini-gel, Invitrogen). The resulting separated proteins were cut 
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from the gel in 10 slices and subjected to in-gel digestion with trypsin. Trypsin 
digested peptides were separated using an Ultimate U3000 nanoflow LC-system 
(Dionex Corporation) consisting of a solvent degasser, micro and nanoflow pumps, 
flow control module, UV detector and a thermostated autosampler. A sample volume 
of 10 μL (comprising 2 μg) was loaded with a constant flow of 20 μL/min onto a 
PepMap C18 trap column (0.3 mm x 5 mm, Dionex Corporation). After trap 
enrichment peptides were eluted onto a PepMap C18 nano column (75 μm x 15 cm, 
Dionex Corporation) with a linear gradient of 5-35 % solvent B (90 % acetonitrile with 
0.1% formic acid) over 65 min at a constant flow rate of 300 nL/min. The HPLC 
system was coupled to a LTQ Orbitrap XL (Thermo Fisher Scientific Inc) via a nano 
ES ion source (Proxeon Biosystems). The spray voltage was set to 1.2 kV and the 
temperature of the heated capillary was set to 200 oC. Full scan MS survey spectra 
(m/z 335-1800) in profile mode were acquired in the Orbitrap with a resolution of 
60,000 after accumulation of 500,000 ions. The five most intense peptide ions from 
the preview scan in the Orbitrap were fragmented by collision-induced dissociation 
(normalized collision energy 35%, activation Q 0.250 and activation time 30 ms) in the 
LTQ after the accumulation of 10,000 ions. Maximal filling times were 1,000 ms for the 
full scans and 150 ms for the MS/MS scans. Precursor ion charge state screening 
was enabled and all unassigned charge states as well as singly charged species were 
rejected. The dynamic exclusion list was restricted to a maximum of 500 entries with a 
maximum retention period of 90 seconds and a relative mass window of 10 ppm. The 
lock mass option was enabled for survey scans to improve mass accuracy. The data 
were acquired using Xcalibur software. 
 
2.2.8.2 Peptide quantification 
Quantification was performed with MaxQuant version 1.0.7.4 (Cox and Mann 2008) 
and was based on two-dimensional centroid of the isotope clusters within each SILAC 
pair. To minimize the effect of outliers, protein ratios were calculated as the median of 
all SILAC pair ratios that belonged to peptides contained in the protein. The 
generation of peak list, SILAC- and extracted ion current-based quantitation, 
calculated posterior error probability, false discovery rate based on search engine 
results, peptide to protein group assembly, and data filtration and presentation was 
carried out using MaxQuant. The derived peak list was searched with the Mascot 
search engine (version 2.1.04; Matrix Science, London, UK) against a concatenated 
database combining 80,412 proteins from International Protein Index (IPI) human 
protein database version 3.6 (forward database), and the reversed sequences of all 
proteins (reverse database). Proteins were quantified if at least one MaxQuant-
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quantifiable SILAC pair was present. Identification was set to a false discovery rate of 
1 % with a minimum of 2 quantifiable peptides.  
 
2.2.9 Virological techniques 
 
2.2.9.1 Virus infection and propagation 
Infectious HAZV was used as the clarified cell culture supernatant from infected SW13 
cells. HAZV was diluted to the desired MOI in SFM, then complete media was 
removed from appropriately seeded cells, which were washed once in PBS. PBS was 
removed from cells and replaced with SFM containing HAZV. Cells were incubated 
with HAZV at 37 °C with gentle rocking for 1 hr to allow HAZV to adsorb to cell 
surfaces, SFM containing HAZV was then removed from cells, cells were washed 
once in PBS, then incubated with DMEM supplemented with 2 % FBS at 37 °C, 5 % 
CO2 in humidified incubators. In all experiments using HAZV, mock infected cells were 
included as a control; mock infections were carried out as described above with the 
exception that the SFM did not contain HAZV.  
HAZV was propagated in SW13 cells seeded in T175 cm2 flasks, when cells 
reached 60-70 % confluency. Cells were infected as described above with HAZV at an 
MOI 0.001. HAZV was allowed to replicate for 4 days, then the supernatant containing 
infectious HAZV was harvested, and clarified by centrifugation at 4000 x g at 4 °C for 
20 minutes. Clarified supernatant was directly used to infect SW13 cells. The titre of 
infectious HAZV was estimated by plaque assay (described below); typical yields from 
virus propagation experiments were between 1 x 105 and 1 x 107 plaque forming units 
per mL (pfu/mL).  
2.2.9.2 HAZV titre determination by plaque assay 
Plaque assays were performed in duplicate in 12-well plates; 25 μL HAZV was diluted 
by a factor of 10 in 225 μL SFM (10-1 dilution), which was further serially diluted to 
generate 10-2 – 10-6 dilutions. These HAZV dilutions were used to infect SW13 cells as 
described in section 2.2.9.1. 2 x 105 SW13 cells were plated out in 12 well plates for 
plaque assays, ensuring cells were ~90-95 % confluent when infected. After HAZV 
adsorption, virus was removed from cells and replaced with complete media diluted 
1:1 with 1.6 % (w/v) high viscosity carboxy-methyl cellulose (CMC; Sigma). The 
CMC/complete media overlay prevented HAZV from migrating through media, and 
ensured that following secretion from an infected cell, HAZV particles could only infect 
cells that immediately neighbour the previously infected cell. HAZV is cytopathic, 
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therefore the CMC/complete media overlay ensured that over the course of the assay 
(6 days), plaques were formed as HAZV infection resulted in cell death in very defined 
regions.  
Cells were incubated for 6 days, then fixed in 20 % (v/v) formalin for 1 hr. Cells were 
washed 3 time in ddH2O, then plaques were visualised by staining cells with crystal 
violet solution (0.1 % (w/v) crystal violet, 20 % ethanol) for 15 minutes. The 
chromophore containing component of crystal violet is positively charged at neutral pH 
and binds to the negatively charged cell membrane; the cell monolayer in a plaque 
assay therefore appears purple, and areas where HAZV has replicated and killed cells 
(plaques) are not stained and appear transparent. Virus titre was estimated using the 
following equation:  
 
𝑉𝑖𝑟𝑢𝑠 𝑡𝑖𝑡𝑟𝑒 (𝑝𝑓𝑢 𝑝𝑒𝑟 𝑚𝐿) =
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑙𝑎𝑞𝑢𝑒𝑠
(𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 𝑥 𝑣𝑜𝑙𝑢𝑚𝑒 (𝑚𝐿))
 
 
2.2.9.3 Purification of HAZV by density gradient centrifugation 
HAZV was purified from clarified cell culture supernatants through the use of density 
gradient centrifugation to remove the culture media and the majority of cellular 
components. A continuous 5 % - 25 % iodixanol gradient was prepared at least 24 hrs 
prior to use by sequentially layering 1 mL of 25 %, 20 %, 15 %, 10 % and 5 % (v/v) 
iodixanol diluted in TNE buffer (0.01 M Tris pH 7.4, 0.1 M NaCl, 1 mM EDTA) into a 
13 x 51 mm PolyClear open-top centrifuge tube (SETON). Between each layer 
application the gradient was frozen on dry ice. Following application of the final layer 
the gradient was stored at -80 °C. Before use, the gradient was thawed at room 
temperature overnight to allow the layers to diffuse into one another. Iodixanol 
supplied as a 60 % solution in water (‘OptiPrep’; density 1.32 g/mL) was used as the 
density gradient medium, as iodixanol is non-ionic, non-toxic to cells, and is 
metabolically inert.  
Clarified supernatant containing infectious HAZV was mixed with 50 % (w/v) 
PEG 6000 in TNE buffer, such that the final concentration of PEG 6000 was 10 % 
(w/v). HAZV was precipitated overnight at 4 °C as this mixture was continually stirred. 
Precipitated HAZV was recovered by centrifugation at 4000 x g for 30 minutes at 4 °C, 
and the resulting pellet was resuspended in 1 mL of TNE buffer and layered over the 
5 % - 25 % continuous iodixanol gradient. The resuspended HAZV pellet and gradient 
were ultracentrifuged at 250,000 x g for 2.5 hrs at 4 °C in an AH650 swinging rotor. 
After ultracentrifugation an opalescent band was observed ~ 2/3 way down the 
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gradient; this was removed using a 1 mL syringe and a 25 gauge needle (~600 μL), 
mixed gently, and frozen at -80 °C. This fraction containing infectious HAZV was 
plaque assayed to estimate infectious virus titre, and BCA assayed to estimate protein 
concentration. A sample containing ~11 μg protein was denatured by heating for 10 
minutes at 95 °C in the presence of LDS and DTT and sent for MS analysis.  
 
2.2.10 Mass spectrometry analysis of the fraction containing infectious HAZV 
 
MS analysis of the fraction containing infectious HAZV was performed to identify 
cellular proteins that co-purified with infectious HAZV. MS analysis was carried out by 
Dr Stuart Armstrong at the University of Liverpool, and is described below.  
 
2.2.10.1 SDS-PAGE and Tryptic digestion 
The viral protein preparation and controls were run approximately 1 cm into a 
NuPAGE® (Life Technologies) precast 4-12% gel Tris-Bis gradient gel and the 
proteins were stained with colloidal Coomassie Blue G-250 (Simply BlueTM, Life 
Technologies) according to the manufacturer’s instructions.                                                                                                                                                                                                                                                                                                                                                                                
The entire gel lane was excised and cut into smaller pieces (approx. 1mm3). Gel 
pieces were destained in 50 % acetonitrile/50 mM ammonium bicarbonate (pH ~8), 
reduced for 30 minutes at 37 °C with 10 mM dithiothreitol (Sigma) in 50 mM 
ammonium bicarbonate and alkylated with 55 mM iodoacetamide (Sigma) in 50 mM 
ammonium bicarbonate for 30 minutes in the dark at room temperature. Gel pieces 
were washed for 15 minutes in 50 mM ammonium bicarbonate and dehydrated with 
100% acetonitrile. Acetonitrile was removed and the gel plugs rehydrated with 0.01 
µg/µL proteomic grade trypsin (Sigma) in 50 mM ammonium bicarbonate. Digestion 
was performed overnight at 37 °C. Peptides were extracted from the gel plugs using 
successive 15 minute incubations of 3% (v/v) acetonitrile 0.1% (v/v) TFA. Peptide 
extracts were pooled and reduced to dryness using a centrifugal evaporator 
(Microfuge concentrator plus) and re-suspended in 3% (v/v) acetonitrile, 0.1% (v/v) 
TFA for analysis by mass spectrometry.  
2.2.10.2 NanoLC MS ESI MS/MS analysis 
Peptide mixtures (2 µL) were analyzed by on-line nanoflow liquid chromatography 
using the nanoACQUITY-nLC system (Waters MS technologies, Manchester, UK) 
coupled to an LTQ-Orbitrap Velos (ThermoFisher Scientific, Bremen, Germany) mass 
spectrometer equipped with the manufacturer’s nanospray ion source. The analytical 
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column (nanoACQUITY UPLCTM BEH130 C18 15cm x 75µm, 1.7µm capillary column) 
was maintained at 35 ⁰C and a flow-rate of 300 nL/min. The gradient consisted of 3-
40 % acetonitrile in 0.1 % formic acid for 150 minutes then a ramp of 40-85 % 
acetonitrile in 0.1 % formic acid for 5 minutes. Full scan MS spectra (m/z range 300-
2000) were acquired by the Orbitrap at a resolution of 30,000. Analysis was 
performed in data dependant mode. The top 20 most intense ions from MS1 scan (full 
MS) were selected for tandem MS by collision induced dissociation (CID) and all 
product spectra were acquired in the LTQ ion trap.  
Spectral data were transformed to .mgf files with Proteowizard (version3.0, 
(Chambers, Maclean et al. 2012) and used for peptide identification using the Mascot 
(version 2.3.02, Matrix Science) search engine. Tandem MS data were searched 
against the HAZV and human predicted proteomes (UniProt Release 2014_02). 
Mascot search parameters were as follows; precursor mass tolerance set to 10ppm 
and fragment mass tolerance set to 0.8 Da. One missed tryptic cleavage was 
permitted. Carbamidomethylation (cysteine) was set as a fixed modification and 
oxidation (methionine) set as a variable modification. Mascot search results were 
further processed using the machine learning algorithm Percolator. The false 
discovery rate was < 1%. Individual ion scores > 13 indicated identity or extensive 
homology (p < 0.05). Approximate, label-free, spectral counting based quantitation of 
the proteins was determined using the Exponentially Modified Protein Abundance 
Index (emPAI) calculated automatically by the mascot search engine (Ishihama, Oda 
et al. 2005).  
 
2.2.11 Inhibitor studies 
 
In all assays the inhibitors remained in the medium throughout the experiment, and 
the final concentration of DMSO in the medium did not exceed 0.2 % (v/v).  
 
2.2.11.1 Inhibition of HSP70 with VER155008 and pifithrin-µ 
The small molecule inhibitors VER155008 (Sigma) and pifithrin-µ (PIF; Sigma) (a 
commonly used synonym for PIF is: 2-Phenylethynesulfonamide (PES)) were used to 
assay the effect of inhibition of HSP70/HSC70 on HAZV replication. VER and PIF 
were both dissolved in dimethyl-sulphoxide (DMSO; Sigma) to make a 50 mM stock, 
which was aliquoted and stored at -20 °C. Immediately prior to use, 50 mM stocks 
were thawed and diluted with DMSO to make 10 mM aliquots; these were further 
diluted in DMEM supplemented with 2 % FBS to the appropriate concentration 
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(between 40 μM and 0.04 μM). 1 x 105 SW13 cells were seeded in 12 well plates such 
that cells were 60-70 % confluent when complete media was removed from cells, cells 
were washed once in PBS, and media containing the appropriate concentration of PIF 
and VER was added to cells. After 1 hr, cells were infected with HAZV at MOI 1 as 
described in section 2.2.9.1; after adsorption HAZV was removed from cells and 
replaced with fresh media containing the appropriate concentrations of PIF and VER. 
24 hrs after infection cell culture supernatants and whole cell lysates were harvested 
and plaque assayed (section 2.2.9.2), or analysed by western blot (section 2.2.6.5).  
 
2.2.11.2 Inhibition of caspase-3 and executioner caspases with Z-DEVD-FMK and Z-
FA-FMK 
Z-DEVD-FMK (BD Biosciences) and Z-FA-FMK (Santa Cruz Biotechnology) were 
used to assess the effect of inhibiting caspase-3 and the executioner caspases on 
HAZV replication. Z-DEVD-FMK and Z-FA-FMK were reconstituted in DMSO to make 
a stock concentration of 20 mM. Immediately prior to use aliquots were thawed and 
diluted in DMEM supplemented with 2 % FBS to a final concentration of 20 µM or 40 
µM. SW13 cells were seeded at 1 x 105 cells per well in 12-well plates, 24 hrs later 
cells were infected with HAZV at an MOI 1 as described in section 2.2.9.1. After 
adsorption of HAZV to cell membranes, SFM containing HAZV was removed from 
cells and replaced with DMEM supplemented with 2 % FBS, and the appropriate 
concentration of either Z-DEVD-FMK, or Z-FA-FMK. Cell culture supernatants and 
whole cell lysates were harvested 24, 48, or 72 hrs after infection and plaque assayed 
(section 2.2.9.2) or analysed by western blot (sections 2.2.6.5).       
 
2.2.12 MTT assay 
 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays were used 
to assess the cytotoxity of siRNA, Z-DEVD-FMK, Z-FA-FMK, PIF, and VER 
treatments on SW13 cells. The MTT assay is a colorimetric assay to determine cell 
viability, that is based on the cleavage of yellow tetrazolium salt (MTT) by 
mitochondrial enzymes to form a soluble, blue formazan product; the amount of 
formazan produced is directly proportional to the number of living, not dead cells, and 
can be detected by absorption of light at 570 nm. 1 x 104 SW13 cells were seeded in 
96 well plates 24 hrs prior to treatment with siRNA, Z-DEVD-FMK, Z-FA-FMK, PIF 
and VER; 24 hrs, 48 hrs, or 72 hrs after treatment, MTT assays were performed using 
the CellTiter 96 Non-radioactive cell proliferation assay kit (Promega), according to 
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the manufacturer’s instructions. A dye solution containing MTT was added directly to 
cells in 96 well plates, cells were incubated at 37 °C for 4 hrs, prior to the addition to 
the solubilisation/stop solution to wells to solubilize the formazan product. After 
overnight incubation, absorbance at 570 nm was recorded with the TECAN infinite 
F50 plate reader. In each case viability of cells treated with siRNA, Z-DEVD-FMK, Z-
FA-FMK, PIF or VER was compared to cells treated with either 0.1 % or 0.2 % (v/v) 
DMSO. Cell viability at these concentrations of DMSO did not vary from untreated 
cells.    
 
2.2.13 TUNEL (terminal dUTP nick-end labelling) assay 
 
DNA fragmentation and apoptosis induced by HAZV was detected with an In Situ Cell 
Death Detection Kit, Fluorescein (Roche) according to the manufacturer’s instructions. 
SW13 cells were seeded onto glass coverslips housed in 6 well plates 24 hrs prior to 
infection. Cells were infected with HAZV at MOI 1 or mock infected (section 2.2.9.1), 
then 24, 48, or 72 hrs after infection, cells were fixed in 4 % (w/v) PFA (section 
2.2.6.6). Cells were permeabilised in 0.1 % (v/v) Triton-X 100 diluted in 0.1 % (w/v) 
sodium citrate for 5 minutes on ice. DNA strand breaks were then identified by 
labelling free 3’-OH DNA ends using the In Situ Cell Death Detection Kit, Fluorescein 
(Roche); this kit contains the enzyme terminal deoxynucleotidyl transferase (TdT) 
which catalyzed the polymerization of fluorescently labelled nucleotides to free 3’-OH 
DNA ends in a template independent manner, when cells were incubated with the 
TUNEL reaction mix for 1 hr at 37 °C. Fluorescein labelled nucleotides incorporated 
into nucleotide polymers were detected and quantified by fluorescence microscopy 
using the upright LSM 510 META confocal microscope (Carl Zeiss Ltd).  
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2.3 LIST OF ANTIBODIES  
 
2.3.1 Primary antibodies used in western blot analysis and/or IF 
 
Table 3 Primary antibodies used in western blot analysis and/or IF staining 
 
Target Vendor 
Catalogue 
number 
WB 
dilution 
IF dilution 
EGFP Santa Cruz  sc-8334 1:1000 N/A 
vimentin Santa Cruz sc-966 1:1000 N/A 
actin Sigma Aldrich A3853 1:1000 N/A 
B23 Santa Cruz sc47725 1:1000 N/A 
p53 Cell Signaling 9282 1:1000 N/A 
GAPDH Abcam ab8245 1:5000 N/A 
CCHFV N in house N/A 1:10,000 1:1000 
HAZV N in house N/A 1:5000 1:500 
HSP70/HSC70 Abcam Ab6535 1:1000 1:100 
HSP70 Enzo Life 
sciences 
ADI-SPA-
810-D 
1:1000 N/A 
HSC70 Santa Cruz sc-7298 1:1000 N/A 
Cleaved caspase-3 
(Asp175) 
Cell Signaling 9664 1:1000 N/A 
Caspase-3 Cell Signaling 9665 1:1000 N/A 
PARP Cell Signaling  9542 1:1000 N/A 
Cleaved PARP Cell Signaling  5625 1:1000 N/A 
Caspase-9 Cell Signaling  9508 1:1000 N/A 
Cleaved caspase-9 
(Asp330) 
Cell Signaling  7237 1:1000 N/A 
Caspase-7 Cell Signaling  12827 1:1000 N/A 
Cleaved caspase-7 
(Asp198) 
Cell signaling  8438 1:1000 N/A 
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2.3.2. Secondary antibodies used in western blot analysis and/or IF 
 
Table 4 Secondary antibodies used in western blot or IF analysis.  
Secondary antibodies were conjugated to either horse radish peroxidase (HRP) or a 
fluorescent label. These are detailed below.  
 
Target-
primary 
antibody 
species 
Conjugation Vendor 
Catalogue 
number 
WB 
dilution 
IF 
dilution 
Mouse HRP Sigma A4116 1:5000 N/A 
Rabbit HRP Sigma A6154 1:5000 N/A 
Rat HRP Sigma A5795 1:5000 N/A 
Sheep HRP Sigma A3415 1:5000 N/A 
Sheep (Light 
chain 
specific) 
HRP Jackson 
ImmunoResearch 
213-032-
177 
1:10,000 N/A 
Mouse Alexa Fluor 
568 
Invitrogen A11061 N/A 1:250 
Sheep Alexa Fluor 
488 
Invitrogen A11015 N/A 1:250 
Mouse IRDye 680RD LiCor 926-68072 1:10,000 N/A 
Rabbit IRDye 
800CW 
LiCor 926-32213 1:10,000 N/A 
Sheep IRDye 
800CW 
LiCor 926-32214 1:10,000 N/A 
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CHAPTER 3: DETERMINING THE CRYSTAL STRUCTURE OF HAZV N 
 
3.1: CHAPTER INTRODUCTION 
 
High resolution X-ray crystallography was used to determine the structure of ~90 % of 
all deposits currently in the Protein Data Bank (PDB). During an X-ray crystallography 
experiment X-rays are diffracted by electrons within a crystal; collection of this data 
allows the calculation of an electron density map, into which an atomic model of the 
molecule can be built. Structure solution by X-ray crystallography poses a number of 
difficulties; some of these are fundamental (e.g the ‘phase problem’, described in 
section 3.3.2, along with the method used in this study to address it in section 3.3.4), 
and other difficulties are practical (e.g. crystal growth and manipulation). However X-
ray crystallography remains the prefered option for high resolution structure solution 
due to the ability to achieve resolutions that are theoretically only limited by crystal 
quality and X-ray wavelength (< 1 Å). 
Other techniques for macromolecular structural analysis, such as nuclear 
magnetic resonance (NMR) and single particle reconstruction of cryo-electron 
microscopy (EM) images, although they have advantages and disadvantages over X-
ray crystallography, can only achieve resolutions equivalent to 3-3.5 Å and > 10 Å, 
respectively. These resolutions are not adequate for structure-guided drug design. 
New techniques are being developed to overcome some of the current limitations of 
X-ray crystallography, such as neutron diffraction (uses the diffration of neutrons from 
protons within the crystal) and X-ray free-electron lasers (X-FEL) (produces intensely 
brilliant, ultrashort X-ray pulses, over 10 times the brightness of synchrotron radiation), 
however these are not yet in widespread use. 
This chapter describes the development of a high yield expression system for 
full length HAZV N, its purification using GST-resin and ion exchange chromatography, 
and crystallisation trials that result in the determination of the crystal structure of 
HAZV N. As a result both apo-HAZV N (RNA free) and RNA bound HAZV N 
structures were solved. In addition purified HAZV N was used to generate polyclonal 
antibodies targeting HAZV N, the uses of these antibodies are described in chapter 4 
and chapter 5. 
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3.1.1 Introduction to bacterial expression of HAZV N 
 
Structural studies require the abundant production of homogeneous protein; over-
expression of recombinant proteins using prokaryotic E. coli based expression 
systems is the most common method of achieving this. The plasmid used here (Figure 
3.1) is a pGEX-based vector in which expression of the target protein is under the 
control of a tac promoter, a hybrid promoter which contains lacUV5 elements. In this 
system IPTG induction directly alleviates repression of the target gene, which results 
in its transcription by the RNA polymerase, as the target protein itself is under lac 
repression. There are several advantages associated with bacterially expressing 
proteins, including homogeneity, low cost, high yield and ease of scale up. One of the 
disadvantages of expressing eukaryotic or viral genes in bacteria is the problem of 
biased codon usage; if the codon bias of the gene to be expressed differs significantly 
from that used by E. coli, there may not be sufficient concentrations of E. coli tRNA 
targeting rarely used codons to allow optimal translation. This can be overcome by co-
expressing rarely used tRNAs, or by altering the target gene to change rare to more 
commonly used codons, optimal for bacterial expression. This section outlines the 
process of optimising bacterial expression and purification of full length HAZV N 
protein. 
 
3.2 RESULTS: EXPRESSION AND PURIFICATION OF HAZV N 
 
3.2.1 Cloning of HAZV N ORF into the pGEX6P2 expression vector 
 
The HAZV N ORF optimised for bacterial expression was synthesised by Dundee Cell 
Products, and was provided cloned into a pET 28-SUMO expression vector, using 5’ 
BamHI and 3’ XhoI restriction sites. This construct did not provide optimal yields of 
HAZV N, so to improve expression the HAZV N ORF was subcloned into the 
pGEX6P2 expression vector, which has an N terminal glutathione S-transferase (GST) 
tag and a human rhinovirus (HRV) 3C protease cleavage site (Figure 3.1 (B)). The 
GST tag allows purification by glutathione affinity chromatography and is known to 
help the solubility of recombinant proteins.      
The HAZV N fragment was subcloned by direct digestion from the pET 28-
SUMO vector and ligation into the pGEX6P2 vector using BamHI and XhoI restriction 
enzymes. Following double digestion of both the pET 28-SUMO vector and empty 
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pGEX6P2 vector, the HAZV N ORF fragment was isolated by agarose gel 
electrophoresis and gel extracted, then ligated into the digested, empty pGEX6P2 
vector and transformed into JM109 cells. The correct orientation and sequence of the 
insert was confirmed by DNA sequence analysis. This construct will be referred to as 
pGEX-HAZV N and resulted in the expression of an N terminally GST tagged HAZV N 
(GST-HAZV N). Following cleavage of the GST tag with HRV 3C protease, five non-
native residues (Gly-Pro-Leu-Gly-Ser) remained at the N-terminus of HAZV N. A 
schematic representation of the GST-HAZV N fusion protein is shown in Figure 3.1 (A) 
and a schematic representation of the pGEX-HAZV N vector used to express it in 
Figure 3.1 (B).  
 
 
Figure 3.1 Schematic representation of GST-HAZV N, and plasmid map of the 
HAZV N ORF in the pGEX6P2 vector.  
HAZV N was fused at the N terminus to GST, which could be cleaved from HAZV N at 
the HRV 3C site using HRV 3C protease (A). The plasmid map (B) was generated 
using SnapGene software. 
A 
B 
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3.2.2 GST-HAZV N expression and purification 
 
3.2.2.1 GST-HAZV N expression 
Initial expression of GST-HAZV N from pGEX-HAZV N was tested using the optimal 
conditions achieved for CCHFV N (Carter, Barr et al. 2012) as a starting point. His-
SUMO-CCHFV N was expressed as follows: overnight induction at 18 °C in Rosetta 2 
cells with 100 µM IPTG; cell recovery by centrifugation and resuspension in lysis 
buffer, sonication of lysates, then clarification of lysates by centrifugation. When using 
these conditions to express GST-HAZV N from pGEX-HAZV N, SDS-PAGE analysis 
showed the GST-HAZV N fusion protein was well expressed, and was soluble, 
although there was also a large amount of insoluble GST-HAZV N. This was 
addressed by increasing the percentage of Triton-X 100 in the lysis buffer from 0.1 % 
to 1 % (v/v), and including a 30 minute incubation stage on ice prior to sonication. The 
predicted molecular weight of GST-HAZV N is 80 kDa; when analysed by SDS PAGE 
GST-HAZV N actually has an apparent molecular weight of slightly lower than 80 kDa, 
however this may just be an artefact of electrophoresis (Figure 3.2).    
 
 
 
Figure 3.2 Initial expression of GST-HAZV N  
Expression of GST-HAZV N from pGEX-HAZV N in Rosetta-2 cells overnight at 18 °C 
with 100 µM IPTG, followed by pellet resuspension in lysis buffer, sonication of 
lysates, and clarification of lysates by centrifugation.  
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Following expression of GST-HAZV N, glutathione sepharose affinity chromatography 
was used to purify GST-HAZV N from bacterial cell lysates. Clarified bacterial cell 
lysate was combined with GST resin in batch, and incubated with rotation at room 
temperature for 1 hr to allow GST-HAZV N to bind. A considerable amount of GST-
HAZV N remained unbound after 1 hr, therefore overnight binding of GST-HAZV N to 
GST resin at 4 °C was also tested. However this resulted in more protein precipitating 
out of solution without any apparent increase in HAZV-N yield, therefore in all 
subsequent experiments clarified lysates were incubated with GST resin for 1 hr at 
room temperature. GST resin with GST-HAZV N bound was washed once in binding 
buffer, then to dissociate E. coli derived RNA from GST-HAZV N, resin was washed 
once in buffer containing 1.5 M NaCl. This resulted in the purification of ‘RNA free’ 
HAZV N that co-eluted with less bacterially derived RNA than RNA bound-HAZV N; 
the 1.5 M NaCl wash step was excluded when RNA-bound HAZV N was purified. 
Resin with GST-HAZV N bound was then equilibrated in another binding buffer wash, 
prior to three successive elutions in buffer containing reduced glutathione to 
dissociate GST-HAZV N from the resin (Figure 3.3). Eluted GST-HAZV N was 
incubated with HRV 3C protease to cleave the GST tag from HAZV N; this resulted in 
the production of a strong band of ~54 kDa (the correct predicted molecular weight for 
HAZV N) when visualised by SDS PAGE and Coomassie staining (Figure 3.3 (B)).    
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Figure 3.3 Expression of GST-HAZV N and removal of the GST tag 
Purification and HRV 3C cleavage of GST-HAZV N resulted in the release of soluble 
HAZV N with an apparent molecular weight (MW) of 54 kDa. (A) SDS PAGE gel 
showing the purification of GST-HAZV N by glutathione sepharose affinity 
chromatography. (B) SDS PAGE gel showing cleavage of GST-HAZV N with HRV 3C 
protease to release HAZV N.  
 
 
3.2.2.2 Size exclusion chromatography 
After removal of the GST tag with HRV 3C protease, further purification of HAZV N 
was needed to isolate fully cleaved HAZV N from uncleaved GST-HAZV N and GST. 
In order to achieve this, and to analyse the oligomeric status of HAZV N, size 
exclusion chromatography was carried out (section 2.2.2.3). Size exclusion 
chromatography can separate protein mixtures on the basis of protein size, due to the 
differential exclusion of larger proteins from pores in the chromatography beads that 
make up the column. Larger proteins and multimers are eluted first, as they cannot 
enter the pores in the beads and pass straight through the column; smaller proteins 
are eluted afterwards, as they interact with the pores in the beads and take a longer 
time to pass through the column. Given the difference in predicted molecular weight of 
A B 
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GST-HAZV N (80 kDa), HAZV N (54 kDa), and GST (26 kDa), these protein species 
should be seperated by size exclusion chromatography.  
The size exclusion column was equilibrated in gel filtration buffer overnight, 
then the cleaved GST-HAZV N protein mixture was concentrated to a 5 mL volume 
and injected onto the column with a 5 mL loop. The column was run at a flow rate of 2 
mL/min until the void volume (V0, ~90 mL) had eluted; fractions were collected from 
this point onwards, until a full column volume of buffer had eluted  (320 mL). The A280 
and A260 traces are shown in Figure 3.4 (A), and SDS PAGE gel analysis of the 
corresponding fractions are shown in Figure 3.4 (B). Cleaved HAZV N seemed to be 
eluted in all fractions analysed between 105 mL and 160 mL. Peak 3 consisted mostly 
of nucleic acid and was not analysed by SDS PAGE. Peak 1 contained a mixture of 
multimerised HAZV N and uncleaved GST-HAZV N. Complete cleavage of GST-
HAZV N could not be achieved despite increasing the ratio of HRV 3C 
protease:elution volume, possibly due to aggregation or misfolding of a small 
proportion of GST-HAZV N. Consistent with the observations of (Carter, Barr et al. 
2012) and (Wang, Dutta et al. 2012) for CCHFV N, the A260/A280 ratio appeared to be 
greater in the multimeric HAZV N peak (peak 1), implying that this species co-eluted 
with more nucleic acid than the monomeric species in Peak 2.  
Size exclusion chromatography confirmed that the majority of HAZV N was 
monomeric in solution, although higher ordered structures did form that contained a 
greater proportion of nucleic acid, in a similar fashion to purified CCHFV N. 
Unfortunately GST in solution (26 kDa) multimerises to form a dimer of 52 kDa, which 
is very similar to the molecular weight of HAZV N (54 kDa). Protein species so close 
in molecular weight cannot be resolved by size exclusion chromatography, therefore 
an alternative method of HAZV N purification was attempted. This is described in the 
next section, where ion exchange chromatography was utilised in order to separate 
HAZV N from uncleaved GST-HAZV N and GST. 
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Figure 3.4 Size exclusion chromatography of  cleaved HAZV N. 
(A) The A280/A260 absorbance trace indicated protein eluted mainly in 2 peaks; most 
protein eluted in peak 2 at 140 mL, which represented proteins of ~54 kDa. (B) SDS 
PAGE analysis of fractions from size exclusion chromatography, with the 
corresponding peaks labelled. HAZV N, 54 kDa, appeared in all fractions analysed, 
although the majority of monomeric HAZV N co-eluted with dimeric GST, therefore 
size exclusion chromatography could not be used to purify HAZV N. 
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3.2.2.3 Ion exchange chromatography 
HAZV N and GST have a significantly different isoelectric point (pI), of 8.73 and ~6 
respectively, which raises the possibility that they could be resolved using ion 
exchange chromatography. A cation exchange column was used (Resource S column) 
with all buffers at pH 7 so that HAZV N would be positively charged and bind to the 
column, whilst GST (and other contaminants) would be negatively charged and pass 
straight through the column without binding. After elution from the GST resin and 
cleavage with HRV 3C protease, HAZV N was dialysed into the initial ion exchange 
buffer, buffer A, which contained 50 mM NaCl. The low NaCl concentration in buffer A 
allowed the positively charged HAZV N to bind to the negatively charged cation 
exchange column through ionic interactions. After GST and other contaminants flowed 
through, the cation exchange column was washed several times with buffer A. HAZV 
N was then eluted by increasing the NaCl concentration in a linear gradient until a 
sufficiantly high NaCl concentration was reached to disrupt the ionic interactions 
between HAZV N and the column. A linear NaCl gradient was generated by gradually 
mixing buffer A (contained 50 mM NaCl) with buffer B (contained 1 M NaCl) using an 
Äkta purifier pump. HAZV N eluted relatively rapidly after the NaCl concentration 
started increasing, which indicated the ionic interaction between HAZV N and the 
Resource S column was relatively weak (Figure 3.5 (A)). 
SDS PAGE analysis (Figure 3.5 (B)) of fractions collected during ion exchange 
chromatography confirmed that the majority of contaminants were removed during this 
procedure, including residual GST-HAZV N and GST, as they flowed through the 
cation exchange column without binding (Figure 3.5 (A) Peak 1). In contrast HAZV N 
bound to the column, and was eluted when the NaCl concentration was increased. 
This resulted in the isolation of >95 % pure cleaved HAZV N, Peak 2 in Figure 3.5. 
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Figure 3.5 Purification of HAZV N using ion exchange chromatography  
Ion exchange chromatography resulted in the isolation of HAZV N from GST-HAZV N 
and GST. (A) A280 absorbance trace shows protein eluted in 2 peaks; Peak 1 
represents protein that flowed through the column without binding, and Peak 2 
represents protein that bound to the column, and was then eluted by an increasing 
NaCl gradient (dashed grey line). (B) SDS PAGE analysis of fractions from ion 
exchange chromatography with the corresponding peaks labelled. The majority of 
HAZV N eluted in Peak 2, whereas GST-HAZV N and GST flowed through the column 
without binding, Peak 1.    
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Expression and purification of HAZV N by ion exchange chromatography produced 4-
7 mg > 95 % pure HAZV N per 4 L bacterial culture. Attempts at further optimisation 
were unsuccessful, and this was sufficient to proceed with crystallisation trials, 
therefore no further optimisation of expression or affinity purification was undertaken. 
Preparations of HAZV N that were washed with 1.5 M NaCl whilst bound to the GST 
resin had an OD260/OD280 ratio of 0.84, indicating that a low level of RNA was present; 
the crystal structure derived from these preparations is referred to as Apo-HAZV N. 
HAZV N protein preparations that did not have this 1.5 M NaCl wash step included 
resulted in purification of HAZV N with an OD260/OD280 ratio of 1.04, indicating more 
nucleic acid (presumably RNA) co-eluted with this protein. The crystal structure that 
resulted from this preparation is referred to as RNA bound-HAZV N.        
 
3.2.3 Section summary 
 
This section presents the optimisation of HAZV N expression and purification from 
bacterial cells, ultimately resulting in the purification of 4-7 mg HAZV N per 4 L 
bacterial culture that was >95 % pure. The HAZV N ORF was subcloned and 
expressed as a GST fusion protein from pGEX-HAZV N, as GST is a well 
documented aid for recombinant protein solubility. GST proteins are enzymes that 
bind reversibly and with high specificity to their their substrate glutathione, a tripeptide 
of glutamate-cysteine-glycine. The ability of GST to bind reversibly to glutathione with 
high specificity and high affinity makes GST ideal for affinity chromatography, and 
often yields high purity protein.  
The 26 kDa GST tag encoded by pGEX vectors is derived from Schistosoma 
japonicum (Smith and Johnson 1988), and forms homodimers in solution. This is one 
of the disadvantages of using a GST tag for purification of 50-60 kDa recombinant 
proteins; GST cannot be removed from the recombinant protein mixture by size 
exclusion chromatography, after HRV 3C cleavage of the fusion protein. As shown in 
section 3.2.2.2, HAZV N co-eluted with GST homodimers during size exclusion 
chromatography, resulting in no further purification of HAZV N. To circumvent this 
problem, HAZV N was seperated from uncleaved GST-HAZV N and GST by cation 
exchange chromatography, which yielded >95 % pure HAZV N. A schematic 
summarising the final optimised purification procedure of HAZV N is shown in Figure 
3.6. 
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Figure 3.6 Schematic summary of final optimised HAZV N expression and 
purification.    
GST-HAZV N was expressed in Rosetta 2 cells, purified by glutathione affinity 
chromatography, then cleaved with HRV 3C protease to release HAZV N. HAZV N 
was further purified by ion exchange chromatography. 
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Purified HAZV N was used in two downstream applications; the primary use of HAZV 
N was for crystallisation trials and structure solution; in addition HAZV N was used to 
generate polyclonal antibodies that bind HAZV N. The strategy used to generate 
these antibodies is described in section 3.2.4, and downstream uses of these 
antibodies are described in chapter 4 and chapter 5.  
 
3.2.4 Generation of polyclonal antibodies that bind HAZV N 
 
Purified HAZV N was used to generate polyclonal antibodies that recognised native 
HAZV N; briefly 1 mg HAZV N protein was sent to Altabioscience, a company that 
specialises in custom antibody production. Altabioscience performed an immunisation 
programme (which is UK home office and USA National Institutes of Health compliant) 
that involved inoculation of a sheep with purified HAZV N, followed by successive 
bleeds at one, two, and three months post inoculation. SDS PAGE analysis of HAZV 
N sent to Altabiosciences confirmed it was >95 % pure (Figure 3.7), therefore the 
serum harvested from these bleeds should contain sheep antibodies that specifically 
recognise HAZV N. Applied uses of anti-HAZV N antibodies are described in chapter 
4 and chapter 5. 
 
 
Figure 3.7 Purified HAZV N used to generate polyclonal anti-HAZV N antibodies  
SDS PAGE analysis confirmed that HAZV N sent to Altabioscience was >95 % pure.  
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3.3 RESULTS: SOLUTION OF THE HAZV N CRYSTAL STRUCTURE 
 
3.3.1 Crystal growth 
 
3.3.1.1 Introduction to crystal growth 
X-ray crystallography requires an abundant source of homogeneous, >95 % pure, 
soluble, concentrated protein. Once this has been achieved, using a methodology 
similar to that described for HAZV N purification in the previous section, the next 
challenge of crystallography is crystal growth. One of the previously mentioned 
difficulties associated with crystallography is the necessity for well ordered, high 
quality, well-diffracting protein crystals. Highly automated systems, such as the use of 
robots for setting up crystal screens, making buffers required for crystallisation, and 
monitoring crystal growth, go someway towards standardising experiments, such that 
crystallisation conditions can be reproduced more accurately. However, even though 
high throughput systems are becoming more common, crystal growth still remains one 
of the more challenging aspects of X-ray crystallography.  
It is necessary to grow crystals because the intensity of diffracted X-rays from 
a single protein molecule are too weak to be detected by even the most sophisticated 
equipment. Instead, crystals which contain many copies of a protein, arranged in a 
periodic, well-ordered lattice, amplify the signal of the diffracted X-rays and enable 
their detection. Protein crystals are grown in the following manner; soluble pure 
protein is mixed with a solution containing a precipitant, and is then concentrated to 
supersaturation, beyond the concentration at which the protein is soluble (the 
solubility curve), such that the phase of the solution moves into the supersaturated 
labile zone (nucleation zone). At this point spontaneous nucleation (ordered 
aggregation) of protein crystals can (sometimes) occur. The concentration of protein 
and precipitants in solution, is not however, allowed to reach the point of precipitation 
(disordered aggregation). A solubility phase diagram is shown in Figure 3.8, which 
depicts this relationship between precipitant and protein concentrations.  
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Figure 3.8 A solubility phase diagram. 
Adapted from: http://www.xray.bioc.cam.ac.uk/xray_resources/whitepapers/xtal-in-
action/node3.html. (A) The phase moves from undersaturated to supersaturated as 
the concentration of the precipitant and protein increases; once this concentration is 
sufficient to enter the supersaturated labile zone (nucleation zone), spontaneous 
nucleation of protein crytals occurs, thus lowering the concentration of protein in 
solution. At this point the metastable zone is entered, which supports sustained crystal 
growth. In the precipitation zone disordered aggregation of protein occurs, and no 
crystals grow. The blue arrows represent protein in solution. (B) Crystal growth by 
vapour diffusion in hanging drop format.  
 
 
Proteins and precipitants are concentrated to supersaturation by suspending the 
protein:precipitant solution over a reservoire of more concentrated precipitant solution 
(the crystallant or ‘mother liquor’ solution) in a closed system (Figure 3.8 (B)). As 
water evaporates from the protein:precipitant solution, and equilibrium is approached 
between the concentration of precipitants in the protein:precipitant solution and the 
mother liquor reservoire, the concentration of both precipitant and protein increases, 
supersaturation is achieved and (sometimes) spontaneous nucleation (ordered 
aggregation) occurs. This decreases the concentration of protein in the 
protein:precipitant solution, allowing the phase to enter the metastable zone, which 
supports sustained crystal growth either until impurities are incorporated into the 
lattice at the surface of the growing crystal, preventing further ordered crystal growth, 
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or until the protein is depleted. This method of growing crystals is known as vapour 
diffusion; droplets of protein:precipitant solutions are either placed on platforms over a 
mother liquor reservoire (‘sitting drop’), or suspended underneath coverslips over a 
mother liquor reservoire (‘hanging drop’) (Figure 3.8 (B)). In both techniques the 
coverslips or platforms are sealed, to create a closed system. On average it takes 
between 3-7 days for sufficiently large protein crystals to grow, although they can 
grow in a matter of hours, or can take weeks or months.  
 
3.3.1.2 HAZV N crystallisation screens and crystal growth 
Commercially available sparse matrix screens were used to screen purified HAZV N 
protein for initial crystallisation conditions. The mother liquor solutions in the sparse 
matrix screens generally contained a combination of precipitants (organic polyalcohols 
e.g polyethylene glycol (PEG)), additives (e.g metal ions, detergents, reducing agents), 
salts (e.g sodium chloride or ammonium sulphate) and buffers of different pHs. The 
mother liquor compositions in the sparse matrix screens were biased towards 
conditions that have previously been successful at supporting protein crystal growth. 
Each screen was supplied in a high throughput 96 well format, which enabled an 
automated robot system to be used that quickly and reproducibly set up sitting drops 
with protein:mother liquor ratios of 50:50 and 70:30. The use of multiple sparse matrix 
screens, each incubated at either 25 °C, 18 °C, or 11 °C allowed hundreds of potential 
HAZV N crystal growth conditions to be assayed. Several different conditions resulted 
in the growth of crystals overnight, which increased in size over 2-3 days. The 
appearance of crystals in several of the initial sparse matrix screening wells enabled 
the optimisation of these conditions, without further extensive screening, or attempting 
to proceed with sub-optimal conditions (for example, conditions in which microcrystals 
grew due to excessive nucleation, or conditions containing crystalline precipitate). 
The two conditions in which the best crystals grew (based on the visual 
apprearance of the crystals e.g sufficient size (>20 µM), single crystals, few splits, 
sharp edges) were: Wizard 4 A6; 28% (v/v) PEG 400, 0.1 M HEPES pH 7.5, 0.2 M 
Calcium chloride and Wizard 3 F5; 15 % (w/v) PEG 10,000, 100 mM sodium citrate 
pH 5.5, 2% (v/v) dioxane. Crystals from the Wizard 3 F5 (WF5) looked most promising 
visually, therefore this condition was taken forward for further optimisation. 
Optimisation was performed using 24-well matrices that were set up manually in 
hanging drop format. The percentage of PEG 10,000 and pH were varied, as was the 
temperature at which the crystals grew (18 °C, 25 °C and 30 °C). Different types of 
PEG (PEG 6000, PEG 8000, PEG 20,000), and different salts (sodium chloride, 
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ammonium acetate, lithium sulphate and magnesium chloride) were added to improve 
crystal growth, as well as using different droplet sizes and different protein: mother 
liquor ratios. Hanging droplets of 1 µl volume, 70:30 protein:mother liquor ratio 
generally yielded high quality crystals. Figure 3.9 shows an example of small crystals 
grown in the protein:mother liquor droplets during optimisation. 
 
 
  
Figure 3.9 Crystals grown in protein:mother liquor droplets.  
Although the crystals grown in the protein:mother liquor droplets in (A) and (B) were 
relatively small, however the crystals in (A) especially, are uniform and substantial, 
and grow as single crystals. In (B) some of the crystals start growing as multiple 
crystals from a single point, which made them less likely to diffract well and made it 
harder to analyse a single crystal.  
 
 
Further crystal growth optimisation also included the use of a commercially available 
additives screen (Hampton research). This screen contained small molecules 
(additives) known to affect crystallisation by disrupting the structure that water 
molecules form around the target protein or by altering protein solubility. The Oryx 6 
robot was used to set up this screen in 96 well sitting drop format at 25 °C, centred 
around the best diffracting condition; 15% PEG 10,000, 100 mM sodium citrate pH 5, 
0.2 M sodium chloride, 2% dioxane. Additives were added to a 110% stock solution of 
the mother liquor, to a final concentration of 10%. Various conditions resulted in 
crystal growth, and a few conditions yielded crystals that were visually improved (e.g 
larger or more cuboidal), however none of the conditions yielded crystals that 
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diffracted to a higher resolution, or that generated diffraction data of any higher quality. 
Streak seeding was also used to try and improve crystal size and quality, but did not 
result in any improvement of diffraction resolution or data quality, and so no further 
optimisation of this condition was undertaken.  
Batch to batch variability between different proteins preparations presented 
significant problems during crystal growth optimisaton. Multiple protein preparations 
were needed to optimise crystal growth because relatively low yields of HAZV N were 
achieved during optimisation of HAZV N expression and purification. Different protein 
preparations varied slightly in terms of final protein concentration, final pH, and in their 
levels of contaminants. These small, unavoidable differences, significantly impacted 
both the ability of HAZV N to form crystals and the quality of the crystals that grew. 
HAZV N was frozen at -80 °C, either in the presence or absence of 5% glycerol, then 
thawed 2 days later on ice and its ability to form crystals was assayed in known 
crystal growth conditions. Although freeze-thawed HAZV N could still crystallise, batch 
to batch variation remained a problem.  
Once single crystals that were big enough (>20 µM), and good enough quality 
grew (no splitting or fracturing), they were manipulated using small loops, in which the 
crystal was suspended in its mother liquor solution, an example of which is shown in 
Figure 3.10. 
 
                        
 
 Figure 3.10 Loop containing a cuboidal HAZV N crystal at the synchrotron 
This crystal was cryo-cooled in liquid nitrogen, and maintained at -173 °C. 
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Large (>20 µM), uniform crystals were picked from protein: mother liquor droplets 
using these small loops, then crystals were cryo-cooled in liquid nitrogen to reduce the 
radiation damage caused by X-rays. Cryo-cooling can be done directly after picking 
crystals from the mother liquor droplets, if the mother liquor contains sufficient cryo-
protectant (low molecular weight PEG, glycerol, ethelyne glycol, DMSO). As HAZV N 
did not crystallise in any conditions that contained sufficient cryo-protectant, crystals 
were instead soaked in cryo-protectant solutions after being picked from mother liquor 
droplets. Cryo-protectants are necessary to avoid water freezing as ice crystals during 
cryo-cooling, as ice crystals can disrupt the protein crystal lattice and cause high 
background diffraction. Cryo-protectants enable water in and around the crystal to 
instead cool into vitreous ice (an amorphous glass), thus preventing ice crystal 
formation.  
Various different cryoprotectants were used to soak HAZV N crystals during 
optimisation of HAZV N crystallisation and diffraction, including PEG 200, PEG 400, 
glycerol, DMSO, ethylene glycol and MPD (2-Methyl-2 4-pentanediol). PEG 200 was 
determined to be the best cryoprotectant, and was used in all subsequent 
experiments. Crystals grown in the following condition (15% PEG 10,000, 0.1 M 
sodium citrate pH 5, 0.1 M NaCl, 2 % dioxane) provided the diffraction data for both 
the Apo-HAZV N, and the RNA bound-HAZV N crystal structures.  
 
3.3.2 Crystal diffraction and data collection 
 
A HAZV N protein crystal was placed in the path of a beam of monochromatic (single 
wavelength) X-rays in order to collect X-ray diffraction data. The X-ray source was a 
synchrotron (a high brilliance, tuneable source of X-rays) located at the Diamond light 
source, the UK national synchrotron science facility. Data was collected using X-rays 
because the wavelength of X-rays (1 Å = 0.1 nm) is in the same order of magnitude 
as the interatomic distances that need to be resolved during a crystallography 
experiment. When the crystal is placed in the path of a beam of X-rays, the majority of 
X-rays pass straight through the crystal, however occasionally a photon from the X-
ray interacts with the electron density around atoms, and is scattered from the crystal. 
The scattered X-ray waves emerge from the protein crystal with different phases and 
scattering angles; depending on the way in which the emerging waves combine with 
each other, either constructive interference (results in waves with higher amplitudes) 
or destructive interference (results in waves with lower amplitudes, or no signal) 
occurs. When these waves hit a detector placed in front of the crystal, a pattern of 
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discrete intensities is recorded; these are known as reflections. The diffraction pattern 
is formed from these reflections, and is the raw data of an X-ray diffraction 
(crystallography) experiment.   
Bragg’s law defines the circumstances that determines when a particular set of 
emerging waves will combine constructively to generate a reflection. Each unit cell 
(defined in section 3.3.3) within the crystal lattice can be intersected by a set of 
parrellel planes (Bragg’s planes) at a fixed point along their axis; two waves will only 
remain in phase after reflecting from these planes if these planes are a distance (d) 
apart, with an angle of incidence (θ) for two incoming X-ray waves of wavelength λ, 
and if the additional distance the second wave must travel (d sinθ) is a multiple (n) of 
the wavelength:  
nλ = 2d sinθ 
 
This is depicted in Figure 3.11. 
 
                 
 
Figure 3.11. Bragg’s law 
This defines the lattice spacing (d) and diffraction angle (θ) the required for scattered 
X-rays to remain in phase with each other. These two waves combine constructively, 
which increases their amplitude, and results in a reflection on the detector. Taken 
from http://www-structmed.cimr.cam.ac.uk/Course/Basic_diffraction/Bragg_planes.gif.  
 
 
The resultant wave that generates a reflection on the detector has contributions from 
each diffracting electron in every unit cell throughout the entire crystal. This is due to 
the fact that Bragg’s planes intersect each unit cell in the same way, therefore each 
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unit cell contributes equivalent constructive interference to the emerging wave, and 
amplify the emerging signal such that it can be detected. The way in which Bragg’s 
planes intersect each unit cell are described by Miller indices (hkl), which are 
assigned to each plane that contributes to the diffraction pattern. Each reflection in the 
diffraction pattern can therefore be assigned corresponding Miller indices during 
indexing of the diffraction data (section 3.3.3). All the contributing waves across the 
whole crystal that result in a single reflection can be added together in the structure 
factor equation, which results in a structure factor Fhkl  being assigned to each 
individual reflection. The structure factor amplitude |Fhkl| is proportional to the square 
root of the reflection intensity (the reflection intensities and their positions are what is 
measured during data collection). Each diffraction pattern only provides information 
about the crystal from a single direction, therefore the crystal must be rotated to 
collect as much information as possible and to generate a complete dataset. A 
different set of resultant waves will be detected at each angle as the crystal is rotated, 
as a different set of planes will satisfy Bragg’s law at each angle.   
However, many scattering electrons do not lie on Bragg’s planes in the unit 
cell (they lie between the planes at fractional values of d). X-ray waves scattered by 
these electrons are out of phase with the resultant waves, and will result in a degree 
of destructive interference with the X-ray waves that generate reflections, decreasing 
the amplitude of these waves, and resulting in a relative decrease in the intensity of 
the reflections. Information about the arrangement of atoms in the unit cell relative to 
Bragg’s planes is therefore provided by the relative intensities of the reflections. 
Information about the arrangement of the asymetric units (AU) (the smallest repeating 
unit of the crystal lattice), and how they are related to each other (i.e the space group), 
is similarly provided in the symmetry of the reflections in the diffraction patterns.   
An example of a diffraction pattern collected from crystals of Apo-HAZV N is 
shown in Figure 3.12. The intensity of reflections in diffraction patterns and their 
symmetry together provides almost all the information needed to generate an electron 
density map from the crystal – with the exception of one vital piece of information; the 
phase of the resultant waves that generate the reflections. In order to generate an 
electron density map from the structure factors, a Fourier transform (a way of 
describing a wave as a sum of all its component waves) is required. It is necessary to 
know the relative phase of these waves to make sure they are added correctly. The 
lack of information about the phases of the resultant waves, due to the way diffraction 
data is currently recorded (photon counts on a detector) leads to the fundamental 
‘phase problem’ that has to be solved in all crystallography (X-ray diffraction) 
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experiments. During analysis of diffraction data from HAZV N crystals, the phase 
problem was addressed using molecular replacement (outlined in section 3.3.4).     
 
 
 
Figure 3.12. Diffraction patterns of Apo-HAZV N . 
The symmetry of the reflections together with their intensities provide all the 
information needed to determine the X-ray structure, apart from the phase of the 
resultant waves that generate the reflections. 
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3.3.3 Data processing 
 
The crystal used generate the Apo-HAZV N dataset diffracted to a resolution of 2.7 Å 
in the P212121 space group, and the crystal used to generate the RNA bound-HAZV N 
dataset diffracted to a resolution of 3 Å in the P21 space group. The space group of 
the crystal describes how the asymmetric units (AU) are arranged in the unit cell, and 
it can be determined by the symmetry of reflections in the diffraction pattern. The AU 
contains the smallest object that can be repeated to make the entire crystal (Figure 
3.13 (B)). The unit cell is the identical repeating unit of the crystal that can be stacked 
together to create the periodically arranged, weakly interacting 3-dimensional lattice of 
protein and solvent molecules, that is the protein crystal. Unit cells are described by 
vectors a, b and c, along axes x, y and z and angles α, β and γ, an example of which 
is shown in Figure 3.13 (A). There are a finite number of space groups (65 for proteins) 
as there is a finite number of ways in which (protein) molecules can be arranged in 
space. 
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Figure 3.13. The unit cell.  
The unit cell is the smallest identical repeating unit of the crystal that can be stacked 
together to create the crystal (B). The unit cell is annotated by vectors a, b, and c 
along axes x, y and z, and angles α, β and γ (A). The AU contains the smallest object 
that can be repeated to make the entire crystal (B). Images are taken from: 
http://www.rcsb.org/pdb/101/static101.do?p=education_discussion/Looking-at-
Structures/bioassembly_tutorial.html and http://www.tutorsglobe.com/homework-
help/physical-chemistry/unit-cell-72605.aspx .  
 
 
The dimensions of the Apo-HAZV N unit cell were a=64.99 Å, b=76.1 Å, c=449.28 Å, 
α=90 °, β=90 °, and λ=90 °, and the RNA-bound HAZV N unit cell were; a=64.7 Å, 
b=84.0 Å, c=104.5 Å, α=90 °, β=105.74 °, and λ=90 °.  
  
After data was collected for Apo-HAZV N and RNA-bound HAZV N crystals, data 
processing was carried out by Dr Antonio Ariza and is briefly described in the 
following section. X-ray data for both Apo-, and RNA bound-HAZV N crystals was 
A 
B 
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indexed and integrated using XDS (Kabsch 2010). Miller indices (hkl) were assigned 
to each reflection in the diffraction pattern, and unit cell size and mosaicity was 
determined during indexing. Integration is the process of recording multiple intensities, 
then averaging with associated error, for each reflection. The dataset was converted 
from a series of images into a numerical list of reflection intensities as these two 
processes were carried out. A programme called AIMLESS was then used to scale 
and merge the dataset; processes that make the dataset internally consistant by 
accounting for variation introduced by radiation damage, beam intensity, and detector 
inconsistancies. AIMLESS then merges multiple observations of each reflection to 
generate an average intensity for each reflection, then calculates a list of normalised 
structure factor amplitudes (|Fhkl|) based on the inverse relationship between the 
intensities of the reflections and the structure factor amplitudes.     
 
AIMLESS also calculates a number of statistics to objectively assess the quality of the 
data: 
 
Rmerge – assesses the agreement between the average intensity of a reflection, 
and each individual observation of that reflection: Rmerge is the basic measure of 
internal consistancy. Higher quality data generally has a lower Rmerge  value, however 
Rmerge increases with multiplicity and so is not always an accurate quality indicator. 
Rpim 
 - the ‘precison indicating R-factor’ is similar to the Rmerge, but multiplicity is 
taken into account. The Rpim therefore reflects the increase in accuracy as more 
observations are merged.  
Completeness – the number of unique reflections as a percentage of the total 
number of possible reflections.  
Multiplicity – the average number of independent measurements of a 
reflection. Multiplicity is calculated by dividing the number of total reflections by the 
number of unique reflections.  
I/σ(I) – the intensities average signal to noise ratio.  
Table 5 presents these statistics for Apo-HAZV N and RNA bound-HAZV N datasets. 
These statistics are acceptable for the 2.7 Å and 3.0 Å resolution cut offs that were 
chosen.   
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Table 5 Data collection and scaling statistics.  
Two datasets are presented here; Apo-HAZV N and RNA-bound HAZV N, both solved 
by molecular replacement. Parentheses indicates highest resolution shell values, and 
confirm that the chosen resolution cut off values are statistically acceptable. 
 
Dataset Apo-HAZV N RNA-bound HAZV N 
Wavelength (Å) (i02) 0.9795 (i03) 0.9763 
Space group P212121 P21 
Cell parameters (Å,°) 
a=64.99 
b=76.1 
c=449.30 
α=90 
β=90 
γ=90 
a=64.7 
b=84.0 
c=104.5 
α=90 
β=105.74 
γ=90 
Total relections 252499 (17368) 296006 (22737) 
Unique reflections 62009 (4410) 21781 
Resolution shells (Å)   
Low 74.88-2.70 50.31-3.0 
High 2.77-2.70 3.08-3.0 
Rmerge, % 11.6 (63.1) 10.6 
Rpim % 8.6 (50.8) 3.1 
Completeness, % 98.9 (98.2) 99.9 (100) 
Multiplicity 4.1 (3.9) 13.6 (14) 
I/σ(I) 9.3 (1.7) 20.8 (3.5) 
  
 
In order to allow calculation and monitoring of Rfree during refinement (which occurs 
later on in the data processing pipeline) approximately 5 % of data were radomly 
selected in AIMLESS and kept aside to be omitted from refinement.   
 
3.3.4 The use of molecular replacement to solve the phase problem 
 
The Apo-HAZV N and RNA-bound HAZV N datasets were both solved via molecular 
replacement (MR) with the globular domain of CCHFV N (PDB accession number: 
4AKL); residues 1-182, and 296-482, using a programme called PHASER (McCoy, 
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Grosse-Kunstleve et al. 2007). The process of molecular replacement involves the 
manipulation of the model molecule; in this case the globular domain of CCHFV N, 
into the same position and orientation in the unit cell as the unknown molecule. If the 
model is sufficiently similar to the unknown molecule, the orientation and position of 
the unknown molecule can be determined, and the phases from the model can be 
used in the structure factor equations of the unknown molecule, along with its 
experimental structure factor amplitudes. A Fourier transform can then be applied to 
generate an electron density map. It is necessary to determine the correct orientation 
and position of the phasing model compared to the unknown structure in the AU 
because the phases of the atomic structure factors, and hence of the molecular 
structure factors, depend upon the location of atoms in the unit cell. If the model used 
for MR is reasonably accurate the calculated electron density map will show features 
missing from the original model that can be built into the unknown molecule.  
Molecular replacement is made possible through the utilisation of Patterson 
maps. Patterson maps are derived from the Fourier transformation of the structure 
factor amplitudes, therefore no knowledge of the phase is required, and results in a 
map not of the position of atoms within a molecule, but of the vectors between the 
atoms. There are two broad types of vectors, intra-molecular vectors, representing the 
distance between two atoms within a molecule, and inter-molecular vectors, that 
represent the distance between two atoms of neighbouring molecules. The way that 
the vectors accumulate in a Patterson map can provide a signature for the protein 
structure, and during MR the orientaton and location of the unknown molecule and 
model are compared through correlation of the intra- and inter-molecular vectors of 
their corresponding Patterson maps. In order to place the model structure in the 
correct orientation and location in the AU, 3 rotation angles and 3 translation 
parameters need to be specified. Intra-molecular vectors are only dependent on 
orientation, so these can be exploited in the rotation function, and inter-molecular 
vectors depend on both the location and orientation of the molecule, therefore these 
can be exploited in the translation function once the orientation is known. The 3 
rotation angles can then be computed from the rotation function, and the translation 
function can place the oriented molecule in the AU.     
MR can be used to solve the phase problem if there is a good structural model 
for a reasonably large fraction of the unknown structure in the crystal. Structural 
similarities between proteins correlate well with sequence identity, and as a general 
rule, if the proteins share >30 % sequence identity, the model can be used for MR of 
the unknown molecule in a straightforward analysis. As the level of sequence identity 
decreases, solving the phase problem by MR becomes progressively more difficult. In 
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this study, even though the amino acid sequences of HAZV N and CCHFV N share 
almost 60 % identity, the fact that the arm domain is in a different position in the two 
structures (Figure 3.24) meant full length CCHFV N could not be used in MR, only the 
globular domain (residues 1-182, and 296-482) could be used.     
 
3.3.5 Model refinement of Apo-HAZV N and RNA bound-HAZV N  
 
Refinement seeks to minimise the difference between the calculated structure factor 
amplitudes of the model, and the experimental structure factor amplitudes derived 
from the diffraction pattern, to generate the most accurate electron density map. 
Initially electron density maps were built using phases derived from the CCHFV N 
globular domain for both Apo-HAZV N and RNA bound-HAZV N. A programme called 
BUCANEER (Cowtan 2006) was then used to auto-build a preliminary structure into 
the electron density maps. BUCANEER finds likely Cα positions and extends them 
laterally, through the addition of more Cα atoms, whilst obeying Ramachandran 
constraints, to create fragments of peptide chains. Sequence information then enables 
side chains to be assigned and built into the electron density, and gradually the 
fragments are extended until they begin to join up. Another programme called COOT 
(Emsley and Cowtan 2004) was then used to manually adjust the position of each 
residue in the protein chain to improve the electron density fit, as well as torsion 
angles and bond lengths.  
Refinement of the model using a programme called REFMAC5 (Murshudov, 
Skubak et al. 2011) was then carried out: REFMAC5 tries to minimise differences 
between the calculated and observed structure factor amplitudes (Rcryst) by  improving 
the atomic positions in the model. The process of improving the model also improves 
the calculated phases, which are used to build an improved electron density map, 
which is used to improve the model that fits it, in an iterative cycle. The process of 
refinement can however introduce bias into the model, as both the model along with 
the diffraction pattern are used to generate the new electron density map at each 
round of refinement. 
Assessment of refinement progress is therefore determined by calculating the 
Rcryst for the 5 % of data that was omitted during scaling. This is the Rfree and it 
calculates how well the current model can be used to predict the structure factor 
amplitudes (the measured intensities) from the original, unrefined dataset as a cross 
validation. Rfree, as well as other statistical calculations can be used to assess the 
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quality of a model; some of these quality indicators are briefly summarised in the 
following section. 
Rcryst – also refered to as the R-factor, or R-value. A measure of the difference 
between the calculated structure factor amplitudes, based on the refined model, and 
the observed structure factor amplitudes. A random set of atoms will have an Rcryst of 
~0.63, and a perfect match would have a value of 0. In practice the acceptable aim for 
protein crystals is to have an Rcryst that is less the 10 % of the resolution of the data; 
for a dataset that diffracted to 2.7 Å, the Rcryst should be < 0.27, or 27 %.    
Rfree – a measure of how well the refined model can predict the original 
structure factor amplitudes from the 5 % data that was omitted completely from the 
refinement process. This is considered to be less biased that the Rcryst and in general 
is slightly higher then the Rcryst. A well refined model should have an Rcryst and an Rfree 
that do not deviate by more than 5 % - 7 %.  
B factors – a measurement of the degree of movement around the atomic 
positions in the model, this reflects the precision of the atomic positions. This could 
vary for two main reasons: thermal motion (the vibration of an atom around its rest 
position) and disorder in the crystal from which the structure was determined (an atom, 
or groups of atoms not residing in the same position in every AU, or in every unit cell, 
or in every molecule in the AU). In a high quality model the B factors can reflect the 
mobility and flexibility in various parts of the molecule. In general low B factors 
indicate little variation in atomic position, and high B factors indicate greater 
uncertainty about the actual atomic position.  
RMSD bond lengths – root mean squared deviation of the models bond 
lengths from an accepted set of values based on the geometry of small organic 
molecules. A refined model should exhibit RMSDs of no more then 0.02 Å for bond 
lengths.    
RMSD bond angles – root mean squared deviations of the models bond 
angles - similar to bond length, these are constrained to accepted values based on 
the geometry of small organic molecules. For a fully refined model the RMSD for bond 
angles should not vary by more the 4 ° from the accepted values.  
Ramachandran plots – peptide bonds are planar, and if unconstrained during 
refinement, should settle down to within a few degrees of planar after the final 
refinement. Other backbone conformational angles (Φ, along the N – Cα bond and  Ψ 
along the Cα – C bond) are also greatly restricted due to steric repulsion between 
adjacent side chains. The allowed pairs of angles (Φ and Ψ) on either side of the Cα 
residue are depicted on a Ramachandran diagram, and occupy ‘allowed’ regions; 
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either regions that do not give steric repulsion (enclosed by light blue polygon) or only 
give modest repulsion (dark blue polygon) (Figure 3.14). The shapes of the polygons 
vary slightly for each of the 20 amino acid residues, and after refinement, all of the 
residues in a crystallographic structure should reside in ‘allowed regions’ in the 
calculated Ramachandran plot. Ramachadran plots highlight any regions of the model 
that are conformationally unrealistic, and if any non-glycine residues lie within 
‘forbidden’ areas on the Ramachadran plot following refinement, a good explanation 
needs to exist in terms of structural constraints that overcome the energetic costs of 
an unusual backbone conformation. Ramachandran plots of the Apo-HAZV N 
monomer A are depicted in Figure 3.14. 
   
 
Figure 3.14. Ramachandran plots for Apo-HAZV N monomer A model 
Backbone phi and psi angles are plotted for Apo-HAZV N monomer A.  ‘Prefered 
regions’ are light blue, ‘allowed regions’ are dark blue. A single proline residue resides 
in the ‘forbidden’ region. Plotted using MolProbity.   
 
 
MolProbity server (Chen, Arendall et al. 2010) – a web based server that 
analyses the quality of the refined model based on the biophysical criteria described 
above, and then outputs a series of scores for a particular model. The addition of 
hydrogen atoms to the model (which are unresolved by crystallography, but whose 
position is defined by the conformaton of the atoms on which they reside) allows 
MolProbity to assess unrealistic side chain rotamers, and common misplacement of 
main chain Cα residues. MolProbity also takes into account side chain clashes and  
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analyses any Ramachandran outliers, then normalises these scores to the resolution 
of the structure.  
 
Apo-HAZV N was refined to statistically acceptable levels, a summary of the 
refinement statistics is presented in Table 6. Apo-HAZV N has 4 monomers in the AU, 
however the electron density for the 4th monomer in the AU was worse then the other 
monomers (this monomer also had higher B factors). However this did not prevent the 
model from being completely refined. 
After several cycles, refinement of RNA bound-HAZV N became unstable, the 
Rcryst and Rfree began to diverge. This could be a result of relatively poor quality 
diffraction images that lead to relatively poor electron density; the overall B factors for 
RNA bound-HAZV are high (73.54 compared to 44.9 for Apo-HAZV N), and the B 
factor for the RNA itself is particularly high (95.24). This could indicate a degree of 
disorder in the crystal that gave rise to the diffraction images, which could occur for a 
variety of reasons. These include the atoms not occupying the same position in every 
molecule, or poor cryo-freezing of the crystal, due to suboptimal cryoprotection 
methods. Refinement of the RNA bound-HAZV N model is not complete, and may well 
require collection of better quality data; current statistics are presented in table 6.  
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Table 6 Refinement statistics. 
 
Dataset Apo-HAZV N RNA bound-HAZV N 
Resolution shells (Å) 
Low 74.88-2.70 50.31-3.00 
High 2.77-2.70 3.079-3.00 
Rcryst  % 22.20 20.49 
Rfree % 26.28 29.06 
VM 2.57 2.54 
Mol. Per AU 4 2 
Reflections working set 58670 20654 
Free R-value set (no. of 
reflections) 
5.1% (3125) 5.1 % (1114) 
RMSD bond lengths (Å) 0.013 0.009 
RMSD bond angles (°) 1.553 1.370 
No. atoms used in refinement 
Non-hydrogen atoms 15226 7556 
Protein atoms 15156 7496 
Water molecules 70 0 
RNA atoms 0 60 
Mean B factor, Å2 
Total 44.90 73.54 
Protein atoms 44.7 67.24 
Water molecules 51.1 N/A 
RNA atoms N/A 95.24 
Ramachandran plot statistics, % 
Preferred region 96.49 87.58 
Allowed region 2.88 9.24 
Outliers 0.27 3.18 
Molprobity clashscore for all 
atoms 
2.85 13.4 
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3.4 RESULTS: THE STRUCTURE OF HAZV N 
 
3.4.1 The HAZV N monomer 
 
To gain mechanistic insights into its multiple functions, we determined the crystal 
structure of the full length N protein of HAZV strain JC280. The crystal structure of 
HAZV N was solved by molecular replacement with the globular domain of CCHFV N, 
residues 1-182, and 296-482; the Apo-HAZV N structure was solved to a maximum 
resolution of 2.7 Å, and the RNA bound-HAZV N structure to 3 Å. Purified HAZV N 
was mostly monomeric, and a monomeric view of Apo-HAZV N (monomer A) is 
shown in Figure 3.15. The description of the HAZV N monomer in the following 
section applies to both Apo-HAZV N and RNA bound-HAZV N. For all monomers 475 
residues were built into the model; residues 187-196 form a disordered loop that is 
missing in the electron density for all monomers.  
Similar to CCHFV N, HAZV N possesses 2 distinct domains, a globular 
domain and an arm domain. The globular domain contains amino acid residues from 
both the N- terminus (residues 1-186, silver in Figure 3.15), and the C terminus 
(residues 298-485, blue in Figure 3.15) of HAZV N. HAZV N is mostly alpha helical; 
the globular domain contains helix α1 - helix α8 from the N terminus, and helix α13 – 
helix α20 from the C terminus (alpha helices are numbered according to Figure 3.16). 
The C-terminal alpha helices form the core of the globular domain, and are 
surrounded by alpha helices from the N terminus of HAZV N. The arm domain (purple 
in Figure 3.15) extends away from the globular domain, and is composed of 2 long 
alpha helices (helix α11 and helix α12), with an exposed loop at the apex, which is 
supported by a small three-helix bundle (helices α9, α10, and ɳ3). The arm domain is 
linked to the C-terminus of the globular domain by a single alpha helix (helix α13), 
however at the N terminus the loop linking the globular domain to the arm domain 
(residues 187-196) is disordered, and missing in the electron density. This is similar to 
CCHFV N, where electron density is also missing for the loop linking the arm domain 
to the N terminus of the globular domain (residues 183-191).   
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Figure 3.15. The HAZV N monomer. 
One monomer from the Apo-HAZV N AU is shown. N- and C-termini are labelled (N 
and C, respectively). Each monomer contains two domains: the globular domain, 
composed of residues from the N terminus (residues 1-186, silver), and the C-
terminus (residues 298-485, blue), and the arm domain (residues 197-297, purple). 
The arm domain extends away from the globular domain and is linked to C-terminus 
of the globular domain by a single alpha helix (helix α13), and to the N terminus by a 
disordered loop (residues 187-196), which is not visible in this structure. α helices are 
numbered according to Figure 3.16.  
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Figure 3.16 Alignment of the secondary structural elements of HAZV N with the 
primary sequence. 
Alpha helices are numbered 1-20 from the N terminus to the C terminus. The N and C 
termini of the globular domain and the arm domain, are represented by horizontal bars 
below the sequence coloured according to Figure 3.15. Helix α1 - helix α8 comprise 
the N terminus of the globular domain, helix α9 – helix α12 the arm domain, and helix 
α13 – helix α20 the C terminus of the globular domain. (Generated using Espript - 
http://espript.ibcp.fr (Gouet, Robert et al. 2003)). ɳ denotes a helix with 3 residues per 
turn, α helices have 3.6 residues per turn, and TT denotes a strict β-turn. 
 
 
Four monomers crystallised in the AU of Apo-HAZV N (Figure 3.17 (B)); the 
monomers are packed in a head-to-tail arrangement, with two pairs of monomers 
running anti-parrallel to each other. Contact between the monomers in each pair is 
between the base of the globular domain of one monomer (residue Pro356) and 
residues from both the apex of the arm domain, and the supporting 3- helix bundle of 
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the adjacent monomer (residues Leu280, Trp264, Lys276, Val272, Glu271, and 
Phe217) Figure 3.17 (A). Due to crystal packing, contact between these residues in 
adjacent monomers (both monomers in the same AU, and monomers in neighbouring 
AUs) is observed in both Apo-HAZV N and RNA bound-HAZV N. It is thought the 6 
residues from the apex of the arm domain and supporting 3-helix bundle form a 
hydrophobic pocket, in which Pro356 from the adjacent globular domain is buried.  
Interestingly, due to the packing of the crystals, the same residues also make 
contact between the CCHFV N monomers in all three CCHFV N crystal forms (Carter, 
Surtees et al. 2012; Guo, Wang et al. 2012; Wang, Dutta et al. 2012). The 
hydrophobic interaction between the arm domain and the base of the globular domain 
of the adjacent monomer results in the formation of long helical chains of HAZV N and 
CCHFV N, which can be seen throughout each of the 5 different crystal forms. The 
conserved nature of this interaction between multiple crystal forms suggests it may be 
a common feature of nairovirus N proteins, and the structures observed in the crystals 
may reflect those that form during RNP assembly. Together with the antiparrallel 
relationship between the pairs of monomers in the Apo-HAZV N AU (which is also 
observed by (Wang, Dutta et al. 2012) in CCHFV N crystals), this potential 
multimerisation arrangement resembles that of Influenza virus RNPs. Influenza virus 
RNPs are double helical, and are composed of 2 N strands of opposite polarity, 
associating with each other along the helix. Both strands are connected by a short 
loop at one end of the particle, and associate with the polymerase complex at the 
other end (Arranz, Coloma et al. 2012).   
Mutational analysis would however, have to be performed to determine 
whether any of the residues involved in the formation of the hydrophobic pocket are 
also involved in CCHFV N and HAZV N function and transcriptional activity. The 
conservation of the head-to-tail interaction between the globular domain of one 
monomer and the arm domain of the adjacent monomer is in contrast to the lateral 
interactions between both CCHFV N and HAZV N monomers (Figure 3.17). These 
vary between both Apo-HAZV N and RNA bound-HAZV N crystals, as well as 
between  all three CCHFV N crystal forms. 
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Figure 3.17 The 4 monomers in the Apo-HAZV N AU. 
(A) A hydrophobic pocket is formed by 6 residues (Leu280, Trp264, Lys276, Val272, 
Glu271, and Phe217) of the arm domain, in which Pro356 of the adjacent globular 
domain is buried. (B) HAZV N monomers are arranged in a head-to-tail fashion with 
two pairs of monomers running antiparrallel to each other in the Apo-HAZV N AU. 
Electron density for the 4th monomer (black) was poor compared to the other 
monomers in the AU. Vertical arrows indicte lateral interactions betwen HAZV N 
monomers. Lateral contacts between monomers vary within the AUs of Apo-HAZV N 
and RNA bound-HAZV N. 
 
 
3.4.2 The surface electrostatic potential of Apo-HAZV N 
 
Given the RNA binding capability of HAZV N, the electrostatic surface potential of 
Apo-HAZV N was analysed. The electrostatic surface potential was calculated using a 
programme called Adaptive Poisson-Boltzmann Solver (APBS) and Figure 3.18 
shows surface representations of the Apo-HAZV N protein colour-coded red to blue 
according to charge (negative to positive respectively). Areas of positive charge (blue) 
are linked to electrostatic interactions with the negative phosphate groups of the RNA 
(or other nucleic acid) backbone. This analysis revealed a positively charged ‘platform’ 
adjacent to the arm domain (Figure 3.18, left) in a similar position to a positively 
charged platform on the surface of the CCHFV N protein (Figure 1.11). This was 
suggested to be a potential RNA binding site, as it is one of the largest areas of 
continuous positive charge on the surface of both HAZV N and CCHFV N. Other 
areas of positive charge include an area on the base of the globular domain, and an 
area on the arm domain.   
On the opposite face of the HAZV N monomer to the positively charged 
platform (rotate HAZV N monomer 180 °, Figure 3.18, right) there is a crevice in the 
surface of HAVZ N, which extends from the base of the globular domain to helix α13 
that links the globular domain to the arm domain. This crevice could also be a 
potential RNA binding site. There are areas of negative charge on the surface of 
HAZV N (red), on the apex and side of the arm domain, and boardering the crevice in 
the globular domain (Figure 3.18, right). However, a large proportion of the surface of 
HAZV N is positively charged, which is consistent with the relatively high pI of HAZV N 
(8.73), and its ability to be purified by cation exchange chromatography.   
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Figure 3.18 Surface representation of Apo-HAZV N electrostatic potential. 
The surface charge of Apo-HAZV N. Electrostatic surface potential is shown colour 
coded from red (negative) to blue (positive) in dimensionless units of kb T ec
-1, where 
kb is Boltzmann’s constant, T is the temperature, and ec is the charge of an electron.  
 
 
3.4.3 The RNA-bound HAZV N model 
 
In the previous section analysis of the electrostatic surface potential of Apo-HAZV N 
revealed several regions that could potentially bind RNA. In the RNA bound-HAZV N 
structure, the crevice in the globular domain was shown to be the RNA binding site, 
rather than the positively charged platform adjacent to the arm domain. RNA bound-
HAZV N was solved by molecular replacement with the globular domain of CCHFV N 
to a final resolution of 3 Å, and contained 2 monomers in the AU (Figure 3.19 (A)). In 
one of the monomers, three nucleotides of ssRNA were bound within the crevice in 
the globular domain that extends from the base of the globular domain to helix α13 
that links the globular domain to the arm domain (Figure 3.19 (B)). 
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Figure 3.19. The two monomers in the RNA bound-HAZV N AU 
RNA bound-HAZV N crystallised with 2 monomers in the AU (A), one monomer had 
RNA bound (yellow) and one did not (raspberry). (B) The RNA bound-HAZV N 
monomer is depicted in the same fashion as the Apo-HAZV N model for clarity; the N 
terminus is silver, the C terminus is blue, and the extended arm domain is purple. The 
RNA is depicted predominantly in yellow (carbon); phosphates are orange, nitrogen 
atoms are blue, and oxygen atoms are red.  
A 
B 
RNA 
RNA 
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The overall structure of RNA bound-HAZV N is the same as Apo-HAZV N; the 
description of the Apo-HAZV N monomer in section 3.4.1 can also be applied to the 
RNA-bound HAZV N monomer. As for Apo-HAZV N, RNA bound-HAZV N is mostly α 
helical, and consists of two domains; a globular domain composed of residues from 
both the N- and C- termini, and an arm domain that extends away from the globular 
domain. The major difference between Apo-HAZV N and RNA bound-HAZV N resides 
in the position of the arm domain relative to the globular domain. This is discussed 
further in section 3.5.1. 
The three RNA nucleotides bound within the crevice may represent RNA that 
is inaccessible to the RNase enzyme used during purification of HAZV N, due to its 
buried position. This might explain why treatment of HAZV N with RNase was not 
sufficient to completely remove bacterially-derived RNA from HAZV N during 
purification, even after extensive RNase treatment (wash buffers containing high 
concentrations of NaCl were used to disrupt the interaction between the RNA and 
protein instead). 
 
3.4.4 The electrostatic surface potential of RNA bound-HAZV N 
 
The electrostatic surface potential of RNA bound-HAZV N was calculated as for Apo-
HAZV N (section 3.4.2). The positively charged platform adjacent to the arm domain is 
highlighted in Figure 3.20, as is the crevice in the globular domain where RNA is 
bound. Comparison of the surface electrostatic potential of Apo-HAZV N (Figure 3.18) 
and RNA bound-HAZV N (Figure 3.20) reveals little difference in the overall surface 
electrostatic potential between the two models. The distribution of the areas of 
positive charge varies according to the change in position of the arm domain, which is 
discussed further in section 3.5.1. This arm domain movement also slightly alters the 
position of the negatively charged areas boardering the RNA binding crevice, however 
whether this has any bearing on the RNA binding ability of HAZV N is unknown.   
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Figure 3.20 Surface representation of RNA bound-HAZV N electrostatic potential. 
The surface charge of RNA-bound HAZV N. Electrostatic surface potential is shown 
colour coded from red (negative) to blue (positive) in dimensionless units of kb T ec
-1, 
where kb is Boltzmann’s constant, T is the temperature, and ec is the charge of an 
electron.  
 
 
3.4.5 Residues of HAZV N potentially involved in RNA binding 
 
The 3 nucleotides of ssRNA bound to HAZV N are random RNA sequences derived 
from the expression host, and this structure of HAZV N is therefore unlikely to reveal 
any sequence specificity. Furthermore the electron density for the 3 RNA nucleotides 
is not good enough to determine whether these bases are purines or pyrimidines (for 
example if a purine base was prefered at a specific position, as has shown to be the 
case for LASV N protein). The 3 RNA nucleotides are oriented with their phosphate 
backbones contacting the foundation of the crevice, and the bases pointing outwards, 
towards the opening of the crevice. It is thought, that in a similar manner to LASV N 
(Hastie, Liu et al. 2011), an extensive network of interactions anchor the RNA 
phosphate backbone and RNA bases to HAZV N. Binding is thought to occur through 
hydrogen bond interactions between key amino acid residues, and both phosphates of 
the RNA backbone and the RNA bases.  
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Previously, to characterise the roles of residues involved in RNA binding, or the 
potential dimerisation site of CCHFV N, a panel of CCHFV N proteins with mutations 
in these residues were examined for their ability to promote luciferase reporter gene 
expression within a CCHFV mini-genome (Carter, Surtees et al. 2012). Mutations in 3 
residues essentially abrogated CCHFV mini-genome transcriptional activity when 
compared to wild type N (K132, Q300 and K411). When the position of these mutated 
residues are mapped onto the RNA bound-HAZV N structure (residues N134, Q303 
and K414 in HAZV N) 2 out of these 3 residues (K414 and Q303) are within bonding 
distance of the RNA backbone in the globular domain RNA binding crevice (Figure 
3.21). Given the close structural similarity between the globular domains of HAZV N 
and CCHFV N (discussed in section 3.5.2), these data strongly suggest that these 
residues are involved in RNA binding in HAZV N, and by inference RNA binding in 
CCHFV N as well (rather than any other effect that could regulate mini-genome 
output).  
K132/N134 is located on an N terminal alpha helix facing away from the 
crevice, and does not contact the RNA bound in the crevice. This residue could 
however be involved in dimerisation, or RNA binding of longer sequences of RNA, or 
L protein interaction. Mutation of residue H456 (residue H459 in HAZV N), which is 
positioned close to one of the RNA bases, has a less pronounced effect, resulting in a 
loss of ~50 % luciferase signal, and mutation of residue H453 (residue H456 in HAZV 
N) has no effect on minireplicon activity. This is similar to LASV N, where mutation of 
several residues contacting the bound RNA has no effect on mini-genome activity, 
whereas mutation of others abrogates mini-genome activity, or decreases the reporter 
gene signal by ~50 % (Hastie, Liu et al. 2011). CCHFV N residue K342 (residue K345 
in HAZV N) was also mutated, as it formed part of the positively charged suspected 
RNA binding site adjacent to the crevice near the base of the globular domain. 
Mutation of K342 however, has no effect on CCHFV mini-genome function, and K345 
is not located near to the bound RNA in HAZV N.    
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Figure 3.21 Potential RNA binding residues of RNA bound-HAZV N. 
The RNA bound-HAZV N monomer with potential RNA binding residues Q303, K414, 
H456, H459, N134 and K345 highlighted. Mutation of Q300 and K411 in CCHFV N 
essentially abrogated CCHFV mini-genome transcriptional activity, and mutation of 
H456 reduced reporter gene expression by ~50 %. The corresponding positions of 
Q303, K414 and H459 in RNA bound-HAZV N, where they make close contact with 
both the RNA backbone and the RNA bases, strongly suggest these residues may be 
important for RNA binding. 
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3.5 COMPARISON OF HAZV N WITH OTHER STRUCTURES 
 
3.5.1 Apo-HAZV N and RNA bound-HAZV N 
 
RNA-bound HAZV N and Apo-HAZV N consist of two domains; a globular domain and 
an extended arm domain. Superposition of Apo-HAZV N and RNA-bound HAZV N 
reveals close structural similarity in the globular domain (RMSD = 1.1 for 368 residues) 
(Figure 3.22). In contrast, whilst the fold in the arm domain is the same (RMSD = 
0.594 for 107 residues) the position of the arm domain is greatly altered with respect 
to the globular domain. The arm is rotated by about 50 °, and the apex of the arm 
domain is shifted by a distance of 29.19 Å (measured from the Cα position of Asp269, 
at the apex of the arm in each monomer). It is possible that the movement of the arm 
domain may be related to the mechanism of RNA binding, analogous to the gating 
mechanism proposed for LASV N.  In the absence of RNA part of helix α5 of LASV N, 
and all of helix α6 lie across the RNA-binding crevice, occluding access to RNA. Upon 
RNA binding the loop linking helix α5 and helix α6 shifts outwards, helix α5 shortens, 
and helix α6 is rotated away from the crevice, enabling RNA to bind (Hastie, Liu et al. 
2011). The electron density of RNA-bound HAZV N is too poor to determine whether a 
similar mechanism occurs upon HAZV N binding RNA; for example, what would be 
helix α13 in Apo-HAZV N (analogous to helix α5 of LASV, Figure 1.13 ) does not have 
secondary structural assignment in RNA bound-HAZV N. However, this could either 
be because it is more flexible and part of the RNA binding mechanism, or the electron 
density is not good enough to assign a secondary structure. 
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Figure 3.22 Superposition of Apo-HAZV N and RNA bound-HAZV N. 
Apo-HAZV N (raspberry) and RNA bound HAZV N (yellow) structurally have very 
similar globular domains, however the relative position of the arm domain is greatly 
altered. Upon RNA binding, the arm domain is rotated by about 50 ° and the apex of 
the arm domain is shifted by 29.19 Å. The change in position of the arm domain may 
be related to the mechanism of RNA binding, however further work is needed to 
confirm the mechanism of HAZV N RNA binding.  
 
 
The arm domain of CCHFV N is known to be flexible, and free to explore a range of 
conformations, indeed it is thought the flexibility of the arm domains of bunyavirus N 
proteins in general are essential to their function. The ability of the arm domain of 
HAZV N to adopt several different positions is therefore to be expected, however 
there appears to be 2 prefered general positions; one which is adopted when RNA is 
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bound, and the other that is adopted when RNA is not bound (Figure 3.23). The 
superposition of the 4 Apo-N monomers in the AU as well as the RNA-free monomer 
from the AU of RNA bound-HAZV N shows that although the position of the arm 
domain does change slightly (similar to observations of CCHFV N by (Wang, Dutta et 
al. 2012), it is nowhere near the huge shift which is seen in the RNA bound structure. 
This suggests that although the arm domain is free to explore different conformations, 
it generally resides in the same position when RNA is not bound. 
 
 
 
 
Figure 3.23 Superposition of RNA free HAZV N   
Superposition of the 4 monomers from the Apo-HAZV N AU (greys and blue), and the 
RNA free monomer from the RNA bound HAZV N AU (raspberry). The globular 
domains superpose almost exactly, and the arm domains reside in a similar position, 
with some slight deviations, similar to CCHFV N (Wang, Dutta et al. 2012).  
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3.5.2 HAZV N and CCHFV N  
 
HAZV N and CCHFV N likely perform the same function in their viral replication cycles, 
and  share ~60 % sequence identity (Figure 1.12); this is reflected in the structural 
similarity between these proteins, which enabled the structure of HAZV N to be solved 
by molecular replacement with the globular domain of CCHFV N (residues 1-182, and 
296-482). In good agreement with this, the crystal structures of HAZV N and CCHFV 
N are very similar (Figure 3.24). The globular domains of HAZV N and CCHFV N align 
extremely closely (RMSD = 0.698, over 368 residues that share 63 % sequence 
identity), as do the arm domains (RMSD = 0.886 over 107 residues that share 48 % 
sequence identity), however the arm domain adopts a different position relative to the 
globular domain (Figure 3.24). The arm domain of CCHFV N is rotated by 73.96 ° and 
translated by 27.05 Å (measured from the Cα of Asp 266/269), compared to the arm 
domain of HAZV N. Although neither HAZV N nor CCHFV N in Figure 3.24 have RNA 
bound, the difference in the position of the arm domain could be due to the different 
primary amino acid sequences of these proteins. Alternatively, the change in the 
position of the arm domain could also be related to differences in the crystal packing 
of these proteins.  
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Figure 3.24 Superposition of CCHFV N and HAZV N 
The globular domain of CCHFV N (green) and HAZV N (raspberry) superpose 
extremely closely. The relative position of the arm domain of CCHFV N is shifted 
compared to HAZV N through a rotation of 73.96 ° and translation of 27.05 Å.  
 
 
3.5.3 HAZV N and LASV N 
 
The globular domain of CCHFV N is structurally similar to the N-terminal RNA binding 
domain of LASV N, a member of the bisegemented Arenaviridae family (RMSD 3.38 Å 
for 237 residues with 8.01 % sequence identity) (Carter, Surtees et al. 2012). 
Unsurprisingly, the globular domain of HAZV N also aligns closely with the N terminal 
domain of LASV N; (Cα RMSD 3.426 for 240 residues) (Figure 3.25). Interestingly, 
superposition of RNA bound-HAZV N with the N-terminal domain of RNA bound LASV 
N (Figure 3.25) revealed not only the close structural similarity of the protein fold in 
the globular domain, but also a very close similarity in the position of the RNA in the 
RNA binding crevice. Of the three RNA bases that are present in the crevice in the 
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globular domain of HAZV N, the position of base 2 and base 3 overlap between HAZV 
N RNA compared to LASV N RNA. The position of base 1 varies slightly between the 
RNA strands, as does the position of the ribose-phosphate backbone, however, 
overall the position of the RNA nucleotides is very similar in these two structurally 
related proteins.  
The electron density is poor for regions of the RNA bound-HAZV N protein, 
and also poor for the RNA in the crevice; the RNA B factors are very high, and the 
electron density is insufficiently accurate to determine the precise position of each 
atom of the 3 RNA nucleotides. However, the position of the RNA in HAZV N was 
determined independently of the LASV N N-terminal domain structure, therefore the 
close overlap in the position of RNA in HAZV N and one of its closest structural 
relatives, LASV N, supports the placement of the RNA in the crevice of the globular 
domain of HAZV N as being correct.        
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Figure 3.25 Superposition of the globular domain of RNA bound-HAZV N, and 
the RNA bound N terminal domain of LASV N. 
The globular domain of RNA bound-HAZV N (yellow) and the N terminus of LASV N 
(blue) align quite closely (RMSD = 3.426). The RNA of HAZV N (yellow) and LASV N 
(light blue) also aligns well; the positions of base 2 and base 3 overlap between the 
two strands of ssRNA, with slight deviations in the position of base 1 and the 
phosphate backbone. Overall, the similarity of the RNA positions supports the correct 
placement of RNA in HAZV N, despite high B factors and poor electron density. 
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3.6 CHAPTER SUMMARY AND DISCUSSION  
 
This chapter presents the optimisation of expression and purification of HAZV N 
protein, and determination of the X-ray structure of both Apo-HAZV N and RNA-bound 
HAZV N, following crystallisation, X-ray diffraction and data collection. HAZV-N was 
expressed from pGEX-GST-HAZV N, GST-HAZV N was purified using glutathione 
affinity chromatography, cleaved with HRV 3C protease, and HAZV N further isolated 
by cation exchange chromatography. This resulted in the purification of 4-7 mgs >95 % 
pure HAZV N, per 4 L bacterial culture. RNA bound-HAZV N was purified by omitting 
a high NaCl concentration binding buffer wash prior to elution of GST-HAZV N from 
the GST resin. This resulted in the purification of RNA bound-HAZV N with an 
A260/A280 ratio of 1.04, and Apo-HAZV N with an A260/A280 ratio of 0.84, indicating RNA-
bound HAZV N co-purified with more nucleic acid. 1 mg of >95 % pure HAZV N was 
used to generate polyclonal antibodies targeting HAZV N, using an immunisation 
programme which is UK home office and USA National Institutes of Health compliant. 
Crystals of Apo-HAZV N diffracted to 2.7 Å in the P212121 space group, and 
crystals of RNA bound-HAZV N diffracted to 3 Å in the P21 space group. Both 
datasets were solved by molecular replacement with the globular domain of CCHFV N 
(residues 1-182 and  296-482). Apo-HAZV N and RNA bound-HAZV N both have very 
similar structures, and similar overall surface electrostatic potential. Apo-HAZV N and 
RNA bound HAZV N are mainly alpha-helical, containing a globular domain composed 
of 16 α helices from both the N and C termini of the protein, and an arm domain 
composed of 2 long alpha helices, that extends away from the globular domain. 
Contact within the pairs of monomers in the Apo-HAZV N AU occurs through a 
hydrophobic interaction, where six residues from the arm domain of one monomer 
forms a hydrophobic pocket in which Pro356 of the adjacent globular domain is buried. 
This interaction occurs in both Apo-HAZV N and RNA bound HAZV N crystals, as well 
as in all three CCHFV N crystal forms, resulting in the formation of long helical chains 
of N protein throughout these crystals. It could be this is a common feature of 
nairovirus N proteins, and may reflect the mechanism of multimerisation of these 
proteins during RNP formation, although mutational analysis would have to be 
performed to confirm this.  
The globular domains and arm domains of Apo-HAZV N and RNA bound 
HAZV N are very similar, they superpose almost exactly, with a Cα RMSD of 1.1 over 
368 amino acids, and 0.594 over 107 residues, respectively. The arm domain has 
shifted position dramatically in the RNA bound-HAZV N structure compared to the 
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Apo-HAZV N structure however, through a translation of 29.19 Å and a rotation of 
~50 °, measured from the Cα of Asp 269. It is possible that this change in the position 
of the arm domain may be connected with the mechanism of RNA binding, analagous 
to the mechanism proposed for the nucleocapsid protein of LASV (Hastie, Liu et al. 
2011). Superposition of RNA bound-HAZV N and the RNA bound N terminal domain 
of LASV N reveals that the RNA resides in a very similar position (base 2 and base 3 
overlap), supporting the crevice in the globular domain as the binding site for RNA in 
HAZV N, even though the electron density is poor. LASV N helix α5 corresponds to 
the beginning of HAZV N helix α13, which links the arm domain to the globular 
domain, and has changed position in Apo-HAZV N compared to RNA bound-HAZV N. 
This supports the theory that the movement of the arm domain of HAZV N might 
possibly ‘gate’ RNA binding, in a similar manner to LASV N.  
Additionally, superposition of the 4 monomers from the AU of Apo-HAZV N, 
and the RNA free monomer from the AU of RNA-bound HAZV N, revealed that both 
the globular domains and arm domains align almost exactly; there are slight shifts in 
the position of the arm domain, but these are nowhere near the movement that is 
observed between Apo-HAZV N and RNA-bound HAZV N arm domains. The similarity 
in the position of the HAZV N arm domains in five monomers, from two different unit 
cells and two different crystals, suggests that although the arm domain is free to 
explore different conformations, it generally resides in the same position when RNA is 
not bound. This supports the theory that a specific trigger (such as the presence of 
RNA, or another ligand or cofactor) is required before the arm domain will change 
position (possibly in order to enable HAZV N to bind RNA in some sort of gating 
mechanism). It is thought that in the absence of a P-protein (the phosphoprotein, a 
protein present in the non-segmented NSVs), sNSVs must have a mechanism to 
ensure monomeric N does not bind cellular RNA non-specifically, or multimerise 
inappropriately, during the virus replication cycle (Green, Cox et al. 2014). A lot more 
work needs to be carried out however, to determine whether the change in the 
position of the HAZV N arm domain is involved in the mechanism of HAZV N RNA 
binding, as the electron density both for regions of the protein domains, and the RNA, 
is too poor to confirm an RNA gating mechanism from this study. 
This is the first time RNA has been co-crystallised with a nairovirus 
nucleocapsid protein. Three nucleotides of RNA bound in a crevice in the globular 
domain, that extends from the base of the globular domain to the helix α13, which 
links the globular domain to the arm domain. The orientation of the nucleotides is with 
the phosphate backbone towards the base of the crevice with the bases pointing 
outwards, towards the opening of the crevice. It is thought the buried position of the 
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nucleotides in the crevice provides protection from RNase treatment during 
purification, and that the nucleotides are not available to base pair during RNA 
synthesis when bound to HAZV N in this crevice. Therefore, in a similar manner to 
LASV N, the N protein surely needs to dissociate from the RNA in the RNP during 
RNA synthesis, before the L protein can access viral RNA. In the case of LASV, it has 
been proposed that the L protein induces a conformational change in N in LASV 
RNPs, enabling N to transiently dissociate from the RNA to allow access by the L 
protein, before N re-encapsidates the RNA (Hastie, Liu et al. 2011). It is possible that 
an analagous mechanism also exists for HAZV N.      
HAZV N is structurally extremely similar to CCHFV N. The globular domains 
align very closely (RMSD = 0.698, over 368 residues that share 63 % sequence 
identity), and the arm domains occupy different positions relative to the globular 
domains (the arm domain is rotated by 73.96 °, and translated by 27.05 Å, measured 
from the Asp 266/269 Cα in CCHFV N compared to HAZV N). The arm domains might 
adopt different positions due to primary sequence differences, or differences in crystal 
packing. The arm domain is flexible – the single alpha helix, and flexible loop (not 
visible in electron density for either structure) linking the arm domain and the globular 
domain is not structurally rigid, and is thought to allow the arm domains of both 
CCHFV N and HAZV N to adopt different conformations. This flexibility between 
domains is proposed to be a common feature of sNSV nucleocapsid proteins, that 
results in the greater flexibility of sNSV RNPs that enables the RNPs to carry out their 
specific functions (Reguera, Cusack et al. 2014). In good agreement with this, the arm 
domain of HAZV N can also adopt a number of different positions.  
The extreme similarity in the globular domains of CCHFV N and HAZV N (the 
site of RNA binding), and the overall similarity in the organisation of the domains, 
suggests that CCHFV N and HAZV N adopt the same mechanisms to carry out their 
functions within their virus replication cycles. This goes someway towards validating 
the use of HAZV as a model for CCHFV infection. Furthermore, careful structure-
based design of small-molecule inhibitors targeting the globular domain of CCHFV, 
should act as effective antivirals against both HAZV and CCHFV. The globular domain 
of CCHFV N and HAZV N is an excellent target for small-molecule inhibitors as it is 
the site of RNA binding; an essential function of these proteins. The RNA is 
sequestered in a crevice in the globular domain, allowing for the design of structure-
based antiviral inhibitors aimed at preventing RNA binding. The fact that HAZV N and 
CCHFV N have such similar globular domains should enable HAZV to act as a model 
for CCHFV infection when examining the potential efficacy of these small molecule 
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inhibitors under containment level 2 conditions, without the need to perform 
experiments under containment level 4 conditions. 
The similarity in the globular domains of HAZV and CCHFV has also enabled 
the identification of residues potentially important in RNA binding. Mutation of residues 
in CCHFV N thought to be involved in RNA binding or dimerisation, and examination 
of the ability of mutant CCHFV N to promote reporter gene expression in a CCHFV 
mini-genome, identified 3 residues whose mutation abrogated reporter gene 
expression (K132, Q300 and K411) (Carter, Surtees et al. 2012). Examination of the 
location of these residues in RNA-bound HAZV N revealed that 2 of these residues 
(Q303 and K414) lie within bonding distance of the RNA backbone. This strongly 
suggests these residues are essential for or are involved in RNA binding in HAZV N 
and CCHFV N, as mutating these residues prevented CCHFV N from carrying out 
essential functions. Observations such as this support the proposal that CCHFV N 
and HAZV N have the same mechanisms of action, and that HAZV is a suitable model 
for CCHFV.    
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CHAPTER 4: IDENTIFYING HOST PROTEINS THAT INTERACT WITH 
CCHFV N AND HAZV N 
 
4.1: CHAPTER INTRODUCTION 
 
RNA viruses, including CCHFV and HAZV, have limited coding capacity and to 
compensate for this, their proteins exhibit remarkable structural economy, often 
possessing multiple functional domains, and the ability to interact with both viral 
proteins and components from the host cell. In addition to RNP formation, where the 
nairovirus N protein makes both homotypic N-N interactions and N-RNA interactions, 
it is thought the nairovirus N protein interacts with numerous host cell proteins. 
Interactions between host cell and viral proteins can have important consequences for 
virus replication; CCHFV N interacts with both actin, and Mx1, in the context of virus 
infection; the interaction of CCHFV N with actin aids viral replication, it is thought by 
trafficking CCHFV N to perinuclear regions of the cell where virus ‘factories’ form, 
whereas Mx1 is thought to inhibit replication (Andersson, Bladh et al. 2004; 
Andersson, Simon et al. 2004). This chapter aims to identify interactions with other 
cellular proteins, and examine whether CCHFV N and HAZV N therefore have other 
functions outside of RNP formation.   
This chapter describes the identification of cellular proteins that interact with 
an (enhanced green fluorescent protein) EGFP-CCHFV N fusion protein by stable 
isotope labelling of amino acids in cell culture (SILAC) based mass spectrometry, 
coupled to EGFP immunoprecipitations (IPs). EGFP IPs were carried out with a GFP-
Trap, that is composed of monoclonal anti-EGFP antibodies covalently coupled to 
agarose beads. This chapter then describes the validation of cellular heat shock 
protein 70 (HSP70) as an interacting partner of untagged CCHFV N, both when 
CCHFV N is expressed from a plasmid, and in the context of actively replicating 
CCHFV. Finally this chapter describes the interaction of HSP70 with HAZV N, both 
within cells, and within fractions containing purified HAZV, and preliminary 
experiments to understand the functional significance of the HSP70-HAZV N 
interaction during the replication cycle of HAZV. 
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4.1.1 Introduction to SILAC based mass spectrometry coupled to GFP-trap IPs 
 
Immunoprecipitations (IPs) coupled to stable isotope labelling by amino acids in cell 
culture (SILAC) in combination with mass spectrometry (MS), provides a method for 
the unbiased identification of cellular proteins that co-IP with a ‘bait’ protein, within the 
context of the cellular environment. MS provides a reliable method of identifying 
peptides, however MS is not innately quantitative; approximate protein abundance 
can be estimated using the emPAI score (the exponentially modified protein 
abundance index; described in more detail in section 4.7.3), however this is not as 
precise as quantitation methods based around isotope labelling (Mann 2006). One of 
these isotope labelling techniques is SILAC, which is a high throughput, quantitative, 
proteomic technique that can be used to compare relative protein levels between two 
or more different cell populations. SILAC can be used to assess global proteome 
changes, or changes in the ‘interactome’; i.e. the total number of cellular proteins that 
interact with a specific ‘bait’ protein in comparison to a negative control. 
Two or more cell populations are distinguished by growing cells in media 
containing isotopically labelled amino acids; these become incorporated into cellular 
proteins over time, as cell grow normally, and replace their equivalent unlabelled 
amino acids (5-7 cell divisions is generally sufficient to ensure > 95 % cellular proteins 
are labelled) (Ong, Blagoev et al. 2002). Several SILAC labelling media recipes exist, 
the most widely used include labelled arginine and lysine residues, due to the fact that 
trypsin cleaves polypeptide chains immediately after arginine and lysine residues. 
These recipes therefore ensure that every peptide generated by in-gel trypsin 
digestion, prior to MS analysis, contains at least one labelled amino acid. All tryptic 
peptides can therefore be distinguished from their functionally identical sister peptides, 
derived from a different cell population. Exceptions to trypsin cleaving polypeptide 
chains immediately after arginine or lysine residues include when either proline 
follows, or aspartic or glutamic acid residues neighbour, arginine or lysine, as this 
blocks or impedes trypsin cleavage respectively (Thiede, Lamer et al. 2000).  
In this study the following SILAC media recipes were used: ‘medium’ (R6K4) 
media which contains 13C-labelled arginine and 2D- (deuterium – a heavy form of 
hydrogen) labelled lysine, and ‘light’ (R0K0) media, which is label free. This enabled 
two different cell populations to be compared simultaneously. 
When analysed by MS, pairs of functionally identical peptides, of different 
isotope composition, can be differentiated as the labelled amino acids will induce a 
shift in the mass/charge ratio (m/z) in comparison to the unlabelled peptides. 
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Comparison of the intensity of the labelled and unlabelled m/z peaks provides 
accurate quantitation of the relative abundance of labelled and unlabelled peptides 
present in the sample. This results in every identified protein being assigned a SILAC 
ratio, which reflects the relative abundance of that protein (derived from a labelled cell 
population) compared to the same protein derived from a control (unlabelled cell 
population) (Ong, Blagoev et al. 2002).  
When applied to IP experiments in this study the SILAC ratio provides a guide 
to the specificity of the potential interaction; a low ratio indicates the identified protein 
immunoprecipitated in almost equal abundance with the control sample (EGFP in this 
study) and the protein of interest (EGFP-CCHFV N in this study), therefore this protein 
most likely bound non-specifically to EGFP, or components of the GFP-Trap. As the 
SILAC ratio of EGFP-CCHFV N/EGFP increases, it becomes increasingly likely that 
the cellular protein immunoprecipitated specifically with EGFP-CCHFV N.  
In this study IPs were performed using a strategy known as mix after 
precipitation (MAP) (Figure 4.1). In MAP IPs, following cell lysis, separate IPs are 
carried out on each cell population, and equal volumes of resulting 
immunoprecipitates are mixed together. Proteins of interest and co-
immunoprecipitating proteins present in the immunoprecipitate are then identified and 
quantified by MS (Figure 4.1). Using the MAP strategy, dynamic or weak interacting 
partners can be efficiently precipitated and quantified. However, as the two IPs are 
performed separately, experimental variability can be easily introduced (for example; 
insufficient/unequal cell lysis resulting in different amounts of lysate being incubated 
with GFP-Trap beads, different volumes of GFP-Trap beads being used, inaccurate 
pipetting when mixing the separate immunoprecipitates) which can be mistaken for 
biological variation. Therefore caution should be taken when preparing samples and 
performing IPs, and biological replicates and subsequent validation are essential. 
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 Figure 4.1 Schematic representation of SILAC labelled MAP IPs 
A mix after immunoprecipitation (MAP) IP strategy was utilised in this study. An 
example involving 3 labelled cell populations is depicted here, however only ‘Medium’ 
and ‘Light’ populations were utilised in this study.   
 
 
4.2 RESULTS: CELLULAR PROTEINS THAT CO-IP WITH EGFP-CCHFV N 
 
4.2.1 Cloning of CCHFV N ORF into pEGFP-C2 expression vector  
 
The CCHFV N ORF was originally obtained in a pCAGGs expression vector (Figure 
4.8). The CCHFV N fragment was subcloned by PCR amplification of the CCHFV N 
ORF using primers to incorporate a 5’ XhoI site and 3’ BamHI restriction 
endonuclease site. Subcloning was completed by direct digestion of this PCR product, 
and ligation into the empty double digested pEGFP-C2 vector using XhoI and BamHI 
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restriction enzymes; the correct orientation and sequence of the insert was then 
confirmed by sequence analysis. This construct will be referred to as pEGFP-C2-
CCHFV N and resulted in the expression of an N terminally EGFP tagged CCHFV N 
fusion protein; EGFP-CCHFV N. A schematic representation of pEGFP-C2-CCHFV N 
is shown in Figure 4.2 (B) and a schematic representation of the EGFP-CCHFV N 
fusion protein in Figure 4.2 (A). 
 
 
 
 
Figure 4.2 Schematic representations of EGFP-CCHFV N and pEGFP-C2-CCHFV 
N 
CCHFV N was fused at the N terminus to EGFP (A), which enabled direct 
visualisation of EGFP-CCHFV N by fluorescence microscopy, and detection of EGFP-
CCHFV N by western blot analysis with anti-EGFP antibodies. The map was 
generated using SnapGene.  
 
A 
B 
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The CMV promoter in pEGFP-C2-CCHFV N enables strong, constitutive expression of 
EGFP-CCHFV N in many mammalian cell types, and the SV40 poly(A) signal 
increases mRNA stability, resulting in high level protein expression. The N-terminal 
EGFP tag allowed direct visualisation of EGFP-CCHFV N in transfected cells by 
fluorescence microscopy. EGFP-CCHFV N could also be detected by commercially 
available antibodies that bind EGFP, when EGFP-CCHFV N expression was analysed 
by western blotting.     
 
4.2.2 EGFP-CCHFV N expression 
 
EGFP-CCHFV N was expressed in HEK293T (293T) cells following calcium 
phosphate mediated transfection. 293T cells are a human kidney epithelial cell line 
that constitutively expresses the SV40 large T antigen, and were chosen due to their 
human origin, which facilitates downstream MS analysis, and their high transfectability. 
Calcium phosphate-mediated transfection is based on the formation of a calcium 
phosphate-DNA precipitate, as a solution of calcium and DNA is slowly added drop-
wise to a solution containing phosphate; calcium phosphate facilitates binding of DNA 
to the cell surface, where it then enters the cell by endocytosis. Following cell entry, 
EGFP-CCHFV N was expressed as a fusion protein of the correct predicted molecular 
weight, 87 kDa, and localised in the cytoplasm of transfected cells (Figure 4.3). 
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Figure 4.3 Expression of EGFP-CCHFV N in 293T cells. 
pEGFP-C2-CCHFV N transfection of 293T cells resulted in the expression of an 
EGFP-CCHFV N fusion protein of the correct molecular weight, 87 kDa, when 
analysed by western blot (A). Live cell imaging confirmed the expression of EGFP-
CCHFV N (B), as did confocal microscopy of formaldehyde-fixed cells (C). In all 
images EGFP-CCHFV N or EGFP is green, and in (C) the nucleus is stained blue with 
DAPI.  
A B 
C 
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293T cells transfected with pEGFP-C2-CCHFV N were analysed by western blot 24 
hrs after transfection; cells were lysed for 30 minutes on ice, then lysates were 
clarified by centrifugation, and protein content quantified by BCA assay. Protein 
samples were denatured, then 2 µg protein lysate was loaded per well, and cellular 
proteins were resolved by SDS PAGE. Proteins were transferred to polyvinylidene 
difluoride (PVDF) membranes, which were blocked and probed with primary rabbit 
polyclonal anti-EGFP antibodies. Secondary anti-rabbit HRP-conjugated antibodies 
were used to detect primary anti-EGFP, and were then visualised after the addition of 
a chemiluminescent substrate (ECL) and exposure to light-sensitive film. EGFP-
CCHFV N could be detected as an 87 kDa fusion protein of the correct predicted 
molecular weight (Figure 4.3 (A)). 
The subcellular distribution of EGFP-CCHFV N was observed by both confocal 
microscopy analysis of 293T cells that were fixed 24 hrs after transfection, and by live 
cell imaging. The cell membranes of formaldehyde fixed cells (C) were permeabilised, 
and the nucleus stained with 4',6-diamidino-2-phenylindole (DAPI), a blue fluorescent 
probe which, upon selective binding to the minor groove of dsDNA, fluoresces brightly 
when excited with light of wavelength ~360 nm. 293T cells were grown on glass 
coverslips prior to transfection and fixation, and following permeabilisation, were 
mounted onto glass slides using a mounting fluid (Vectorshield) containing DAPI. 
Confocal images were captured on a Zeiss 510 META laser scanning microscope 
(LSM). 
Transfection of 293T cells with pEGFP-C2 was used as a control to visualise 
the subcellular distribution of native EGFP, in the absence of the CCHFV N moiety. 
The subcellular distribution EGFP was diffuse within both the cytoplasm and nucleus 
of 293T cells (Figure 4.3 (B) and (C)). In contrast, EGFP-CCHFV N localised in the 
cytoplasm of transfected cells, and was often found in perinuclear regions, but could 
also be visualised in other areas of the cytoplasm, often in discrete puncta. This was 
similar to the previously described subcellular distribution of CCHFV N both during 
infection, and transfection of CCHFV N in the absence of other viral proteins or RNA 
(Andersson, Simon et al. 2004), where CCHFV N was observed in the cytoplasm, 
often in perinuclear regions. It is thought trafficking of CCHFV N to these perinuclear 
regions is dependent on an intact actin cytoskeleton, and occurs over time (up to 8 hrs 
following infection); the initial cytoplasmic distribution of CCHFV N during infection is 
more disperse (Andersson, Simon et al. 2004). 
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4.2.3 IP of EGFP-CCHFV N  
 
After transfection of pEGFP-C2-CCHFV N or pEGFP-C2, and expression of EGFP-
CCHFV N or EGFP, EGFP-CCHFV N and EGFP were immunoprecipitated (IP’d) from 
293T cells using a GFP-Trap. GFP-Traps are composed of agarose beads covalently 
conjugated to camelid antibodies (only contain the antibody ‘heavy’ chain; GFP-Traps 
only contain the variable domains of these antibodies to reduce non-specific binding) 
that specifically recognise and bind to EGFP. The variable domain of anti-EGFP 
antibodies within GFP traps bind strongly to EGFP with high specificity, enabling the 
IP of sufficient quantities of EGFP-CCHFV N to allow identification and quantification 
of cellular proteins that co-IP with EGFP-CCHFV N by MS.  
293T cells were grown in ‘light’ (R0K0), or ‘medium’ (R6K4) SILAC media for 
two weeks prior to transfection to allow sufficient SILAC labelling, as described in 
section 2.2.4.3.  ‘Light’ (R0K0) cells were transfected with pEGFP-C2-CCHFV N, and 
‘medium’ (R6K4) cells were transfected with pEGFP-C2. 24 hrs later, two separate 
GFP-Trap based IPs were carried out, and EGFP or EGFP-CCHFV N was IP’d from 
labelled cells (Figure 4.4). Briefly; cells were lysed for 30 minutes on ice, then protein 
lysates were clarified by centrifugation. Clarified lysates were incubated with GFP-
Trap beads for 2 hrs to allow EGFP or EGFP-CCHFV N to bind, then, after several 
wash steps, proteins were eluted from the GFP-Trap beads by heating at 95 °C for 10 
minutes in the presence of 2x LDS-sample buffer. The resulting immunoprecipitates 
contained EGFP or EGFP-CCHFV N, as well as cellular proteins that 
immunoprecipitated with them. Equal volumes of these immunoprecipitates were 
mixed together and the proteins identified and quantified by MS. 
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Figure 4.4 IP of EGFP and EGFP-CCHFV N from 293T cells     
SDS PAGE (left) and western blot analysis (right) of GFP-Trap based IPs confirmed 
the immunoprecipitation of EGFP or EGFP-CCHFV N from SILAC labelled cells. 
 
 
Western blot analysis with anti-EGFP confirmed the IP of EGFP or EGFP-CCHFV N 
from transfected cells (Figure 4.4, right). SDS PAGE analysis followed by Coomassie 
staining confirmed the co-IP of cellular proteins; faint bands are present in the EGFP-
CCHFV N IP lanes in Figure 4.4 (left), which represented cellular protein that 
immunoprecipitated with EGFP-CCHFV N. Generally, the ability to see proteins that 
co-IP with EGFP-CCHFV N by SDS PAGE analysis corresponds well with the ability 
to identify and quantify these cellular proteins by MS. 
IP of EGFP from pEGFP-C2 transfected cells was used as a control to identify 
and quantify cellular proteins that bound non-specifically to EGFP or to components of 
the GFP-Trap (the camelid antibodies, or the agarose beads) during the IP. This 
enabled differentiation between proteins that bound non-specifically to EGFP, or 
components of the GFP-Trap, and those that bound specifically to EGFP-CCHFV N, 
when immunoprecipitates were combined and analysed by SILAC-based MS.  
 
Chapter 4: Identifying host proteins that interact with CCHFV N and HAZV N 
142 
 
4.2.4 Identification and quantification of immunoprecipitated cellular proteins by 
MS analysis  
 
Cellular proteins that immunoprecipitated with EGFP or EGFP-CCHFV N were 
identified and quantified by SILAC based MS analysis. MS analysis was performed by 
Dundee Cell Products, and was carried out twice on the same sample; these methods 
are described in section 2.2.8.  
MS identification and quantification of immunoprecipitated proteins resulted in 
the generation of a unique SILAC ratio for each identified protein (EGFP-CCHFV 
N/EGFP); this was a measure of the relative abundance of a protein that 
immunoprecipitated with EGFP-CCHFV N, compared to EGFP. For all identified 
proteins, the ratio of its abundance that co-immunoprecipitated with EGFP-CCHFV N 
compared to EGFP could be used as a guide to the specificity of its interaction with 
EGFP-CCHFV N. Although the same MAP IP sample was analysed twice, the results 
of each analysis varied slightly; between the two analyses a total of 192 proteins were 
identified, 112 proteins were common to both analyses, 46 proteins unique to the first 
analysis and 34 proteins unique to the second. This variability between MS runs 
emphasised the need to validate potential interacting partners by independent 
methods, such as western blot analysis. The results of the two MAP analyses in this 
study are referred to as MAP1 and MAP2. 
A protein ratio frequency graph was generated using the SILAC ratios in order 
to differentiate between proteins that bound non-specifically to components of the 
GFP-Trap, or EGFP, and those that bound specifically to EGFP-CCHFV N (Figure 
4.5). Previous studies have suggested that the majority of proteins identified by mass 
spectrometry in SILAC-based IP experiments represent proteins that bind non-
specifically to EGFP, or components of the GFP-Trap (Trinkle-Mulcahy, Boulon et al. 
2008). Examination of the EGFP-CCHFV N/EGFP ratio for the two MAP datasets 
(Figure 4.5) indicated that the majority of proteins exhibited fewer than a 6-fold 
difference, therefore a 6-fold ratio or below was chosen as a cut-off threshold for non-
specific interacting proteins in this study. Cellular proteins exhibiting ratios of 6 or 
greater were considered to potentially represent specific interacting partners of EGFP-
CCHFV N. This 6-fold cut off value was arbitrary, and served to reduce the number of 
candidate interacting proteins that would be validated by western blot analysis. 
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Figure 4.5 Protein ratio frequency graphs of EGFP-CCHFV N IP analysis 
The protein ratio frequency graph of the MAP IPs shows the numbers of identified 
cellular proteins with each SILAC ratio (EGFP-CCHFV N/EGFP). In IP experiments of 
this type, many of the identified IP’d proteins represent experimental contaminants, 
which bind non-specifically to components of the GFP-Trap. An increased abundance 
ratio indicated an increased likelihood the protein is a specific interacting partner of 
EGFP-CCHFV N. In this analysis the majority of proteins were described by a normal 
distribution centered around a ratio of 5, and a 6-fold cut off value was chosen to 
distinguish between specific and nonspecific EGFP-CCHFV N interacting partners. 
The MS analysis was performed twice on the same sample, and the ratios derived 
from each analysis are represented as green and red bars. Highlighted are some 
proteins that were validated by western blot analysis for their ability to co-IP with 
EGFP-CCHFV N (Figure 4.6).  
 
 
A table summarising the data from these two mass spectrometry analyses is included 
in Appendix II. 
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4.2.5 Independent validation of potential interacting partners of EGFP-CCHFV N 
by western blot analysis 
 
Putative cellular interacting partners of EGFP-CCHFV N were initially identified by 
SILAC based MS analysis using immunoprecipitates from labelled 293T cells. IPs 
were repeated using lysates from unlabelled 293T cells expressing either EGFP-
CCHFV N or native EGFP, in order to validate selected co-immunoprecipitated 
proteins (highlighted in Figure 4.5) by western blot analysis (Figure 4.6). Selected 
cellular proteins were chosen due to their identification in the MS analysis by multiple 
peptides, and their significantly greater abundance in immunoprecipitates from EGFP-
CCHFV N expressing cells, compared to EGFP expressing cells.  
Control IPs were performed using both uncoupled agarose beads, and an 
RFP-trap (single domain anti-RFP antibodies conjugated to the same agarose bead 
matrix as used in the GFP-trap), to verify the selected cellular proteins did not IP non-
specifically with components of the GFP-trap. Western blot analysis with anti-EGFP 
confirmed the GFP-trap specifically IP’d EGFP-CCHFV N and EGFP, whereas the 
RFP-trap and the agarose bead controls did not (Figure 4.6). This confirmed the 
effectiveness of the GFP-trap methodology for the specific IP of EGFP and EGFP-
CCHFV N.  
CCHFV N has previously been shown to bind to actin (Andersson, Simon et al. 
2004); this known interaction was used to assess the success of the GFP-trap and 
MS identification procedure, and as a positive control in western blot validation 
experiments. In good agreement with previous work, western blot analysis of IPs from 
EGFP-CCHFV N expressing cell lysates revealed actin immunoprecipitated 
abundantly with EGFP-CCHFV N, but was not immunoprecipitated, or was 
immunoprecipitated to a much lower extent, with the control RFP-trap or unbound 
agarose beads (Figure 4.6). 
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Figure 4.6 Independent validation of potential interacting partners of EGFP-
CCHFV N by western blot analysis. 
Western blot analysis (left) confirmed the specific co-IP of actin, HSP70/HSC70 (heat 
shock 70 kDa protein 1 (HSP70) and heat shock cognate 71 kDa (HSC70); the 
antibody used does not distinguish between these two proteins), vimentin, p53, and β-
tubulin. GAPDH and B23 did not co-IP with EGFP-CCHFV N, supporting the 6-fold cut 
off value chosen for specific interacting partners. The table presenting the SILAC 
ratios for these proteins (right) includes the UniProt accession number, which was 
used to access information about the proteins (gene name, primary sequence, 
function) from the online UniProt database. 
 
 
Cytoplasmic actin was identified in both MAP1 and MAP2 MS analyses by 19 and 17 
peptides with increased ratios of 6.8 and 16.5 -fold, respectively. Other cellular 
proteins that exhibited high SILAC ratios included heat shock protein 70 (HSP70), 
heat shock cognate 71 kDa (HSC70), vimentin, and the tumor suppressor protein p53. 
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For each of these cellular proteins, western blot analysis of immunoprecipitates from 
EGFP-CCHFV N expressing cells detected a corresponding protein of appropriate 
molecular weight in both the input material and following IP with the GFP-trap, with no 
or much reduced binding to the unbound agarose beads, or the RFP-trap. These 
cellular proteins were not identified in GFP-trap immunoprecipitates from cells 
expressing EGFP, which strongly suggested that the interaction between each of the 
listed cellular proteins was specific to EGFP-CCHFV N, rather than EGFP.  
In the case of HSP70, the anti-HSP70 antibody used to probe western blots 
also detected HSC70 (HSC70 was also assigned high SILAC ratios in both MS 
analyses (Figure 4.6, right)). HSP70 and HSC70 are both members of the HSP70 
family of molecular chaperones; they are structurally very similar, share > 85 % 
sequence identity, and perform many identical functions within the cell (Liu, Daniels et 
al. 2012). In sections 4.4 – 4.8, this anti-HSP70 antibody was used to analyse IPs, 
and the identified protein is referred to as HSP70 for clarity.  
GAPDH and nucleophosmin (B23.1/NPM1) were identified in the MAP MS 
analyses with low EGFP-CCHFV N/EGFP SILAC ratios of 3.95 and 4.5, respectively 
(Figure 4.6). As described above, previous work by others has indicated these ratios 
likely represent proteins that interacted non-specifically with EGFP, or components of 
the GFP-Trap (Boulon, Ahmad et al. 2010). In agreement with this, western blot 
analysis failed to detect the presence of either of these proteins in the GFP trap 
immunoprecipitate from EGFP-CCHFV N expressing cells (Figure 4.6), indicating 
these proteins likely bound non-specifically to EGFP or components of the GFP-Trap.  
-tubulin also exhibited relatively low ratios of 5.1 and 5.5 in the two MAP MS 
analyses. However, -tubulin was detected in GFP trap immunoprecipitates from 
EGFP-CCHFV N transfected cells, although with much reduced abundance compared 
to the amount of tubulin present in the input cell lysate. This was in contrast to HSP70, 
p53, and vimentin, which exhibited relatively high abundances in EGFP-CCHFV N IPs; 
this suggested -tubulin may represent a weak or transient interacting protein. 
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4.3 SECTION SUMMARY 
 
This section has presented the identification of cellular proteins that interact with 
EGFP-CCHFV N, through the use of SILAC-based MS analysis of GFP-Trap IPs. IP 
of EGFP-CCHFV N and EGFP from different SILAC labelled cell populations allowed 
the discrimination between cellular proteins that interacted specifically with EGFP-
CCHFV N, and those that bound non-specifically to EGFP or components of the GFP-
Trap. The MS analysis was performed twice on the same sample, and a total of 192 
proteins were identified, 112 proteins were common to both analyses, 46 proteins 
unique to the first analysis and 34 proteins unique to the second.  
Each identified protein was assigned a SILAC ratio, which acted as a guide to 
the specificity of its interaction with EGFP-CCHFV N; the higher the ratio, the more 
likely the identified protein was a specific interacting partner of EGFP-CCHFV N. Due 
to the majority of proteins having a ratio of 6 or below, a ratio of 6 was arbitrarily 
chosen as the cut-off for specific interacting partners; proteins with a ratio above 6 
were considered to potentially be interacting partners of EGFP-CCHFV N, and those 
with a ratio below 6 were considered to be non-specific. The cellular protein actin, a 
known interacting partner of CCHFV N (Andersson, Simon et al. 2004) was used as a 
positive control to assess the success of the GFP-Trap and identification in the MS 
procedure. In good agreement with previous work, actin bound specifically to EGFP-
CCHFV N (Figure 4.6), and was identified in the MS analysis with a ratio of 16.46 and 
6.8. Independent validation of potential interacting partners of EGFP-CCHFV N was 
undertaken by western blot analysis, which confirmed the specific IP of several 
proteins (including actin) with high ratios; HSP70 (37.85, 40.11), vimentin (25.44, 
28.33), and cellular tumor antigen p53 (26.26). β-tubulin had a lower ratio (5.12, 5.51), 
but still immunoprecipitated with EGFP-CCHFV N. GAPDH and B23 had low SILAC 
ratios, (3.95, 4.53 respectively) and did not co-IP with EGFP-CCHFV N.      
HSP70 was chosen to be further validated as an interacting partner of 
untagged CCHFV N and HAZV N due to the high SILAC ratio of HSP70 (and HSC70) 
in both MS analyses, the abundance of HSP70 that immunoprecipitated with EGFP-
CCHFV N when analysed by western blot (Figure 4.6), and evidence from the 
literature that HSP70 interacts with viral proteins from several different viruses and is 
recruited during their replication cycles (Mayer 2005). In some instances the 
recruitment of HSP70 is beneficial to the virus replication cycle, in others viral protein 
interaction with HSP70 appeared to be detrimental to virus replication (Yu, Ye et al. 
2009). In either case the interaction of HSP70 with viral proteins impacted virus 
replication, which suggested the interaction of HSP70 with EGFP-CCHFV N could 
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also potentially impact CCHFV replication. Experiments examining the interaction of 
HSP70 with un-tagged CCHFV N and HAZV N are summarised in the following 
sections. 
 
4.4 RESULTS: IMMUNOPRECIPITATION OF HSP70 WITH CCHFV N  
 
IPs of un-tagged CCHFV N were carried out to confirm that the co-IP of HSP70 with 
EGFP-CCHFV N was not an artefact of overexpressing the EGFP-CCHFV N fusion 
protein.   
 
4.4.1 Validation of anti-CCHFV N antibodies derived from sheep serum  
 
Antibodies targeting CCHFV N were generated using the same method described for 
the anti-HAZV N antibodies (section 3.2.4). Briefly, recombinant CCHFV N was 
purified from E. coli (Carter, Barr et al. 2012) and 1 mg >95 % pure CCHFV N was 
sent to Altabioscience. A sheep immunisation programme compliant with UK home 
office regulations was undertaken, which resulted in 3 succesive serum bleeds 
containing antibodies recognising CCHFV N. The ability of anti-CCHFV N antibodies 
present in the 3rd bleed serum to recognise CCHFV N expressed from several 
different sources was assayed by western blot analysis (Figure 4.7) using the same 
methodology described in section 4.2.2. The serum will be refered to as anti-CCHFV 
N. 
Anti-CCHFV N specifically recognised CCHFV N from several different 
sources; purifed from E. coli, 293T cell expressed EGFP-CCHFV N, and untagged 
CCHFV N (expressed from a pCAGGS plasmid, described in section 4.4.2), whilst not 
cross reacting with cellular proteins in 293T whole cell lysate (Figure 4.7). This 
confirmed the success of the immunisation programme, and anti-CCHFV N was 
subsequently used to detect CCHFV N during western blot analysis, IP experiments 
and immunofluorescence (IF) experiments. 
 
Chapter 4: Identifying host proteins that interact with CCHFV N and HAZV N 
149 
 
 
 
Figure 4.7 Western blot analysis of CCHFV N from diffferent sources using anti-
CCHFV N.   
Anti-CCHFV N specifically recognised CCHFV N purified from E. coli, expressed from 
a pCAGGs-CCHFV N plasmid (described section 4.4.2), EGFP-CCHFV N, and IP’d 
EGFP-CCHFV N. The absence of bands of corresponding molecular weight in whole 
cell lysate from 293T cells indicates anti-CCHFV N did not cross-react with cellular 
proteins when diluted 1:10,000 (v/v) in 5 % (w/v) BSA in TBST. At higher 
concentrations of anti-CCHFV N (1:1000-, 1:5000 (v/v) in 5 % (w/v) BSA in TBST), 
there were faint bands in the 293T whole cell lysate lane; these may either represent 
bleed-over from adjacent lanes, or cellular proteins cross-reacting. Western blot 
courtesy of Alex Brown.  
 
 
4.4.2 CCHFV N expression 
CCHFV N was expressed from the pCAGGS-CCHFV N plasmid (Figure 4.8). High 
level gene expression in mammalian cells is driven by the synthetic CAG promoter, 
and resulted in the expression of un-tagged CCHFV N.  
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Figure 4.8 Plasmid map of the CCHFV N ORF in a pCAGGs vector 
Untagged CCHFV N was expressed from pCAGGs-CCHFV N in mammalian cells. 
Image generated with SnapGene.   
 
 
CCHFV N was expressed in 293T cells using calcium phosphate mediated 
transfection, and in HUH-7 cells (a hepatocyte derived carcinoma cell line, originally 
isolated from a liver tumor) using lipofectamine-2000 based transfection. 
Lipofectamine 2000, and RNAiMAX (utilised in section 4.9.1) are specially designed 
cationic lipids that facility entry of DNA and siRNA into cells. CCHFV N was expressed 
as a 53 kDa protein (Figure 4.9 (A)), which was detected by western blot analysis 
(described in section 4.2.2) and indirect IF staining (Figure 4.9 (B)) using anti-CCHFV 
N.   
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Figure 4.9 Expression of CCHFV N in 293T and HUH-7 cells 
pCAGGs-CCHFV N transfection of 293T cells followed by western blot analysis 
resulted in detection of expressed CCHFV N of the predicted molecular weight with 
anti-CCHFV N (A). Indirect IF analysis of pCAGGs-CCHFV N transfected HUH-7 cells 
using secondary anti-sheep alexaFluor 488 conjugated antibodies to detect anti-
CCHFV N (B). Anti-CCHFV N specifically detected CCHFV N (green), which was 
localised predominantly in the cytoplasm of transfected cells, often in perinuclear 
regions. In all images the nucleus is stained blue with DAPI.    
 
 
HUH-7 cells were chosen to perform indirect IF analysis due to the larger diameter of 
their cytoplasm compared to 293T cells. Briefly; HUH-7 cells were grown on 
coverslips, and 24 hrs after transfection with pCAGGs-CCHFV N, cells were fixed, cell 
membranes permeabilised, and CCHFV N detected with anti-CCHFV N. Anti-CCHFV 
N bound to CCHFV N was then detected with alexaFluor 488 conjugated secondary 
anti-sheep antibodies and coverslips were mounted onto glass slides in ProLong Gold 
containing DAPI, to allow visualisation of cell nuclei. Confocal images were captured 
on a Zeiss 510 META laser scanning microscope (LSM). In good agreement with 
previous work the subcellular distribution of CCHFV N was cytoplasmic, and CCHFV 
N often localised in discrete perinuclear regions (Figure 4.9 (B)) (Andersson, Simon et 
al. 2004; Bergeron, Albarino et al. 2010).  
A B 
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Expression of CCHFV N in the context of actively replicating virus was also analysed 
by western blot and indirect IF using anti-CCHFV N (Figure 4.10). Infection of SW13 
cells with actively replicating CCHFV was carried out at Porton Down by Dr Stuart 
Dowall of Public Health England. SW13 cells are a human adrenal cortex carcinoma 
cell line, originally derived from a small cell carcinoma tissue biopsy. 48 hrs after 
CCHFV infection, cells were fixed overnight, then indirect IF analysis was carried out 
as previously described. The sub-cellular distribution of CCHFV N in the context of 
actively replicating CCHFV was similar to that of CCHFV N expressed from pCAGGs-
CCHFV N; CCHFV N was cytoplasmic, and was often observed in discrete 
perinuclear regions (Figure 4.10 (B)). Lysis of CCHFV infected SW13 cells, and 
western blot analysis confirmed the specific recognition of CCHFV N (53 kDa) by anti-
CCHFV N (Figure 4.10 (A)).  
 
 
Figure 4.10. Western blot and IF analysis of CCHFV N in the context of actively 
replicating CCHFV. 
During CCHFV infection, CCHFV N was expressed as a 53 kDa protein that was 
detectable by western blot analysis (A) using anti-CCHFV N. (B) The subcellular 
localisation of CCHFV N during infection was cytoplasmic; CCHFV N was often 
observed in discrete perinuclear regions, similar to the subcellular distribution of 
CCHFV N expressed from pCAGGs-CCHFV N.  
 
A B 
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The similarity between the subcellular distribution of CCHFV N expressed in the 
context of viral infection, and expressed from pCAGGs-CCHFV N, suggested that 
CCHFV N might be trafficked in a similar way in transfected- and infected-cells. This 
subcellular distribution of CCHFV N varied slightly from the subcellular distribution of 
EGFP-CCHFV N. Although both EGFP-CCHFV N and CCHFV N were cytoplasmic, 
EGFP-CCHFV N often localised in a single discrete region adjacent to the nucleus, 
whereas CCHFV N localised in several areas in the cytoplasm both adjacent to the 
nucleus, and in other regions. In both cases several smaller, discrete puncta in other 
areas of the cytoplasm were also observed, in addition to the larger accumulations of 
EGFP-CCHFV N or CCHFV N.         
 
4.4.3 Immunoprecipitation of CCHFV N from transfected and infected cells 
 
IPs were repeated using CCHFV N instead of EGFP-CCHFV N, to confirm that co-IP 
of HSP70 was not an artefact of the EGFP-CCHFV N fusion protein. CCHFV N was 
IP’d from both pCAGGs-CCHFV N transfected cells, and from CCHFV infected cells, 
using anti-CCHFV N conjugated to Protein G-coupled Dynabeads (Figure 4.11). 
Dynabeads are uniform, 2.8 μm superparamagnetic beads with recombinant protein G 
(a bacterial protein that binds antibodies (in this case anti-CCHFV N) via their Fc 
region) covalently conjugated to their surface. The use of Dynabeads instead of 
agarose/sepharose slurry enabled fast, gentle, isolation of protein complexes without 
time-consuming and potentially physically damaging centrifugation steps. Briefly; 
Dynabeads were incubated with anti-CCHFV N to allow antibodies to bind, then anti-
CCHFV N bound Dynabeads were incubated with cell lysates either from pCAGGs-
CCHFV N transfected cells, or CCHFV infected cells, to enable anti-CCHFV N to bind 
CCHFV N. After washing Dynabeads with antigen-antibody complexes bound, 
proteins were eluted by heating at 95 °C in 2 x LDS buffer. Anti-CCHFV N bound 
Dynabeads were incubated with mock transfected/mock infected cell lysates, and un-
bound Dynabeads were incubated with pCAGGs-CCHFV N transfected, or CCHFV 
infected cell lysates, to control for cellular proteins binding non-specifically to anti-
CCHFV N or the Dynabeads.   
CCHFV N was IP’d when anti-CCHFV N bound Dynabeads were incubated 
with lysates from pCAGGs-CCHFV N expressing, and CCHFV infected, cells (Figure 
4.11, boxed lanes). HSP70 co-immunoprecipitated with CCHFV N, both in the context 
of virus infection (Figure 4.11 (B)), and when CCHFV N was expressed from 
pCAGGs-CCHFV N (Figure 4.11 (A)). HSP70 was absent from, or present to a much 
lesser extent in, control lanes, suggesting HSP70 immunoprecipitated specifically with 
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CCHFV-N from both CCHFV infected- and pCAGGs-CCHFV N transfected-cells. The 
presence of small amounts of HSP70 in the mock anti-CCHFV N lanes could be due 
to the fact that anti-CCHFV N does not represent purified antibodies; the anti-CCHFV 
N antibodies are utilised within a mixture of other proteins in sheep serum; some of 
which could bind non-specifically to Dynabeads and cellular proteins (such as HSP70) 
in cell lysates.  
B23 and GAPDH did not co-IP with EGFP-CCHFV N, when results of the MS 
analysis were validated by western blot (Figure 4.6). B23 and GAPDH had low SILAC 
ratios (3.95 and 4.24) and their presence in the MS analysis was thought to be due to 
non-specific binding to EGFP or components of the GFP-Trap during IP of EGFP-
CCHFV N. In good agreement with these observations, neither B23 nor GAPDH 
immunoprecipitated with CCHFV N, but HSP70 did co-IP with CCHFV N (Figure 4.11 
(A), boxed lane), further validating the MS analysis in section 4.2, and the choice of a 
6-fold cut off value for cellular proteins considered to be specific interacting partners of 
EGFP-CCHFV N. 
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Figure 4.11. Co-immunoprecipitation of HSP70 with CCHFV N from pCAGGs 
transfected and CCHFV infected cells. 
Anti-CCHFV N was used to IP CCHFV N from 293T cells expressing pCAGGs-
CCHFV N (A), and from CCHFV infected SW13 cells (B) using Protein G coupled 
Dynabeads. In both cases CCHFV N was IP’d when anti-CCHFV N was incubated 
with lysates from pCAGGs-CCHFV N transfected or CCHFV infected cells (lane: N 
anti-CCHFV N, highlighted with a box), but is absent from, or present to a much lesser 
extent in, control lanes (lanes: N unbound, and mock anti-CCHFV N). HSP70 
immunoprecipitated with CCHFV N from both pCAGGs-CCHFV N transfected and 
CCHFV infected cells, and is absent from, or present to a much lesser extent in, 
control lanes (A and B). B23 and GAPDH do not co-IP with CCHFV N (A), further 
validating MS results from section 4.2.  
 
4.5 SECTION SUMMARY 
 
This section presents the co-IP of HSP70 with CCHFV N, both in the context of 
actively replicating CCHFV, and when CCHFV N is expressed from pCAGGs-CCHFV 
N. Expression of CCHFV N in mammalian cells from pCAGGs-CCHFV N and during 
CCHFV infection was detected by western blot and indirect IF analysis using anti-
A B 
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CCHFV N; transfection of pCAGGs-CCHFV N resulted in the expression of CCHFV N 
of the correct molecular weight (53 kDa), which localised in the cytoplasm of cells, 
often in discrete perinuclear regions. The subcellular localisation of pCAGGs-CCHFV 
N expressed CCHFV-N was shown to be similar to that of CCHFV N during infection, 
which suggested pCAGGs-CCHFV N expressed CCHFV N was trafficked in a similar 
manner to CCHFV N during infection.  
The specific recognition of CCHFV N by anti-CCHFV N enabled the IP of 
CCHFV N from both pCAGGs-CCHFV N transfected, and CCHFV infected cell lysates, 
using anti-CCHFV N coupled Dynabeads. HSP70 was shown to co-IP with CCHFV N 
from both pCAGGs-CCHFV N transfected, and CCHFV infected cell lysates. This 
suggested that the co-IP of HSP70 with EGFP-CCHFV N was not due to expression 
of the EGFP-CCHFV N fusion protein; instead HSP70 appeared to co-IP specifically 
with the CCHFV N moiety of EGFP-CCHFV N. 
HSP70 is a member of the HSP70 family of cellular chaperones. The HSP70 
family of proteins are involved in a wide variety of cellular processes, including the 
folding of newly synthesised polypeptides, the assembly and disassembly of 
oligomeric structures, the disaggregation of protein aggregates, and the refolding of 
stress denatured proteins, amongst other processes. During infection, viruses need to 
synthesise a large number of viral proteins in a relatively short space of time, and it is 
thought that protein folding can become a rate-limiting step (Mayer 2005). It has been 
proposed that most viruses therefore require cellular chaperones during their 
replication cycles; many viruses recruit members of the HSP70 family as they are 
central components of the cellular chaperone network (Mayer 2005). In addition, 
HSP70 family members are involved in the regulation of several cellular pathways, 
including the ER stress response, the cell cycle, and apoptosis. Viruses are also 
thought to interact with HSP70 family members in order to influence the regulation of 
these cellular pathways, to create a cellular environment more favourable for virus 
replication (Mayer 2005).  
CCHFV N interacted with HSP70, however the consequences of this interaction for 
the host cellular environment, and for the replication cycle of CCHFV remained 
unknown. To further investigate this HAZV was used as a model for CCHFV infection, 
as it can be more easily manipulated under containment level 2 conditions. The 
manipulation of HAZV, and the interaction of HAZV N with HSP70, is described in the 
following sections.  
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4.6 RESULTS: IMMUNOPRECIPITATION OF HSP70 WITH HAZV N 
 
4.6.1 HAZV growth curves 
 
Actively replicating HAZV was a kind gift from Dr Roger Hewson and Dr Stuart Dowall 
of Public Health England. HAZV was obtained as an SW13 cell culture supernatant at 
an infectious titre of 1.7 x 106 pfu/mL (plaque forming units per mL). All assays using 
HAZV were carried out in SW13 cells (defined in section 2.1.3). Conditions were 
optimised for HAZV infection so that a stock of HAZV could be grown for use in 
subsequent experiments (Figure 4.12). Briefly; SW13 cells were infected at 3 different 
MOIs (multiplicity of infection; an estimation of the number of virus particles available 
to infect each cell), MOI 0.001, MOI 0.01, and MOI 0.1. Cytopathic effects were not 
observed 24 hours after infection when cells were infected at MOI 0.001, MOI 0.01 or 
MOI 0.1, therefore virus-containing cell culture supernatants were harvested day 2, 
day 3, day 4 and day 5 post-infection, to determine the time point at which the most 
virus could be harvested (Figure 4.12 (A)).  
Infectious HAZV was diluted by the appropriate factor in serum-free media 
(SFM) to infect SW13 cells in a 96-well plate format at MOI 0.001, MOI 0.01 and MOI 
0.1. Complete media was removed from SW13 cells, which were washed once in PBS, 
prior to the application of HAZV-containing SFM, diluted to infect cells at the 
appropriate MOI. HAZV was incubated with SW13 cells for 1 hr at 37 °C with gentle 
rocking, to allow HAZV to adsorb to cell surfaces; HAZV containing SFM was then 
removed and replaced with DMEM containing 2 % FBS. HAZV was allowed to 
replicate in SW13 cells for 2-, 3-, 4- or 5- days; at each time point the total volume of 
cellular supernatant was removed and the infectious HAZV titre estimated by plaque 
assay, and plotted against the number of days post-infection (Figure 4.12 (A)). Figure 
4.12 (B) shows a representative HAZV plaque assay.   
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Figure 4.12 HAZV growth curve and representative HAZV plaque assay 
Conditions for growing viral stocks of HAZV were determined by infecting SW13 cells 
at MOI 0.001, MOI 0.01, and MOI 0.1, and harvesting infectious supernatant 2-, 3-, 4- 
and 5- days after infection. Viral titre was estimated by plaque assay (B), and plotted 
against the number days of HAZV replication prior to harvesting (A). Cells that were 
infected at an MOI of 0.001, and the supernatant harvested 4 days later, secreted the 
most infectious HAZV into the supernatant. 
B 
A 
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Plaque assays were performed in duplicate in 12-well plates; 25 μL HAZV was diluted 
by a factor of 10 in 225 μL SFM (10-1 dilution), which was further serially diluted by a 
factor of 10 to generate 10-2 – 10-6 dilutions. These were used to infect cells as 
described above; after HAZV adsorption, virus was removed from cells and replaced 
with complete media diluted 1:1 with 1.6 % carboxy-methyl cellulose (CMC). HAZV is 
cytopathic, therefore the CMC/complete media overlay ensured that over the course 
of the assay (6 days), plaques (areas where cells were absent) were formed as HAZV 
infection resulted in cell death in very defined regions. After fixing cells, plaques were 
visualised by staining cells with crystal violet solution. The virus stock plaque assayed 
in Figure 4.12 (B) had an estimated titre of ~6 x 106 pfu/mL.  
SW13 cells infected with HAZV at an MOI 0.001 secreted the most infectious 
virus 4 days after infection; therefore these conditions were used to grow all 
subsequent stocks of HAZV. After the peak titre of infectious HAZV was reached (day 
4 if infected at MOI 0.001 and day 3 if infected at MOI 0.01) the titre of infectious 
HAZV in the supernatant declined sharply. This has previously been reported during 
HAZV infection (Clerx, Casals et al. 1981), however the reason why this occurs is 
unknown, but could be related to the stability of HAZV particles in the cell culture 
supernatant at 37 °C.     
   
4.6.2 Detection of HAZV N  
 
HAZV N was detected in HAZV infected cells with anti-HAZV N antibodies that were 
generated using the same sheep immunisation programme used to generate anti-
CCHFV N. Section 3.2 describes the purification of >95 % pure HAZV N, which was 
used to inoculate sheep; antibodies targeting HAZV N are contained within the sheep 
serum that was harvested in 3 successive bleeds. Sheep serum containing anti-HAZV 
N antibodies will be referred to as anti-HAZV N. 
The ability of anti-HAZV N to specifically recognise HAZV N was assayed by 
western blot and indirect IF analysis (Figure 4.13). Western blot analysis was carried 
out as follows; SW13 cells were infected with HAZV at an MOI 1 for 24 hrs then lysed 
for 30 minutes on ice. Following clarification of cell lysates by centrifugation, total 
protein was quantified by BCA assay, and 5 μg protein loaded per lane, after 
denaturing protein samples. Cell lysates were resolved by SDS PAGE, then proteins 
were transferred to FL-PVDF (fluorescent polyvinylidene difluoride) membranes. 
Membranes were blocked, then incubated with anti-HAZV N, which bound HAZV N. 
Anti-HAZV N was detected by secondary anti-sheep antibodies covalently conjugated 
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to IRDye 800CW, a fluorescent dye that was visible in the 800 channel when analysed 
with the LiCor Odyssey Sa Infrared imaging system.  
 
 
 
 
Figure 4.13 Detection of HAZV N by western blot and indirect IF analysis. 
Anti-HAZV N recognised HAZV N from HAZV infected cells when analysed by 
western blot (A) and indirect IF (B). In (A) anti-HAZV N detected a protein of the 
correct predicted molecular weight (54 kDa) from HAZV infected cells when analysed 
by western blot. In (B) HAZV N was detected in the cytoplasm of infected cells (green); 
the subcellular distribution of HAZV N was similar to that of CCHFV N. The nucleus is 
stained blue with DAPI in (B). The absence of bands in the mock infected lanes in (A) 
and the absence of immunofluorescent staining in mock infected cells in (B) indicated 
that anti-HAZV specifically recognised HAZV N and did not cross react with cellular 
proteins.  
 
 
Anti-HAZV N detected a protein of the predicted molecular weight of HAZV N (54 kDa) 
in lysates from HAZV infected cells, which was absent from lysates of mock infected 
cells (Figure 4.13 (A)). This indicated that anti-HAZV N specifically recognised HAZV 
N, and did not cross react with cellular proteins. Indirect IF analysis of HAZV infected 
A B 
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cells was carried out 24 hrs after HAZV infection using anti-HAZV N as described in 
section 2.2.6.6. The subcellular distribution of HAZV N was cytoplasmic, and was 
similar to the subcellular distribution of CCHFV N (Figure 4.13 (B)).   
 
4.6.3 The interaction of HSP70 with HAZV N 
 
HAZV N and CCHFV N are structurally very similar (section 3.5.2); CCHFV and HAZV 
belong in the same serogroup within the same genus, and therefore share similar 
replication strategies. CCHFV N immunoprecipitated with HSP70, and given the 
structural similarity in these N proteins, and the replication strategy shared by these 
viruses, the ability of HAZV N to co-IP with HSP70 was also examined. Anti-HAZV N 
specifically recognised HAZV N synthesised during infection, and was therefore 
suitable to use to IP HAZV N from infected cells.  
Briefly; anti-HAZV N was bound to Protein G conjugated Dynabeads, as 
described in section 2.2.7.2. SW13 cells were infected with HAZV for 24 hrs, then 
lysed for 30 minutes on ice. IP of HAZV N from infected cell lysates was carried out as 
described in section 2.2.7.2; lysates from mock infected cells were incubated with 
anti-HAZV N bound Dynabeads to control for cellular proteins binding non-specifically 
to anti-HAZV N, and HAZV infected lysates were incubated with unbound Dynabeads, 
to control for HAZV N and cellular proteins binding non-specifically to Dynabeads.  
HAZV N was efficiently IP’d from infected cell lysates using this protocol 
(Figure 4.14 (A)). In good agreement with the CCHFV N IPs, HSP70 
immunoprecipitated with HAZV N from HAZV infected cells (Figure 4.14 (A) boxed 
lane). HSP70 was absent from, or present to a much lesser extent in control lanes, 
suggesting HSP70 immunoprecipitated specifically with HAZV-N. The presence of 
small amounts of HSP70 in the mock anti-HAZV N lanes could be due to the fact that 
anti-HAZV N does not represent purified antibodies; the anti-HAZV N antibodies are 
utilised within a mixture of other proteins in sheep serum; some of which could bind 
non-specifically to Dynabeads and cellular proteins (such as HSP70) in cell lysates.  
Indirect IF analysis was used to determine the subcellular localisation of 
HSP70 during HAZV infection (Figure 4.14 (B)). Experiments were carried out using a 
similar protocol to that described in section 2.2.6.6, however antibody incubations 
were performed sequentially; following cell permeabilisation and blocking, primary 
mouse anti-HSP70 antibody was applied, which bound HSP70. After several PBS 
washes, secondary alexaFluor 594-conjugated anti-mouse antibody was applied, 
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which bound the anti-HSP70 mouse primary antibody, and resulted in visualisation of 
HSP70 when excited with light of 594 nm. Anti-HAZV N was then applied, which 
bound HAZV N, and alexaFluor488 conjugated anti-sheep secondary antibody was 
used to bind to and visualise HAZV N, when excited with light of wavelength 488 nm. 
Coverslips were mounted in ProLong Gold containing DAPI to allow visualisation of 
cell nuclei, and images were captured on a Zeiss LSM510 confocal microscope. 
HSP70 (red, Figure 4.14 (B)) was detected within both the cytoplasm and nucleus of 
mock- infected and HAZV-infected cells. In HAZV infected cells (green, Figure 4.14 
(B)), HSP70 occasionally co-localised with HAZV N in distinct puncta in the cytoplasm 
(yellow, Figure 4.14 (B)). The partial co-localisation of HSP70 with HAZV N within the 
cytoplasm of infected cells supported western blot analysis of the co-IP of HSP70 and 
HAZV N, and suggested a possible role for HSP70 during the replication cycle of 
HAZV.  
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Figure 4.14 Co-IP and co-localisation of HSP70 and HAZV N 
HSP70 immunoprecipitated with HAZV N from HAZV infected cells (A, boxed lane), 
and HSP70 is absent from, or present to a much lesser extent in control lanes. 
Indirect IF analysis indicated that HSP70 (red) was present in both the cell cytoplasm 
and nucleus, and localised in discrete cytoplasmic puncta. Occasionally HAZV N 
(green) co-localised with HSP70 in the cytoplasm (yellow), which supported the IP 
data (A), and suggested that HSP70 may have a function within the replication cycle 
of HAZV. The nucleus is stained blue with DAPI.   
 
A 
B 
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4.7 RESULTS: PURIFICATION OF HAZV PARTICLES, AND THE INTERACTION 
BETWEEN HSP70 AND HAZV N 
 
4.7.1 Purification of HAZV particles 
 
Members of the HSP70 family are detected in purified virus particles of several 
viruses whose proteins interact with HSP70, including rabies virus, hepatitis C virus 
(HCV) and respiratory syncytial virus (RSV) (Sagara and Kawai 1992; Parent, Qu et al. 
2009; Radhakrishnan, Yeo et al. 2010). To determine whether HAZV particles also co-
purified with HSP70, HAZV was purified from the supernatant of infected cells, and 
the virus containing fraction analysed by western blot using anti-HSP70 antibodies. 
HAZV was purified from the supernatant of infected cells by overnight precipitation at 
4 °C with PEG 6000; the precipitate was centrifuged at 4 °C and the resulting pellet 
resuspended in TNE buffer. Precipitated HAZV diluted in TNE buffer was 
ultracentrifuged through a 5 % - 25 % continuous iodixanol gradient to further purify 
HAZV particles by density gradient centrifugation. After ultracentrifugation HAZV 
particles were isolated as a white band, with an approximate density between 0.33 
g/mL and 0.55 g/mL; the fraction containing purified HAZV was aspirated from the 
gradient, then plaque assayed to estimate infectious virus titre (Figure 4.15).  
 
 
Figure 4.15 Plaque assay of the fraction containing infectious HAZV 
After aspiration from the 5 %-25 % iodixanol gradient, the fraction containing purified 
HAZV particles was plaque assayed as described in section 2.2.9.2. The fraction 
containing purified HAZV had an estimated titre of ~2 x 105 pfu/mL. 
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Iodixanol supplied as a 60 % solution in water (‘OptiPrep’; density 1.32 g/mL) was 
used as the density gradient medium in the purification of HAZV particles, as iodixanol 
is non-ionic, non-toxic to cells, and is metabolically inert. In contrast to sucrose, 
iodixanol solutions have low viscosity and low osmolarity therefore HAZV particles 
purified by density gradient centrifugation through a 5 % - 25 % iodixanol gradient 
could be directly applied to cells, without dialysis, or affecting the osmotic properties of 
DMEM.        
The fraction containing purified HAZV particles had an estimated titre of ~2 x 
105 pfu/mL. The titre of HAZV decreased during purification, (the supernatant from 
which HAZV particles were purified had an estimated titre of ~5 x 106 pfu/mL) 
however the titre remained high enough to use the fraction containing infectious HAZV 
in further experiments. In addition to the fraction containing infectious HAZV particles, 
4 more fractions were collected from the iodixanol gradient, (numbered 2-5 in Figure 
4.16, representing fractions collected from the bottom of the iodixanol gradient (5) to 
the top of the gradient (2)). Fractions from the iodixanol gradient were mixed 1:1 in 2 x 
LDS buffer, heated at 95 °C for 10 minutes, then analysed by SDS PAGE; resolved 
gels were stained with Coomassie solution or silver stained (Figure 4.16).   
Both Coomassie and silver stain analysis suggested the fraction containing 
infectious HAZV had the highest abundance of total protein. This was not unexpected, 
as cellular supernatant (from which HAZV was purified) should not contain a very high 
concentration of protein, with the exception of BSA (bovine serum albumin), the 
dominant protein species in FBS (foetal bovine serum) used to supplement DMEM. A 
band corresponding to the predicted molecular weight of BSA (66.4 kDa) was 
detected in fraction 2, fraction 3, and fraction 4 when fractions were silver stained.  
When fractions were Coomassie stained (Figure 4.16 (A)), a band 
corresponding to the predicted molecular weight of HAZV N (54 kDa) could clearly be 
seen in the infectious HAZV containing fraction (lane; aspirated HAZV), and appeared 
to be the most abundant protein in this fraction.  
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Figure 4.16 SDS PAGE analysis of density gradient centrifugation fractions from 
HAZV purification. 
The final stage in the purification of HAZV particles from infectious SW13 cell 
supernatants was density gradient centrifugation through a 5 % - 25 % iodixanol 
gradient. HAZV particles were isolated as a white band 2/3 way down the gradient; 
this fraction was aspirated (lane; aspirated HAZV), and the remaining 5 fractions 
collected from the bottom of the gradient (5) to the top of the gradient (2). Fractions 
were analysed by SDS PAGE, and either Coomassie stained (A) or silver stained (B).  
 
 
In addition to this proposed band of HAZV N, several fainter bands could be detected 
by Coomassie stain, and many more bands could be detected by silver stain, in the 
fraction containing infectious HAZV. This suggested the fraction containing infectious 
HAZV particles also contained multiple cellular proteins, in addition to HAZV encoded 
proteins. 
 
 
A B 
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4.7.2 Analysis of fractions containing purified HAZV particles using western 
blotting and IP 
 
Fractions from the 5 % - 25 % iodixanol gradient were analysed by western blot, as 
described in section 4.6.2, to confirm the presence of HAZV N in the fraction 
containing infectious HAZV particles (Figure 4.17 (A)). When probed with anti-HAZV N, 
a band of the correct molecular weight (54 kDa) was identified in the ‘aspirated HAZV’ 
lane. HAZV N was also detected to a much lesser extent in lanes corresponding to 
fraction 2 and fraction 4; these may represent isolated RNPs, or virus particles that 
migrate to a different density for unknown reasons. Interestingly, when fractions were 
probed with anti-HSP70 antibodies, HSP70 could also be detected in the fraction 
containing infectious HAZV, suggesting HSP70 co-purified with infectious HAZV 
particles (Figure 4.17 (A)).  
Next, HAZV N was IP’d from the fraction containing infectious HAZV using 
anti-HAZV N, as described in section 2.2.7.2. Control samples used in this experiment 
were the fraction containing infectious HAZV IP’d with unbound Dynabeads, and 
fraction 3 IP’d with anti-HAZV N bound Dynabeads. Immunoprecipitates were 
analysed by western blot using anti-HAZV N, and anti-HSP70 antibodies; HAZV N 
IP’d specifically with anti-HAZV N (Figure 4.17 (B) boxed lane); there was no HAZV N 
detected in the control lanes. HSP70 also immunoprecipitated with HAZV N from the 
fraction containing infectious HAZV (Figure 4.17 (B) boxed lane); there was very little 
or no HSP70 detected in the control lanes. This suggested that HAZV N remained 
associated with HSP70 during multiple stages of the virus replication cycle; HAZV N 
may even remain interacting with HSP70 within secreted HAZV particles.   
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Figure 4.17 HSP70 in the fraction containing infectious HAZV, and the co-IP of 
HSP70 with HAZV N from this fraction 
HAZV N and HSP70 were both detected in the fraction containing infectious HAZV 
when fractions from the iodixanol gradient were analysed by western blot (A). IP of 
HAZV N from the fraction containing infectious HAZV confirmed the co-IP of HSP70 
with HAZV N (B), boxed lane, suggesting it is possible that HAZV N and HSP70 
remained associated during multiple stages of the virus replication cycle, and might be 
occasionally packaged together into secreted HAZV particles.  
 
 
4.7.3 Mass spectrometry analysis of the fraction containing infectious HAZV 
 
HAZV N and HSP70 were both detected by western blot analysis in the fraction 
containing infectious HAZV. To identify other proteins in this fraction, that were visible 
by Coomassie and silver stain analysis (Figure 4.16), mass spectrometry (MS) 
analysis of the fraction containing infectious HAZV was carried out by Dr Stuart 
Armstrong at Liverpool University. Briefly; the fraction containing infectious HAZV and 
fraction 3 were denatured, then ~11 µg total protein from these fractions was sent for 
MS analysis. Equivalent amounts of denatured protein from fraction 3 (~11 µg) was 
sent as a negative control, to determine whether any cellular proteins were present 
throughout the iodixanol gradient.  
A B 
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All four structural proteins of HAZV were identified in the fraction containing infectious 
HAZV (table 7); in good agreement with the Coomassie stained gel in Figure 4.16 
HAZV N was identified as the most abundant protein in the whole fraction. Of the 
HAZV structural proteins, the glycoproteins GN and GC were identified as the next 
most abundant, with the L protein detected as the least abundant viral protein in 
purified HAZV particles. Approximate protein abundance was estimated using the 
emPAI score (the exponentially modified protein abundance index) which is calculated 
automatically during protein identification with the Mascot database search engine. 
The emPAI score is based on protein coverage by the peptide matches in a database 
search result to determine an approximate, label free, relative quantitation of the 
proteins in a mixture; the number of identified peptides correlates well with protein 
abundance (Ishihama, Oda et al. 2005). The emPAI score is however, only a crude 
estimate of protein abundance, providing a guideline to the abundance of a specific 
protein within a mixture, and is not as precise as SILAC-based quantitation methods.  
 
Table 7 HAZV proteins detected in the fraction containing infectious HAZV. 
The protein accession number can be entered into the UniProtKB database to obtain 
a description of the protein. The protein mass is estimated based on the Mascot 
database prediction and the emPAI score provides an approximate estimate of the 
abundance of each protein.  
 
Protein_accession 
number 
Protein_description Protein_mass 
(Da) 
emPAI 
M4PWE6  Nucleocapsid protein  54639 16.61 
A6XIP3  Glycoproteins GN and GC  161105 1.23 
A6XA53  L protein  450300 0.01 
 
 
Including HAZV N, GN, GC and L protein, MS analysis identified 264 proteins in the 
fraction containing infectious HAZV, and 82 proteins in fraction 3. Of these 82 proteins 
identified in fraction 3, only 13 were not identified in the fraction containing infectious 
HAZV. The proteins identified in fraction 3 could therefore be used as a guide to 
identify proteins that were present in multiple fractions, and therefore unlikely to be 
contained within, or associated with, purified HAZV particles. However as HAZV N, GN 
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and GC are also identified in fraction 3 (albeit with much lower emPAI scores; GN and 
GC: 1.23 and 0.06, HAZV N: 16.61 and 0.51, respectively) it is harder to confirm that 
these proteins were not associated with components of the virus particles, or the 
particles themselves. Proteins identified by MS, and thought to be present in the 
fraction containing infectious HAZV should be validated by western blot analysis. A 
complete list of all proteins identified in the fraction containing infectious HAZV is 
provided in appendix III.  
Several members of the HSP70 family were identified in the fraction containing 
infectious HAZV; table 8 summarises the identity of these HSP70 family members, 
their emPAI scores, and a brief description of their function (adapted from the UniProt 
database). HSC70 was identified in the fraction containing infectious HAZV, in good 
agreement with Figure 4.17 (A); where western blot analysis of the fraction containing 
infectious HAZV detected a protein of the predicted molecular weight using the anti-
HSP70 antibody that recognised both HSC70 and HSP70. It is likely the antibody 
detected only HSC70 in Figure 4.17. The identification of HSC70 in the fraction 
containing infectious HAZV also supported both the original MS data from both EGFP-
CCHFV N IPs, which identified HSC70 in EGFP-N immunoprecipitates with high 
SILAC ratios (27.11, 24.72), and all subsequent IPs of both CCHFV N and HAZV N 
which identified HSP70 in N-immunoprecipitates using anti-HSP70 that also 
recognises HSC70. It is possible that HAZV N and HSC70 remained associated 
during multiple stages of the HAZV replication cycle, such that HSC70 might be 
packaged within secreted HAZV particles; alternatively HSC70 may be associated 
with the outside of secreted HAZV particles.  
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Table 8 Summary of members of the HSP70 family identified in the infectious 
HAZV containing fraction 
The protein accession number can be entered into the UniProtKB database to obtain 
a description of the protein. The emPAI score provided an approximate estimate of 
the abundance of each protein. A brief description of the function of each protein is 
also provided, based on the UniProt database description. 
 
Protein 
accession 
number 
Protein_description emPAI Function 
P11142 
Heat shock cognate 71 
kDa protein (HSC70  - 
heat shock cognate 
protein 70) 
0.97 
Constitutively expressed molecular 
chaperone; facilitates correct folding of 
nascent proteins, helps  disrupt multi-
protein complexes, regulates cell 
signaling and apoptosis, amongst 
many other functions. 
P17066 
Heat shock 70 kDa 
protein 6 (Heat shock 
70 kDa protein B) 
0.2 
Molecular chaperone that stabilises 
pre-existing proteins against 
aggregation, and helps nascent 
proteins fold correctly. Expressed in 
response to the unfolded protein 
response, and cellular stress. 
P34931 
Heat shock 70 kDa 
protein 1-like 
0.15 
Molecular chaperone, increased 
expression following induction of the 
unfolded protein response. Interacts 
with PARK2 (E3 ubiquitin ligase). 
P11021 
78 kDa glucose-
regulated protein (Bip) 
0.09 
Endoplasmic reticulum (ER) located 
molecular chaperone. Facilitates the 
assembly of multimeric protein 
complexes within the ER. 
Q9Y4L1 
Hypoxia up-regulated 
protein 1 
0.06 
Located in the lumen of the ER and is 
induced by hypoxia. Highly expressed 
in tissues that have a well developed 
ER and synthesise large amounts of 
secretory proteins. Highly expressed in 
the liver. 
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4.8 SECTION SUMMARY 
 
This section presents the use of actively replicating HAZV, to investigate the 
interaction between HSP70 and HAZV N. Conditions for HAZV infection were 
optimised to enable stocks of HAZV to be grown, these were used to infected SW13 
cells and assay the ability of anti-HAZV N to detect HAZV N synthesised during 
infection, through western blot and indirect IF analysis. HAZV N was IP’d from HAZV 
infected cells using anti-HAZV N and immunoprecipitates were analysed by western 
blot; this confirmed the IP of HAZV N, and the co-IP of HSP70. The association 
between HAZV N and HSP70 was supported by indirect IF analysis, where HAZV N 
could be observed co-localising with HSP70 in certain cytoplasmic puncta. Secreted 
HAZV particles were purified from the supernatant of infected cells by PEG6000 
precipitation and density gradient centrifugation. The fraction containing infectious 
HAZV from the gradient was analysed by western blot; both HAZV N and HSP70 were 
detected in this fraction; furthermore HSP70 immunoprecipitated with HAZV N from 
this fraction. MS analysis of the fraction containing infectious HAZV identified 264 
cellular proteins, as well as all four structural HAZV proteins and HSC70, which was 
also detected during western blot analysis of this fraction with the anti-HSP70 
antibody. The ratio of infectious HAZV particles: defective, non-infectious particles in 
this fraction is unknown however.   
The results in this section suggested HSP70/HSC70 interacted with HAZV N 
at multiple stages of the virus replication cycle, and may be packaged into, or 
associated with secreted HAZV particles. There is growing evidence that enveloped 
virus particles carry multiple host proteins both internally and externally during 
infection (Cantin, Methot et al. 2005). HSP70 and/or HSC70 is associated with purified 
RSV particles, rabies virus particles, HCV particles, Newcastle disease virus particles, 
and herpes simplex virus (HSV) particles, amongst others (Sagara and Kawai 1992; 
Cantin, Methot et al. 2005; Parent, Qu et al. 2009; Radhakrishnan, Yeo et al. 2010; 
Stegen, Yakova et al. 2013). This suggests that association of members of the HSP70 
family with extracellular virus particles may be common strategy adopted by viruses of 
multiple different families to aid virus replication. Few studies have investigated the 
significance of the incorporated fraction of cellular proteins to virus infectivity; (Stegen, 
Yakova et al. 2013) however were able to show that depletion of HSC70 in purified 
HSV particles using siRNA reduced the infectious titre of these particles by > 50 %. 
Various studies have depleted HSP70 and/or HSC70 in cells using siRNA, or used 
small molecule inhibitors of HSP70/HSC70, and assayed the effect on virus 
replication; for example titres of rabies virus and HCV both decreased when HSP70 or 
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HSC70 was depleted from infected cells (Lahaye, Vidy et al. 2012; Khachatoorian, 
Ganapathy et al. 2014). The following section presents experiments designed to 
assay the effect on HAZV replication of depleting HSP70 from SW13 cells using 
siRNA, or interfering with the function of these proteins using small molecule inhibitors 
of HSP70 and HSC70. 
 
4.9 RESULTS: THE EFFECT OF DEPLETING OR INHIBITING HSP70/HSC70 ON 
HAZV REPLICATION  
 
This section describes preliminary experiments to determine the functional effects on 
HAZV replication of depleting HSP70 levels with siRNA, or inhibiting HSP70/HSC70 
using the small molecule inhibitors, VER155008 and pifithrin-µ. 
 
4.9.1 The effect of HSP70 depletion by siRNA on HAZV replication 
 
In this section siRNA (short interfering RNA) targeting HSP70 (HSPA1A gene) was 
utilised to examine the role of HSP70 during HAZV replication. HSP70 was chosen for 
depletion as the SILAC ratios for HSP70 in the initial MS analysis of EGFP-CCHFV N 
IPs were higher than the HSC70 ratios (37.85 and 40.11, compared to 27.11 and 
24.72 respectively) and it was thought CCHFV N (and by inference HAZV N) might 
preferentially interact with HSP70. In addition, multiple studies have shown that 
depletion of HSC70 results in upregulation of HSP70 expression (Schlecht, Scholz et 
al. 2013; Khachatoorian, Ganapathy et al. 2014); if recruitment of HSP70 and HSC70 
by HAZV is interchangeable due to HAZV replication requiring a conserved function 
possessed by both HSC70 and HSP70, any effects on HAZV replication due to 
depletion of HSC70 may be masked by the upregulation of HSP70.  
SW13 cells were transfected with 80 pmole HSP70 siRNA per well to knock 
down HSP70, or 80 pmole scrambled siRNA was transfected as a negative control for 
off-target effects due to siRNA transfection. RNAiMAX, a cationic lipid-based 
transfection reagent was used to transfect SW13 cells with siRNA, as described in 
section 2.2.5.2. Following cell entry siRNA (which consists of short, 21 nucleotides 
long strands of dsRNA, complimentary to nucleotide sequences of specific mRNA 
molecules) is detected by the cellular protein DICER, and transferred to ARGONAUT, 
to form the RISC complex (RNA induced silencing complex). ARGONAUT breaks the 
hydrogen bonds between the dsRNA to generate a ssRNA strand, the ‘guide strand’ 
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which is complimentary to the mRNA of the specific gene to be silenced. The guide 
strands anneals to its target mRNA, which is then degraded by the exonuclease 
activity of the RISC complex. Degradation of mRNA ensures the protein encoded by a 
specific gene (in this case HSP70 encoded by HSPA1A) is not translated, and over 
time, cellular protein turnover ensures depletion of the specific protein.  
Depletion of cellular proteins can be cytotoxic, which can result in reduced 
virus replication. SW13 cells transfected with HSP70 siRNA, or scrambled siRNA, 
were MTT assayed 24 hrs and 48 hrs after transfection, to ensure depletion of HSP70 
was not cytotoxic. The MTT assay is a colorimetric assay to determine cell viability, 
based on the cleavage of yellow tetrazolium salt (MTT) by mitochondrial enzymes to 
form a soluble, blue formazan product; the amount of formazan produced is directly 
proportional to the number of living, not dead cells, and can be detected by absorption 
of light at 570 nm (Figure 4.18 (C)) (Sylvester 2011).  
Depletion of HSP70 by siRNA transfection was not cytotoxic (Figure 4.18 (C)) 
and 24 hrs after transfection, resulted in a 67.8 % reduction of HSP70 protein levels, 
relative to HSP70 protein levels from scrambled siRNA transfected cells (Figure 4.18 
(A) and (B)). HSP70 protein levels were quantified using StudioImage software, after 
scanning membranes probed with fluorescent secondary antibodies (which bound 
primary anti-GAPDH and anti-HSP70 antibodies; ‘anti-HSP72’ antibodies from Enzo 
Life sciences were utilised, which specifically detect the HSPA1A gene product) using 
the LiCor Odyssey Sa Infrared imaging system. Fluorescent signals from HSP70 were 
normalised to GAPDH signals, and the geometric mean of HSP70 signals from the 
three repeat siRNA experiments using either HSP70 siRNA, or scrambled siRNA, was 
calculated. The geometric mean was used to determine the difference in HSP70 
protein levels in HSP70 siRNA, compared to scrambled siRNA, transfected cells.  
However, 48 hrs after transfection expression levels of HSP70 had increased, 
and there was only a 45.2 % reduction of HSP70 protein levels, relative to HSP70 
protein levels from scrambled siRNA transfected cells (Figure 4.18 (A) and (B)). Re-
transfecting cells with HSP70 siRNA at the 24 hr time point did not result in increased 
HSP70 depletion at future time points; neither did altering the amount of siRNA or 
RNAiMAX in the transfection mix. This assay should be repeated using different 
siRNA sequences targeting HSP70, or a mixed pool of siRNA sequences targeting 
multiple regions of the HSP70 mRNA, to determine the effect of more efficient HSP70 
depletion on HAZV replication. 
Depletion of HSP70 was highly specific, and did not affect expression levels of 
HSC70 (detected using antibodies specific to HSC70), or GAPDH (Figure 4.18 (A)). 
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Cells were infected with HAZV at an MOI 1 following overnight transfection with 
HSP70 siRNA, or scrambled siRNA; when cell supernatant and proteins were 
harvested 24 hrs after siRNA transfection, HAZV had been replicating in SW13 cells 
for 6 hrs. After 6 hrs of replication HAZV N could be detected by western blot with 
anti-HAZV N in the SW13 cell lysate (Figure 4.18 (A)), however secreted HAZV could 
not be detected by plaque assay. There were slightly reduced levels of HAZV N in 
HSP70 depleted cells 6 hrs after infection, compared to scrambled siRNA transfected 
cells; HAZV N expression was at 85.4 % of levels of HAZV N detected in lysates from 
scrambled siRNA transfected cells. HAZV N expression levels were quantified as 
described for HSP70, after normalisation of HAZV N fluorescent signals to GAPDH 
signals.  
Cell lysates harvested 48 hrs after siRNA transfection (30 hrs after HAZV 
infection) were analysed by western blot; the level of HSP70 depletion was not as 
pronounced as at 24 hrs post-transfection (HSP70 levels were reduced by 45.2 %, 
compared to 67.8 % at 24 hrs post-transfection). However the abundance of HAZV N 
in HSP70 siRNA-transfected cells at 48 hrs was still slightly reduced compared to 
scrambled siRNA transfected cells (HAZV N proteins levels remained at 84 % of those 
detected in lysates from scrambled siRNA transfected cells) (Figure 4.18 (B)). 
Analysis of secreted infectious HAZV by plaque assay also revealed a slight decrease 
in titre in HAZV secreted from HSP70 depleted cells compared to scrambled siRNA 
transfected cells; HAZV secreted from HSP70 depleted cells had an average titre of 
9.4 x 104 pfu/mL, and HAZV secreted from scrambled siRNA transfected cells had an 
average titre of 1.3 x 105 pfu/mL (Figure 4.18 (D)).  
 
 
Figure 4.18 siRNA mediated depletion of HSP70 and effects on HAZV replication 
(Below) siRNA mediated depletion of HSP70 in SW13 cells was not cytotoxic when 
compared to scrambled siRNA transfection, when cell viability was measured by MTT 
assay (C). Depletion of HSP70 was specific, (expression levels of HSC70 and 
GAPDH were unchanged) and the greatest depletion of HSP70 occurred 24 hrs after 
transfection with HSP70 siRNA; expression levels of HSP70 had increased again by 
48 hrs post-transfection (A) and (B). HAZV N protein expression levels were slightly 
reduced in HSP70 depleted cells compared with cells that had been transfected with 
scrambled siRNA (B) and titres of infectious HAZV secreted from HSP70 depleted 
cells were also slightly reduced compared to scrambled siRNA transfected cell 
supernatant (D).    
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These data suggested that the interaction between HSP70 and HAZV N was not 
detrimental to virus replication, as no increase in HAZV replication was observed 
when HSP70 was depleted. The reduction in expression levels of HAZV N, and the 
decrease in secreted infectious HAZV titre, between HSP70 siRNA transfected cells 
compared to scrambled siRNA transfected cells, were modest (15 % reduction in 
HAZV N expression and 28 % reduction in virus titre). It could be that a more efficient 
depletion of HSP70 could result in a greater reduction in HAZV N expression and 
secreted infectious HAZV titre. Alternatively, siRNA mediated depletion of HSC70 
could have a greater effect on the HAZV replication cycle, and HAZV secretion, then 
depletion of HSP70, as has been shown for HCV (Khachatoorian, Ganapathy et al. 
2014).   
 
4.9.2 Effect on HAZV replication of inhibiting HSP70/HSC70 with VER155008 and 
pifithrin-µ 
 
VER155008 (VER) and pifithrin-µ (PIF) (a commonly used synonym for PIF is: 2-
Phenylethynesulfonamide (PES)) are both small molecule inhibitors of HSP70/HSC70. 
All functions of HSP70 family members are controlled by binding of HSP70 to protein 
targets via a C-terminal substrate binding domain (SBD); this binding is allosterically 
controlled by a nucleotide (ATP) binding in the N-terminal ATP-ase domain (the 
nucleotide binding domain (NBD)) (Schlecht, Scholz et al. 2013).  VER was developed 
as a small molecule inhibitor of HSP70 ATPase activity; VER acts as an ATP-
competitive inhibitor of HSP70 by binding to the HSP70 NBD and arresting it in a ‘half-
open’ conformation, thereby preventing ATP from binding, and inhibiting the allosteric 
control between the NBD and SBD (Massey, Williamson et al. 2010; Schlecht, Scholz 
et al. 2013). PIF is thought to target the SBD of HSP70; interaction of PIF with the 
HSP70 SBD disrupts the association between HSP70 and several of its cofactors and 
client proteins, thereby inhibiting HSP70 function (Kondoh and Osada 2013). VER and 
PIF are not specific for individual HSP70 family members, they target both HSP70 and 
HSC70 (Schlecht, Scholz et al. 2013). 
The cytotoxic effects of VER and PIF on SW13 cells were estimated by MTT 
assay over multiple concentrations of VER and PIF; VER and PIF were dissolved in 
DMSO, then diluted in complete media and applied to SW13 cells for 24 hrs prior to 
the MTT assay (Figure 4.19). (The highest concentration of VER was limited by the 
solubility of this compound in DMEM). This defined working concentrations of VER 
and PIF which did not affect cell viability, which were then used to assay the ability of 
HAZV to replicate in the presence of these compounds. 
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Figure 4.19 Cytotoxic effects of VER and PIF measured by MTT assay over 
multiple compound concentrations. 
SW13 cells were treated with VER and PIF for 24 hrs over a range of concentrations 
(40 µM – 0.04 µM), and cell viability was measured relative to cells treated with 0.1 % 
DMSO (a DMSO concentration greater than that present at the highest concentration 
of compound). Cell viability relative to 0.1 % DMSO was plotted against compound 
concentration.  
 
 
SW13 cells were pre-treated with VER and PIF for 1 hr, prior to infection with HAZV at 
an MOI of 1. SW13 cells were infected as described in section 2.2.9.1, however after 
HAZV adsorbed to cells for 1hr and HAZV diluted in SFM was removed, media 
containing 2 % FBS with the appropriate concentration of VER and PIF was layered 
over cells. HAZV was allowed to replicate in SW13 cells in the presence of various 
concentrations of VER and PIF for 24 hrs, cell lysates and supernatants were then 
harvested; HAZV N was detected by western blot analysis, and secreted HAZV by 
plaque assay (Figure 4.20).  
HAZV N expression decreased in the presence of increasing concentrations of 
PIF, such that HAZV N expression was not detected in the lysates of cells grown in 6 
μM PIF for 24 hrs (Figure 4.20 (B)); this corresponded well with plaque assays of 
HAZV secreted from SW13 cells treated with 0.5 µM and 2 µM PIF. The amount of 
HAZV secreted from SW13 cells grown in the presence 0.5 µM PIF for 24 hrs was 
decreased by 75 % relative to amount of HAZV secreted from cells grown in the 
presence of 0.2 % DMSO, and HAZV secreted from cells grown in 2 µM PIF for 24 hrs 
was undetectable by plaque assay (Figure 4.20 (C)). In contrast, although levels of 
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HAZV N expression decreased in the presence of increasing concentrations of VER 
when assayed by western blot (Figure 4.20 (B)), HAZV N expression was still 
detectable in the lysates of cells grown in the presence of 20 μM VER for 24 hrs.  
However plaque assays of HAZV secreted from SW13 cells treated with 16 µM VER 
for 24 hrs, revealed a 95 % decrease in HAZV titre, when compared to HAZV 
secreted from cells treated with 0.2 % DMSO.  
MTT assay of uninfected SW13 cells treated with corresponding 
concentrations PIF (Figure 4.20 (A)) showed little cytotoxicity that could account for 
the decrease in HAZV replication observed. Viability of cells treated with between 6 
µM and 20 µM VER decreased to 80 % of the viability level of cells treated with 0.2 % 
DMS0 (a DMSO concentration greater than that present in any dilution of VER or PIF). 
This decrease in cell viability may have contributed to the decrease in HAZV titres 
observed at 16 µM VER, however the decrease in cell viability is not as great as the 
decrease in virus titre at 16 µM VER. 
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Figure 4.20 The effect of VER and PIF on HAZV replication 
SW13 cells were treated with VER and PIF, at concentrations ranging from 4 µM – 20 
µM, and 0.5 µM to 10 µM, respectively. After 24 hrs incubation of VER and PIF with 
SW13 cells in the absence of HAZV, cytotoxicity was estimated by MTT assay (A). 
SW13 cells grown in the presence of PIF and VER were then infected with HAZV for 
24 hrs, and virus replication efficiency was determined through western blot analysis 
of HAZV N and plaque assay (B) and (C). Plaque assays were performed once. 
Western blot analysis was performed after total protein concentration of cell lysates 
was determined by BCA assay; then equal amounts of protein were loaded onto SDS 
PAGE gels, prior to transfer of protein to FL-PVDF membranes and probing with anti-
HAZV N and anti-GAPDH antibodies. 
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The decrease in HAZV N expression, and decrease in titre of secreted HAZV from 
cells treated with PIF and VER, in comparison to cells treated with 0.2 % DMSO, is 
consistent with a positive role for HSP70/HSC70 in the HAZV replication cycle. 
However, in this assay, the decrease in HAZV N expression and HAZV titre in the 
presence of PIF and VER, could not be directly linked to the involvement of 
HSP70/HSC70 in the HAZV replication cycle. This was due to the lack of a specific 
cellular HSP70/HSC70 function to assay, in order to determine the efficacy of 
HSP70/HSC70 inhibition by PIF and VER. HSP70 and HSC70 behave in a relatively 
non-specific manner in the control of protein folding, therefore there are currently no 
reliably identified ‘client proteins’ of HSP70 or HSC70 (Budina-Kolomets, Balaburski et 
al. 2014). Degradation of chaperone client proteins is an established method to assay 
the inhibition of chaperones by small molecule inhibitors; inhibition of HSP90 for 
example, results in the ubiquitin dependent proteosomal degradation of HSP90 client 
proteins, including Her2, CDK4, Raf1 and AKT (Massey, Williamson et al. 2010). 
Given that HSP70 has been shown to play a key role in the HSP90 chaperone 
machinery (inhibition of HSP90 results in up regulation of HSP70 expression, in 
addition to client protein degradation), reduced levels of the HSP90 client protein Raf1 
have been used to measure the efficacy of HSP70 inhibition by VER in the past 
(Massey, Williamson et al. 2010). However concentrations of VER at which Raf1 
expression levels are reduced are cytotoxic, and any effect on virus replication could 
be attributed to HSP90 inhibition. 
 
4.10 CHAPTER SUMMARY AND DISCUSSION 
 
This chapter presents the identification of cellular proteins that interact with EGFP-
CCHFV N, and validation of the interaction of HSP70 with un-tagged CCHFV N and 
HAZV N. This chapter also presents the purification of secreted HAZV particles from 
the supernatant of infected cells, the detection of HSC70 within the fraction containing 
infectious HAZV by both western blot and MS analysis, and the co-IP of HSP70 with 
HAZV N from this fraction. This chapter then goes on to describe preliminary 
experiments to dissect the role of HSP70/HSC70 within the HAZV replication cycle 
using siRNA and small molecular inhibitors of HSP70/HSC70.  
 The N proteins of other bunyaviridae interact with components of their host 
cells, including cellular proteins, and these interactions can have important 
consequences both for viral replication and for the cell. The hantavirus N protein, for 
example, has been shown to have multiple roles in the host cell; hantavirus N 
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interacts with the 5’ caps of cellular RNAs in cytoplasmic P bodies and protects them 
from degradation (Mir, Duran et al. 2008). As these cellular 5’ capped 
oligoribonucleotides are then used to prime viral transcription, it is thought that the 
hantavirus N protein therefore has a role to play in the cap snatching mechanism 
essential for initiation of viral transcription. In addition, the hantavirus N protein 
interacts with the ribosomal protein S19, a component of the 40S ribosomal subunit 
(Haque and Mir 2010). This interaction recruits the 40S ribosomal subunit to viral 
mRNA transcripts and initiates N-mediated translation initiation. In this way, the 
hantavirus N protein is thought to functionally replace the entire cellular eIF4F cap 
binding and translation initiation complex, to preferentially enhance translation 
initiation of viral mRNA transcripts (Cheng, Haque et al. 2011). The N protein of BUNV 
interacts with the cellular protein poly (A) binding protein (PABP), which helps to 
shuttle polyadenylated mRNAs from the nucleus to the cytoplasm. PABP is 
predominately cytoplasmic, however BUNV N co-localises with PABP in the 
cytoplasm of infected cells at early timepoints after infection, and at later time points, 
causes a dramatic re-distribution of PABP to the nucleus. It is thought this interferes 
with poly (A) dependent cellular translation initiation, and thus aids viral poly (A) 
independent translation initiation (Blakqori, van Knippenberg et al. 2009).   
To determine whether CCHFV N could also have a role within the host cell, in 
a similar manner to the hantavirus and BUNV N proteins, SILAC-based MS analysis 
coupled to GFP-Trap IPs was used for the unbiased identification of cellular proteins 
that immunoprecipitated with EGFP-CCHFV N from transfected 293T cells. The use of 
SILAC enabled the effective discrimination between cellular proteins that interacted 
specifically with EGFP-CCHFV N, and those that bound non-specifically to 
components of the GFP trap. After EGFP-CCHFV N was IP’d from cell lysates, MS 
analysis was performed twice on the same sample; in total 192 cellular protein were 
identified and quantified that immunoprecipitated with EGFP-CCHFV N; 112 proteins 
were common to both analyses, 46 proteins unique to the first analysis and 34 
proteins unique to the second. The difference in MS results generated from the same 
sample emphasised the importance of validating potential interacting proteins using 
an independent method. Independent western blot analysis confirmed the co-IP of 
several cellular proteins with high SILAC ratios with EGFP-CCHFV N, including actin 
(a known cellular interacting partner of CCHFV N) (Andersson, Simon et al. 2004), 
vimentin, p53 and HSP70/HSC70. The identification of actin by MS, and confirmation 
of the co-IP of actin with EGFP-CCHFV N provided a measure of confidence in the 
MS results. Furthermore, the absence of GAPDH and B23 (both proteins that were 
identified with low SILAC ratios in the MS analysis) in immunoprecipitates from GFP-
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Trap IP’d EGFP-CCHFV N supported the 6-fold cut off ratio that was chosen to 
differentiate between proteins that immunoprecipitated specifically with EGFP-CCHFV 
N, and those that bound non-specifically to components of the GFP-Trap.  
HSP70 was chosen to be further validated as an interacting partner of 
untagged CCHFV N due to the high SILAC ratios of both HSP70 and HSC70, and the 
abundance of HSP70 that immunoprecipitated with EGFP-CCHFV N when analysed 
by western blot. Growing evidence from the literature indicates HSP70 interacts with 
viral proteins from several different families including: the nucleocapsid protein of 
rabies virus (RV), NS5A of HCV, the PB2 and PB1 monomers of influenza A virus 
(IAV) and both the nucleoprotein and phosphoprotein of RSV (Brown, Rixon et al. 
2005; Lahaye, Vidy et al. 2012; Oliveira, Simabuco et al. 2013; Khachatoorian, 
Ganapathy et al. 2014; Manzoor, Kuroda et al. 2014). HSP70 was shown to have a 
positive functional role in the replication cycles of RV, HCV and IAV, as depletion of 
HSP70 using siRNA resulted in reduced virus transcription and replication. However 
increased HSP70 expression during Hantaan virus infection decreased virus 
replication, and the interaction between HSP70 and the Hantaan virus N protein is 
thought to be detrimental to virus replication; this suggests the role of HSP70 in virus 
replication cycles is not always beneficial for the virus (Yu, Ye et al. 2009). The choice 
of HSP70 to be further validated was therefore also based on previous studies that 
had shown HSP70 to be involved in the replication of several different viruses, raising 
the possibility that HSP70 could also be involved in CCHFV replication. 
To confirm the co-IP of HSP70 was not an artefact of overexpression of the 
EGFP-CCHFV N fusion protein, untagged CCHFV N was IP’d from cells transfected 
with pCAGGs-CCHFV N, and from CCHFV infected cells, using anti-CCHFV N 
conjugated to Dynabeads. In IP experiments from both CCHFV infected and 
pCAGGs-CCHFV N transfected cells, HSP70 immunoprecipitated with CCHFV N, as 
verified by western blot analysis. The co-IP of HSP70 with CCHFV N from CCHFV 
infected cells suggested that HSP70 interacted with CCHFV N during infection, and 
therefore that HSP70 may play a role in the replication cycle of CCHFV.  
One of the main factors that limits investigations into the CCHFV replication 
cycle is the requirement to work under containment levels 4 conditions when 
manipulating CCHFV, due to the highly pathogenic and lethal nature of CCHF. In 
2011, the discovery that HAZV infection of IFNα/βR-/- mice resulted in very similar 
symptoms and pathology to CCHFV infection, suggested that HAZV infection in this 
small animal system may be a valid model to act as a CCHFV surrogate (Dowall, 
Findlay-Wilson et al. 2012). Data presented in chapter 3 indicated that CCHFV N and 
HAZV N are structurally very similar, and support the use of HAZV as a model for 
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CCHFV infection. HAZV and CCHFV are classified in the same serogroup within the 
same bunyavirus genus, which suggests these viruses adopt similar replication 
strategies; however in contrast to CCHFV, HAZV can be manipulated under 
containment level 2 conditions, and is not known to be pathogenic in humans. 
Experiments were therefore carried out to determine whether HSP70 also interacted 
with HAZV N, as the potential functional role of HSP70 within the replication cycle of 
HAZV could be more easily investigated under containment level 2 conditions.  
Optimal conditions for growth of HAZV stocks were determined; infection of 
SW13 cells with HAZV at an MOI of 0.001 and harvesting cell supernatants 4 days 
after infection, resulted in the highest HAZV titres. HAZV infection of SW13 cells 
resulted in expression of HAZV N, which could be detected by western blot and IF 
analysis with anti-HAZV N antibodies (prepared using recombinant HAZV N protein, 
as described in section 3.2.4); HAZV N had a molecular weight of ~54 kDa, and was 
detected in the cytoplasm of infected cells, with a similar subcellular distribution to 
CCHFV N. In good agreement with CCHFV N IP’s, HSP70 also immunoprecipitated 
with HAZV N from the lysates of infected cells, and HSP70 partially co-localised with 
HAZV N in the cytoplasm. These data supported a role for HSP70 during the 
replication cycle of HAZV.  
Multiple different viruses (including several whose component proteins interact 
with members of the HSP70 family) have HSP70 family members packaged into, or 
associated with, secreted purified virus particles, including: RSV, rabies virus, HCV, 
HIV and Newcastle disease virus, amongst others (Sagara and Kawai 1992; Chertova, 
Chertov et al. 2006; Parent, Qu et al. 2009; Radhakrishnan, Yeo et al. 2010; Ren, Xue 
et al. 2012). Others viruses whose secreted virions have been analysed by mass 
spectrometry, but have not incorporated HSP70 include influenza virus (Shaw, Stone 
et al. 2008). Whilst not all host proteins are necessarily incorporated specifically into 
secreted virus particles, the association of HSP70 with virus particles from so many 
different families possibly indicates a conserved involvement of HSP70 in the 
replication cycle of multiple different viruses. As HSP70 immunoprecipitated with 
HAZV N, the association between HSP70 and purified HAZV particles was 
investigated; secreted HAZV particles from the supernatant of infected cells were 
purified by PEG 6000 precipitation, followed by density gradient centrifugation through 
a 5 %- 25 % iodixanol gradient. When the fraction containing infectious HAZV was 
analysed by western blot; HAZV N could be detected in this fraction, as could HSP70.  
Coomassie and silver stain analysis of the fraction containing infectious HAZV 
revealed the presence of multiple protein bands, not all of which could be attributed to 
HAZV proteins. There is growing evidence that multiple host cell proteins are 
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incorporated into, or onto newly formed enveloped viruses; it is thought that given the 
simplicity of viral proteomes, and the complexity of cell entry and exit, secreted virus 
particles may incorporate cellular proteins to aid these processes, and virion 
associated cellular proteins may therefore represent novel antiviral targets (Stegen, 
Yakova et al. 2013). MS analysis was used to identify cellular proteins in the fraction 
containing infectious HAZV.   
MS analysis identified all 4 HAZV proteins (N, GN, GC and L) in the fraction 
containing infectious HAZV, with N present in the highest abundance. MS analysis 
also identified several members of the HSP70 family, including HSC70, which was 
presumed to be detected in all previous IPs with an anti-HSP70 antibody that bound 
both HSP70 and HSC70, and in western blot analysis of this fraction. Furthermore 
HSP70 immunoprecipitated with HAZV N from the fraction containing infectious HAZV, 
which suggested that HAZV N associated with HSP70 at multiple stages of the HAZV 
replication cycle.  
The role of HSP70 within the replication cycle of HAZV was therefore 
investigated using siRNA that targeted HSP70 (gene HSPA1A) and the small 
molecule inhibitors of HSP70 and HSC70, VER and PIF. HSP70 expression was 
reduced by siRNA treatment to 33 % and 54 % of levels observed in scrambled siRNA 
treated cells at 24 hrs and 48 hrs post-transfection, respectively. Western blot analysis 
of HAZV N expression levels in HSP70 depleted cells 24 hrs and 48 hrs after 
transfection, revealed a ~15 % decrease in HAZV N protein levels compared to 
scrambled siRNA transfected cells. In agreement with this slight decrease in HAZV N 
expression, there was a modest decrease in the titre of secreted HAZV 48 hrs after 
transfection with HSP70 siRNA, compared to scrambled siRNA. 
Depletion of HSP70 expression in cells did not result in an increase in HAZV 
replication, indicating the interaction between HSP70 and HAZV N was likely not 
detrimental to the HAZV replication cycle. Complete knock down of HSP70 could not 
be achieved in this study, but could result in a greater reduction in HAZV replication. 
Alternatively knock down of HSC70 could have a greater effect on the HAZV 
replication cycle, as has been shown for HCV (Khachatoorian, Ganapathy et al. 2014). 
Simultaneous knockdown of HSP70 and HSC70 could also have an additive effect on 
inhibition of HAZV replication. 
Preliminary experiments with the HSP70 inhibitors VER and PIF, revealed a 
decrease in HAZV replication in the presence of these compounds; 16 µM VER 
reduced the titre of secreted HAZV by 95 %, and 0.5 µM PIF reduced the titre of 
secreted HAZV by 75 %, when compared to HAZV replication in the presence of 0.2 % 
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DMSO. This suggested a positive role for HSP70 within the HAZV replication cycle. 
The reduction in HAZV replication could not be solely attributed to the inhibition of 
HSP70/HSC70 however, as there are no reliably identified client proteins of HSP70, 
which are proteolytically degraded when HSP70/HSC70 is inhibited (Budina-Kolomets, 
Balaburski et al. 2014). Recent work has suggested that HSP90 client protein 
expression was reduced when HSP70 was inhibited, due to the closely linked nature 
of the HSP70 and HSP90 chaperone systems (Massey, Williamson et al. 2010). 
Expression levels of HSP90 client proteins could be analysed in the future to 
determine the efficacy of HSP70 inhibition, however effects on HAZV replication could 
potentially then be attributed to HSP90 inhibition. Interestingly HSP90 was also 
detected in the fraction containing infectious HAZV, which suggests HSP90 may also 
have a role within the HAZV replication cycle.  
HSP70 and HSC70 are essential cellular ‘housekeeping’ proteins, therefore 
inhibiting HSC70/HSP70 function can be cytotoxic; in this study there was a 20 % 
reduction in cell viability in the presence of 16 µM VER, and PIF was cytotoxic at 
concentrations >5 µM. HSP70 inhibitors were designed to kill cancerous cells; several 
different types of cancer have upregulated expression levels of HSP70; knock down of 
HSP70, or inhibition of HSP70 results in the death of these cells (Nylandsted, Brand 
et al. 2000). Although it is thought that host directed antiviral therapeutics have the 
advantage of the slower mutation rate of the virus host, which should prevent virus 
escape mutants developing as quickly, a disadvantage of these therapeutics is that 
inhibition of cellular proteins can also be toxic to the host cell. The therapeutic window 
of the HSP70 inhibitors utilised in this study as anti-viral agents appeared to be 
relatively small. On the other hand the SW13 cell line utilised may depend on elevated 
expression levels HSP70 for survival; inhibition of HSP70 in a primary cell line may be 
less toxic.      
HSP70 and HSC70 have been shown to directly aid virus replication at 
multiple stages of different virus replication cycles ranging from cell entry, genome 
replication, RNP formation and virion assembly (Mayer 2005). In the paramyxovirus, 
canine distemper virus, it was noted that induction of the stress response promoted 
the cytopathic effects of canine distemper virus infections, and that HSP70 and 
HSC70 associated with viral RNPs (Oglesbee, Ringler et al. 1990). The addition of 
anti-HSP70 antibodies reduced RNA polymerase activity associated with purified 
nucleocapsid particles, demonstrating the importance of the association between 
HSP70 and viral RNPs for genome transcription and replication (Oglesbee, Liu et al. 
1996). More recently it was shown that the addition of anti-HSP70 antibodies to 
purified RSV polymerase complexes on lipid raft membranes also decreased RNA 
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polymerase activity (Brown, Rixon et al. 2005). It was hypothesised that HSP70s are 
required to interact with and remodel the N protein to make the RNA accessible to the 
polymerase, or that HSP70 and HSC70 could directly chaperone the polymerase, and 
thereby enhance its activity (Mayer 2005). A similar mechanism could exist for 
CCHFV and HAZV.   
HSP70 and HSC70 share significant (85 %) homology; HSC70 is the 
constitutively expressed homologue of HSP70. HCV NS5A interacts with both HSC70 
and HSP70, and recently the differential roles of HSP70 and HSC70 in the replication 
cycle of HCV have begun to be dissected. siRNA mediated knockdown of both HSP70 
and HSC70 resulted in a decrease in titre of secreted HCV; and simultaneous knock 
down of HSP70 and HSC70 had an additive effect on the decrease in HCV titre. 
Interestingly, HSP70 was shown to be involved in virus transcription and translation, 
whereas HSC70 was shown to have an important role in the assembly of virus 
particles (Khachatoorian, Ganapathy et al. 2014). This could also be the case during 
HAZV infection as HSC70, not HSP70 was identified in the fraction containing 
infectious HAZV.  
In addition to direct involvement in the virus replication cycle, the interaction 
between HSP70 and viral proteins, can modulate cellular pathways regulated by 
HSP70. For example, IAV M1 protein interacts with HSP70, and by doing so disrupts 
the interaction between HSP70 and Apaf1, thereby enhancing the effects of apoptosis 
inducers; siRNA knock down of M1 during infection inhibited virus-induced apoptosis, 
but expression of M1 itself did not induce apoptosis (Halder, Bagchi et al. 2011).          
There is currently a lack of effective therapeutics to treat CCHF; any insight 
gained into the replication cycle of CCHFV (and by inference, HAZV) could help 
reveal new strategies to combat these viruses. Members of the HSP70 family interact 
with viral proteins from multiple virus families, and are associated with or packaged 
into secreted virus particles. A growing number of studies are addressing the 
importance of HSP70 to the replication cycle of these viruses, using siRNA 
approaches, and small molecule inhibitors of HSP70 family members. A reduction in 
expression, or inhibition, of members of the HSP70 family resulted in a decrease in 
virus replication in many cases. This suggested that targeting HSP70 family members 
may be a promising strategy to inhibit replication of viruses from multiple different 
families, including CCHFV and HAZV.              
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CHAPTER 5: THE INDUCTION OF APOPTOSIS BY HAZV  
 
5.1 CHAPTER INTRODUCTION 
 
Apoptosis is a tightly regulated mechanism of controlled cell death, which can be 
activated in response to viral invasion, and is often a critical factor determining the 
outcome of infection. Hallmarks of cell death by apoptosis include expression of active 
caspases, DNA fragmentation, membrane ‘flipping’ (the expression of the normally 
inward facing phosphatidylserine on the plasma membrane outer leaflet), expression 
of Annexin V on the plasma membrane outer leaflet, cell shrinkage and membrane 
‘blebbing’ as well as extensive protein cross linking (Elmore 2007). There are two 
main apoptotic pathways, the intrinsic pathway, which is activated in response to 
intracellular stimuli, and the extrinsic pathway, which is induced as a result of the 
activation of cell surface ‘death receptors’. Activation of various different cellular 
pathways results in the induction of apoptosis during virus infection, including 
activation of cell surface ‘death receptors’, the ER stress response and unfolded 
protein response (UPR), and activation of IRF 3, amongst others. Apoptosis can either 
be detrimental or beneficial to virus replication cycles, depending on the virus in 
question; in some cases apoptosis is considered to be an antiviral response to 
infection, with cell death limiting the spread of progeny virions. In other cases, viruses 
are thought to deliberately induce apoptosis to aid virus dissemination.   
This chapter describes the activation of caspases-9, -3, and -7, and the 
induction of apoptosis by HAZV, over a 72 hr time course of infection. This chapter 
also describes the cleavage of HAZV N over this 72 hr time course, and investigations 
into the cellular proteins responsible for HAZV N cleavage using the inhibitor of 
caspase-3, Z-DEVD-FMK, and the inhibitor of executioner caspases, Z-FA-FMK. This 
chapter then goes on to examine the effect of these inhibitors (Z-DEVD-FMK and Z-
FA-FMK) on HAZV replication. 
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5.1.1 Summary of the induction of apoptosis by CCHFV, and cleavage of CCHFV 
N by caspase-3 
 
It has previously been reported that CCHFV induces apoptosis at a relatively late time 
point after infection; activation of procaspase-3 and TUNEL positive cells were 
detected 48 hrs after CCHFV infection, and increased at 72 hrs after infection, when 
major cytopathic effect (CPE) was observed (Karlberg, Tan et al. 2011). Induction of 
apoptosis by CCHFV was thought to occur after activation of the ER stress response 
and UPR; CCHFV was therefore thought to induce apoptosis via the intrinsic 
mitochondrial pathway (Figure 1.14) (Rodrigues, Paranhos-Baccala et al. 2012). 
During CCHFV infection it was shown that active caspase-3 cleaved CCHFV N at a 
conserved DEVD motif, located at the apex of the arm domain (Figure 5.1 (A)) to 
generate a 30 kDa and a 22 kDa CCHFV N fragment, that were detectable by western 
blot analysis (Karlberg, Tan et al. 2011). Cleavage of CCHFV N occurred in infected 
cells during apoptosis, when CCHFV N was transfected into cells and apoptosis was 
induced, and in vitro using recombinant CCHFV N and recombinant caspase-3 
expressed in E. coli. After cleavage by caspase-3, the N- and C-terminal CCHFV N 
fragments remained associated with each other, and eluted from a size exclusion 
column in a single peak (Carter, Surtees et al. 2012).  
The CCHFV N DEVD motif is conserved among all currently sequenced 
CCHFV isolates and site directed mutagenesis confirmed the DEVD motif as the 
specific site for caspase-3 cleavage; however during infection, only a small proportion 
of total CCHFV N was cleaved by caspase-3. It could be that, given the location of the 
DEVD motif on the apex of the arm domain, only monomeric CCHFV N is a substrate 
for active caspase-3. The majority of CCHFV N is thought to be multimerised and 
bound to RNA in an infected cell and the crystal structure suggests that the DEVD 
motif is inaccessible in RNPs. Nevertheless, inhibition of caspase-3 using Z-DEVD-
FMK resulted in an increase in secreted CCHFV titre, which suggested that cleavage 
of CCHFV N by caspase-3, and the induction of apoptosis, formed part of the cellular 
defence against CCHFV infection.  
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 Figure 5.1 CCHFV N and HAZV N with DEVD and DQVD motifs highlighted 
CCHFV N (A) contains a conserved DEVD (Asp, Glu, Val, Asp) motif on the apex of 
the arm domain (blue) that is cleaved by active caspase-3 during apoptosis to 
generate two fragments of 30 kDa and 22 kDa. HAZV N (B) possesses a DQVD (Asp, 
Gln, Val, Asp) motif on the apex of the arm domain (blue), in a similar position to the 
DEVD motif on the apex of the arm domain of CCHFV N.   
 
 
5.1.2 The crystal structure of HAZV N revealed a DQVD motif on the apex of the 
arm domain 
 
Comparison of CCHFV N and HAZV N (Figure 1.12) primary sequences revealed that 
HAZV N did not possess a DEVD motif, but instead contained a DQVD (Asp, Gln, Val, 
Asp) sequence. Analysis of the crystal structure of HAZV N showed this DQVD 
sequence resided on the apex of the arm domain, in approximately the same position 
as the DEVD motif of CCHFV N (Figure 5.1 (B)). DQVD is not a characterized 
caspase-3 cleavage motif, however there are many uncharacterized caspase-3 
cleavage motifs, whose amino acid composition has yet to be determined. Caspases 
recognize a tetra-peptide repeat Asp-x-x-Asp, therefore DQVD could potentially 
represent a currently uncharacterized caspase-3 cleavage site. Similar to CCHFV N, 
A B 
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the exposed position of the DQVD motif on the apex of the arm domain suggested the 
motif would be accessible to cellular caspases during infection. However little is 
known about the effect of HAZV replication on the host cell environment; and it is not 
known whether HAZV infection results in activation of cellular caspases or the 
induction of apoptosis. Experiments were therefore carried out to establish whether 
cellular caspases were activated during HAZV infection, and whether this led to the 
induction of apoptosis and cleavage of HAZV N.   
 
5.2 RESULTS: HAZV INFECTION RESULTED IN ACTIVATION OF CELLULAR 
CASPASES AND THE INDUCTION OF APOPTOSIS 
 
5.2.1 HAZV infection resulted in activation of caspase-9, -3, and -7 
 
Caspases are constitutive components of mammalian cells that are widely expressed 
in most cells in an inactive proenzyme form. The caspase family of proteins can be 
broadly divided into three categories; the initiator caspases (capase-2, -8, -9 and -10), 
the executioner caspases (caspase-3, -6, and -7) and the inflammatory caspases 
(capase-1, -4 and -5). Upon activation of the intrinsic or extrinsic apoptotic pathways, 
the initiator caspases are cleaved and activated; some procaspases can aggregate 
and autoactive (self-cleave), other procaspases are cleaved by active initiator 
caspases. Once activated, one of the main proteolytic targets of the initiator caspases 
are the executioner procaspases; procaspase-3 for example can be cleaved by any of 
the initiator caspases. Cleavage of executioner procaspases results in their activation; 
active executioner caspases then cleave both other executioner procaspases, and 
some initiator procaspases. This proteolytic cascade amplifies the apoptotic signal 
and leads to rapid cell death (Elmore 2007). In addition to procaspases, active 
executioner caspases have multiple other proteolytic targets; for example caspase-3 
and -7 cleave poly-ADP ribose polymerase (PARP) and inhibitor of caspase activated 
DNase (ICAD).      
To determine whether HAZV infection resulted in cleavage and activation of 
initiator or executioner caspases, SW13 cells were infected with HAZV at an MOI 1, or 
mock infected with SFM. At 24, 48 and 72 hrs post infection, cells were harvested; 
both adherent cells and culture media containing detached cells were harvested 
together. Following cell lysis, total protein concentration was determined by BCA 
assay, and 20 μg protein loaded per well after samples were denatured in LDS buffer 
for 10 minutes. Following transfer of proteins to FL-PVDF membranes and blocking, 
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membranes were probed with primary antibodies that targeted the following proteins; 
procaspase-3, cleaved caspase-3, procaspase-7, cleaved caspases-7, procaspase-9, 
cleaved caspase-9, PARP, cleaved PARP, anti-HAZV N and GAPDH. Primary 
antibodies were detected using fluorescently conjugated secondary antibodies, and 
membranes were analysed with a LiCor Odyssey Sa Infrared imaging system in the 
700 and 800 channels. The results of this analysis are shown in Figure 5.2; HAZV N 
was detected with anti-HAZV N 24, 48, and 72 hrs after infection.  
   
 
 
Figure 5.2 HAZV infection resulted in activation of procaspases-3, -7, and -9 
HAZV infected or mock infected cells were harvested 24, 48, and 72 hrs after infection, 
and lysates were analysed by western blot for the proenzyme and active form of 
several cellular caspases including caspases-3, -7, and -9. Abundance of uncleaved 
and cleaved PARP was also analysed, and GAPDH expression levels were used as a 
loading control. Anti-HAZV N confirmed successful HAZV replication.    
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The constitutive proenzymes of caspases-3, -7, and -9 were detected in both mock 
infected and HAZV infected cells 24, 48, and 72 hrs after infection. Procaspases-3, -7 
and -9 were detected in similar abundances in all samples, and expression levels of 
these proteins remained relatively constant during the time course of the experiment 
in mock and HAZV infected cells. In contrast protein levels of cleaved, and therefore 
active, caspases-3, -7 and -9 increased dramatically 48 and 72 hrs post HAZV 
infection, compared to mock infected cells. Distinct bands corresponding to the correct 
molecular weight of cleaved caspases-3, -7 and -9 are detected in HAZV infected 
cells 48 and 72 hrs post infection, but are absent from, or present at very low levels in 
mock infected cell lysates at these time points. This indicated that HAZV infection 
specifically resulted in the activation of these enzymes, rather than their activation 
being a product of prolonged incubation in 12 well dishes (up to 72 hrs). There 
appeared to be a greater abundance of cleaved caspase-3 and caspase-7 at 72 hrs, 
compared to 48 hrs post HAZV infection, whereas expression levels of active 
caspases-9 did not appear to increase to the same extent at 72 compared to 48 hrs 
post infection. The increase in abundance of active caspase-3, -7, and -9 in HAZV 
infected cells at 48 and 72 hrs post infection could not be attributed to varying 
expression levels of the constitutive, proenzymes of these caspases, as the 
proenzymes are present in similar abundances in HAZV infected and mock infected 
cells.   
Expression levels of one of the proteolytic targets of caspase-3 and caspase-7, 
PARP, was also analysed, to confirm activated caspase-3 and caspases-7 were 
functional in HAZV infected cells. Similar to the expression profiles of procaspases-3, 
7-, and -9, levels of uncleaved PARP remained relatively constant in both mock and 
HAZV infected cells 24, 48, and 72 hrs after infection, whereas the abundance of 
cleaved PARP increased dramatically 48 and 72 hrs after HAZV infection, compared 
to mock infected cells. This indicated that active caspase-3 and -7 were functional, 
and cleaved at least one of their proteolytic targets. In all samples expression levels of 
GAPDH remained constant therefore changes in abundance of cellular proteins could 
not be attributed to unequal protein loading. 
Taken together, these data indicated that HAZV infection resulted in the 
cleavage and activation of the initiator procaspase-9, and the executioner 
procaspase-3 and procaspase-7, 48 and 72 hrs after HAZV infection. Cleaved PARP 
was also detected in HAZV infected cells 48 and 72 hrs after infection, which indicated 
active caspase-3 and caspase-7 were functional. 
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5.2.2 HAZV infection resulted in DNA fragmentation 
 
To confirm that the presence of cleaved PARP and active caspases-9, -3 and -7 in 
HAZV infected cells correlated with the induction of apoptosis, TUNEL (terminal dUTP 
nick-end labelling) assays were carried out 24, 48, and 72 hrs after HAZV infection or 
mock infection. The TUNEL assay detects intrachromosomal DNA strand breaks, one 
of the final stages of apoptosis that results in cell death. SW13 cells were grown on 
glass coverslips prior to HAZV infection at MOI 1, or mock infection; at 24, 48 and 72 
hrs cells were fixed in 4 % paraformaldehyde, and after permeabilisation, TUNEL 
assays were carried out according to the manufacturer’s instructions. TUNEL assay 
analysis was performed on the Zeiss LSM 510 laser scanning confocal microscope; 5 
images were taken of HAZV-infected and mock-infected cells at each time point, and 
the total number of cells was used to calculate the number of TUNEL positive nuclei 
relative to DAPI-stained nuclei at 24, 48, and 72 hrs post infection. The results of this 
analysis are shown in Figure 5.3 (B), along with representative confocal images at 24, 
48, and 72 hrs post HAZV- or mock infection (Figure 5.3 (A)).         
Confocal microscopy analysis revealed HAZV infection resulted in a greater 
proportion of TUNEL positive cells compared to mock-infected cells at 48 and 72 hrs 
post-infection.  At 24 hrs post HAZV infection, the relative proportion of TUNEL 
positive cells compared to DAPI positive nuclei was 2.7 %, this increased to 5.3 % 48 
hrs post infection, and by 72 hrs post infection, 23 % of cells in wells that had been 
infected with HAZV were TUNEL positive. The increase in the proportion of TUNEL 
positive nuclei at each time point indicated HAZV infection resulted in apoptosis at 48 
hrs post infection, which was more pronounced at 72 hrs post infection. In contrast the 
relative proportion of TUNEL positive nuclei compared to DAPI positive nuclei in mock 
infected cells was 5.1 % at 24 hrs, this decreased to 2.3 % 48 hrs post mock infection, 
and by 72 hrs post mock infection, the relative proportion of TUNEL positive nuclei 
was 3 % in mock infected cells. The greater proportion of TUNEL positive nuclei (23 % 
nuclei) in HAZV infected cells compared to mock infected cells (3 % nuclei) at 72 hrs 
post infection indicated HAZV infection resulted in apoptosis at this time point; 48 hrs 
after infection the difference between the number of TUNEL positive cells in HAZV 
infected wells compared to mock was not as great (5.3 % compared to 2.3 %), 
possibly indicating the induction of apoptosis was not as pronounced at this time point. 
This study did not investigate whether the induction of apoptosis was a direct 
result of HAZV infection, or an indirect consequence of cellular processes (such as 
the IFN response) activated by HAZV infection. These data indicated that HAZV 
infection resulted in the induction of apoptosis at a relatively late time point after 
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infection, in a similar manner to CCHFV. A greater proportion of TUNEL positive cells 
were detected 48 and 72 hrs after HAZV infection compared to mock-infected cells; 
active caspase-3, caspase-7 and cleaved PARP were also increased in abundance in 
HAZV infected cells compared to mock infected cells at these time points. There may 
have been a slight increase in abundance of the initiator capase-9 24 hrs post HAZV 
infection compared to mock-infected cells, however activation of the executioner 
caspases and increased detection of intrachromosomal DNA strand breaks were not 
observed until 48 hrs after HAZV infection.  
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Figure 5.3 TUNEL assay confirmed the induction of apoptosis in HAZV infected 
cells 48 hrs and 72 hrs post HAZV infection     
HAZV infection resulted in a greater proportion of TUNEL positive cells 48 and 72 hrs 
after infection, compared to mock infected cells ((A) and (B)). In all cases green nuclei 
represent TUNEL positive cells. This indicated HAZV infection induced apoptosis at 
relatively late time points, similar to CCHFV infection.       
A B 
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5.3 RESULTS: THE CLEAVAGE OF HAZV N OVER THE 72 HR TIME COURSE OF 
INFECTION 
 
HAZV infection of SW13 cells resulted in the activation of caspases-9, -3, and -7, 
cleavage of PARP, and the induction of apoptosis 48 and 72 hrs after infection. To 
investigate whether HAZV N was cleaved over this 72 hr time course, SW13 cells 
were infected with HAZV at an MOI 1, or mock infected with SFM. Cells were lysed 
and proteins were harvested at 24, 48, and 72 hrs post infection; proteins were 
quantified by BCA assay, then 5 µg protein loaded per lane and resolved by SDS 
PAGE prior to western blot analysis, as described in section 2.2.6.5. Membranes were 
probed with primary anti-HAZV N and anti-GAPDH, which were detected with 
fluorescently conjugated secondary antibodies and analysed using the LiCor Odyssey 
Sa Infrared imaging system.  
Western blot analysis revealed that HAZV N was cleaved over the 72 hr time 
course of infection, and several cleavage products were detected (Figure 5.4). The 
predominant protein species detected at all time points is a band of ~54 kDa, which 
corresponds to the predicted molecular weight of full length HAZV N (Figure 5.4, 
arrow). At 24 hrs post infection a cleavage product of ~40 kDa was observed (Figure 
5.4 *), and a very weak band corresponding to a molecular weight of ~20 kDa was 
faintly visible (Figure 5.4 **). This band with an approximate molecular weight of ~20 
kDa increased in intensity at 48 and 72 hrs post infection, which suggested this HAZV 
N cleavage product increased in abundance at these time points. A band with an 
approximate molecular weight of ~ 30 kDa was also detected at 48 hrs and 72 hrs 
post infection (Figure 5.4 ***). Bands of corresponding molecular weights were absent 
from mock infected cells, which suggested these were cleavage products of HAZV N, 
rather than cross reacting cellular proteins. The increase in abundance of the ~20 kDa 
band corresponded with the induction of apoptosis, described in the previous section. 
This suggested the ~20 kDa cleavage product may be generated by proteins that are 
activated, or have increased expression levels, during apoptosis. 
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Figure 5.4 Cleavage products of HAZV N over a 72 hr time course of infection 
Several HAZV N cleavage products were detected with anti-HAZV N in cell lysates 
harvested 24, 48, and 72 hrs post HAZV infection. HAZV N cleavage products with 
approximate molecular weights of 20 kDa (**) and 30 kDa (***) were increased in 
abundance 48 and 72 hrs post infection, and a cleavage product with an approximate 
molecular weight of 40 kDa (*) was detected 24 hrs post infection.  
 
 
5.3.1 Treatment of cells with the caspase-3 inhibitor (Z-DEVD-FMK) and the 
executioner caspase inhibitor (Z-FA-FMK) 
 
Cleavage products of HAZV N were detected in infected cell lysates with anti-HAZV N 
over the 72 hrs time course of infection; however, the cellular factor required to 
produce these cleavage products and the specific cleavage site in HAZV N was 
unknown. To determine whether, in a similar manner to CCHFV N, HAZV N could be 
cleaved by active caspase-3 at 48 and 72 hrs post infection, SW13 cells were treated 
with the caspase-3 inhibitor Z-DEVD-FMK during a 72 hr time course of HAZV 
infection. Cells were also treated with Z-FA-FMK, an inhibitor of the executioner 
caspases, to confirm the results obtained with Z-DEVD-FMK. Z-DEVD-FMK and Z-
FA-FMK are both irreversible cysteine protease inhibitors; these compounds are 
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fluoromethyl ketone derivatives of peptides that resemble the cleavage sites of known 
caspase substrates, and irreversibly alkylate the cysteine residues in the active site of 
caspases (Schotte, Declercq et al. 1999). Z-DEVD-FMK shows greater specificity for 
caspase-3, whereas Z-FA-FMK can inhibit the DEVD-ase activity of caspase-2, -3, -7, 
and -6 (Lopez-Hernandez, Ortiz et al. 2003).  
Initially, uninfected SW13 cells were treated with 20 μM and 40 μM Z-DEVD-
FMK and Z-FA-FMK; 20 μM was the concentration used to treat SW13 cells during 
CCHFV infection in the study carried out by (Karlberg, Tan et al. 2011), and 40 μM 
was utilized to determine whether a dose dependent effect could be observed. 24, 48, 
and 72 hrs after treatment with these compounds, an MTT assay was performed (as 
described in section 2.2.12) to assess cell viability. Cell viability levels relative to cells 
treated with 0.1 % DMSO were determined for SW13 cells treated with 20 µM or 40 
µM of each compound (Figure 5.5).  
Growth of SW13 cells in the presence of 20 μM or 40 μM Z-DEVD-FMK 
resulted in cell viability levels that were ~80 % the level of cells treated with 0.1 % 
DMSO at each time point, when measured by MTT assay. A similar result was 
obtained when SW13 cells were treated with Z-FA-FMK, which indicated these 
compounds might have slightly affected cell growth or metabolism. However little 
difference was observed in viability levels between cells grown in the presence of 20 
µM Z-DEVD-FMK or Z-FA-FMK and cells grown in the presence of 40 µM Z-DEVD-
FMK or Z-FA-FMK, indicating the effect these compounds had on cell growth or 
metabolism was not dose-responsive.     
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Figure 5.5 Cell viability in the presence Z-DEVD-FMK or Z-FA-FMK  
Cells were treated with either 20 μM or 40 μM Z-DEVD-FMK, or Z-FA-FMK, or cells 
were treated with 0.1 % or 0.2 % DMSO in triplicate. 24, 48, and 72 hrs later, cell 
viability was examined by MTT assay; viability levels of cells treated with 20 μM or 40 
μM Z-DEVD-FMK, or Z-FA-FMK are expressed relative to viability levels of cells 
treated with 0.1 % DMSO. The graph represents the average of each of the 3 
absorbance readings.                        
 
 
SW13 cells were then infected with HAZV at an MOI 1, or mock infected; after 
adsorption of HAZV to cells for 1 hr at 37 °C, SFM containing HAZV was removed and 
replaced with DMEM containing 2 % FBS and the appropriate concentration of Z-
DEVD-FMK or Z-FA-FMK. HAZV was allowed to replicate in the presence of these 
compounds for 24, 48, or 72 hrs, then proteins were harvested as previously 
described (section 2.2.6.1). Lysates of cells mock infected, or infected with HAZV that 
had been replicating in the presence of Z-DEVD-FMK or Z-FA-FMK for 24, 48 or 72 
hrs were analysed by western blot using antibodies that targeted HAZV N, GAPDH, or 
cleaved PARP. Expression levels of cleaved PARP at 72 hrs post infection were 
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examined to confirm the inhibition of caspase-3, or the executioner caspases; 
expression levels of cleaved PARP at 72 hrs were quantified with StudioImage 
software, as previously described (Section 4.9.1) and plotted relative to GAPDH levels 
(Figure 5.6 (D)).  
The abundance of cleaved PARP was decreased in the presence of 20 μM or 
40 μM Z-DEVD-FMK or Z-FA-FMK (on average 16 % and 11 % the level of GAPDH, 
respectively), compared to HAZV infected cells treated with 0.1 % or 0.2 % DMSO (on 
average 25 % the level of GAPDH) (Figure 5.6 (D)). This indicated PARP cleavage 
was impaired in the presence of both Z-DEVD-FMK and Z-FA-FMK, and that less 
PARP was cleaved in the presence of Z-FA-FMK. These observations were 
consistent with reports that PARP can be cleaved by both active caspase-3 and 
caspase-7. Inhibition of PARP cleavage was not complete even using 40 μM Z-FA-
FMK, which suggested either incomplete inhibition of the executioner caspases, or 
PARP cleavage by another cellular protein. There was not a greater decrease in the 
amount of cleaved PARP produced in the presence of 40 μM Z-DEVD-FMK or Z-FA-
FMK, compared to 20 μM Z-DEVD-FMK or Z-FA-FMK, which indicated that increasing 
the concentration of these compounds did not result in a greater inhibition of caspase-
3 or the executioner caspases.   
Examination of HAZV N cleavage in the presence of 20 μM or 40 μM Z-DEVD-
FMK did not reveal an obvious decrease in abundance of the ~20 kDa cleavage 
product compared to cells treated with 0.2 % DMSO at 48 and 72 hrs post infection 
(Figure 5.6 (B) and (C)). This suggested HAZV N was not cleaved by active caspase-
3. Interestingly, examination of HAZV N cleavage products produced in the presence 
of either 20 μM or 40 μM Z-FA-FMK, revealed an almost complete abolishment of the 
~20 kDa band compared to cells treated with 0.2 % DMSO at 48 and 72 hrs post 
infection (arrow, Figure 5.6). This suggested that although HAZV N was possibly not 
cleaved by active caspase-3, HAZV N could instead have been cleaved by either 
another executioner caspase (caspases-6 or -7), or the downstream product of one of 
these other executioner caspases.  
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Figure 5.6. Cleavage products of HAZV N detected in the presence of 20 μM or 
40 μM Z-DEVD-FMK or Z-FA-FMK.   
HAZV N was cleaved during infection, with the cleavage product of ~20 kDa 
becoming more abundant 48 and then 72 hrs after infection. Inhibition of caspase-3 
with 20 μM or 40 μM Z-DEVD-FMK resulted in a reduction in cleaved PARP levels, 
compared to cells treated with 0.2 % DMSO, and inhibition of the executioner 
caspases with Z-FA-FMK resulted in a slightly greater decrease in cleaved PARP 
A B 
C D 
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levels compared to cells treated with 0.2 % DMSO (D). Interestingly, treatment of cells 
with Z-FA-FMK resulted in an almost complete abolishment of the ~20 kDa HAZV N 
cleavage product compared to cells treated with 0.2 % DMSO (B) and (C). Treatment 
of cells with the caspase-3 inhibitor on the other hand, did not obviously decrease the 
intensity of the ~20 kDa HAZV N cleavage product band. This indicated HAZV N 
might have been primarily cleaved by either other executioner caspases, or their 
downstream substrates during infection, rather than by active caspase-3.         
  
 
5.3.2 The effect on HAZV replication of Z-DEVD-FMK and Z-FA-FMK 
 
Treatment of cells with Z-FA-FMK prevented the production of the ~20 kDa cleavage 
product of HAZV N, observed 48 and 72 hrs after HAZV infection. This suggested that 
HAZV N may have been cleaved by one of the other executioner caspases, or one of 
their downstream targets during the 72 hrs time course of infection. Next, preliminary 
experiments were carried out to examine the effects of the presence of 20 µM Z-
DEVD-FMK and Z-FA-FMK on HAZV replication. As previously described (section 
2.2.9.1) SW13 cells were infected with HAZV at an MOI 1, and after adsorption to 
cells for 1 hr at 37 °C, SFM containing HAZV was removed and replaced with media 
containing 20 µM Z-DEVD-FMK or Z-FA-FMK. HAZV was allowed to replicate for 24, 
48, or 72 hrs in the presence of these compounds; cell culture supernatants were then 
harvested, and the amount of infectious HAZV present estimated by plaque assay, as 
described in section 2.2.9.2. The estimated infectious titre of HAZV secreted from 
cells grown in 20 µM Z-DEVD-FMK or 20 µM Z-FA-FMK, or grown in the absence of 
these compounds was plotted against the number of hours of HAZV replication, and is 
shown in Figure 5.7.        
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Figure 5.7 Titre of HAZV secreted from cells treated with Z-DEVD-FMK or Z-FA-
FMK 
SW13 cells were infected with HAZV at MOI 1, and HAZV was then allowed to 
replicate in the presence of 20 µM Z-DEVD-FMK or Z-FA-FMK, or in the absence of 
these compounds. Cell culture supernatants were harvested 24, 48, and 72 hrs after 
infection, and the titre of secreted HAZV was estimated once by plaque assay, then 
plotted against time after infection. 
 
 
The titre of infectious HAZV secreted from SW13 cells in the presence of these 
compounds does not increase 24 and 48 hrs after infection, compared to untreated 
cells. This suggested that the activation of cellular caspases and cleavage of HAZV N 
observed 48 hrs after infection was not detrimental to virus infection, as secreted 
HAZV titre did not increase when these processes were impaired. Plaque assays 
were performed once and gave the following results: 24 hrs after infection, 1.5 fold 
less infectious HAZV was secreted into the supernatant of cells treated with 20 µM Z-
DEVD-FMK and compared to untreated cells (1.6 x 104 pfu/mL compared to 2.4 x 104 
pfu/mL), and 4.6 fold less infectious HAZV was secreted into the supernatant of cells 
treated with Z-FA-FMK, compared to untreated cells (0.52 x 104 pfu/mL compared to 
2.4 x 104 pfu/mL). The titre of secreted HAZV from cells treated with Z-DEVD-FMK 
and Z-FA-FMK increased 48 hrs after infection (2.4 x 105 pfu/mL and 1.2 x 105 pfu/mL, 
respectively), but remained below the levels of HAZV secreted from untreated cells (8 
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x 105 pfu/mL). In contrast, at 72 hrs post infection, the titre of infectious HAZV 
secreted from untreated cells (5.2 x 104 pfu/mL) had decreased to slightly below the 
levels of HAZV secreted from cells grown in the presence of Z-DEVD-FMK or Z-FA-
FMK (1.6 x 105 pfu/mL and 8 x 104 pfu/mL, respectively).    
The decrease in titre of HAZV secreted from cells grown in the presence of 
these compounds at 24 and 48 hrs post infection could be a reflection of the slight 
decrease in cell viability observed when SW13 cells were treated with Z-DEVD-FMK 
or Z-FA-FMK. However overall, these data suggested that activation of cellular 
caspases and cleavage of HAZV N was not detrimental to the replication cycle of 
HAZV. 
 
5.4 CHAPTER SUMMARY AND DISCUSSION 
 
This chapter presents the activation of procaspases-9, -3, and -7, and the induction of 
apoptosis during the replication cycle of HAZV, 48 and 72 hrs after HAZV infection. 
This chapter also presents the cleavage of HAZV N during the replication cycle of 
HAZV, and the inhibition of this cleavage with the executioner caspase inhibitor Z-FA-
FMK, as well as the effect of the caspase-3 inhibitor Z-DEVD-FMK, and Z-FA-FMK on 
the replication cycle of HAZV.  
The crystal structure of HAZV N, presented in chapter 3, revealed the 
presence of a DQVD motif on the apex of the arm domain of HAZV N, in a similar 
position to a DEVD motif on the apex of the arm domain of CCHFV N, which is 
cleaved by active caspase-3 during the CCHFV replication cycle. The DQVD motif of 
HAZV N is not a characterized caspase-3 cleavage site, however this motif contains 
the minimum requirement for cleavage by caspase-3, which recognizes Asp-X-X-Asp. 
In this chapter HAZV infection was shown to result in the activation of the 
procaspases-9, -3, and -7 by western blot analysis 48 and 72 hrs after HAZV infection. 
In addition, protein levels of cleaved PARP (one of the proteolytic targets of active 
caspase-3 and -7) increased in abundance in the lysates of HAZV infected cells 48 
and 72 hrs after infection, which indicated active caspase-3 and -7 were functional, 
and effectively cleaved their target substrates. 
The induction of apoptosis in HAZV infected cells 48 and 72 hrs after infection 
was confirmed using a TUNEL assay, which detected intrachromosomal DNA strand 
breaks, and indicated that one of the final stages of apoptosis had been initiated. The 
percentage of TUNEL positive nuclei relative to DAPI positive nuclei in HAZV infected 
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cells 48 and 72 hrs after HAZV infection was 5.3 % and 23 %, compared to mock 
infected cells, which was 2.3 % and 3 % at the same time points. This indicated the 
induction of apoptosis was specific to HAZV infected cells. TUNEL positive nuclei 
were detected by microscopy analysis using a Zeiss LSM 510 confocal microscope; 
due to the method used to prepare these cells (growth of SW13 cells on glass 
coverslips, infection with HAZV or mock infection, followed by cell fixation, 
permeabilisation and TUNEL assay) a proportion of non-adherent TUNEL positive 
cells would have been removed with the media at the cell fixation stage. The results 
presented in Figure 5.3 could therefore be an underestimation of the percentage of 
TUNEL positive cells induced during HAZV infection.  
Multiple viruses induce apoptosis during their replication cycles, including 
several other members of the Bunyaviridae family; such as the orthobunyaviruses 
LACV, oropouche virus (OROV) and BUNV and the hantaviruses, Hantaan, Sin 
Nombre, Andes, and Seoul virus (Pekosz, Phillips et al. 1996; Kang, Park et al. 1999; 
Kohl, Clayton et al. 2003; Markotic, Hensley et al. 2003; Acrani, Gomes et al. 2010). 
In the case of BUNV, apoptosis was linked to activation of IRF-3 and downstream 
IRF-3 signalling; apoptosis was induced 48 hrs after infection with BUNV and was 
inhibited at earlier time points by the activity of the BUNV NSs protein. CCHFV has 
also been shown to delay expression of IFN and IFN stimulated genes, possibly 
through interfering with IRF-3 activity, until 48 hrs after infection (Andersson, Karlberg 
et al. 2008). It could be the delay in apoptosis until 48 hrs after CCHFV infection is 
linked to the delayed activation and function of IRF-3 and IFN during CCHFV 
replication. CCHFV induced apoptosis has however, also been linked to ER stress 
and the UPR (Rodrigues, Paranhos-Baccala et al. 2012).  
HAZV induced apoptosis at the same relatively late time point as CCHFV (48 
hrs after infection), therefore HAZV may also possess a mechanism to delay the 
induction of apoptosis until this time point. Interestingly, 24 hrs after HAZV infection or 
mock infection, there was a higher proportion of TUNEL positive nuclei in mock 
infected cells (5.1 %) compared to HAZV infected cells (2.7 %); it is possible HAZV is 
able to counteract some of the possibly-stress induced cell death observed at this 
time point. This study did not examine whether apoptosis induced by HAZV was a 
direct result of HAZV infection and replication, or a consequence of indirect processes 
induced by HAZV infection, such as activation of the IFN response. Interestingly the 
induction of apoptosis by LACV was linked to inhibiting the anti-apoptotic activity of 
HSC70, and the M1 protein of IAV exerts a proapoptotic effect by binding to HSP70 
and disrupting the interaction between HSP70 and Apaf-1 (Colon-Ramos, Irusta et al. 
2003; Halder, Bagchi et al. 2011). The contribution towards the induction of apoptosis, 
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if any, of HAZV N interacting with HSP70/HSC70 is unknown; however it is possible 
that HAZV N binding to HSP70 may enhance the apoptotic consequences of HAZV 
infection. 
Western blot analysis revealed that during a 72 hrs time course of HAZV 
infection, HAZV N was cleaved in infected cells; cleavage products of HAZV N were 
detected with anti-HAZV N 24, 48 and 72 hrs after infection. An HAZV N cleavage 
product of ~20 kDa increased in intensity over the time course of infection, which 
suggested this ~20 kDa cleavage product increased in abundance at 48 and 72 hrs 
post infection. As this increase in abundance corresponded with the induction of 
apoptosis, it could be that one of the cellular proteins that was activated or 
upregulated during apoptosis was responsible for cleavage of HAZV N to generate the 
~20 kDa cleavage product, in an analogous fashion to the cleavage of CCHFV N by 
active caspase-3. Although the site at which HAZV N was cleaved to generate the 
~20 kDa cleavage product was not identified in this study, cleavage of HAZV N at the 
DQVD motif is predicted to result in HAZV N fragments of ~30 kDa and 23 kDa; it is 
possible the observed HAZV N ~20 kDa fragment could be derived from HAZV N 
cleavage at the DQVD motif, and migrates with an apparent lower molecular weight 
by SDS PAGE.   
SW13 cells were infected with HAZV in the presence of the caspase-3 inhibitor 
Z-DEVD-FMK, and executioner caspase inhibitor Z-FA-FMK, to examine the possible 
role of cellular caspases in the cleavage of HAZV N. Z-DEVD-FMK and Z-FA-FMK are 
both fluoromethyl ketone derivatives of peptides that resemble the cleavage site of 
known caspase substrates, and irreversibly inhibit caspases by alkylating the cysteine 
residue in the caspase active site (Schotte, Declercq et al. 1999; Lopez-Hernandez, 
Ortiz et al. 2003). Analysis of levels of cleaved PARP 72 hrs after HAZV infection in 
the presence of these compounds revealed a decrease in the levels of cleaved PARP 
in cells that that been treated with both Z-DEVD-FMK and Z-FA-FMK compared to 
untreated cells, which suggested these compounds were impairing the function of 
caspase-3 and the executioner caspases. A greater decrease could be observed in 
the expression levels of cleaved PARP in HAZV infected cells treated with Z-FA-FMK 
than in cells treated with Z-DEVD-FMK, consistent with the cleavage of PARP by both 
caspase-3 and -7.  
Replication of HAZV in the presence of Z-FA-FMK, prevented the production 
of the ~20 kDa cleavage product of HAZV N, whereas replication of HAZV in the 
presence of Z-DEVD-FMK did not. This suggested the ~20 kDa cleavage product of 
HAZV N was the result of cleavage of HAZV N by executioner caspases-6 or -7, 
rather than caspase-3, or one of their downstream proteolytic substrates. However, Z-
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FA-FMK can also inhibit cathepsin B (a lysosomal enzyme involved in protein turnover 
and metabolism), and papain, amongst other papain-like cysteine proteases (Schotte, 
Declercq et al. 1999). HAZV N could be cleaved by one of these other enzymes 
during apoptosis; cathepsin B for example has a role in the mitochondrial intrinsic 
apoptotic pathway and can cleave and activate the pro-apoptotic protein BID (Sandes, 
Lodillinsky et al. 2007). The production of the ~20 kDa cleavage product of HAZV N in 
the presence of Z-DEVD-FMK suggested that caspase-3 was not responsible for 
cleavage of HAZV N. This indicated that cleavage of HAZV N potentially did not occur 
at the DQVD site; it was not concluded in this study at which site HAZV N was 
cleaved during apoptosis, more work needs to be carried out to resolve this point, and 
possibly identify where HAZV N is cleaved.  
The position of the DQVD site on the apex of the arm domain is adjacent to, 
and also contains residues thought to be involved in, the multimerisation of HAZV N, 
as described in section 3.4.1. The suggested mechanism of multimerisation involved 
residues both on the apex and other areas of the arm domain forming a hydrophobic 
pocket, in which Pro351 on the base of the globular domain of an adjacent monomer 
is buried. The potential involvement of DQVD residues in HAZV N multimerisation 
implies that only monomeric HAZV N could be cleaved at the DQVD motif. The role of 
monomeric HAZV N during HAZV replication is currently unclear; however monomeric 
HAZV N could be involved in the recruitment of cellular proteins (such as 
HSP70/HSC70 (described in chapter 4), or other manipulations of the host cell 
environment. However, if only monomeric HAZV N or CCHFV N can be cleaved at 
this site on the apex of the arm domain, it could be an explanation for why such a 
small proportion of CCHFV N is cleaved by active caspase-3 during CCHFV 
replication.    
Viral proteins from multiple families of viruses are cleaved by cellular caspases 
during their replication cycles; the consequences of viral protein cleavage by cellular 
caspases have been shown to be both beneficial and detrimental to virus replication 
cycles, and to both inhibit and enhance apoptosis (Richard and Tulasne 2012). The 
baculovirus P35 and P49 proteins for example, are both cleaved by human cellular 
caspases. After cleavage of P35 the cleavage product remains irreversibly associated 
with the caspase active site and in this way P35 directly inhibits caspases-1, -3, -6, -7, 
-8 and -10. Inhibition of these caspases inhibits apoptosis induction and this inhibition 
of apoptosis is crucial for virus replication (Zhou, Krebs et al. 1998). On the other 
hand the NS1 protein of the parvovirus Aleutian mink disease virus possess two 
caspase cleavage sites; upon permissive infection cellular caspases are activated and 
cleave NS1 to release 5 protein products that are essential for virus amplification 
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(Best, Shelton et al. 2003). Without the induction of apoptosis and activation of cellular 
caspases this virus cannot replicate.  
In many cases the consequences for viral replication of the induction of 
apoptosis remains unclear. OROV induces apoptosis, which is detectable 30 hrs post 
infection and is dependent on expression of viral proteins and viral genome replication. 
However the induction of apoptosis did not appear to affect the virus replication cycle, 
as inhibition of apoptosis with a pan-caspase inhibitor prevented apoptosis but did not 
affect progeny virus production (Acrani, Gomes et al. 2010).  
To begin to examine the possible involvement of cellular caspases in the 
HAZV virus replication cycle, the titre of secreted HAZV that had been replicating in 
the presence of Z-DEVD-FMK, or Z-FA-FMK was assayed and compared to untreated 
cells. In both cases at 24 and 48 hrs post infection, the titre of secreted HAZV was 
lower from Z-DEVD-FMK and Z-FA-FMK treated cells compared to untreated cells. 
This implied that the activation of cellular caspases was not detrimental for HAZV 
replication, as no increase in titre was observed at these times points. The slight 
decrease in titre could be related to the slight decrease in cell viability (as measured 
by MTT assay) of cells grown in the presence of these compounds. Intriguingly the 
vOTU domain possessed by the L protein of CCHFV (and by sequence homology, 
HAZV) is a papain-like cysteine protease; members of this family of proteins are 
inhibited by Z-FA-FMK (Schotte, Declercq et al. 1999). It is conceivable that the vOTU 
of HAZV could be partially inhibited by Z-FA-FMK, and therefore this could possibly 
affect the replication of these viruses in the presence of this compound.  
At 72 hrs post infection the titre of secreted HAZV was lower from untreated 
cells then from Z-DEVD-FMK or Z-FA-FMK treated cells, possibly due to the 
availability of more live cells at this time point in the presence of Z-DEVD-FMK and Z-
FA-FMK, to allow continued HAZV replication. It would be interesting to expand this 
experiment to include later time points to examine whether HAZV replication 
continued to increase in the presence of Z-DEVD-FMK and Z-FA-FMK. If that was the 
case, it could be that apoptosis does represent a host cell antiviral mechanism to 
control HAZV infection, and, in an analogous manner to CCHFV, HAZV has 
developed a way of delaying the activation of apoptosis until sufficient virus replication 
has occurred to allow efficient progeny spread. However, the plaque assays were only 
carried out once, and should therefore be repeated. In addition, this study did not 
address the extent to which apoptosis was inhibited by Z-DEVD-FMK and Z-FA-FMK, 
therefore it was not possible to draw conclusions regarding the role of apoptosis in the 
replication cycle of HAZV.    
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Cell death by apoptosis can be advantageous for viruses; during apoptosis the entire 
cellular contents, including progeny virions, are packaged into membrane bound 
apoptotic bodies that are rapidly taken up by surrounding cells, a process which 
severely limits the inflammatory response, and allows the virus to spread undetected 
(Hay and Kannourakis 2002). Virus particles within enclosed vesicles are protected 
from inactivation by host antibodies and proteases; thus virus dissemination can be 
enhanced. IAV infection of cells induces apoptosis for example; inhibition of apoptosis 
results in decreased IAV replication, and conversely, increased apoptosis results in an 
increase in IAV replication. It has been suggested that the cell and virus struggle to 
control apoptosis, as appropriately timed apoptosis could be crucial for efficient IAV 
replication (McLean, Datan et al. 2009). It could be an analogous struggle occurs 
during CCHFV and HAZV replication; it has already been suggested that the outcome 
of CCHFV infection is dependent on the timing of the activation of the IFN response, 
and the same could be true of the activation of apoptosis. RNA viruses have high 
mutation rates, therefore maintaining the N protein caspase cleavage site seems 
unlikely if CCHFV and HAZV do not somehow profit from them.  
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CHAPTER 6: DISCUSSION 
 
6.1 THE X-RAY CRYSTAL STRUCTURE OF HAZV N REVEALS AN RNA BINDING 
SITE AND PROVIDES NEW INSIGHTS INTO THE FUNCTION OF HAZV N AND 
CCHFV N 
 
The high resolution crystal structures presented here of Apo-HAZV N and RNA 
bound-HAZV N reveal new and important insights into HAZV N protein structure and 
function. HAZV N is primarily alpha-helical and consists of two domains; a globular 
domain that contains amino acid residues from both the N- and C-termini of HAZV N, 
and an arm domain that extends away from the globular domain. The arm domain is 
linked to the globular domain by a disordered loop (which is not visible in either crystal 
structure), and a single alpha helix, helix α13. This is the first time a nairovirus N 
protein has been co-crystallised with RNA. A crevice in the globular domain that 
channels from the base of the globular domain almost to helix α13 was shown to be 
an RNA binding site (rather than the positively charged patch on the surface of HAZV 
N adjacent to the arm domain) and had three nucleotides of ssRNA bound in the RNA 
bound-HAZV N structure. 
The structure of HAZV N is very similar to the structure of CCHFV N; the 
globular domains align very closely and although the position of the arm domain 
relative to the globular domain is greatly altered, the fold in the arm domain is the 
same. The change in the position of the arm domain may be linked to changes in 
primary amino acid sequence between the two proteins. CCHFV N and HAZV N have 
very similar functions within their viral replication cycles; the great structural similarity 
between CCHFV N and HAZV N suggests these proteins use a similar mechanism to 
perform these functions, and supports the use of HAZV as a model for CCHFV 
infection. Due to the highly pathogenic nature of CCHFV and the high mortality rate of 
CCHF, manipulation of infectious CCHFV must be carried out under containment level 
4 conditions. HAZV belongs in the same serogroup as CCHFV, but is not pathogenic 
to humans, and can therefore be manipulated under containment level 2 conditions. 
However HAZV infection does result in a very similar disease course in the IFNα/βR-/- 
mouse model as CCHFV. It has been proposed that HAZV can be used as a model to 
examine the replication cycle of these viruses and test novel antivirals, therefore 
bypassing the necessity of working under containment level 4 conditions; the data 
presented in chapter 3 supports this use of HAZV as a model for CCHFV infection. 
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Currently few treatment options exist for CCHF, and most are palliative; therefore 
there is an urgent need for novel therapeutics against CCHFV. Given the structural 
similarity in the globular domains of HAZV N and CCHFV N, novel small molecule 
inhibitors that target the RNA binding crevice of HAZV N could also target the RNA 
binding crevice in CCHFV N.      
The functions of nairovirus N proteins within their viral replication cycles are 
dependent on their ability to bind viral RNA. Therefore, the identification of an RNA 
binding site enables the potential exploitation of this knowledge for the structure 
guided design of small molecules to prevent N protein function, through abolishment 
of N’s ability to bind RNA. Alternatively the N-N interaction site could also be targeted. 
Targeting nucleocapsid proteins for the development of novel antivirals is becoming 
more common; the N protein of HIV (Ramalingam, Duclair et al. 2011), IAV (Kao, 
Yang et al. 2010) and RSV (Chapman, Abbott et al. 2007) have all been shown to be 
effective antiviral targets. More recently, a high-throughput molecular target assay 
was used to identify compounds that could disrupt the interaction between RVFV N 
and RNA in vitro (Ellenbecker, Lanchy et al. 2012). The compound that was found to 
be the most effective at inhibiting RNA binding of RVFV N in the high throughput 
screening assay was suramin, an FDA approved drug used to treat trypanosomiasis. 
Interestingly, suramin was also shown to bind the RNA binding site in the N protein of 
the closely related phlebovirus, severe fever with thrombocytopenia syndrome virus 
(SFTSV), and to inhibit replication of SFTSV in Vero cells (Jiao, Ouyang et al. 2013). 
These studies support the hypothesis that antiviral compounds that target the RNA 
binding site of HAZV N may also be effective at targeting the RNA binding site in 
CCHFV N, and might possibly inhibit CCHFV (and HAZV) replication.  
When the N-terminal RNA binding domain of LASV N is superposed on the 
globular domain of HAZV N, not only do the protein folds align very closely but the 
three nucleotides of RNA bound in the crevice in the globular domain of HAZV N 
overlap almost completely with the RNA in the RNA binding site of LASV N. This not 
only supports the position of RNA in the crevice in the globular domain of HAZV N as 
being correct, but suggests that LASV N, HAZV N, and CCHFV N may be more 
closely related to each other than to other members of the Bunyaviridae family, and 
implies that N proteins from multiple different sNSV families share common features, 
and possibly a common ancestor. The structural similarity between LASV N and 
HAZV N, and the striking change in the position of the arm domain observed between 
Apo-HAZV N and RNA bound-HAZV N suggests that the change in the position of the 
arm domain may possibly regulate the mechanism of RNA binding of HAZV N, 
analogous to the ‘gating’ mechanism described for LASV N (the position of helix α5 in 
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LASV N corresponds to helix α13 in HAZV N, which links the arm domain to the 
globular domain).  
The crystal structures of the nucleocapsid proteins of various sNSVs have 
been solved, and they are thought to share common features and use common 
mechanisms to perform their functions. One of the primary functions of sNSV N 
proteins is to bind vRNA or cRNA to form functional RNPs; these RNPs act as the 
template for further RNA synthesis rather than naked RNA. The interaction of N with 
vRNA and cRNA is specific, N does not bind viral mRNA, or host cell RNA. RNPs also 
interact with viral glycoproteins during assembly and this interaction is thought to drive 
the budding of progeny virions into the Golgi cisternae. In order to carry out these 
functions, it has been proposed that sNSV N proteins possess common features such 
as; a mechanism to keep N monomeric, in order to prevent inappropriate 
multimerisation and RNA binding, a parallel orientation of subunits in the nucleocapsid 
which results in nucleocapsids with linear symmetry, and a cavity for the sequestration 
of RNA, that protects the RNA from degradation by RNA nucleases to a certain 
degree (Green, Cox et al. 2014; Reguera, Cusack et al. 2014).  
The crystal structures of Apo-HAZV N and RNA bound-HAZV N presented 
here reveal potential mechanisms by which all of these criteria are met. The change in 
the position of the arm domain that could potentially represent a ‘gating’ mechanism of 
RNA binding analogous to LASV N, also reveals a mechanism for keeping monomeric 
HAZV N from binding RNA, as has been proposed for LASV N (Hastie, Liu et al. 
2011). In lieu of a co-chaperone P protein, helix α6 and part of helix α5 occlude the 
RNA binding crevice of LASV N in the absence of RNA; this is proposed to help keep 
LASV N monomeric, and prevent LASV N from binding RNA inappropriately (Hastie, 
Liu et al. 2011). A similar mechanism has been proposed for RVFV N, where an N 
terminal loop involved in N multimerisation folds back on itself, and an alpha helix 
occludes the RNA binding site in the absence of RNA (Raymond, Piper et al. 2010; 
Raymond, Piper et al. 2012). It is not known what the subsequent trigger is for RNA 
binding, however it is hypothesised the L protein might induce conformational 
changes in N to enable RNA to bind. Given the limited coding capacity of 
bunyaviruses, the ability of N and L to regulate RNA binding of N is more economical 
than encoding an additional protein (such as the P protein of nsNSVs) to perform this 
function.    
The crystal structure of Apo-HAZV N reveals a potential mechanism of HAZV 
N multimerisation involving the hydrophobic interaction between residues from the 
base of the globular domain of one monomer and the arm domain of the adjacent 
monomer, which results in the presence of linear chains of HAZV N throughout both 
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Apo-HAZV N and RNA bound-HAZV N crystals. This could reflect multimerisation 
events that occur when viral RNPs form, in which case viral RNPs would potentially 
possess a linear nucleocapsid symmetry, with a parallel orientation of N subunits. The 
involvement of residues on the apex of the arm domain of HAZV N and CCHFV N in N 
multimerisation (including some residues of the DQVD or DEVD motif) could possibly 
provide an explanation for the conservation of the DEVD motif in CCHFV N, despite 
its cleavage by capase-3. Finally, RNA bound-HAZV N reveals an RNA binding site 
deep within a crevice in the globular domain where the RNA is partially protected from 
degradation by RNA nucleases.         
 
6.2 CCHFV N AND HAZV N INTERACT WITH HSP70/HSC70 
 
The interaction between CCHFV N and HAZV N and HSP70/HSC70 presented here 
potentially reveals new insights into the replication cycles of these viruses. The 
successful recruitment of host cell factors is essential for virus proliferation; viruses 
are dependent on cellular proteins for every aspect of their replication cycles from cell 
entry, to genome replication, protein synthesis, virion assembly and secretion of 
progeny virions. It is often the role of viral proteins to recruit specific cellular factors to 
aid virus replication; indeed the function of a viral protein within the cellular 
environment can be defined by the multiple protein-protein interactions it makes. 
Therefore various studies have focused on examining viral protein ‘interactomes’, 
often through the use of mass spectrometry based proteomics. In order to identify 
cellular proteins that interacted with CCHFV N, we used a GFP-Trap to IP an EGFP-
CCHFV N fusion protein from transfected cells, and SILAC based MS to identify 
cellular proteins that immunoprecipitated with EGFP-CCHFV N. SILAC enabled the 
differentiation between cellular proteins that interacted non-specifically with EGFP or 
components of the GFP-Trap, and those that interacted specifically with EGFP-
CCHFV N. Although multiple cellular proteins were identified that potentially interacted 
with EGFP-CCHFV N, this study could not provide a complete ‘interactome’ of 
CCHFV N as the use of the EGFP tag potentially obscured cellular binding partners, 
as does the use of any antibody to IP protein complexes. Isolation of protein 
complexes by size exclusion chromatography based methods, and identification of 
their protein compositions by MS has been suggested as a method for elucidating 
comprehensive ‘interactomes’.  
MS analysis revealed that HSP70 and HSC70 both immunoprecipitated with 
EGFP-CCHFV N, and were chosen for further examination. HSP70/HSC70 also 
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immunoprecipitated with untagged CCHFV N both in the context of actively replicating 
CCHFV, and from pCAGGs-CCHFV N expressing cells. Furthermore, HSP70/HSC70 
immunoprecipitated with HAZV N from HAZV infected cells. Members of the HSP70 
family of proteins are molecular chaperones, located in the cytoplasm and most 
cellular organelles that play a central role in multiple cellular processes including 
protein translation, folding, degradation, intracellular trafficking, and the assembly and 
disassembly of oligomeric structures, amongst other roles (Mayer 2005). Members of 
the HSP70 family are frequently recruited by viruses and the precise role within virus 
replication cycles of HSP70 family members varies. Some viruses are thought to 
recruit HSP70 family members to assist with viral protein folding, as this can become 
a rate limiting step during replication, some are thought to be recruited to assist 
transcription by viral polymerases, and others are recruited to assist virus assembly. 
Several studies have reported an association between HSP70 and viral polymerase 
complexes of HCV, RSV (HSP70 is thought to be recruited to lipid raft domains, 
where viral replication complexes assemble), RV and IAV (Brown, Rixon et al. 2005; 
Lahaye, Vidy et al. 2012; Khachatoorian, Ganapathy et al. 2014; Manzoor, Kuroda et 
al. 2014). HSP70 has been shown to stimulate the viral polymerase in vitro activity of 
several paramyxoviruses, including canine distemper virus and RSV, however it is not 
clear whether HSP70 assists the folding of N in an active form, or whether HSP70 
directly acts as a cofactor of the enzymatic process (Oglesbee, Liu et al. 1996; Brown, 
Rixon et al. 2005). HSP70 protein levels may or may not be upregulated in cells 
infected with viruses that recruit HSP70 as part of their replication strategy.   
HSP70 and/or HSC70 interacts with NS5A of HCV, NS1 and M1 of IAV, N and 
P protein of RSV, and the N protein of RV, in addition to many other viral proteins 
(Halder, Bagchi et al. 2011; Lahaye, Vidy et al. 2012; Oliveira, Simabuco et al. 2013; 
Khachatoorian, Ganapathy et al. 2014; Manzoor, Kuroda et al. 2014). Similar to 
CCHFV N, NS5A of HCV interacts with both HSP70 and HSC70, and interestingly, 
HSP70 and HSC70 were shown to have different roles within the HCV replication 
cycle. HSP70 was involved in genome transcription and viral protein translation, 
whereas HSC70 was involved in virion assembly; HSC70 is also found within or 
associated with, purified HCV particles (Parent, Qu et al. 2009; Khachatoorian, 
Ganapathy et al. 2014). Generally the interaction of viral proteins with HSP70 and/or 
HSC70 and the recruitment of these chaperones, is beneficial to virus replication 
cycles; siRNA mediated knock down of HSP70 and/or HSC70 inhibits the replication 
of HCV, RV, HSV, PRRSV, and IAV (Stegen, Yakova et al. 2013; Gao, Xiao et al. 
2014). In good agreement with siRNA studies, inhibition of HSP70 expression with the 
bioflavonoid quercetin inhibits the replication of RV, HCV, and PRRSV (Gonzalez, 
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Fontanes et al. 2009). In some cases however, the interaction of HSP70 with viral 
proteins has been found to inhibit virus replication; infection of cells with Hantaan virus 
induces the expression of HSP70 4 hrs after infection. HSP70 interacts with Hantaan 
virus N protein, and overexpression of HSP70 reduces Hantaan virus replication and 
N protein expression (Yu, Ye et al. 2009). HSP70 has also been implicated in 
mediating the antiviral effects of prostaglandins (Santoro 1994). 
Depletion of HSP70 from HAZV infected cells modestly reduced HAZV N 
expression levels compared to scrambled siRNA transfected cells. Modestly reduced 
titres of HAZV were also secreted from HSP70 depleted cells, compared to scrambled 
siRNA transfected cells. Complete and sustained depletion of HSP70 over long time 
periods could not be achieved however; it could be that a greater effect on HAZV 
replication could be observed with longer term HSP70 depletion, or depletion of 
HSC70 could have a greater effect on HAZV replication. Preliminary experiments 
using the HSP70 inhibitors VER and PIF also resulted in decreased HAZV replication 
in SW13 cells compared to DMSO controls, which suggested a positive role for 
HSP70/HSC70 within the HAZV replication cycle. However the precise role of HSP70 
and/or HSC70 within the replication cycles of HAZV and CCHFV remains to be 
determined.  
The secreted virions of enveloped viruses contain multiple host cell proteins in 
addition to viral proteins; virions contain all the molecular machinery needed to enter 
and exit host cells, and, given the simplicity of viral proteomes, and the complexity of 
these processes, it is thought virions contain cellular proteins to help perform these 
tasks (Cantin, Methot et al. 2005; Nuss, Kehn-Hall et al. 2014). Cellular proteins 
associated with virions can therefore act as essential or important host cell factors for 
viral infection, and represent novel targets for antiviral therapeutic development. 
HSP70 and/or HSC70 have been found associated with the extracellular virus 
particles of RSV, RV, HCV, HSV, RVFV and HIV-1, amongst others (Chertova, 
Chertov et al. 2006; Radhakrishnan, Yeo et al. 2010; Stegen, Yakova et al. 2013; 
Nuss, Kehn-Hall et al. 2014).  
In this study, MS analysis of the fraction containing infectious HAZV identified 
HSC70 in this fraction, as well as all 4 viral structural proteins. The presence of HAZV 
N and HSC70 in the fraction containing infectious HAZV was verified by western blot 
analysis, and furthermore, HSC70/HSP70 immunoprecipitated with HAZV N from the 
fraction containing infectious HAZV. This indicated HSC70 might associate with HAZV 
N during multiple stages of the virus replication cycle, and may be packaged into, or 
associated with, secreted HAZV particles. In addition to HSC70, MS analysis 
identified 260 cellular proteins in the fraction containing infectious HAZV. Interestingly, 
Chapter 6: Discussion 
217 
 
a recent study carried out by (Nuss, Kehn-Hall et al. 2014) identified ~270 cellular 
proteins associated with secreted RVFV particles, in the first published proteomic 
analysis of purified bunyavirus particles. RVFV particle preparations were enriched in 
host cell chaperones, and many of the proteins identified in this study were common 
to both HAZV and RVFV particle preparations, including the cellular chaperones 
HSC70, HSPA5, HSP90, CCT6a (T-complex protein 1 subunit zeta) and CCT2 (T-
complex protein 1 subunit beta), and the cytoskeletal proteins actin and tubulin, 
amongst others. Interestingly CCT6a and CCT2 were also both identified in the GFP-
Trap MS analysis as being potential interacting partners of EGFP-CCHFV N (SILAC 
ratios of 4.2, and 5.54, 6.13 respectively). siRNA depletion of HSPA5, HSP90, CCT6a 
and CCT2 resulted in decreased RVFV replication compared to scrambled siRNA, 
whereas depletion of HSC70 resulted in increased RVFV replication compared to 
scrambled siRNA.  
The heat shock protein 90 (HSP90) inhibitor 17-AAG, and the HSP70 
inhibitors KNK437 (blocks induction of chaperones from HSP70, 72 and 105 families) 
and BAPTA-AM (a calcium chelator that decreases expression of BiP mRNA) greatly 
inhibited RVFV replication without any cytotoxic effect (Nuss, Kehn-Hall et al. 2014). 
This suggests HSP90, and some members of the HSP70 family play a positive role in 
RVFV replication, and could possibly represent promising therapeutic targets. It could 
be that HSPA5, HSP90, CCT6a, and CCT2 also play a role in HAZV (and CCHFV) 
replication, and these cellular chaperones may be recruited as part of a common 
replication strategy by these viruses. It must be noted however, that in both these 
studies the ratio of infectious virus particles:defective, non-infectious virus particles 
analysed by MS is unknown.   
The identification of specific cellular proteins and pathways required by 
individual viruses, provides novel targets for host-directed antiviral development. 
Additionally, the identification of common cellular proteins recruited by multiple 
different viruses could potentially lead to the identification of host-directed antiviral 
therapeutics with broad-spectrum antiviral activity. For example HSP90, an ubiquitous 
cytoplasmic molecular chaperone, is involved in the replication cycle of multiple 
different RNA viruses; HSP90 is thought to stabilise viral RNA-dependent RNA 
polymerases. Several small molecule HSP90 inhibitors including geldanamycin, and 
its derivative 17-AAG, inhibit the replication cycle of vaccinia virus, IAV, HSV, VSV, 
several paramyxoviruses, LACV, RVFV and HCV (Nuss, Kehn-Hall et al. 2014). 17-
AAG is currently in Phase 2 clinical trials as an anti-cancer therapeutic and it is hoped 
17-AAG, as well as other HSP90 inhibitors could also be developed as broad-
spectrum antivirals. Given the abundant recruitment of members of the HSP70 family 
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by multiple different viruses, and the development of HSP70 inhibitors as anti-cancer 
therapeutics, it is hoped HSP70 inhibitors could also potentially be developed as 
antiviral agents. Interestingly a synergistic effect against cancerous cells can be 
observed when compounds targeting HSP90 and HSP70 are administered 
concurrently, a similar effect could also be observed when targeting virus replication. 
However the benefits of designing host-directed antivirals, such as the slower 
mutation rates of mammalian proteins reducing the rate at which virus escape 
mutants develop, is tempered by the potentially cytotoxic effects of targeting host 
proteins. 
 
6.3 HAZV INDUCES APOPTOSIS IN SW13 CELLS 
 
In this study HAZV infection of SW13 cells was shown to result in the induction of 
apoptosis 48 and 72 hrs after infection, which occurred concomitantly with the 
cleavage and activation of caspase-9, -3, -7, and cleavage of PARP. Viral control of 
apoptosis is often a critical factor determining the outcome of virus infection. Viral 
replication is dependent on the exploitation of existing cellular pathways and proteins; 
upon detection of viruses mammalian cells have developed strategies to limit viral 
spread, often through the elimination of these crucial proteins and pathways by 
controlled cell death, or apoptosis. Apoptosis is induced during the replication cycle of 
CCHFV, in addition to several other bunyaviruses. The induction of apoptosis for 
many of these viruses, including OROV and CCHFV is dependent on live virus 
replication and the synthesis of viral RNA or proteins, as UV inactivated virus fails to 
induce apoptosis (Acrani, Gomes et al. 2010; Rodrigues, Paranhos-Baccala et al. 
2012). It is not known whether live virus replication is necessary for the induction of 
apoptosis observed during HAZV infection. This is in contrast to other viruses such as 
HIV-1, where the interaction of the virus glycoprotein gp120 with cell surface receptors 
is sufficient to induce apoptosis. It is thought the ability of gp120 to induce apoptosis 
in this manner could account for some of the bystander effects and pathogenesis 
observed during HIV-1 replication, such as depletion of CD4 positive cells (Anand and 
Ganju 2006).  
It has been suggested that the ability of CCHFV to replicate to high titres and 
induce apoptosis in HUH-7 cells, may be related to CCHF disease pathogenesis, 
where the liver is one of the main target organs during infection, high viral loads in the 
blood are an effective predictor of disease outcome, and death of macrophages and 
other cells in a manner that is consistent with apoptosis can be observed in the liver 
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and spleen. Apoptosis induction in CCHFV infected cells is thought to be linked to ER 
stress; this results in increased expression of the pro-apoptotic proteins PUMA, Noxa, 
and BAX, and induction of apoptosis is thought to occur through the mitochondrial 
pathway (Rodrigues, Paranhos-Baccala et al. 2012). Apoptosis is induced 48 and 72 
hrs after infection, and results in the activation of caspase-3, which subsequently 
cleaves CCHFV N at a conserved DEVD motif on the apex of the arm domain 
(Karlberg, Tan et al. 2011).  
HAZV infection of the IFNRα/β-/- mouse model results in a similar disease 
progression to CCHFV, including high viral loads in the blood, elevated serum levels 
of pro-inflammatory cytokines, and the liver was also one of the main targets for HAZV 
replication (Dowall, Findlay-Wilson et al. 2012). Although apoptosis has not been 
definitively demonstrated in the liver and spleen of HAZV infected IFNRα/β-/- mice, 
lymphocyte depletion in the spleen is observed that could very well be due to 
apoptosis. The ability of HAZV to induce apoptosis in cultured mammalian cells 
suggests that apoptosis might also possibly occur during HAZV infection of IFNRα/β-/- 
mice, and this might be a contributing factor towards disease pathogenesis. This 
study did not address the mechanism through which apoptosis occurred in HAZV 
infected cells; it could be that apoptosis induction was linked to ER stress and up 
regulation of pro-apoptotic proteins, such as BAX. The activation of caspase-9 
suggested that apoptosis occurred via the mitochondrial pathway, however there is 
crosstalk between the extrinsic and intrinsic apoptotic pathways (for example 
caspase-8 cleaves Bid, converting it to tBid, which translocates to the mitochondria 
and aids the release of cytochrome C from the intermembrane space, resulting in the 
formation of an ‘apoptosome’ and activation of caspase-9) therefore either one or both 
could be activated during HAZV infection. There is evidence that CCHFV is possibly 
able to modulate both the intrinsic and extrinsic apoptotic pathways (Rodrigues, 
Paranhos-Baccala et al. 2012).  
HAZV and CCHFV both induce apoptosis at relatively late time points after 
infection; during CCHFV replication apoptosis was detected 48 hrs after infection. 
CCHFV delays activation of the IFN response possibly through delaying translocation 
of IRF-3 to the nucleus; it is possible that both CCHFV and HAZV also possess 
mechanisms to delay the activation of apoptosis until sufficient progeny virions have 
been released to ensure productive infection. Interestingly the Hantaan virus N protein 
has been shown to modulate apoptosis; tumor necrosis factor (TNF) stimulated cells 
expressing Hantaan virus N sequester nuclear factor kappa B (NFκB) in the 
cytoplasm, and have reduced caspase-7 activity; similar mechanisms could occur 
during CCHFV and HAZV replication (Ontiveros, Li et al. 2010). 
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This study showed that HAZV N was cleaved during a 72 hr course of infection, and 
the abundance of the ~20 kDa cleavage product increased at 48 and 72 hrs after 
infection, concomitant with the induction of apoptosis. In contrast to cleavage of 
CCHFV N, which could be blocked by treatment of cells with the caspase-3 inhibitor 
Z-DEVD-FMK (Karlberg, Tan et al. 2011), cleavage of HAZV N was not blocked in the 
presence of this compound, but was instead inhibited when cells were treated with the 
inhibitor of executioner caspases, Z-FA-FMK. This suggested that HAZV N was 
cleaved either by one of the other executioner caspases, one of their downstream 
targets, or another enzyme (such as cathepsin B), which is also inhibited by Z-FA-
FMK (Schotte, Declercq et al. 1999). The specific site at which HAZV N was cleaved 
was not identified, however it is possible cleavage occurred at the DQVD site, as the 
~20 kDa HAZV N cleavage product is similar in size to that which could be produced 
by cleavage at the DQVD site. The cleavage of viral proteins during apoptosis has 
been widely reported in the literature; and the outcome for virus infection of this 
cleavage varies substantially (Richard and Tulasne 2012).  
Preliminary experiments were carried out to assay the effect on HAZV 
replication of treatment of SW13 cells with Z-DEVD-FMK and Z-FA-FMK. However it 
is not known whether apoptosis was fully inhibited in this study, therefore it is hard to 
draw conclusions regarding the effect of apoptosis on HAZV replication. In contrast to 
CCHFV however, HAZV titres did not increase in the presence of Z-DEVD-FMK; this 
could either be due to the slight decrease in the viability of cells grown in the presence 
of Z-DEVD-FMK, or activation of caspase-3 was not detrimental to HAZV replication. 
It could be that, analogous to OROV infection, where inhibition of apoptosis does not 
affect the titre of secreted virions, inhibition of apoptosis might not affect HAZV 
replication (Acrani, Gomes et al. 2010; Karlberg, Tan et al. 2011).  
Apoptosis is often considered to be an antiviral response to infection, which 
viruses have to avoid or inhibit in order to replicate successfully. However, viruses can 
also take advantage of apoptosis; ultimately apoptosis results in the disintegration of 
the cell into small membrane bound entities, or apoptotic bodies, which pinch off from 
the dying cell, and are then phagocytised by neighbouring cells without inducing an 
inflammatory response. The phagocytosis of virus containing apoptotic bodies could 
enable the dissemination of progeny virions without their release into the extracellular 
fluid; an action that would result in the induction of a host response (Hay and 
Kannourakis 2002). During Sindbis virus replication the induction of apoptosis is timed 
to coincide with completion of the replication cycle; and although the induction of 
apoptosis during DNA replication of an adenovirus vector was detrimental to virus 
infection, apoptosis induced after virion assembly aided virus dissemination, and 
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virions could be visualised within, or associated with, apoptotic bodies by EM (Lewis, 
Wesselingh et al. 1996; Everett and McFadden 1999; Mi, Li et al. 2001; Hay and 
Kannourakis 2002). CCHFV and HAZV infection of SW13 cells both result in 
productive replication, therefore these viruses must have evolved a way of 
circumventing the detrimental effects of apoptosis; such as delaying activation of 
apoptosis or replicating undetected in cells for long enough to sustain a productive 
infection. It is thought that the fast mutation rate of RNA viruses ensures that viruses 
with replication strategies and protein motifs that are not beneficial to replication are 
quickly out competed. The conservation of the DEVD motif among CCHFV strains, 
and the late induction of apoptosis during both CCHFV and HAZV replication could 
somehow be beneficial to the virus. However, it should be borne in mind that humans 
are not the natural host for CCHFV or HAZV, and the outcome of infection for their tick 
vectors and animals hosts is very different to human infection, in the case of CCHFV.  
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APPENDIX I CCHFV N AND HAZV N NUCLEOTIDE SEQUENCES 
 
Start codon, stop codon  
 
CCHFV N strain 10200 nucleotide sequence 
ATGGAAAACAAGATCGAGGTGAATAACAAAGATGAGATGAACAGGTGGTTTGAA
GAGTTCAAAAAAGGAAATGGACTTGTGGACACCTTCACAAACTCCTATTCCTTTT
GCGAGAGTGTTCCCAATTTGGACAGGTTTGTGTTTCAGATGGCCAGTGCCACCG
ATGATGCACAGAAGGACTCCATCTACGCATCTGCTCTGGTGGAGGCAACAAAGT
TTTGTGCACCTATATATGAGTGCGCATGGGTTAGCTCCACTGGCATTGTAAAAAA
GGGACTTGAATGGTTCGAGAAAAATGCAGGAACCATTAAGTCCTGGGATGAAAG
TTATACTGAGCTAAAGGTCGACGTCCCGAAAATAGAGCAGCTTACCGGTTACCAA
CAAGCTGCCTTGAAGTGGAGAAAAGACATAGGTTTCCGTGTCAATGCCAACACA
GCAGCTCTGAGCAACAAAGTCCTCGCAGAATACAAAGTCCCTGGTGAGATTGTG
ATGTCTGTCAAAGAGATGCTGTCAGACATGATTAGGAGAAGGAACCTGATTCTAA
ACAGGGGTGGTGATGAGAACCCACGTGGCCCAGTGAGCCATGAGCATGTAGAC
TGGTGCAGGGAGTTTGTCAAAGGCAAATACATCATGGCCTTCAACCCACCATGG
GGGGACATCAACAAGTCAGGCCGTTCAGGAATAGCACTTGTTGCAACAGGCCTT
GCTAAGCTTGCAGAGACTGAAGGAAAGGGAATATTTGATGAAGCCAAAAAGACT
GTGGAGGCCCTCAACGGGTATCTGGACAAGCATAAGGACGAAGTTGATAGAGCA
AGCGCCGACAGCATGATAACAAACCTTCTTAAGCATATTGCCAAGGCACAGGAG
CTCTATAAAAATTCATCTGCACTTCGTGCACAAAGCGCACAGATTGACACTGCTT
TCAGCTCATACTATTGGCTTTACAAGGCTGGCGTGACTCCTGAAACCTTCCCGAC
GGTGTCACAGTTCCTCTTTGAGCTAGGGAAACAGCCAAGAGGTACCAAGAAAAT
GAAGAAGGCTCTTCTGAGCACCCCAATGAAGTGGGGGAAGAAGCTTTATGAGCT
CTTTGCCGATGATTCTTTCCAGCAGAACAGGATTTACATGCATCCTGCCGTGCTT
ACAGCTGGTAGAATCAGTGAAATGGGAGTCTGCTTTGGGACAATCCCTGTGGCC
AATCCTGATGATGCTGCCCAAGGATCTGGACACACTAAGTCTATTCTCAACCTCC
GTACCAACACTGAGACCAATAATCCGTGTGCCAAAACCATCGTCAAGCTATTTGA
AGTTCAAAAAACAGGGTTCAACATTCAGGACATGGACATAGTGGCCTCTGAGCA
CTTGCTACACCAATCCCTTGTTGGCAAGCAATCCCCATTCCAGAACGCCTACAAC
GTCAAGGGCAATGCCACCAGTGCTAACATCATTTAA 
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HAZV N strain JC280 nucleotide sequence  
 
ATGGAAAACAAGATCGTGGCTAGCACCAAGGAAGAGTTCAACACGTGGTACAAA
CAGTTTGCTGAAAAGCACAAACTGAATAACAAATACACGGAATCTGCATCCTTCT
GTGCAGAAATTCCACAACTGGACACTTATAAGTACAAAATGGAACTGGCATCCAC
CGATAACGAACGCGACGCGATCTACAGCTCTGCTCTGATCGAGGCTACTCGTTT
CTGTGCTCCGATCATGGAATGCGCATGGGCATCTTGCACTGGTACCGTAAAACG
TGGTCTGGAGTGGTTTGATAAGAACAAAGATTCCGATACTGTTAAAGTGTGGGAT
GCGAACTACCAGAAACTGCGTACCGAAACTCCACCTGCAGAAGCGCTGCTGGCT
TATCAGAAAGCGGCACTGAACTGGCGTAAAGATGTCGGTTTCTCCATCGGTGAG
TACACCAGCATTCTGAAGAAAGCTGTTGCCGCAGAATATAAAGTTCCGGGTACC
GTTATTAACAACATCAAAGAAATGCTGAGCGACATGATTCGTCGTCGCAACCGTA
TTATCAACGGTGGTAGCGACGACGCACCGAAACGCGGTCCGGTTGGCCGTGAG
CATCTGGATTGGTGTCGTGAGTTCGCGAGCGGCAAGTTTCTGAACGCTTTCAAT
CCGCCGTGGGGTGAGATCAACAAAGCGGGCAAGAGCGGCTATCCGCTGCTGGC
GACTGGTCTGGCTAAGCTGGTTGAACTGGAAGGCAAAGACGTTATGGACAAAGC
GAAGGCATCCATCGCTCAGCTGGAAGGTTGGGTGAAAGAGAATAAAGATCAGGT
TGACCAGGACAAAGCGGAGGATCTGCTGAAAGGCGTACGCGAATCTTACAAAAC
CGCCCTGGCGCTGGCTAAACAGTCTAATGCATTCCGCGCGCAGGGTGCGCAGA
TCGATACTGTTTTCTCCTCCTACTACTGGCTGTGGAAAGCAGGCGTAACCCCGGT
AACCTTTCCGTCCGTGTCCCAGTTCCTGTTTGAACTGGGTAAGAACCCGAAGGG
CCAGAAGAAGATGCAGAAAGCCCTGATCAACACCCCGCTGAAATGGGGCAAACG
TCTGATCGAACTGTTCGCTGACAATGACTTCACCGAAAACCGTATCTATATGCAC
CCATGCGTTCTGACCTCTGGTCGTATGTCCGAGCTGGGTATTTCCTTCGGCGCG
GTGCCAGTTACGTCTCCGGATGATGCAGCGCAGGGCAGCGGCCATACTAAAGC
GGTGCTGAACTACAAAACCAAAACCGAAGTGGGCAACCCATGTGCGTGTATTAT
CTCCTCTCTGTTCGAGATCCAGAAAGCGGGTTACGACATTGAGAGCATGGACAT
TGTTGCGAGCGAACACCTGCTGCATCAGTCCCTGGTTGGCAAACGCTCTCCGTT
CCAGAACGCCTATCTGATTAAAGGTAACGCAACTAACATTAACATTATCTAA  
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APPENDIX II. PROTEINS IDENTIFIED AND QUANTIFIED IN THE EGFP-
CCHFV N IP 
MAP1 dataset (white) and MAP2 dataset (green). 
 
Accession 
number 
Protein Name 
EGFP 
only 
EGFP
-N  
Peptides 
(seq) 
PEP  Protein function 
IPI00000816.
1 
14-3-3 protein 
epsilon 
0.55 1.81 2 
4.48E-
06 
Adaptor protein 
involved in 
intracellular 
signalling. 0.30 3.33 4 
1.1827
E-15 
IPI00008599.
3 
3-beta-
hydroxysteroid-
Delta(8),Delta(7)
-isomerase 
0.39 2.59 2 
0.0191
56 
Involved in steroid 
and cholesterol 
biosynthesis.  
IPI00011253.
3 
40S ribosomal 
protein S3 
0.26 3.86 6 
2.0921
E-14 
Involved in protein 
biosynthesis.  
IPI00554481.
1 
4F2 cell-surface 
antigen heavy 
chain 
0.19 5.22 6 
8.79E-
27 
Amino acid 
transport into cells 
at the plasma 
membrane.  
Required for the 
function of light 
chain amino-acid 
transporters. 
0.17 5.94 6 
2.7026
E-13 
IPI00784402.
1 
5-azacytidine-
induced protein 
1 
0.09 10.57 4 
2.1667
E-13 
A component of 
the cytoskeleton, 
localised to the 
centrosomes and 
intracellular 
membrane bound 
organelles. 
IPI00784154.
1 
60 kDa heat 
shock protein, 
mitochondrial 
0.42 2.4 13 
7.7237
E-55 
Mitochondrial 
protein import and 
macromolecular 
assembly. May 
facilitate the 
correct folding of 
imported proteins.  
0.40 2.48 16 
5.27E-
74 
IPI00008530.
1 
60S acidic 
ribosomal 
protein P0 
0.32 3.15 2 
0.0001
0867 Involved in protein 
biosynthesis.  
0.26 3.79 2 
5.35E-
05 
IPI00376798.
3 
60S ribosomal 
protein L11 
0.55 1.83 2 
4.66E-
14 
Binds to 5S 
ribosomal RNA. 
Required for rRNA 
maturation and 
formation of the 
60S ribosomal 
subunits. 
0.44 2.28 2 
1.3345
E-13 
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IPI00215790.
6 
60S ribosomal 
protein L38 
0.71 1.4 2 
0.0002
6745 
Belongs to the 
ribosomal protein 
L38e family. 
Involved in protein 
biogenesis. 
0.62 1.6 2 
9.47E-
10 
IPI00003362.
2 
78 kDa glucose-
regulated protein 
0.20 5.1 17 
2.7815
E-102 
Plays a role in 
facilitating the 
assembly of 
multimeric protein 
complexes inside 
the ER.  
0.17 5.87 13 
4.74E-
108 
IPI00023006.
1 
Actin, alpha 
cardiac muscle 1 
0.08 13 12 
1.10E-
34 
Highly conserved 
cytoskeletal 
protein. Involved 
in various types of 
cell motility and 
are ubiquitously 
expressed in all 
eukaryotic cells.  
0.07 15.02 9 
2.3388
E-51 
IPI00021440.
1 
Actin, 
cytoplasmic 2 
0.15 6.8 19 
3.68E-
73 
0.06 16.46 17 
1.5247
E-146 
IPI00031131.
4 
Adipocyte 
plasma 
membrane-
associated 
protein 
0.18 5.64 4 
4.8038
E-08 
Type II 
transmembrane 
glycoprotein, 
localised to the 
plasma 
membrane. 
IPI00007188.
5 
ADP/ATP 
translocase 2 
0.05 18.25 7 
5.52E-
64 
A multipass 
transmembrane 
protein located on 
the inner 
mitochondrial 
membrane.  
0.05 18.5 8 
2.3689
E-69 
IPI00291467.
7 
ADP/ATP 
translocase 3 
0.16 6.32 5 
6.7723
E-48 
Inner 
mitochondrial 
membrane 
protein.  
IPI00465248.
5 
Alpha-enolase 0.34 2.96 3 
1.5824
E-09 
Multifunctional 
enzyme; involved 
in glycolysis, 
growth control, 
and hypoxia 
tolerance. 
IPI00001453.
2 
Alpha-internexin 0.22 4.47 4 
4.7225
E-08 
Structural 
constituent of the 
cytoskeleton.  
IPI00163085.
2 
Angiomotin 
0.09 10.63 26 
8.7864
E-137 
Cell surface 
protein that plays 
a central role in 
tight junction 
maintenance. 
0.07 13.39 8 
3.81E-
29 
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IPI00292953.
6 
Ankycorbin 0.19 5.38 6 
2.195E
-12 
 Indirectly 
associated with 
the cortical actin 
cytoskeleton 
structures.  
IPI00329801.
12 
Annexin A5 0.24 4.18 3 
3.60E-
13 
Involved in 
intracellular 
signalling: an anti-
apoptotic, 
anticoagulant 
protein.  
IPI00440493.
2 
ATP synthase 
subunit alpha, 
mitochondrial 
0.13 7.5 12 
8.7414
E-53 
Mitochondrial 
membrane ATP 
synthase (F1F0 
ATP synthase or 
Complex V) 
produces ATP 
from ADP in the 
presence of a 
proton gradient 
across the inner 
mitochondrial 
membrane.  
0.13 7.75 13 
1.33E-
72 
IPI00029133.
4 
ATP synthase 
subunit b, 
mitochondrial 
0.24 4.22 2 
0.0008
6751 
0.18 5.42 2 
0.0000
39858 
IPI00303476.
1 
ATP synthase 
subunit beta, 
mitochondrial 
0.13 7.87 19 
4.4014
E-115 
0.12 8.26 20 
3.86E-
91 
IPI00478410.
2 
ATP synthase 
subunit gamma, 
mitochondrial 
0.18 5.7 2 
1.92E-
16 
IPI00007611.
1 
ATP synthase 
subunit O, 
mitochondrial 
0.18 5.64 2 
2.2646
E-11 
IPI00844578.
1 
ATP-dependent 
RNA helicase A 
0.19 5.2 3 
2.0152
E-07 
Unwinds double-
stranded DNA and 
RNA in a 3' to 5' 
direction. 
Functions as a 
transcriptional 
activator.  
IPI00295992.
4 
ATPase family 
AAA domain-
containing 
protein 3A 
0.15 6.78 3 
2.35E-
47 
A novel anti-
apoptotic factor. 
Hydrolyses ATP. 
IPI00218200.
7 
B-cell receptor-
associated 
protein 31 
0.29 3.4 2 
0.0003
3456 
May play a role in 
anterograde 
transport of 
membrane 
proteins from the 
endoplasmic 
reticulum to the 
Golgi.  
IPI00218019.
1 
Basigin 0.18 5.65 3 
3.43E-
08 
Cell surface 
receptor involved 
in intracellular 
signalling. 
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0.10 9.67 5 
3.1937
E-24 
Involved in blood 
coagulation, and 
leukocyte 
migration. 
IPI00301263.
2 
CAD protein 
0.20 4.99 3 
4.2939
E-10 Essential for 
pyrimidine 
biosynthesis.  0.11 9.37 3 
4.57E-
38 
IPI00290085.
2 
Cadherin-2 
0.18 5.44 5 
4.6633
E-08 
Calcium 
dependent cell 
adhesion proteins. 
Involved in cell 
junction assembly. 
0.13 7.49 6 
2.62E-
09 
IPI00007084.
2 
Calcium-binding 
mitochondrial 
carrier protein 
Aralar2 
0.08 12.33 7 
1.04E-
12 
Calcium-
dependent 
mitochondrial 
aspartate and 
glutamate carrier. 
Located on the 
mitchondrial inner 
membrane.  
IPI00020984.
2 
Calnexin 
0.14 6.94 12 
8.01E-
59 
Calcium-binding 
protein that 
interacts with 
newly synthesized 
glycoproteins in 
the endoplasmic 
reticulum.  
0.14 6.98 15 
6.3345
E-66 
IPI00215948.
4 
Catenin alpha-1 
0.13 7.89 20 
2.5896
E-97 
Involved in cell-
cell adhesion. 
Found at cell-cell 
boundaries and 
probably at cell-
matrix boundaries. 
0.12 8.38 10 
1.45E-
63 
IPI00017292.
1 
Catenin beta-1 
0.11 9.16 11 
2.4315
E-107 
Involved in the 
regulation of cell 
adhesion and 
signal 
transduction.  
0.06 16.86 6 
2.55E-
70 
IPI00182540.
5 
Catenin delta-1 
0.18 5.7 3 
2.64E-
06 
Belongs to a 
multiprotein cell-
cell adhesion 
complex and helps 
regulate cell-cell 
adhesion.  
0.16 6.19 8 
8.3676
E-21 
IPI00909515.
1 
cDNA FLJ51495  0.24 4.12 2 
6.42E-
26 
Function 
unknown. 
Evidence at 
transcript level.  
IPI00910164.
1 
cDNA FLJ53381  0.14 7.02 2 
0.0002
7342 
Function 
unknown. 
Evidence at 
transcript level.  
  
IPI00910142.
1 
cDNA FLJ54183 0.28 3.59 2 
7.8515
E-10 
Appendix II 
 
244 
 
IPI00911039.
1 
cDNA FLJ54303 0.04 22.65 27 
3.491E
-233 
IPI00797612.
1 
cDNA FLJ56382 
0.22 4.48 5 
6.9793
E-10 
0.08 12.67 3 
6.60E-
06 
IPI00798127.
1 
cDNA FLJ75516 
0.06 16.89 3 
5.2114
E-17 
0.06 17.4 2 
1.73E-
08 
IPI00871856.
2 
cDNA FLJ76863 0.17 6.01 6 
2.9531
E-29 
IPI00025087.
2 
Cellular tumor 
antigen p53 
0.04 26.26 11 
2.6606
E-26 
Transcription 
factor that can 
induce growth 
arrest or 
apoptosis. 
IPI00844508.
1 
Cingulin 
0.17 5.91 5 
1.97E-
06 
Plays a role in the 
formation and 
regulation of the 
tight junction (TJ) 
paracellular 
permeability 
barrier. 
0.11 8.73 24 
1.5854
E-131 
IPI00024067.
4 
Clathrin heavy 
chain 1 
0.20 5.07 5 
2.96E-
31 
Involved in 
endocytosis and 
post-Golgi vesicle-
mediated 
transport.  
0.19 5.26 10 
6.7783
E-37 
IPI00015833.
1 
Coiled-coil-helix-
coiled-coil-helix 
domain-
containing 
protein 3, 
mitochondrial 
0.12 8.01 3 
1.8502
E-11 
Located in the 
mitochondria. A 
myristoylated 
protein that acts 
as a scaffold. 
IPI00014230.
1 
Complement 
component 1 Q 
subcomponent-
binding protein, 
mitochondrial 
0.22 4.63 3 
8.1298
E-24 Precise function is 
unknown.  
0.18 5.57 2 
2.16E-
23 
IPI00867509.
1 
Coronin-1C 0.11 8.77 7 
2.3358
E-93 
A 55KDa actin 
binding protein.  
IPI00004839.
1 
Crk-like protein 
0.79 1.26 7 
2.6825
E-29 
May mediate the 
transduction of 
intracellular 
signals. 0.67 1.49 10 
3.02E-
37 
IPI00290142.
5 
CTP synthase 1 
0.55 1.82 10 
7.3185
E-62 
Involved in 
pyrimidine 
metabolism.  0.54 1.86 13 
8.29E-
40 
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IPI00013847.
4 
Cytochrome b-
c1 complex 
subunit 1, 
mitochondrial 
0.18 5.62 3 
3.1523
E-11 
Component of the 
ubiquinol-
cytochrome c 
reductase 
complex. Part of 
the mitochondrial 
respiratory chain.  
IPI00305383.
1 
Cytochrome b-
c1 complex 
subunit 2, 
mitochondrial 
0.13 7.72 4 
4.77E-
05 
0.13 7.76 9 
3.2128
E-43 
IPI00303954.
3 
Cytochrome b5 
type B 
0.13 7.41 3 
1.31E-
06 
Involved in 
respiration. A 
mitochondrial 
membrane bound 
hemoprotein. 
IPI00017510.
3 
Cytochrome c 
oxidase subunit 
2 
0.12 8.41 5 
1.06E-
08 
The component of 
the respiratory 
chain that 
catalyzes the 
reduction of 
oxygen to water.  
0.06 15.41 4 
8.774E
-09 
IPI00178072.
7 
Cytospin-A 0.17 6.05 4 
7.6775
E-11 
Involved in the cell 
cycle and cell 
division.  
IPI00011200.
5 
D-3-
phosphoglycerat
e 
dehydrogenase 
0.31 3.21 3 
8.86E-
09 Involved in amino-
acid biosynthesis. 
0.29 3.43 2 
0.0000
08134 
IPI00028931.
2 
Desmoglein-2 
0.11 9.16 9 
5.54E-
26 
 A component of 
intercellular 
desmosome 
junctions, involved 
in cell-cell 
adhesion. 
0.07 14.45 12 
8.3794
E-44 
IPI00013933.
2 
Desmoplakin 
0.18 5.49 25 
1.0673
E-101 
Found in 
desmosomes (a 
type of junctional 
complex involved 
in cell-cell 
adhesion). 
0.12 8.07 15 
1.51E-
125 
IPI00296337.
2 
DNA-dependent 
protein kinase 
catalytic subunit 
0.30 3.38 2 
1.317E
-12 
Serine/threonine-
protein kinase that 
acts as a 
molecular sensor 
for DNA damage.  
IPI00012535.
1 
DnaJ homolog 
subfamily A 
member 1 
0.09 11.19 4 
5.22E-
06 Co-chaperone of 
Hsc70.  
0.08 12.41 4 
2.8045
E-08 
IPI00032406.
1 
DnaJ homolog 
subfamily A 
member 2 
0.19 5.34 2 
9.48E-
07 
Co-chaperone of 
Hsc70.  
IPI00297084.
7 
Dolichyl-
diphosphooligos
accharide--
0.23 4.27 3 
1.0906
E-20 
Located in the 
endoplasmic 
reticulum and is a 
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protein 
glycosyltransfera
se 48 kDa 
subunit 
0.21 4.83 3 
1.50E-
12 
component of the 
oligosaccharyltran
sferase (OST) 
complex, which is 
involved in the N-
linked 
glycosylation of 
nascent 
polypeptide 
chains. 
IPI00025874.
2 
Dolichyl-
diphosphooligos
accharide--
protein 
glycosyltransfera
se subunit 1 
0.22 4.47 11 
1.264E
-43 
0.18 5.63 14 
2.15E-
44 
IPI00396485.
3 
Elongation factor 
1-alpha 1 
0.77 1.3 9 
4.8239
E-44 Involved in protein 
biosynthesis. 
0.65 1.54 11 
1.15E-
10 
IPI00186290.
6 
Elongation factor 
2 
0.53 1.89 4 
2.2533
E-10 
Involved in protein 
biogenesis.  
IPI00027107.
5 
Elongation factor 
Tu, 
mitochondrial 
0.32 3.16 5 
1.1891
E-13 Involved in protein 
biosynthesis.  
0.27 3.69 2 
0.0449
81 
IPI00027230.
3 
Endoplasmin 0.23 4.33 3 
5.409E
-09 
Molecular 
chaperone. 
IPI00386604.
1 
Eukaryotic 
initiation factor 
4A-II 
0.36 2.8 2 
1.0505
E-14 
Involved in 
translation 
initiation.  
IPI00022744.
5 
Exportin-2 0.40 2.51 6 
2.5175
E-17 
Involved in export 
of proteins from 
the nucleus to the 
cytoplasm. 
IPI00005969.
3 
F-actin-capping 
protein subunit 
alpha-1 
0.33 3.05 2 
0.0006
1655 
Binds in a Ca2+-
independent 
manner to the fast 
growing ends of 
actin filaments.  
0.19 5.27 2 
0.0008
3775 
IPI00026781.
2 
Fatty acid 
synthase 
0.36 2.78 3 
0.0000
10311 
Catalyzes the 
formation of long-
chain fatty acids.  0.36 2.81 3 
1.22E-
20 
IPI00333541.
6 
Filamin-A 
0.33 3.04 3 
8.7719
E-07 
Links actin 
filaments to 
membrane 
glycoproteins. 
0.15 6.64 2 
1.05E-
07 
IPI00027438.
2 
Flotillin-1 
0.15 6.69 3 
6.09E-
19 
Peripheral 
membrane protein 
involved in clathrin 
independent 
endocytosis.  
0.10 10.47 4 
4.8171
E-24 
IPI00795979.
1 
Flotillin-2 
0.15 6.53 6 
1.0811
E-23 
Participates in the 
formation of 
caveolae or 
caveolae-like 
vesicles.  
0.05 20.32 2 
2.76E-
09 
IPI00465121.
1 
Galphai2 protein 0.17 5.86 4 
6.87E-
17 
Located on the 
plasma membrane 
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0.08 12.46 5 
4.1954
E-31 
and functions as a 
G-protein family 
member. 
CON_GFP GFP 
10.80 0.09 17 
1.175E
-152 
  
3.19 0.31 14 
5.52E-
95 
IPI00788737.
1 
Glyceraldehyde-
3-phosphate 
dehydrogenase 
0.25 3.95 2 
8.01E-
05 
A key enzyme in 
glycolysis.  
IPI00221232.
9 
Guanine 
nucleotide-
binding protein 
G(I)/G(S)/G(O) 
subunit gamma-
12 
0.15 6.47 2 
0.0001
1933 
Involved in 
intracellular 
signalling: 
Guanine 
nucleotide-binding 
proteins (G 
proteins) function 
as modulators or 
transducers in 
various 
transmembrane 
signaling systems.  
IPI00003348.
3 
Guanine 
nucleotide-
binding protein 
G(I)/G(S)/G(T) 
subunit beta-2 
0.06 16.99 5 
2.82E-
09 
IPI00220578.
3 
Guanine 
nucleotide-
binding protein 
G(k) subunit 
alpha 
0.10 10.37 5 
4.7018
E-23 
0.08 13.08 6 
2.97E-
63 
IPI00305551.
3 
Guanine 
nucleotide-
binding protein 
subunit alpha-11 
0.23 4.43 2 
0.0010
169 
Acts as an 
activator of 
phospholipase C. 
Belongs to the G-
alpha family.  
0.18 5.62 2 
0.0054
347 
IPI00012451.
3 
Guanine 
nucleotide-
binding protein 
subunit beta-4 
0.08 12.46 3 
2.0849
E-10 
G protein involved 
in the cellular 
response to 
glucagon stimulus. 
IPI00010440.
5 
HCLS1-
associated 
protein X-1 
0.13 7.71 2 
0.0017
254 
Promotes cell 
survival. Involved 
in the clathrin-
mediated 
endocytosis 
pathway.  
IPI00304925.
5 
Heat shock 70 
kDa protein 1 
0.03 37.85 31 
2.0709
E-253 
Hsp70s stabilize 
preexisting 
proteins against 
aggregation and 
mediate the 
folding of newly 
translated 
polypeptides in the 
cytosol as well as 
within organelles. 
0.02 40.11 27 
5.98E-
236 
IPI00002966.
2 
Heat shock 70 
kDa protein 4 
0.15 6.61 2 
1.45E-
29 Protein 
chaperone.   
0.12 8.61 8 
1.8125
E-34 
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IPI00003865.
1 
Heat shock 
cognate 71 kDa 
protein 
0.04 24.72 24 
9.46E-
159 
Protein 
chaperone. 
Localized in 
cytoplasmic 
mRNP granules 
containing 
untranslated 
mRNAs.  
0.04 27.11 24 
5.6703
E-207 
IPI00514983.
4 
Heat shock 
protein 105 kDa 
0.21 4.72 4 
5.53E-
15 
Belongs to the 
heat shock protein 
70 family.  0.08 12.42 3 
6.2195
E-10 
IPI00382470.
3 
Heat shock 
protein HSP 90-
alpha 
0.14 7.38 8 
3.64E-
20 Molecular 
chaperone.  
0.11 9.17 14 
2.4805
E-52 
IPI00414676.
6 
Heat shock 
protein HSP 90-
beta 
0.11 9.09 13 
2.8509
E-68 Molecular 
chaperone.  
0.09 10.88 12 
2.10E-
52 
IPI00479191.
2 
Heterogeneous 
nuclear 
ribonucleoprotei
n H 
0.35 2.87 3 
1.16E-
24 
A component of 
the heterogeneous 
nuclear 
ribonucleoprotein 
(hnRNP) 
complexes.  
0.33 3.04 3 
1.2262
E-36 
IPI00216746.
1 
Heterogeneous 
nuclear 
ribonucleoprotei
n K 
0.31 3.18 2 
0.0000
45576 
One of the major 
pre-mRNA-binding 
proteins.  0.27 3.68 4 
1.90E-
24 
IPI00644079.
2 
Heterogeneous 
nuclear 
ribonucleoprotei
n U (Scaffold 
attachment 
factor A) 
0.22 4.61 2 
0.0057
521 
Binds to pre-
mRNA. Localized 
in cytoplasmic 
mRNP granules 
containing 
untranslated 
mRNAs.  
IPI00874030.
3 
Heterogeneous 
nuclear 
ribonucleoprotei
ns A2/B1 
0.17 5.81 4 
1.59E-
28 
Involved with pre-
mRNA processing.  
IPI00477313.
3 
Heterogeneous 
nuclear 
ribonucleoprotei
ns C1/C2 
0.23 4.28 3 
2.08E-
23 
Binds pre-mRNA 
and nucleates the 
assembly of 40S 
hnRNP particles.  
 
IPI00005711.
4 
Histone 
deacetylase 6 
0.58 1.73 4 
2.2145
E-16 Deacetylates 
lysine residues on 
the N-terminal part 
of the core 
histones.  
0.57 1.77 2 
0.0006
3255 
IPI00902514.
1 
Histone H2A 
0.30 3.31 2 
0.0005
2103 Core component 
of nucleosome.  
0.15 6.72 2 
3.92E-
07 
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IPI00001639.
2 
Importin subunit 
beta-1 
0.27 3.71 2 
1.71E-
20 
Functions in 
nuclear protein 
import.  IPI00793443.
1 
Importin-5 
0.46 2.16 2 
5.48E-
09 
0.33 3.02 2 
4.7107
E-06 
IPI00020729.
1 
Insulin receptor 
substrate 4 
0.19 5.4 2 
5.1293
E-06 
Involved in 
intracellular 
signalling.   
IPI00554711.
3 
Junction 
plakoglobin 
0.13 7.59 4 
2.5381
E-14 
Common 
junctional plaque 
protein. Interacts 
with calveolin.  
IPI00299554.
3 
Kinesin-like 
protein KIF14 
0.36 2.76 8 
1.9519
E-24 
Plays an essential 
role in cytokinesis.  
IPI00219217.
3 
L-lactate 
dehydrogenase 
B chain 
0.39 2.58 2 
0.0001
1347 Involved in 
glycolysis. 
0.31 3.2 2 
0.0054
615 
IPI00017592.
1 
LETM1 and EF-
hand domain-
containing 
protein 1, 
mitochondrial 
0.17 5.89 2 
1.4935
E-16 
Crucial for the 
maintenance of 
mitochondrial 
tubular networks.  
IPI00783271.
1 
Leucine-rich 
PPR motif-
containing 
protein, 
mitochondrial 
0.30 3.37 4 
1.1446
E-10 
May play a role in 
RNA metabolism 
in both nuclei and 
mitochondria. 
IPI00216172.
2 
Lysosomal-
associated 
membrane 
protein 2C 
0.18 5.66 2 
1.80E-
09 
Function of this 
LAMP2 isoform is 
unknown. LAMP2 
may help protect 
lysosomal 
membranes from 
autodigestion.  
IPI00293276.
10 
Macrophage 
migration 
inhibitory factor 
0.78 1.29 2 
9.0766
E-16 Pro-inflammatory 
cytokine.  
0.61 1.64 2 
3.30E-
20 
IPI00639812.
1 
Microsomal 
glutathione S-
transferase 3 
variant 
0.10 10.08 2 
1.65E-
10 
Precise function 
unknown - 
ervidence only at 
the transcript 
level.  
IPI00418497.
1 
Mitochondrial 
import inner 
membrane 
translocase 
subunit TIM50 
0.17 5.99 4 
3.89E-
10 
Essential 
component of the 
TIM23 complex, 
that mediates the 
translocation of 
proteins across 
the mitochondrial 
inner membrane. 
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IPI00024976.
5 
Mitochondrial 
import receptor 
subunit TOM22 
homolog 
0.08 12.17 3 
3.69E-
30 
Central receptor 
component of the 
translocase of the 
outer membrane 
of mitochondria 
(TOM complex). 
0.08 12.38 2 
6.0602
E-26 
IPI00015602.
1 
Mitochondrial 
import receptor 
subunit TOM70 
0.17 5.82 2 
2.57E-
07 
Central receptor 
component of the 
translocase of the 
outer membrane 
of mitochondria 
(TOM complex).  
0.10 10.34 2 
1.431E
-07 
IPI00009960.
6 
Mitochondrial 
inner membrane 
protein 
0.10 10.37 6 
1.674E
-19 
Controls cristae 
morphology. 
IPI00844172.
1 
Myosin 
0.15 6.53 4 
1.99E-
66 
Evidence only at 
transcript level. 
Function 
unknown. 0.13 7.86 14 
3.1085
E-77 
IPI00335168.
9 
Myosin light 
polypeptide 6 
0.07 13.39 4 
2.28E-
08 
Regulatory light 
chain of myosin..  
IPI00295457.
6 
Myosin 
phosphatase 
Rho-interacting 
protein 
0.15 6.55 14 
1.4312
E-46 
Targets myosin 
phosphatase to 
the actin 
cytoskeleton.  
0.11 8.83 4 
4.52E-
37 
IPI00604523.
1 
Myosin 
regulatory light 
chain MRCL3 
variant 
0.19 5.39 2 
3.3658
E-06 
A variant of the 
regulatory light 
chain of myosin.  0.18 5.44 3 
4.57E-
22 
IPI00790503.
3 
Myosin-10 
0.11 9.47 61 0 Cellular myosin 
that appears to 
play a role in 
cytokinesis.  
0.08 11.96 43 0 
IPI00019502.
3 
Myosin-9 
0.15 6.82 42 0 Cellular myosin 
that appears to 
play a role in 
cytokinesis.  
0.12 8.14 34 0 
IPI00376344.
3 
Myosin-Ib 0.08 12.34 3 
8.0095
E-09 
Motor protein 
associated with 
the actin 
cytoskeleton. 
IPI00743335.
1 
Myosin-Ic 0.27 3.69 2 
0.0005
8806 
Actin-based motor 
molecule with 
ATPase activity.  
IPI00337541.
3 
NAD(P) 
transhydrogenas
e, mitochondrial 
1.53 0.65 2 
0.0000
96694 
An oxidoreductase 
enzyme located in 
the mitochondrial 
inner membrane.  
IPI00025796.
3 
NADH 
dehydrogenase 
[ubiquinone] 
iron-sulfur 
protein 3, 
mitochondrial 
0.22 4.45 3 
1.06E-
19 
Core subunit of 
the mitochondrial 
membrane 
respiratory chain 
NADH 
dehydrogenase: 
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IPI00010845.
3 
NADH 
dehydrogenase 
[ubiquinone] 
iron-sulfur 
protein 8, 
mitochondrial 
0.38 2.66 2 
0.0002
2751 
Complex I, which 
transfers electrons 
from NADH to the 
respiratory chain.  
IPI00217507.
5 
Neurofilament 
medium 
polypeptide 
0.15 6.81 12 
7.2389
E-53 A component of 
the cytoskeleton.  
0.03 39.77 5 
2.40E-
20 
IPI00019472.
4 
Neutral amino 
acid transporter 
B(0) 
0.26 3.9 3 
3.0873
E-08 
Transports neutral 
amino acids 
across the plasma 
membrane. 
IPI00465432.
3 
Nodal modulator 
2 
0.31 3.26 2 
5.65E-
05 
May antagonize 
Nodal signalling.  
IPI00783781.
1 
Nuclear pore 
complex protein 
Nup205 
0.38 2.65 2 
1.7656
E-06 
Involved in 
regulating the 
import and export 
of proteins into the 
nucleus. 
IPI00549248.
4 
Nucleophosmin 0.22 4.53 4 
1.78E-
29 
Involved in 
ribosome 
biogenesis, 
centrosome 
duplication, and 
protein 
chaperoning. 
IPI00001654.
5 
Pericentriolar 
material 1 
protein 
0.19 5.19 11 
5.8684
E-33 
Required for 
centrosome 
assembly and 
function.  
0.09 11.76 4 
6.76E-
18 
IPI00000874.
1 
Peroxiredoxin-1 
0.59 1.7 8 
9.3036
E-15 
Involved in redox 
regulation of the 
cell.  0.52 1.92 7 
2.02E-
12 
IPI00014898.
3 
Plectin-1 
0.11 9.5 33 
2.27E-
264 
Interlinks 
intermediate 
filaments with 
microtubules.  
0.09 10.53 97 0 
IPI00008524.
1 
Polyadenylate-
binding protein 1 
0.21 4.7 5 
6.6144
E-21 
Binds the poly(A) 
tail of mRNA. 
Helps initiate 
translation. 
0.16 6.41 4 
1.26E-
07 
IPI00384280.
5 
Prenylcysteine 
oxidase 1 
0.24 4.14 3 
1.29E-
29 
Involved in the 
degradation of 
prenylated 
proteins.  
0.18 5.56 3 
1.2038
E-10 
IPI00017617.
1 
Probable ATP-
dependent RNA 
helicase DDX5 
0.28 3.6 2 
0.0046
811 
RNA-dependent 
ATPase activity.  
IPI00017334.
1 
Prohibitin 
0.09 10.82 8 
1.07E-
42 Inhibits DNA 
synthesis.  
0.08 11.96 9 
2.8807
E-72 
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IPI00027252.
6 
Prohibitin-2 
0.09 11.13 9 
3.4011
E-41 
Acts as a mediator 
of transcriptional 
repression via 
recruitment of 
histone 
deacetylases.  
0.07 13.9 6 
9.93E-
62 
IPI00385250.
1 
Protease, 
serine, 3 
0.03 37.01 2 
1.3265
E-07 
A serine type 
endopeptidase.  
IPI00299571.
5 
Protein disulfide-
isomerase A6 
0.65 1.55 5 
3.9058
E-31 
May function as a 
chaperone that 
inhibits 
aggregation of 
misfolded 
proteins.  
0.54 1.84 4 
9.12E-
26 
IPI00298547.
3 
Protein DJ-1 0.54 1.85 2 0.4226 
Protects cells 
against oxidative 
stress and cell 
death.  
IPI00183002.
6 
Protein 
phosphatase 1 
regulatory 
subunit 12A 
0.22 4.52 6 
1.3646
E-19 
Regulates myosin 
phosphatase 
activity.  
IPI00794221.
1 
Putative 
uncharacterized 
protein DBN1 
0.13 7.85 9 
1.6611
E-37 
N/A 
0.04 23.74 2 
3.23E-
36 
IPI00418169.
3 
Putative 
uncharacterized 
protein 
DKFZp686P031
59 
0.25 4.07 2 
2.2855
E-07 
N/A 
0.24 4.12 3 
8.30E-
05 
IPI00792352.
1 
Putative 
uncharacterized 
protein RAN 
0.45 2.21 2 
0.0057
561 
N/A 
0.28 3.56 2 
0.0000
77029 
IPI00872387.
1 
Putative 
uncharacterized 
protein 
RPL7P23 
0.30 3.37 2 
7.87E-
08 
N/A 
0.21 4.84 2 
0.0000
13341 
IPI00879810.
1 
Putative 
uncharacterized 
protein SPTAN1 
0.11 9.28 44 
6.4285
E-210 N/A 
0.10 10.05 37 0 
IPI00016513.
5 
Ras-related 
protein Rab-10 
0.18 5.45 2 
9.5794
E-12 
May be involved in 
vesicular 
trafficking and 
neurotransmitter 
release.  
0.14 7.08 2 
2.85E-
13 
IPI00429190.
4 
Ras-related 
protein Rab-11A 
0.18 5.42 2 
4.47E-
05 
Modulates 
endosomal 
trafficking.  0.17 5.94 5 
1.3516
E-08 
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IPI00008964.
3 
Ras-related 
protein Rab-1B 
0.18 5.6 3 
1.835E
-08 
Regulates 
vesicular transport 
between the ER 
and successive 
Golgi 
compartments.  
IPI00031169.
1 
Ras-related 
protein Rab-2A 
0.31 3.2 2 
0.0025
402 
Transports 
proteins from the 
ER to the Golgi 
complex.  
IPI00016342.
1 
Ras-related 
protein Rab-7a 
0.22 4.61 3 
7.03E-
14 
Involved in late 
endocytic 
transport.  0.19 5.29 3 
2.902E
-18 
IPI00019345.
1 
Ras-related 
protein Rap-1A 
0.21 4.72 2 
0.0001
4642 
Lipid anchored in 
the cell 
membrane. 
Belongs to the 
small GTPase 
superfamily.  
0.17 5.83 2 
6.7779
E-21 
IPI00028635.
4 
Ribophorin II 
0.26 3.82 2 
4.7453
E-15 
Involved in N-
linked 
glycosylation of 
nascent 
polypeptides.  
0.17 6.06 2 
1.69E-
08 
IPI00450975.
1 
RPS16 protein 0.20 4.93 2 
5.98E-
07 
Evidence only at 
transcript level. 
Function 
unknown. 
IPI00009104.
7 
RuvB-like 2 0.15 6.64 2 
0.0031
93 
Possesses single-
stranded DNA-
stimulated 
ATPase and ATP-
dependent DNA 
helicase (5' to 3') 
activity.  
IPI00219078.
5 
Sarcoplasmic/en
doplasmic 
reticulum 
calcium ATPase 
2 
0.27 3.68 2 
3.0435
E-06 
Catalyzes the 
hydrolysis of ATP 
coupled with the 
translocation of 
calcium from the 
cytosol to the 
sarcoplasmic 
reticulum lumen. 
IPI00902512.
1 
Serine/threonine 
protein 
phosphatase 
0.14 7.37 2 
2.07E-
09 
Evidence at 
transcript level. 
IPI00009368.
4 
Sideroflexin-1 
0.08 11.97 2 
4.48E-
07 
An ion transporter 
located in the 
mitochondrial 
membrane. 
0.06 16.31 2 
2.4121
E-06 
IPI00295098.
3 
Signal 
recognition 
particle receptor 
subunit beta 
0.26 3.91 2 
1.91E-
16 
Helps ensures the 
correct targeting of  
nascent secretory 
proteins to the ER 
membrane 
system.  
0.22 4.59 3 
6.269E
-24 
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IPI00006482.
1 
Sodium/potassiu
m-transporting 
ATPase subunit 
alpha-1 
0.10 9.55 20 
4.5674
E-157 
Enzyme involved 
in the exchange of 
Na+ and K+ ions 
across the plasma 
membrane.  
0.09 10.63 11 
7.90E-
58 
IPI00008167.
1 
Sodium/potassiu
m-transporting 
ATPase subunit 
beta-3 
0.18 5.7 3 
1.4291
E-11 
Involved in the 
exchange of Na+ 
and K+ ions 
across the plasma 
membrane.  
IPI00871932.
1 
Spectrin beta 
chain, brain 1 
0.13 7.82 39 
3.4409
E-242 
May be involved in 
the movement of 
the cytoskeleton at 
the membrane.  
0.12 8.14 25 
1.45E-
130 
IPI00479946.
3 
STIP1 protein 0.10 9.69 6 
1.72E-
49 
Protein function 
unknown. 
Evidence at 
transcript level.  
IPI00334190.
4 
Stomatin-like 
protein 2 
0.10 10.15 3 
7.33E-
13 
Peripheral plasma 
membrane protein 
associated with 
the cytoskeleton.  
IPI00007765.
5 
Stress-70 
protein, 
mitochondrial 
0.15 6.84 12 
2.24E-
72 
Protein chaperone 
of the HSP70 
family.  0.13 7.75 21 
2.6842
E-76 
IPI00290566.
1 
T-complex 
protein 1 subunit 
alpha 
0.21 4.85 2 
2.0364
E-06 
The T-complex is 
located in the 
cytoplasm - it is 
associated with 
the cytoskeleton, 
especially at 
centrosomes. The 
T-complex 
functions as a 
molecular 
chaperone; it 
assists the folding 
of proteins upon 
ATP hydrolysis 
and plays a role in 
'de novo' post-
translational 
protein folding. 
0.17 5.81 4 
1.00E-
18 
IPI00297779.
7 
T-complex 
protein 1 subunit 
beta 
0.24 4.24 5 
3.69E-
20 
IPI00010720.
1 
T-complex 
protein 1 subunit 
epsilon 
0.21 4.75 3 
2.1314
E-08 
IPI00018465.
1 
T-complex 
protein 1 subunit 
eta 
0.13 7.69 4 
1.30E-
05 
IPI00553185.
2 
T-complex 
protein 1 subunit 
gamma 
0.18 5.65 3 
2.2641
E-11 
0.13 7.66 4 
2.02E-
28 
IPI00784090.
2 
T-complex 
protein 1 subunit 
theta 
0.14 7.19 8 
6.45E-
24 
0.13 7.7 2 
5.2692
E-09 
IPI00027626.
3 
T-complex 
protein 1 subunit 
zeta 
0.18 5.54 3 
1.3074
E-25 
0.16 6.13 5 
3.81E-
18 
IPI00873222.
2 
T-complex 
protein 1, delta 
subunit 
0.15 6.78 3 
1.99E-
25 
0.12 8.05 3 
8.3691
E-08 
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IPI00216298.
6 
Thioredoxin 
0.78 1.28 3 
3.2122
E-18 
Involved in various 
redox reactions 
through the 
reversible 
oxidation of its 
active center 
dithiol to a 
disulfide.  
0.53 1.88 3 
2.51E-
12 
IPI00395887.
4 
Thioredoxin-
related 
transmembrane 
protein 1 
0.18 5.6 2 
0.0133
69 
Involved in 
electron transport, 
and ER to Golgi 
vesicle-mediated 
transport.  
IPI00216219.
3 
Tight junction 
protein ZO-1 
0.17 5.8 15 
5.82E-
70 
Peripheral plasma 
membrane protein 
involved in the 
formation of tight 
junctions between 
cells.  
0.07 14.68 38 
6.9093
E-188 
IPI00019385.
3 
Translocon-
associated 
protein subunit 
delta 
0.24 4.13 2 
0.0000
81258 
Located in the ER 
and involved in 
intracellular 
protein transport.  
0.15 6.74 2 
1.74E-
24 
IPI00028055.
4 
Transmembrane 
emp24 domain-
containing 
protein 10 
0.32 3.12 2 
1.5648
E-09 
Involved in 
vesicular protein 
trafficking and in 
golgi-ER transport.   
IPI00031522.
2 
Trifunctional 
enzyme subunit 
alpha, 
mitochondrial 
0.17 5.78 6 
4.57E-
27 Involved in fatty 
acid metabolism. 
0.14 7.19 9 
3.1728
E-37 
IPI00022793.
5 
Trifunctional 
enzyme subunit 
beta, 
mitochondrial 
0.34 2.92 3 
3.5042
E-13 
Involved in fatty 
acid metabolism 
IPI00218319.
3 
Tropomyosin 
alpha-3 chain 
0.11 9.2 7 
1.373E
-34 
Binds to actin 
filaments in 
muscle and non-
muscle cells.  
0.11 9.43 4 
7.25E-
07 
IPI00180675.
4 
Tubulin alpha-
1A chain 
0.12 8.63 16 
1.46E-
89 
The major 
constituent of 
microtubules.  IPI00387144.
4 
Tubulin alpha 6 
variant 
0.12 8.5 16 
2.12E-
69 
IPI00011654.
2 
Tubulin beta 
chain 
0.20 5.12 18 
5.5184
E-133 
Tubulin is the 
major constituent 
of microtubules.  
0.18 5.51 16 
5.88E-
96 
IPI00007752.
1 
Tubulin beta-2C 
chain 
0.29 3.4 14 
2.02E-
69 
0.26 3.84 15 
8.2464
E-97 
IPI00418471.
6 
Vimentin 0.04 25.44 33 
9.9185
E-201 
Forms 
intermediate 
Appendix II 
 
256 
 
0.03 28.83 31 
2.20E-
225 
filaments. 
Structural 
constituent of the 
cyoskeleton.  
IPI00216308.
5 
Voltage-
dependent 
anion-selective 
channel protein 
1 
0.17 5.95 6 
9.0807
E-34 
Forms a channel 
through the 
mitochondrial 
outer membrane. 
May participate in 
the formation of 
the permeability 
transition pore 
complex (PTPC). 
0.07 13.84 7 
2.91E-
15 
IPI00024145.
1 
Voltage-
dependent 
anion-selective 
channel protein 
2 
0.06 15.67 4 
2.26E-
13 
A porin found in 
the mitochondrial 
outer membrane, 
that allows 
diffusion of small 
hydrophilic 
molecules.  
IPI00216026.
2 
Voltage-
dependent 
anion-selective 
channel protein 
2 
0.06 16.03 7 
1.1548
E-19 
newprotein99
9 
N-protein 
CCHFV 
0.05 19.79 26 0   
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APPENDIX III MS ANALYSIS OF THE FRACTION CONTAINING 
INFECTIOUS HAZV 
Proteins identified and quantified in the MS analysis of the fraction containing 
infectious HAZV. 
 
Accessio
n number 
Protein name MW 
Da 
Peptide
s 
emPAI Function 
P62258 14-3-3 protein epsilon 29437 2 0.24 Adaptor protein 
involved in 
intracellular 
signalling. 
P27348 14-3-3 protein theta  28143 2 0.25 
P63104 14-3-3 protein zeta/delta 28010 2 0.25 
P62333 26S protease regulatory 
subunit 10B  
44541 2 0.15 The 26S protease is 
involved in the ATP-
dependent 
degradation of 
ubiquitinated 
proteins. The 
regulatory (or 
ATPase) complex 
confers ATP 
dependency and 
substrate specificity 
to the 26S complex. 
P62191 26S protease regulatory 
subunit 4  
49436 5 0.38 
P17980 26S protease regulatory 
subunit 6A 
49569 3 0.21 
P62195 26S protease regulatory 
subunit 8  
45879 4 0.32 
O00231 26S proteasome non-
ATPase regulatory 
subunit 11  
47830 2 0.14 Component of the 
lid subcomplex of 
the 26S 
proteasome. 
O00232 26S proteasome non-
ATPase regulatory 
subunit 12  
53381 2 0.13  Acts as a 
regulatory subunit 
of the 26S 
proteasome which 
is involved in the 
ATP-dependent 
degradation of 
ubiquitinated 
proteins 
  
Q9UNM6 26S proteasome non-
ATPase regulatory 
subunit 13  
43314 2 0.16 
Q13200 26S proteasome non-
ATPase regulatory 
subunit 2  
10098
8 
6 0.21 
P51665 26S proteasome non-
ATPase regulatory 
subunit 7  
37171 3 0.29 
P62249 40S ribosomal protein 
S16  
16660 2 0.45 Involved in protein 
biogenesis. 
Component of the 
small ribosomal 
subunit. Mature 
ribosomes consist 
of a small (40S) and 
a large (60S) 
subunit. The 40S 
subunit contains 
about 33 different 
P62269 40S ribosomal protein 
S18  
17819 2 0.41 
P15880 40S ribosomal protein 
S2  
31701 5 0.64 
P23396 40S ribosomal protein 
S3  
26953 5 0.79 
P61247 40S ribosomal protein 30265 5 0.68 
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S3a  proteins and 1 
molecule of RNA 
(18S). The 60S 
subunit contains 
about 49 different 
proteins and 3 
molecules of RNA 
(28S, 5.8S and 
5S).   
  
P62701 40S ribosomal protein 
S4, X isoform   
29918 4 0.52 
P46782 40S ribosomal protein 
S5  
23144 4 0.71 
P62241 40S ribosomal protein 
S8  
24586 3 0.47 
P46781 40S ribosomal protein 
S9  
22746 2 0.32 
P08865 40S ribosomal protein 
SA  
33058 4 0.47 
P05388 60S acidic ribosomal 
protein P0  
34534 6 0.73 Involved in protein 
biogenesis. 
Component of the 
large ribosomal 
subunit. The 60S 
subunit contains 
about 49 different 
proteins and 3 
molecules of RNA 
(28S, 5.8S and 
5S).    
P62906 60S ribosomal protein 
L10a  
25098 2 0.28 
P46776 60S ribosomal protein 
L27a  
16776 2 0.44 
P36578 60S ribosomal protein 
L4  
48064 4 0.3 
P46777 60S ribosomal protein 
L5  
34680 5 0.58 
P62424 60S ribosomal protein 
L7a 
30259 3 0.37 
P11021 78 kDa glucose-
regulated protein 
72513 2 0.09 Protein chaperone. 
Facilitates the 
assembly of 
multimeric protein 
complexes inside 
the ER.  
P60709 Actin, cytoplasmic 1   42163 22 3.52 Major component of 
the actin 
cytoskeleton 
O15145 Actin-related protein 2/3 
complex subunit 3   
20872 2 0.35 Regulates actin 
polymerization 
P61158 Actin-related protein 3  47908 3 0.22 Regulates actin 
polymerization  
P07741 Adenine 
phosphoribosyltransfera
se  
19878 2 0.37 Involved in purine 
metabolism 
P23526 Adenosylhomocysteinas
e  
48366 8 0.69 Involved in amino 
acid biosynthesis 
Q01518 Adenylyl cyclase-
associated protein 1  
52436 4 0.28 Peripheral 
membrane protein 
that directly 
regulates actin 
filament dynamics  
P18085 ADP-ribosylation factor 
4  
20723 2 0.35 Involved in protein 
trafficking; may 
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modulate vesicle 
budding and 
uncoating within the 
Golgi apparatus 
O00468 Agrin  22535
7 
3 0.04 Glycoprotein that 
plays a central role 
in the formation and 
the maintenance of 
the neuromuscular 
junction (NMJ)  
P01023 Alpha-2-macroglobulin  16472
4 
5 0.1  Protease inhibitor 
P61163 Alpha-centractin 42812 3 0.25 Involved in 
microtubule based 
vesicle motility. 
P06733 Alpha-enolase  47592 13 1.39 Enzyme involved in 
glycolysis 
P02771 Alpha-fetoprotein  70569 4 0.2 Secreted protein. 
Binds copper and 
nickel 
P04083 Annexin A1  39029 14 2.12 Promotes 
membrane fusion 
and is involved in 
exocytosis. 
P07355 Annexin A2  38919 6 0.63 May be involved 
with exocytosis. 
Q10567 AP-1 complex subunit 
beta-1  
10559
3 
3 0.1 Subunit of clathrin-
associated AP 1 
complex that plays 
a role in protein 
sorting in the late-
Golgi/trans-Golgi 
network (TGN) 
and/or endosomes. 
P63010 AP-2 complex subunit 
beta  
10550
9 
4 0.13 The adaptor protein 
complex 2 (AP-2) is 
involved in clathrin-
dependent 
endocytosis  
Q96CW1 AP-2 complex subunit 
mu  
50076 3 0.21 
P08243 Asparagine synthetase 
[glutamine-hydrolyzing] 
65010 3 0.16 Involved in amino 
acid biosynthesis 
P14868 Aspartate--tRNA ligase, 
cytoplasmic  
57610 4 0.25 Involved in protein 
biosynthesis 
P06576 ATP synthase subunit 
beta, mitochondrial  
56636 3 0.18 Mitochondrial 
protein involved in 
respiration 
P53396 ATP-citrate synthase  12178
5 
7 0.2 Involved in de novo 
lipid synthesis 
Q08211 ATP-dependent RNA 
helicase A  
14229
2 
6 0.15 Unwinds double-
stranded DNA and 
RNA in a 3' to 5' 
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direction.  
O00571 ATP-dependent RNA 
helicase DDX3X  
73708 4 0.19 Multifunctional ATP-
dependent RNA 
helicase. Involved in 
IRF-3 signalling 
Q562R1 Beta-actin-like protein 2  42429 8 0.69 Associated with the 
actin cytoskeleton 
P13929 Beta-enolase  47410 5 0.4 Involved in 
glycolysis 
P16278 Beta-galactosidase  76594 2 0.09 Cleaves beta-linked 
terminal galactosyl 
residues from 
gangliosides, 
glycoproteins, and 
glycosaminoglycans
.  
P07814 Bifunctional 
glutamate/proline--tRNA 
ligase 
17219
1 
5 0.1 Involved in protein 
biosynthesis 
P31939 Bifunctional purine 
biosynthesis protein 
PURH  
65200 7 0.41 Involved in purine 
biosynthesis 
P11586 C-1-tetrahydrofolate 
synthase, cytoplasmic  
10229
1 
12 0.46 Involved in amino 
acid biosynthesis 
P27708 CAD protein  24527
8 
5 0.07 Involved in 
pyrimidine 
biosynthesis 
Q00610 Clathrin heavy chain 1 19337
1 
54 1.47 The major protein of 
the polyhedral coat 
of coated pits and 
vesicles involved in 
endocytosis and 
protein sorting in 
the Golgi network.   
P53675 Clathrin heavy chain 2  18913
1 
16 0.31 
P12259 Coagulation factor V  25279
7 
4 0.05 Central regulator of 
hemostasis 
P53621 Coatomer subunit alpha 13990
8 
5 0.12 The coatomer is a 
cytosolic protein 
complex that helps 
mediate protein 
transport from the 
ER, via the Golgi up 
to the trans Golgi 
network. Coatomer 
complex is required 
for budding from 
Golgi membranes, 
and is essential for 
the retrograde 
Golgi-to-ER 
transport of dilysine-
tagged proteins.   
P53618 Coatomer subunit beta  10832
5 
3 0.09 
P48444 Coatomer subunit delta  57741 2 0.12 
Q9Y678 Coatomer subunit 
gamma-1  
99078 2 0.07 
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P12109 Collagen alpha-1(VI) 
chain  
10971
3 
2 0.06 Secreted protein 
involved in cell 
adhesion. 
  
  
P12107 Collagen alpha-1(XI) 
chain  
18169
2 
23 0.45 
P05997 Collagen alpha-2(V) 
chain 
14590
1 
6 0.14 
P01024 Complement C3  18868
0 
13 0.21 Secreted protein 
involved in the 
complement 
pathway 
P0C0L4 Complement C4-A  19437
2 
8 0.14 
P29279 Connective tissue 
growth factor  
40400 13 1.57  Secreted protein 
involved in cell 
adhesion. 
Q14204 Cytoplasmic dynein 1 
heavy chain 1  
53492
0 
16 0.1 Acts as a motor for 
the intracellular 
retrograde motility 
of vesicles and 
organelles along 
microtubules.  
Q7L576 Cytoplasmic FMR1-
interacting protein 1 
14685
3 
18 0.49 Involved in 
translation 
Q96F07 Cytoplasmic FMR1-
interacting protein 2 
15040
9 
10 0.24 Involved in the 
p53/TP53-
dependent induction 
of apoptosis. 
P15924 Desmoplakin  33413
2 
3 0.03 Found in 
desmosomes. 
P78527 DNA-dependent protein 
kinase catalytic subunit  
47386
0 
5 0.03 Molecular sensor 
for DNA damage 
Q9UBS4 DnaJ homolog 
subfamily B member 11  
40885 10 1.18 Co-chaperone for 
HSPA5 
Q5T4S7 E3 ubiquitin-protein 
ligase UBR4  
58065
8 
2 0.01 Involved in the 
ubiqutin conjugation 
pathway 
Q05639 Elongation factor 1-
alpha 2  
50891 9 0.76 Involved in protein 
biosynthesis 
  
  
  
  
P24534 Elongation factor 1-beta  25030 2 0.29 
P29692 Elongation factor 1-delta  31328 3 0.35 
P26641 Elongation factor 1-
gamma  
50540 6 0.46 
P13639 Elongation factor 2  96357 34 1.91 
P14625 Endoplasmin 92807 3 0.11 Protein chaperone 
P60842 Eukaryotic initiation 
factor 4A-I  
46464 4 0.32 Involved in protein 
biosynthesis 
  
  
P05198 Eukaryotic translation 
initiation factor 2 subunit 
1  
36485 6 0.68 
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P41091 Eukaryotic translation 
initiation factor 2 subunit 
3  
51758 6 0.45   
  
  
  
  
  
  
  
Q14152 Eukaryotic translation 
initiation factor 3 subunit 
A  
16697
8 
11 0.24 
P55884 Eukaryotic translation 
initiation factor 3 subunit 
B 
92934 5 0.19 
Q99613 Eukaryotic translation 
initiation factor 3 subunit 
C  
10607
3 
3 0.1 
O00303 Eukaryotic translation 
initiation factor 3 subunit 
F  
37765 4 0.4 
Q13347 Eukaryotic translation 
initiation factor 3 subunit 
I  
36989 3 0.29 
Q9Y262 Eukaryotic translation 
initiation factor 3 subunit 
L  
67023 8 0.47 
P55010 Eukaryotic translation 
initiation factor 5  
49759 2 0.14 
P15311 Ezrin  69595 2 0.1 Probably involved in 
connections of 
major cytoskeletal 
structures to the 
plasma membrane. 
Q08945 FACT complex subunit 
SSRP1  
81478 2 0.08 Involved in DNA 
and mRNA 
synthesis 
P49327 Fatty acid synthase  27598
8 
33 0.47 Involved in fatty 
acid biosynthesis 
P02751 Fibronectin  26616
3 
10 0.13 Involved in cell 
adhesion, cell 
motility, 
opsonization, and 
maintenance of cell 
shape. 
P21333 Filamin-A  28341
2 
24 0.32 Links actin filaments 
to membrane 
glycoproteins. 
Q14315 Filamin-C  29351
8 
2 0.02 Actin cytoskeletal 
reorganisation 
P09104 Gamma-enolase  47692 4 0.31 Involved in 
glycolysis 
P04406 Glyceraldehyde-3-
phosphate 
dehydrogenase  
36312 13 2.11 A key enzyme in 
glycolysis. 
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A6XIP3 Glycoprotein  16110
5 
40 1.23 HAZV glycoprotein 
polypeptide 
P62826 GTP-binding nuclear 
protein Ran  
24690 4 0.66 GTP-binding protein 
involved in 
nucleocytoplasmic 
transport 
P62873 Guanine nucleotide-
binding protein 
G(I)/G(S)/G(T) subunit 
beta-1 
38262 2 0.18 A modulator or 
transducer in 
various 
transmembrane 
signaling systems.  
P63244 Guanine nucleotide-
binding protein subunit 
beta-2-like 1  
35622 9 1.23 Involved in the 
recruitment, 
assembly and/or 
regulation of a 
variety of signaling 
molecules. 
P34931 Heat shock 70 kDa 
protein 1-like  
70841 3 0.15 Hsp70s stabilize 
preexistent proteins 
against aggregation 
and mediate the 
folding of newly 
translated 
polypeptides in the 
cytosol as well as 
within organelles.  
P17066 Heat shock 70 kDa 
protein 6  
71551 4 0.2 
P11142 Heat shock cognate 71 
kDa protein 
71193 15 0.97 
P07900 Heat shock protein HSP 
90-alpha  
85117 11 0.46  Protein chaperone. 
P08238 Heat shock protein HSP 
90-beta  
83665 21 1.16  Protein chaperone. 
O60812 Heterogeneous nuclear 
ribonucleoprotein C-like 
1  
32291 2 0.22 May play a role in 
nucleosome 
assembly  
P31943 Heterogeneous nuclear 
ribonucleoprotein H  
49595 2 0.14 A component of the 
heterogeneous 
nuclear 
ribonucleoprotein 
(hnRNP) complexes 
which provide the 
substrate for the 
processing events 
that pre-mRNAs 
undergo before 
becoming 
functional, 
translatable mRNAs 
in the cytoplasm. 
Mediates pre-
mRNA alternative 
splicing regulation. 
P61978 Heterogeneous nuclear 
ribonucleoprotein K  
51341 5 0.36 
O60506 Heterogeneous nuclear 
ribonucleoprotein Q  
69899 3 0.15 
O43390 Heterogeneous nuclear 
ribonucleoprotein R  
71295 2 0.09 
Q00839 Heterogeneous nuclear 
ribonucleoprotein U  
91380 2 0.07 
P07910 Heterogeneous nuclear 
ribonucleoproteins 
C1/C2  
33818 3 0.32 
O14929 Histone 
acetyltransferase type B 
catalytic subunit  
49991 2 0.14 Acetylates soluble 
but not nucleosomal 
histone H4  
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P0C0S8 Histone H2A type 1  14194 3 0.91 Core component of 
nucleosome. 
Nucleosomes wrap 
and compact DNA 
into chromatin. 
  
P06899 Histone H2B type 1-J  14007 4 1.39 
Q5QNW6 Histone H2B type 2-F  14023 3 0.92 
Q71DI3 Histone H3.2  15547 5 1.69 
P62805 Histone H4   11471 9 9.69 
Q86YZ3 Hornerin  28325
1 
2 0.02 Involved in 
keratinization. 
Q9Y4L1 Hypoxia up-regulated 
protein 1 
11160
5 
2 0.06  Protein chaperone. 
O00505 Importin subunit alpha-3  58399 2 0.12 Involved in nuclear 
import of proteins.   
Q14974 Importin subunit beta-1  98531 3 0.1 
P12268 Inosine-5~-
monophosphate 
dehydrogenase 2  
56337 4 0.25 Involved in purine 
biosynthesis 
Q9Y6M1 Insulin-like growth factor 
2 mRNA-binding protein 
2  
66306 2 0.1 Involved in mRNA 
transport. 
P19827 Inter-alpha-trypsin 
inhibitor heavy chain H1  
10189
3 
2 0.07 Secreted protein 
that may act as a 
carrier of 
hyaluronan in 
serum. Protease 
inhibitor. 
P19823 Inter-alpha-trypsin 
inhibitor heavy chain H2  
10696
4 
4 0.13 
Q06033 Inter-alpha-trypsin 
inhibitor heavy chain H3  
10018
3 
3 0.1 
Q12905 Interleukin enhancer-
binding factor 2  
43374 3 0.25 Involved in 
transcription 
regulation. 
P41252 Isoleucine--tRNA ligase, 
cytoplasmic  
14582
9 
3 0.07 Involved in protein 
biosynthesis 
P13645 Keratin, type I 
cytoskeletal 10  
59131 38 6.82 Components of the 
cytoskeleton. Kerati
ns form 
intermediate 
filaments, which are 
composed of a 
heterotetramer of 
two type I and two 
type II keratins. 
There are two types 
of cytoskeletal and 
microfibrillar keratin: 
I (acidic; 40-55 kDa) 
and II (neutral to 
basic; 56-70 kDa). 
Different species of 
keratin have various 
different roles 
including; 
involvement in 
signalling various 
P13646 Keratin, type I 
cytoskeletal 13  
50011 5 0.38 
|P02533 Keratin, type I 
cytoskeletal 14  
51983 25 3.65 
P08779 Keratin, type I 
cytoskeletal 16  
51689 31 5.78 
Q04695 Keratin, type I 
cytoskeletal 17 
48472 17 2.06 
P08727 Keratin, type I 
cytoskeletal 19   
44190 6 0.54 
P35900 Keratin, type I 
cytoskeletal 20  
48625 2 0.14 
Q7Z3Z0 Keratin, type I 
cytoskeletal 25  
49969 3 0.21 
Q7Z3Y8 Keratin, type I 50530 3 0.21 
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cytoskeletal 27 pathways, involved 
in the organization 
of myofibers. 
Together with 
KRT8, these 
keratins help to link 
the contractile 
apparatus to 
dystrophin at the 
costameres of 
striated muscle. 
Some species play 
a significant role in 
maintaining keratin 
filament 
organization in 
intestinal epithelia. 
When 
phosphorylated, 
these keratins play 
a role in the 
secretion of mucin 
in the small 
intestine. 
  
  
  
  
  
  
  
  
  
  
  
  
   
  
  
  
P04264 Keratin, type II 
cytoskeletal 1  
66281 49 8.26 
Q7Z794 Keratin, type II 
cytoskeletal 1b  
62260 4 0.23 
Q01546 Keratin, type II 
cytoskeletal 2 oral  
66481 6 0.34 
P12035 Keratin, type II 
cytoskeletal 3  
64660 9 0.56 
P19013 Keratin, type II 
cytoskeletal 4  
57760 3 0.18 
P13647 Keratin, type II 
cytoskeletal 5  
62679 15 1.04 
P02538 Keratin, type II 
cytoskeletal 6A  
60404 24 2.39 
P04259 Keratin, type II 
cytoskeletal 6B  
60426 23 2.21 
P48668 Keratin, type II 
cytoskeletal 6C  
60384 24 2.39 
P08729 Keratin, type II 
cytoskeletal 7 
51522 4 0.28 
Q3SY84 Keratin, type II 
cytoskeletal 71  
57880 4 0.25 
Q14CN4 Keratin, type II 
cytoskeletal 72  
56581 6 0.4 
Q7RTS7 Keratin, type II 
cytoskeletal 74  
58340 4 0.25 
O95678 Keratin, type II 
cytoskeletal 75  
59920 8 0.45 
Q5XKE5 Keratin, type II 
cytoskeletal 79   
58196 7 0.39 
P05787 Keratin, type II 
cytoskeletal 8  
53782 4 0.27 
Q6KB66 Keratin, type II 
cytoskeletal 80  
51118 2 0.13 
O60282 Kinesin heavy chain 
isoform 5C  
11010
8 
2 0.06 Microtubule-
dependent motor 
involved in 
organelle transport. 
P33176 Kinesin-1 heavy chain  11046
9 
3 0.09 
P00338 L-lactate 
dehydrogenase A chain 
37061 2 0.19  Involved in 
glycolysis 
P07195 L-lactate 
dehydrogenase B chain 
37011 2 0.19  Involved in 
glycolysis 
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P26038 Moesin  68003 2 0.1 Probably involved in 
connections of 
major cytoskeletal 
structures to the 
plasma membrane.  
P22234 Multifunctional protein 
ADE2  
47901 4 0.3 Involved in purine 
biosynthesis 
P35580 Myosin-10  22993
8 
2 0.03 Cellular myosin that 
appears to play a 
role in cytokinesis, 
cell shape and other 
functions such as 
secretion and 
capping  
Q7Z406 Myosin-14  22881
2 
2 0.03 
P35579 Myosin-9  22775
7 
19 0.31 
Q9Y2A7 Nck-associated protein 
1  
13012
9 
8 0.22 Regulates actin 
reorganisation. 
Q14697 Neutral alpha-
glucosidase AB  
10737
4 
3 0.09 Involved in glycan 
metabolism in ER 
and golgi 
M4PWE6 Nucleocapsid protein  54639 56 16.61  HAZV N 
Q9NR30 Nucleolar RNA helicase 
2  
87915 2 0.08 Can unwind double-
stranded RNA  
P19338 Nucleolin  76736 6 0.29 The major nucleolar 
protein 
P06748 Nucleophosmin  32837 7 0.96 Involved in 
ribosome 
biogenesis, 
centrosome 
duplication, and 
protein 
chaperoning. 
P55209 Nucleosome assembly 
protein 1-like 1  
45742 2 0.15 May be involved in 
modulating 
chromatin formation 
P32119 Peroxiredoxin-2  22160 2 0.32 Involved in redox 
regulation of the 
cell.  
Q9Y285 Phenylalanine--tRNA 
ligase alpha subunit  
57696 3 0.18 Involved in protein 
biosynthesis 
Q9NSD9 Phenylalanine--tRNA 
ligase beta subunit 
66812 6 0.33 Involved in protein 
biosynthesis 
P36955 Pigment epithelium-
derived factor  
46565 5 0.41 Secreted protease 
inhibitor  
P00747 Plasminogen  93358 4 0.15 Involved in blood 
coagulation 
P43034 Platelet-activating factor 
acetylhydrolase IB 
subunit alpha  
47289 2 0.14 Involved in dynein 
mediated 
microtubule-based 
transport 
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P09874 Poly [ADP-ribose] 
polymerase 1  
11392
2 
3 0.09 Involved in DNA 
repair. 
Q15366 Poly(rC)-binding protein 
2  
39066 2 0.18 Negatively 
regulates cellular 
antiviral responses 
mediated by MAVS 
signaling.  
P11940 Polyadenylate-binding 
protein 1  
70965 2 0.09 Involved in mRNA 
processing. 
P0CG47 Polyubiquitin-B  25914 3 0.44 Involved in protein 
signalling and 
degradation 
Q6S8J3 POTE ankyrin domain 
family member E  
12299
3 
11 0.3 Cytoplasmic. Co-
localises with actin 
filaments  
P0CG39 POTE ankyrin domain 
family member J 
11885
1 
4 0.11 
P20742 Pregnancy zone protein  16535
3 
3 0.06 Secreted protease 
inhibitor 
P02545 Prelamin-A/C  74491 3 0.14 Component of the 
nuclear lamina 
Q9UMS4 Pre-mRNA-processing 
factor 19  
55714 4 0.26 Plays a role in DNA 
double-strand break 
(DSB) repair 
Q92841 Probable ATP-
dependent RNA 
helicase DDX17  
81017 3 0.13 Involved in 
transcriptional 
regulation 
Q93008 Probable ubiquitin 
carboxyl-terminal 
hydrolase FAF-X  
29562
6 
4 0.04 De-ubiquitinates 
target proteins 
Q02809 Procollagen-lysine,2-
oxoglutarate 5-
dioxygenase 1  
84179 5 0.21 Forms 
hydroxylysine 
residues in 
collagens  
Q9UQ80 Proliferation-associated 
protein 2G4  
44212 2 0.16 Involved in 
transcription 
regulation 
Q5VYK3 Proteasome-associated 
protein ECM29 homolog  
20609
6 
2 0.03 May couple the 
proteasome to 
different 
compartments  
Q99873 Protein arginine N-
methyltransferase 1 
42170 5 0.46 Methylates amino 
acid residues of 
specific proteins 
 
O60678 Protein arginine N-
methyltransferase 3  
60633 2 0.11 
O14744 Protein arginine N-
methyltransferase 5  
73433 2 0.09 
P00734 Prothrombin  71586 3 0.14 Involved in 
haemostasis 
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Q5VTE0 Putative elongation 
factor 1-alpha-like 3  
50606 14 1.42  N/A 
Q58FF6 Putative heat shock 
protein HSP 90-beta 4 
58966 2 0.11  N/A 
Q58FF7 Putative heat shock 
protein HSP 90-beta-3 
68735 3 0.15  N/A 
O43143 Putative pre-mRNA-
splicing factor ATP-
dependent RNA 
helicase DHX15 
91784 2 0.07  N/A 
Q9H853 Putative tubulin-like 
protein alpha-4B  
27930 3 0.4  N/A 
P14618 Pyruvate kinase 
isozymes M1/M2  
58581 22 2.15  Involved in 
glycolysis 
P46940 Ras GTPase-activating-
like protein IQGAP1  
18987
2 
6 0.11 Could be involved in 
signal transduction 
P61026 Ras-related protein 
Rab-10  
22866 3 0.51 The small GTPases 
Rab are key 
regulators of 
intracellular 
membrane 
trafficking, from the 
formation of 
transport vesicles to 
their fusion with 
membranes. Some 
regulate transport of 
vesicles from the 
ER through 
successive Golgi 
compartments.  
P59190 Ras-related protein 
Rab-15  
24771 2 0.29 
Q9H0U4 Ras-related protein 
Rab-1B  
22439 3 0.52 
Q15286 Ras-related protein 
Rab-35 
23407 2 0.31 
P00352 Retinal dehydrogenase 
1  
55565 12 0.99 Oxidoreductase 
enzyme. 
Q13464 Rho-associated protein 
kinase 1  
15921
3 
2 0.04 A key regulator of 
the actin 
cytoskeleton and 
cell polarity 
Q9Y265 RuvB-like 1  50649 5 0.37 Involved in 
transcription 
regulation 
Q14563 Semaphorin-3A  90027 5 0.2 Involved in cell 
differentiation. 
O95025 Semaphorin-3D 90846 19 0.89 
Q9NVA2 Septin-11  49763 2 0.14 Involved in actin 
cytoskeleton 
organisation  
Q15019 Septin-2  41800 6 0.58 
Q07955 Serine/arginine-rich 
splicing factor 1 
27953 3 0.4 Involved in mRNA 
processing 
P30153 Serine/threonine-protein 
phosphatase 2A 65 kDa 
regulatory subunit A 
66176 2 0.1 Involved in 
chromosome 
segregation 
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alpha isoform  
P62714 Serine/threonine-protein 
phosphatase 2A 
catalytic subunit beta 
isoform  
36234 3 0.3 Modulates the 
activity of 
phosphorylase B 
kinase casein 
kinase 2, mitogen-
stimulated S6 
kinase, and MAP-2 
kinase 
P62136 Serine/threonine-protein 
phosphatase PP1-alpha 
catalytic subunit  
38340 4 0.39 Protein 
phosphatase that 
associates with over 
200 regulatory 
proteins to form 
highly specific 
holoenzymes which 
dephosphorylate 
hundreds of 
biological targets.  
Q9Y3F4 Serine-threonine kinase 
receptor-associated 
protein   
38867 2 0.18 Involved in mRNA 
processing 
P49591 Serine--tRNA ligase, 
cytoplasmic 
59364 3 0.18 Involved in protein 
biosynthesis 
P10768 S-formylglutathione 
hydrolase  
32067 2 0.22 Involved in the 
detoxification of 
formaldehyde. 
Q99519 Sialidase-1  46063 2 0.15 Removes of sialic 
acid moities from 
glycoproteins and 
glycolipids 
P63162 Small nuclear 
ribonucleoprotein-
associated protein N  
24880 3 0.46 Involved in RNA 
processing. 
Q13813 Spectrin alpha chain, 
non-erythrocytic 1  
28527
4 
4 0.05  Involved in 
secretion 
O75533 Splicing factor 3B 
subunit 1  
14659
0 
2 0.05  Involved in mRNA 
processing 
  
  
Q15393 Splicing factor 3B 
subunit 3  
13668
6 
9 0.24 
P23246 Splicing factor, proline- 
and glutamine-rich  
76327 5 0.23 
Q7KZF4 Staphylococcal 
nuclease domain-
containing protein 1  
10272
9 
3 0.1 Involved in 
transcription 
regulation 
P31948 Stress-induced-
phosphoprotein 1  
63338 2 0.11 Mediates the 
association of the 
molecular 
chaperones HSC70 
and HSP90 
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Q9Y490 Talin-1  27187
7 
15 0.2 Involved in 
connections of 
major cytoskeletal 
structures to the 
plasma 
membrane.   
Q9Y4G6 Talin-2  27389
2 
4 0.05 
P17987 T-complex protein 1 
subunit alpha  
60930 25 2.72 Molecular 
chaperone; assists 
the folding of 
proteins upon ATP 
hydrolysis. As part 
of the BBS/CCT 
complex may play a 
role in the assembly 
of BBSome, a 
complex involved in 
ciliogenesis 
regulating transport 
vesicles to the 
cilia.   
  
  
  
  
P78371 T-complex protein 1 
subunit beta  
57905 26 3.2 
P50991 T-complex protein 1 
subunit delta  
58512 17 1.54 
P48643 T-complex protein 1 
subunit epsilon  
60200 12 0.89 
Q99832 T-complex protein 1 
subunit eta  
59953 21 1.91 
P49368 T-complex protein 1 
subunit gamma  
61177 19 1.7 
P50990 T-complex protein 1 
subunit theta  
60264 24 2.58 
P40227 T-complex protein 1 
subunit zeta  
58555 19 1.82 
Q92526 T-complex protein 1 
subunit zeta-2  
58466 6 0.39 
P07996 Thrombospondin-1  13340
2 
14 0.4 Adhesive 
glycoprotein that 
mediates cell-to-cell 
and cell-to-matrix 
interactions 
P10646 Tissue factor pathway 
inhibitor  
36186 2 0.19 Involved in 
haemostasis 
P02786 Transferrin receptor 
protein 1  
85385 2 0.08 Involved in cellular 
uptake of iron 
P55072 Transitional 
endoplasmic reticulum 
ATPase 
90061 2 0.07 Involved in the 
transfer of 
membranes from 
the ER to the Golgi 
apparatus 
Q92616 Translational activator 
GCN1 
29507
8 
2 0.02 Involved in 
translation 
regulation 
Q92973 Transportin-1  10388
2 
2 0.06 Involved in nuclear 
protein import 
Q71U36 Tubulin alpha-1A chain  50899 20 2.5 The major 
constituent of 
microtubules 
  
P68363 Tubulin alpha-1B chain  50915 22 2.97 
P68366 Tubulin alpha-4A chain  50745 18 2.11 
P07437 Tubulin beta chain  50206 25 3.61 
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Q9H4B7 Tubulin beta-1 chain 50976 6 0.37   
  
  
  
  
Q13509 Tubulin beta-3 chain  50967 16 1.56 
P68371 Tubulin beta-4B chain  50366 20 2.33 
O75643 U5 small nuclear 
ribonucleoprotein 200 
kDa helicase 
24611
7 
8 0.11 Involved in mRNA 
processing 
P22314 Ubiquitin-like modifier-
activating enzyme 1  
11896
9 
13 0.42 Involved in ubiquitin 
conjugation 
pathway 
Q96QK1 Vacuolar protein 
sorting-associated 
protein 35  
92558 3 0.11 Component of the 
retromer complex 
P13010 X-ray repair cross-
complementing protein 
5  
83333 7 0.31 Involved in DNA 
repair 
P12956 X-ray repair cross-
complementing protein 
6  
70195 7 0.38 
 
 
 
 
 
